{"710ffab9a220e72e2511ac70203e13c2d02e133e": [["mucosal immunity and even can increase quality of life (Heydarian et al., 2010; Jafari et al., 2013) .", [["mucosal", "ANATOMY", 0, 7], ["mucosal", "MULTI-TISSUE_STRUCTURE", 0, 7]]], ["On the other hand, administration of antibiotics in patients with URTI has a negative effect on the immune system and resulted in incompetent virus-specific CD4+ and CD8+T cell responses (Ichinohe et al., 2011) .", [["immune system", "ANATOMY", 100, 113], ["CD4+ and CD8+T cell", "ANATOMY", 157, 176], ["URTI", "DISEASE", 66, 70], ["patients", "ORGANISM", 52, 60], ["immune system", "ANATOMICAL_SYSTEM", 100, 113], ["CD4", "GENE_OR_GENE_PRODUCT", 157, 160], ["CD8", "GENE_OR_GENE_PRODUCT", 166, 169], ["CD4", "PROTEIN", 157, 160], ["CD8", "PROTEIN", 166, 169], ["patients", "SPECIES", 52, 60], ["antibiotics", "TREATMENT", 37, 48], ["URTI", "PROBLEM", 66, 70], ["the immune system", "TEST", 96, 113], ["incompetent virus", "PROBLEM", 130, 147], ["incompetent virus", "OBSERVATION", 130, 147]]], ["Viral respiratory tract infections are more important in specific age groups (e.g., preterm infants or the elderly) and also individuals with underlying disease such as asthma.Viral Infections and AsthmaIn vitro infection of airway epithelial cells from asthmatic and healthy adults with HRV have demonstrated that asthmatic cells produce less IFN-\u03b2 and IFN-\u03bb making them potentially more susceptible to infection.", [["respiratory tract", "ANATOMY", 6, 23], ["airway epithelial cells", "ANATOMY", 225, 248], ["asthmatic cells", "ANATOMY", 315, 330], ["Viral respiratory tract infections", "DISEASE", 0, 34], ["asthma", "DISEASE", 169, 175], ["Viral Infections", "DISEASE", 176, 192], ["infection", "DISEASE", 212, 221], ["infection", "DISEASE", 404, 413], ["Viral respiratory tract", "ORGANISM", 0, 23], ["infants", "ORGANISM", 92, 99], ["airway epithelial cells", "CELL", 225, 248], ["asthmatic cells", "CELL", 315, 330], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 344, 349], ["IFN-\u03bb", "GENE_OR_GENE_PRODUCT", 354, 359], ["airway epithelial cells", "CELL_TYPE", 225, 248], ["asthmatic cells", "CELL_TYPE", 315, 330], ["IFN", "PROTEIN", 344, 347], ["IFN", "PROTEIN", 354, 357], ["\u03bb", "PROTEIN", 358, 359], ["infants", "SPECIES", 92, 99], ["Viral respiratory tract infections", "PROBLEM", 0, 34], ["underlying disease", "PROBLEM", 142, 160], ["asthma", "PROBLEM", 169, 175], ["Viral Infections", "PROBLEM", 176, 192], ["AsthmaIn vitro infection of airway epithelial cells", "PROBLEM", 197, 248], ["asthmatic and healthy adults", "PROBLEM", 254, 282], ["HRV", "PROBLEM", 288, 291], ["asthmatic cells", "PROBLEM", 315, 330], ["IFN", "PROBLEM", 354, 357], ["infection", "PROBLEM", 404, 413], ["respiratory tract", "ANATOMY", 6, 23], ["infections", "OBSERVATION", 24, 34], ["asthma", "OBSERVATION", 169, 175], ["Infections", "OBSERVATION", 182, 192], ["infection", "OBSERVATION", 212, 221], ["airway epithelial cells", "OBSERVATION", 225, 248], ["asthmatic cells", "OBSERVATION", 315, 330], ["infection", "OBSERVATION", 404, 413]]], ["URTI is the main cause of asthma exacerbations in children and adults and a major risk factor for admission in hospital every autumn.", [["URTI", "DISEASE", 0, 4], ["asthma exacerbations", "DISEASE", 26, 46], ["children", "ORGANISM", 50, 58], ["children", "SPECIES", 50, 58], ["URTI", "PROBLEM", 0, 4], ["asthma exacerbations", "PROBLEM", 26, 46], ["main", "OBSERVATION_MODIFIER", 12, 16], ["asthma", "OBSERVATION", 26, 32]]], ["Asthmatic patients are concerned about acute asthma exacerbations following a common cold, asking how to minimize the risk during the winter viral season.", [["Asthmatic", "DISEASE", 0, 9], ["asthma", "DISEASE", 45, 51], ["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["Asthmatic", "PROBLEM", 0, 9], ["acute asthma exacerbations", "PROBLEM", 39, 65], ["acute", "OBSERVATION_MODIFIER", 39, 44], ["asthma", "OBSERVATION", 45, 51]]], ["Acute exacerbations are associated with decreased lung growth and, as such, add to both the cost and morbidity associated with asthma.", [["lung", "ANATOMY", 50, 54], ["asthma", "DISEASE", 127, 133], ["lung", "ORGAN", 50, 54], ["Acute exacerbations", "PROBLEM", 0, 19], ["decreased lung growth", "PROBLEM", 40, 61], ["asthma", "PROBLEM", 127, 133], ["exacerbations", "OBSERVATION", 6, 19], ["decreased", "OBSERVATION_MODIFIER", 40, 49], ["lung", "ANATOMY", 50, 54], ["growth", "OBSERVATION_MODIFIER", 55, 61], ["asthma", "OBSERVATION", 127, 133]]], ["Viral respiratory infections are the most common cause of asthma exacerbations in children (80-85%) and are a major risk factor for admission to a hospital.", [["respiratory", "ANATOMY", 6, 17], ["Viral respiratory infections", "DISEASE", 0, 28], ["asthma exacerbations", "DISEASE", 58, 78], ["children", "ORGANISM", 82, 90], ["children", "SPECIES", 82, 90], ["Viral respiratory infections", "PROBLEM", 0, 28], ["asthma exacerbations", "PROBLEM", 58, 78], ["respiratory", "ANATOMY", 6, 17], ["infections", "OBSERVATION", 18, 28], ["most common", "OBSERVATION_MODIFIER", 37, 48], ["asthma", "OBSERVATION", 58, 64]]], ["HRVs are the most common viral agents.", [["HRVs", "SIMPLE_CHEMICAL", 0, 4], ["HRVs", "PROBLEM", 0, 4]]], ["Current drugs for the prevention and treatment of virus-induced exacerbation of asthma are poorly effective, and novel alternative therapies are needed.", [["asthma", "DISEASE", 80, 86], ["Current drugs", "TREATMENT", 0, 13], ["the prevention", "TREATMENT", 18, 32], ["treatment", "TREATMENT", 37, 46], ["virus", "PROBLEM", 50, 55], ["asthma", "PROBLEM", 80, 86], ["novel alternative therapies", "TREATMENT", 113, 140], ["asthma", "OBSERVATION", 80, 86]]], ["There are a growing number of clinical trials using probiotics, prebiotics, and synbiotics for the prevention of respiratory infections in asthmatic individuals.", [["respiratory", "ANATOMY", 113, 124], ["respiratory infections", "DISEASE", 113, 135], ["asthmatic", "DISEASE", 139, 148], ["synbiotics", "SIMPLE_CHEMICAL", 80, 90], ["clinical trials", "TREATMENT", 30, 45], ["probiotics", "TREATMENT", 52, 62], ["prebiotics", "TREATMENT", 64, 74], ["synbiotics", "TREATMENT", 80, 90], ["respiratory infections", "PROBLEM", 113, 135], ["asthmatic individuals", "PROBLEM", 139, 160], ["growing", "OBSERVATION_MODIFIER", 12, 19], ["respiratory", "ANATOMY", 113, 124], ["infections", "OBSERVATION", 125, 135], ["asthmatic individuals", "OBSERVATION", 139, 160]]], ["Proposed mechanisms include probiotics compete against pathogens; increase the barrier function in respiratory epithelium; immunostimulatory effects by enhancing cellular immunity with increased activity of natural killer cells and macrophages in airways (Hales et al., 2012; Holt and Sly, 2011) .Viral Infections and AsthmaRecent research interest has focused more on the role that respiratory viral infections play in the inception of asthma.", [["barrier", "ANATOMY", 79, 86], ["respiratory epithelium", "ANATOMY", 99, 121], ["cellular", "ANATOMY", 162, 170], ["natural killer cells", "ANATOMY", 207, 227], ["macrophages", "ANATOMY", 232, 243], ["airways", "ANATOMY", 247, 254], ["Viral Infections", "DISEASE", 297, 313], ["respiratory viral infections", "DISEASE", 383, 411], ["asthma", "DISEASE", 437, 443], ["barrier", "TISSUE", 79, 86], ["respiratory epithelium", "TISSUE", 99, 121], ["cellular", "CELL", 162, 170], ["natural killer cells", "CELL", 207, 227], ["macrophages", "CELL", 232, 243], ["airways", "MULTI-TISSUE_STRUCTURE", 247, 254], ["natural killer cells", "CELL_TYPE", 207, 227], ["macrophages", "CELL_TYPE", 232, 243], ["probiotics", "TREATMENT", 28, 38], ["pathogens", "PROBLEM", 55, 64], ["the barrier function", "TREATMENT", 75, 95], ["respiratory epithelium", "PROBLEM", 99, 121], ["immunostimulatory effects", "PROBLEM", 123, 148], ["enhancing cellular immunity", "PROBLEM", 152, 179], ["natural killer cells", "TREATMENT", 207, 227], ["macrophages in airways", "PROBLEM", 232, 254], ["Viral Infections", "PROBLEM", 297, 313], ["respiratory viral infections", "PROBLEM", 383, 411], ["asthma", "PROBLEM", 437, 443], ["barrier function", "OBSERVATION_MODIFIER", 79, 95], ["respiratory epithelium", "ANATOMY", 99, 121], ["natural killer cells", "OBSERVATION", 207, 227], ["airways", "ANATOMY", 247, 254], ["Infections", "OBSERVATION", 303, 313], ["viral infections", "OBSERVATION", 395, 411], ["asthma", "OBSERVATION", 437, 443]]], ["Epidemiological studies have shown an increased risk of asthma with lower respiratory tract infection (LRTI) caused by HRV even more than RSV.", [["lower respiratory tract", "ANATOMY", 68, 91], ["asthma", "DISEASE", 56, 62], ["lower respiratory tract infection", "DISEASE", 68, 101], ["LRTI", "DISEASE", 103, 107], ["lower", "ORGANISM_SUBDIVISION", 68, 73], ["respiratory tract", "ORGANISM_SUBDIVISION", 74, 91], ["RSV", "ORGANISM", 138, 141], ["RSV", "SPECIES", 138, 141], ["Epidemiological studies", "TEST", 0, 23], ["asthma", "PROBLEM", 56, 62], ["lower respiratory tract infection", "PROBLEM", 68, 101], ["HRV", "PROBLEM", 119, 122], ["RSV", "PROBLEM", 138, 141], ["increased", "OBSERVATION_MODIFIER", 38, 47], ["asthma", "OBSERVATION", 56, 62], ["lower", "ANATOMY_MODIFIER", 68, 73], ["respiratory tract", "ANATOMY", 74, 91], ["infection", "OBSERVATION", 92, 101]]], ["It is proposed that a synergistic interaction exists between viral infection and allergic sensitization, suggesting a \"two hit\" model for induction of persistent asthma.", [["viral infection", "DISEASE", 61, 76], ["allergic sensitization", "DISEASE", 81, 103], ["asthma", "DISEASE", 162, 168], ["a synergistic interaction", "PROBLEM", 20, 45], ["viral infection", "PROBLEM", 61, 76], ["allergic sensitization", "PROBLEM", 81, 103], ["persistent asthma", "PROBLEM", 151, 168], ["viral", "OBSERVATION_MODIFIER", 61, 66], ["infection", "OBSERVATION", 67, 76], ["persistent", "OBSERVATION_MODIFIER", 151, 161], ["asthma", "OBSERVATION", 162, 168]]], ["This information provides a series of novel strategies for the primary prevention of asthma by the prevention of either allergic sensitization or LRTI by probiotics or immunostimulants (Ahanchian et al., 2012) .Viral Infection in InfantsInfectious disease is the most important cause of morbidity in infants.", [["asthma", "DISEASE", 85, 91], ["allergic sensitization", "DISEASE", 120, 142], ["LRTI", "DISEASE", 146, 150], ["Viral Infection", "DISEASE", 211, 226], ["Infectious disease", "DISEASE", 237, 255], ["infants", "ORGANISM", 300, 307], ["Infants", "SPECIES", 230, 237], ["infants", "SPECIES", 300, 307], ["novel strategies", "TREATMENT", 38, 54], ["asthma", "PROBLEM", 85, 91], ["allergic sensitization", "PROBLEM", 120, 142], ["LRTI", "PROBLEM", 146, 150], ["Viral Infection", "PROBLEM", 211, 226], ["morbidity in infants", "PROBLEM", 287, 307], ["asthma", "OBSERVATION", 85, 91], ["Infection", "OBSERVATION", 217, 226], ["Infectious", "OBSERVATION", 237, 247], ["morbidity", "OBSERVATION", 287, 296]]], ["Worthy of note is that 11% of all infants are born premature that means 12.9 million infants per year worldwide.", [["infants", "ORGANISM", 34, 41], ["infants", "ORGANISM", 85, 92], ["infants", "SPECIES", 34, 41], ["infants", "SPECIES", 85, 92]]], ["Preterm infants carry a heightened risk of infectious ailments, both bacterial and viral.", [["infectious ailments", "DISEASE", 43, 62], ["infants", "ORGANISM", 8, 15], ["infants", "SPECIES", 8, 15], ["infectious ailments", "PROBLEM", 43, 62], ["both bacterial and viral", "PROBLEM", 64, 88], ["infectious", "OBSERVATION", 43, 53], ["bacterial", "OBSERVATION_MODIFIER", 69, 78], ["viral", "OBSERVATION", 83, 88]]], ["RTIs are a major cause of mortality and morbidity worldwide, particularly during the early years of life, with rhinovirus being the main pathogen.", [["RTIs", "DISEASE", 0, 4], ["rhinovirus", "ORGANISM", 111, 121], ["RTIs", "PROBLEM", 0, 4], ["mortality", "PROBLEM", 26, 35], ["morbidity", "PROBLEM", 40, 49], ["rhinovirus", "PROBLEM", 111, 121], ["mortality", "OBSERVATION", 26, 35], ["morbidity", "OBSERVATION", 40, 49], ["rhinovirus", "OBSERVATION", 111, 121]]], ["Although strict hygiene measures have been shown to reduce viral transmission, no definitive preventive measures have thus far been discovered for the effective control of this entity.", [["strict hygiene measures", "TREATMENT", 9, 32]]], ["Gut microbiota modulation with specific prebiotics, probiotics, or both could offer a cost-effective tool in the fight against RTIs, hopefully also in the developing world (Luoto et al., 2014; Rautava et al., 2009 ).MECHANISMS OF ACTIONCertain probiotic lactic acid bacteria strains, termed immunobiotics, can exert their beneficial effect on the host through their immunomodulatory activity.", [["Gut microbiota", "ANATOMY", 0, 14], ["RTIs", "DISEASE", 127, 131], ["lactic acid", "CHEMICAL", 254, 265], ["lactic acid", "CHEMICAL", 254, 265], ["lactic acid", "SIMPLE_CHEMICAL", 254, 265], ["specific prebiotics", "TREATMENT", 31, 50], ["probiotics", "TREATMENT", 52, 62], ["RTIs", "PROBLEM", 127, 131], ["ACTIONCertain probiotic", "TREATMENT", 230, 253], ["lactic acid bacteria strains", "PROBLEM", 254, 282]]], ["Immunobiotics have been used for the development of functional foods with the ability to stimulate mucosal immunity to provide protection in other mucosal sites distant from the gut.", [["mucosal", "ANATOMY", 99, 106], ["mucosal sites", "ANATOMY", 147, 160], ["gut", "ANATOMY", 178, 181], ["mucosal", "MULTI-TISSUE_STRUCTURE", 99, 106], ["mucosal sites", "MULTI-TISSUE_STRUCTURE", 147, 160], ["gut", "ORGANISM_SUBDIVISION", 178, 181], ["Immunobiotics", "TREATMENT", 0, 13], ["mucosal immunity", "TREATMENT", 99, 115], ["protection", "TREATMENT", 127, 137], ["gut", "ANATOMY", 178, 181]]], ["Studies have shown that oral administration of immunobiotics is able to increase resistance against respiratory viral infections.MECHANISMS OF ACTIONThe induction of antiviral cytokines such as interferons (IFNs), as well as proinflammatory cytokines and chemokines, upon antigen recognition in epithelial cells or underlying effector cells such as macrophages, dendritic cells, and neutrophils play a key role in virus infections by initiating cell-mediated viral elimination and adaptive immune responses.MECHANISMS OF ACTIONThe proposed mechanisms include the production of type I IFNs, the activity of NK cells, the generation of Th1 responses as well as the production of specific antibodies, and the regulation of inflammatory lung injury (Farid et al., 2011; Zelaya et al., 2014) .MECHANISMS OF ACTIONProbiotics mediate their antiviral effects against respiratory viruses, possibly by eliciting systemic immune responses via the gut or enhancing cellular immunity in the airways with increased activity of natural killer cells and macrophages.", [["oral", "ANATOMY", 24, 28], ["epithelial cells", "ANATOMY", 295, 311], ["effector cells", "ANATOMY", 326, 340], ["macrophages", "ANATOMY", 349, 360], ["dendritic cells", "ANATOMY", 362, 377], ["neutrophils", "ANATOMY", 383, 394], ["cell", "ANATOMY", 445, 449], ["NK cells", "ANATOMY", 606, 614], ["lung", "ANATOMY", 733, 737], ["gut", "ANATOMY", 936, 939], ["cellular", "ANATOMY", 953, 961], ["airways", "ANATOMY", 978, 985], ["natural killer cells", "ANATOMY", 1013, 1033], ["macrophages", "ANATOMY", 1038, 1049], ["immunobiotics", "CHEMICAL", 47, 60], ["respiratory viral infections", "DISEASE", 100, 128], ["infections", "DISEASE", 420, 430], ["lung injury", "DISEASE", 733, 744], ["respiratory viruses", "DISEASE", 859, 878], ["oral", "ORGANISM_SUBDIVISION", 24, 28], ["immunobiotics", "SIMPLE_CHEMICAL", 47, 60], ["interferons", "GENE_OR_GENE_PRODUCT", 194, 205], ["IFNs", "GENE_OR_GENE_PRODUCT", 207, 211], ["epithelial cells", "CELL", 295, 311], ["effector cells", "CELL", 326, 340], ["macrophages", "CELL", 349, 360], ["dendritic cells", "CELL", 362, 377], ["neutrophils", "CELL", 383, 394], ["cell", "CELL", 445, 449], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 577, 588], ["NK cells", "CELL", 606, 614], ["lung", "ORGAN", 733, 737], ["gut", "ORGANISM_SUBDIVISION", 936, 939], ["cellular", "CELL", 953, 961], ["airways", "MULTI-TISSUE_STRUCTURE", 978, 985], ["natural killer cells", "CELL", 1013, 1033], ["macrophages", "CELL", 1038, 1049], ["antiviral cytokines", "PROTEIN", 166, 185], ["interferons", "PROTEIN", 194, 205], ["IFNs", "PROTEIN", 207, 211], ["proinflammatory cytokines", "PROTEIN", 225, 250], ["chemokines", "PROTEIN", 255, 265], ["epithelial cells", "CELL_TYPE", 295, 311], ["effector cells", "CELL_TYPE", 326, 340], ["macrophages", "CELL_TYPE", 349, 360], ["dendritic cells", "CELL_TYPE", 362, 377], ["neutrophils", "CELL_TYPE", 383, 394], ["type I IFNs", "PROTEIN", 577, 588], ["NK cells", "CELL_TYPE", 606, 614], ["specific antibodies", "PROTEIN", 677, 696], ["natural killer cells", "CELL_TYPE", 1013, 1033], ["macrophages", "CELL_TYPE", 1038, 1049], ["Studies", "TEST", 0, 7], ["oral administration of immunobiotics", "TREATMENT", 24, 60], ["respiratory viral infections", "PROBLEM", 100, 128], ["antiviral cytokines", "TREATMENT", 166, 185], ["interferons (IFNs)", "TREATMENT", 194, 212], ["proinflammatory cytokines", "TREATMENT", 225, 250], ["chemokines", "TREATMENT", 255, 265], ["epithelial cells", "PROBLEM", 295, 311], ["underlying effector cells", "PROBLEM", 315, 340], ["macrophages", "PROBLEM", 349, 360], ["dendritic cells", "PROBLEM", 362, 377], ["neutrophils", "PROBLEM", 383, 394], ["virus infections", "PROBLEM", 414, 430], ["cell-mediated viral elimination", "TREATMENT", 445, 476], ["type I IFNs", "PROBLEM", 577, 588], ["NK cells", "PROBLEM", 606, 614], ["specific antibodies", "TEST", 677, 696], ["inflammatory lung injury", "PROBLEM", 720, 744], ["ACTIONProbiotics", "TREATMENT", 802, 818], ["their antiviral effects", "TREATMENT", 827, 850], ["respiratory viruses", "PROBLEM", 859, 878], ["enhancing cellular immunity in the airways", "PROBLEM", 943, 985], ["viral infections", "OBSERVATION", 112, 128], ["epithelial cells", "OBSERVATION", 295, 311], ["effector cells", "OBSERVATION", 326, 340], ["dendritic cells", "OBSERVATION", 362, 377], ["NK cells", "OBSERVATION", 606, 614], ["inflammatory", "OBSERVATION_MODIFIER", 720, 732], ["lung", "ANATOMY", 733, 737], ["injury", "OBSERVATION", 738, 744], ["antiviral", "OBSERVATION", 833, 842], ["viruses", "OBSERVATION", 871, 878], ["gut", "ANATOMY", 936, 939], ["enhancing", "OBSERVATION_MODIFIER", 943, 952], ["cellular immunity", "OBSERVATION", 953, 970], ["airways", "ANATOMY", 978, 985], ["increased", "OBSERVATION_MODIFIER", 991, 1000], ["activity", "OBSERVATION_MODIFIER", 1001, 1009], ["natural killer cells", "OBSERVATION", 1013, 1033]]], ["In the gut epithelial cells and/or antigen-presenting cells, probiotics are recognized by toll-like receptors and modulate cytokine expression patterns through epithelial cells and through underlying professional antigen-presenting cells, such as macrophages and dendritic cells.MECHANISMS OF ACTIONAs probiotics functions are strain dependent, different probiotic bacteria have been associated with variable stimuli to the human innate and adaptive immune system and comediate metabolic and immune homeostasis, with different levels of success.", [["gut epithelial cells", "ANATOMY", 7, 27], ["antigen-presenting cells", "ANATOMY", 35, 59], ["epithelial cells", "ANATOMY", 160, 176], ["cells", "ANATOMY", 232, 237], ["macrophages", "ANATOMY", 247, 258], ["dendritic cells", "ANATOMY", 263, 278], ["immune system", "ANATOMY", 450, 463], ["gut epithelial cells", "CELL", 7, 27], ["cells", "CELL", 54, 59], ["toll-like receptors", "GENE_OR_GENE_PRODUCT", 90, 109], ["epithelial cells", "CELL", 160, 176], ["cells", "CELL", 232, 237], ["macrophages", "CELL", 247, 258], ["dendritic cells", "CELL", 263, 278], ["human", "ORGANISM", 424, 429], ["immune system", "ANATOMICAL_SYSTEM", 450, 463], ["gut epithelial cells", "CELL_TYPE", 7, 27], ["antigen-presenting cells", "CELL_TYPE", 35, 59], ["toll-like receptors", "PROTEIN", 90, 109], ["cytokine", "PROTEIN", 123, 131], ["epithelial cells", "CELL_TYPE", 160, 176], ["professional antigen-presenting cells", "CELL_TYPE", 200, 237], ["macrophages", "CELL_TYPE", 247, 258], ["dendritic cells", "CELL_TYPE", 263, 278], ["human", "SPECIES", 424, 429], ["human", "SPECIES", 424, 429], ["presenting cells", "PROBLEM", 43, 59], ["probiotics", "TREATMENT", 61, 71], ["epithelial cells", "PROBLEM", 160, 176], ["presenting cells", "PROBLEM", 221, 237], ["macrophages", "PROBLEM", 247, 258], ["dendritic cells", "PROBLEM", 263, 278], ["ACTIONAs probiotics", "TREATMENT", 293, 312], ["strain dependent", "PROBLEM", 327, 343], ["different probiotic bacteria", "PROBLEM", 345, 373], ["variable stimuli", "PROBLEM", 400, 416], ["comediate metabolic and immune homeostasis", "PROBLEM", 468, 510], ["gut", "ANATOMY", 7, 10], ["epithelial cells", "OBSERVATION", 11, 27], ["cytokine expression", "OBSERVATION", 123, 142], ["epithelial cells", "OBSERVATION", 160, 176], ["macrophages", "ANATOMY", 247, 258], ["dendritic cells", "OBSERVATION", 263, 278], ["immune homeostasis", "OBSERVATION", 492, 510]]], ["In an experimental model of lung inflammation based on the administration of the artificial viral pathogenassociated molecular pattern, in order to mimic the proinflammatory and physiopathological consequences of RNA viral infections in the lung, after oral administration of Lactobacillus rhamnosus CRL 1505 and CRL 1506, the authors found that CRL 1506 had no effect, whereas CRL 1505 increased bronchoalveolar lavage concentrations of interleukin (IL)-6, IFN-\u03b3, and IL-10, and the number of pulmonary CD3 + CD4 + IFN-\u03b3 + T cells.", [["lung", "ANATOMY", 28, 32], ["lung", "ANATOMY", 241, 245], ["oral", "ANATOMY", 253, 257], ["bronchoalveolar lavage", "ANATOMY", 397, 419], ["pulmonary CD3 + CD4 + IFN-\u03b3 + T cells", "ANATOMY", 494, 531], ["lung inflammation", "DISEASE", 28, 45], ["viral infections", "DISEASE", 217, 233], ["Lactobacillus rhamnosus CRL 1505", "CHEMICAL", 276, 308], ["CRL 1506", "CHEMICAL", 313, 321], ["CRL 1506", "CHEMICAL", 346, 354], ["CRL 1505", "CHEMICAL", 378, 386], ["lung", "ORGAN", 28, 32], ["lung", "ORGAN", 241, 245], ["oral", "ORGANISM_SUBDIVISION", 253, 257], ["Lactobacillus rhamnosus CRL 1505", "ORGANISM", 276, 308], ["CRL 1506", "ORGANISM", 313, 321], ["CRL 1505", "SIMPLE_CHEMICAL", 378, 386], ["bronchoalveolar lavage", "ORGANISM_SUBSTANCE", 397, 419], ["interleukin (IL)-6", "GENE_OR_GENE_PRODUCT", 438, 456], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 458, 463], ["IL-10", "GENE_OR_GENE_PRODUCT", 469, 474], ["CD3", "GENE_OR_GENE_PRODUCT", 504, 507], ["CD4", "GENE_OR_GENE_PRODUCT", 510, 513], ["interleukin (IL)-6", "PROTEIN", 438, 456], ["IFN", "PROTEIN", 458, 461], ["IL-10", "PROTEIN", 469, 474], ["CD3", "PROTEIN", 504, 507], ["CD4", "PROTEIN", 510, 513], ["IFN", "PROTEIN", 516, 519], ["T cells", "CELL_TYPE", 524, 531], ["Lactobacillus rhamnosus", "SPECIES", 276, 299], ["Lactobacillus rhamnosus CRL 1505", "SPECIES", 276, 308], ["lung inflammation", "PROBLEM", 28, 45], ["the artificial viral pathogenassociated molecular pattern", "PROBLEM", 77, 134], ["RNA viral infections in the lung", "PROBLEM", 213, 245], ["oral administration of Lactobacillus rhamnosus", "TREATMENT", 253, 299], ["CRL", "TEST", 346, 349], ["bronchoalveolar lavage concentrations", "TEST", 397, 434], ["interleukin (IL)", "TEST", 438, 454], ["IFN", "TEST", 458, 461], ["IL", "TEST", 469, 471], ["pulmonary CD3", "TEST", 494, 507], ["CD4", "TEST", 510, 513], ["IFN", "PROBLEM", 516, 519], ["T cells", "PROBLEM", 524, 531], ["lung", "ANATOMY", 28, 32], ["inflammation", "OBSERVATION", 33, 45], ["RNA viral infections", "OBSERVATION", 213, 233], ["lung", "ANATOMY", 241, 245], ["increased", "OBSERVATION_MODIFIER", 387, 396], ["bronchoalveolar lavage", "OBSERVATION", 397, 419], ["pulmonary CD3", "ANATOMY", 494, 507]]], ["The preventive effects on the respiratory airway immunity induced by CRL 1505 suggested that, if the target of probiotic administration is to prevent recurrent URTIs, an appropriate strain of L. rhamnosus should be selected (Esposito et al., 2014) .", [["respiratory airway", "ANATOMY", 30, 48], ["CRL 1505", "CHEMICAL", 69, 77], ["URTIs", "DISEASE", 160, 165], ["airway", "MULTI-TISSUE_STRUCTURE", 42, 48], ["L. rhamnosus", "ORGANISM", 192, 204], ["L. rhamnosus", "SPECIES", 192, 204], ["L. rhamnosus", "SPECIES", 192, 204], ["probiotic administration", "TREATMENT", 111, 135], ["recurrent URTIs", "PROBLEM", 150, 165], ["L. rhamnosus", "PROBLEM", 192, 204], ["respiratory airway", "ANATOMY", 30, 48]]], ["Zelaya et al. (2014) demonstrated that the preventive treatment with the probiotic bacteria beneficially modulates the fine tune balance between clearing respiratory viruses (RSV and influenza virus) and controlling immune-coagulative responses in the lung, allowing normal lung function to be maintained in the face of a viral attack.", [["lung", "ANATOMY", 252, 256], ["lung", "ANATOMY", 274, 278], ["RSV", "ORGANISM", 175, 178], ["influenza virus", "ORGANISM", 183, 198], ["lung", "ORGAN", 252, 256], ["lung", "ORGAN", 274, 278], ["influenza virus", "SPECIES", 183, 198], ["RSV", "SPECIES", 175, 178], ["influenza virus", "SPECIES", 183, 198], ["the preventive treatment", "TREATMENT", 39, 63], ["the probiotic bacteria", "TREATMENT", 69, 91], ["clearing respiratory viruses", "PROBLEM", 145, 173], ["RSV", "PROBLEM", 175, 178], ["influenza virus", "PROBLEM", 183, 198], ["a viral attack", "PROBLEM", 320, 334], ["respiratory viruses", "OBSERVATION", 154, 173], ["lung", "ANATOMY", 252, 256], ["lung", "ANATOMY", 274, 278], ["viral attack", "OBSERVATION", 322, 334]]], ["Their data also pinpoint a crucial role for IL-10 in the immune protection induced by L. rhamnosus CRL 1505 during respiratory viral infections.MECHANISMS OF ACTIONMoreover, studies demonstrated that L. rhamnosus CRL 1505 is able to increase the number of CD3 + CD4 + IFN-\u03b3 + T cells in the gut, induce a mobilization of these cells into the respiratory mucosa, and improve local production of IFN-\u03b3 and the activity of lung antigen presenting cells (Villena et al., 2012) .MECHANISMS OF ACTIONRSV susceptible infants exhibit characteristics of Th2 responses and, in general, a Th2 immune response is favored during RSV infection, especially in younger hosts.", [["CD3 + CD4 + IFN-\u03b3 + T cells", "ANATOMY", 256, 283], ["gut", "ANATOMY", 291, 294], ["cells", "ANATOMY", 327, 332], ["respiratory mucosa", "ANATOMY", 342, 360], ["lung antigen presenting cells", "ANATOMY", 420, 449], ["L. rhamnosus CRL 1505", "CHEMICAL", 86, 107], ["respiratory viral infections", "DISEASE", 115, 143], ["CRL 1505", "CHEMICAL", 213, 221], ["RSV infection", "DISEASE", 616, 629], ["IL-10", "GENE_OR_GENE_PRODUCT", 44, 49], ["L. rhamnosus CRL 1505", "ORGANISM", 86, 107], ["L. rhamnosus CRL 1505", "ORGANISM", 200, 221], ["CD3", "GENE_OR_GENE_PRODUCT", 256, 259], ["CD4", "GENE_OR_GENE_PRODUCT", 262, 265], ["gut", "ORGAN", 291, 294], ["cells", "CELL", 327, 332], ["respiratory mucosa", "MULTI-TISSUE_STRUCTURE", 342, 360], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 394, 399], ["lung", "ORGAN", 420, 424], ["cells", "CELL", 444, 449], ["infants", "ORGANISM", 510, 517], ["Th2", "GENE_OR_GENE_PRODUCT", 545, 548], ["RSV", "ORGANISM", 616, 619], ["IL-10", "PROTEIN", 44, 49], ["CD3", "PROTEIN", 256, 259], ["CD4", "PROTEIN", 262, 265], ["IFN", "PROTEIN", 268, 271], ["T cells", "CELL_TYPE", 276, 283], ["IFN", "PROTEIN", 394, 397], ["lung antigen presenting cells", "CELL_TYPE", 420, 449], ["L. rhamnosus", "SPECIES", 86, 98], ["L. rhamnosus", "SPECIES", 200, 212], ["infants", "SPECIES", 510, 517], ["L. rhamnosus CRL 1505", "SPECIES", 86, 107], ["L. rhamnosus CRL 1505", "SPECIES", 200, 221], ["RSV", "SPECIES", 616, 619], ["IL", "TREATMENT", 44, 46], ["the immune protection", "TREATMENT", 53, 74], ["respiratory viral infections", "PROBLEM", 115, 143], ["CD3", "TEST", 256, 259], ["CD4", "TEST", 262, 265], ["IFN", "PROBLEM", 268, 271], ["T cells in the gut", "PROBLEM", 276, 294], ["a mobilization of these cells", "TREATMENT", 303, 332], ["IFN", "TREATMENT", 394, 397], ["ACTIONRSV susceptible infants", "PROBLEM", 488, 517], ["RSV infection", "PROBLEM", 616, 629], ["respiratory", "ANATOMY", 115, 126], ["viral infections", "OBSERVATION", 127, 143], ["gut", "ANATOMY", 291, 294], ["mobilization", "OBSERVATION", 305, 317], ["respiratory mucosa", "ANATOMY", 342, 360], ["lung", "ANATOMY", 420, 424], ["Th2 responses", "OBSERVATION", 545, 558], ["RSV infection", "OBSERVATION", 616, 629]]], ["Researchers showed that treatment of infant mice with L. rhamnosus CRL 1505 significantly improved the production of IFN-\u03b3 in response to RSV infection and increased the capacity of mice to clear the virus.", [["L. rhamnosus", "CHEMICAL", 54, 66], ["CRL 1505", "CHEMICAL", 67, 75], ["RSV infection", "DISEASE", 138, 151], ["mice", "ORGANISM", 44, 48], ["L. rhamnosus CRL 1505", "ORGANISM", 54, 75], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 117, 122], ["RSV", "ORGANISM", 138, 141], ["mice", "ORGANISM", 182, 186], ["IFN", "PROTEIN", 117, 120], ["\u03b3", "PROTEIN", 121, 122], ["infant", "SPECIES", 37, 43], ["mice", "SPECIES", 44, 48], ["L. rhamnosus", "SPECIES", 54, 66], ["mice", "SPECIES", 182, 186], ["mice", "SPECIES", 44, 48], ["L. rhamnosus", "SPECIES", 54, 66], ["RSV", "SPECIES", 138, 141], ["mice", "SPECIES", 182, 186], ["IFN", "PROBLEM", 117, 120], ["RSV infection", "PROBLEM", 138, 151], ["the virus", "PROBLEM", 196, 205], ["RSV infection", "OBSERVATION", 138, 151]]], ["Others demonstrated that L. rhamnosus CRL 1505 significantly reduces lung viral loads and tissue injuries after the challenge with RSV through its capacity to beneficially modulate proinflammatory IL-10 and Th1/Th2 balances in the respiratory tract (Chiba et al., 2013) .", [["lung", "ANATOMY", 69, 73], ["tissue", "ANATOMY", 90, 96], ["respiratory tract", "ANATOMY", 231, 248], ["L. rhamnosus", "CHEMICAL", 25, 37], ["CRL 1505", "CHEMICAL", 38, 46], ["tissue injuries", "DISEASE", 90, 105], ["L. rhamnosus CRL 1505", "ORGANISM", 25, 46], ["lung", "ORGAN", 69, 73], ["tissue", "TISSUE", 90, 96], ["RSV", "ORGANISM", 131, 134], ["IL-10", "GENE_OR_GENE_PRODUCT", 197, 202], ["Th1", "GENE_OR_GENE_PRODUCT", 207, 210], ["Th2", "GENE_OR_GENE_PRODUCT", 211, 214], ["respiratory tract", "ORGANISM_SUBDIVISION", 231, 248], ["L. rhamnosus", "SPECIES", 25, 37], ["L. rhamnosus CRL 1505", "SPECIES", 25, 46], ["RSV", "SPECIES", 131, 134], ["lung viral loads", "PROBLEM", 69, 85], ["tissue injuries", "PROBLEM", 90, 105], ["the challenge", "TREATMENT", 112, 125], ["RSV", "TREATMENT", 131, 134], ["proinflammatory IL", "TEST", 181, 199], ["Th1/Th2 balances", "TREATMENT", 207, 223], ["L.", "OBSERVATION_MODIFIER", 25, 27], ["rhamnosus", "OBSERVATION", 28, 37], ["lung", "ANATOMY", 69, 73], ["viral loads", "OBSERVATION", 74, 85], ["tissue", "OBSERVATION_MODIFIER", 90, 96], ["injuries", "OBSERVATION", 97, 105], ["proinflammatory", "OBSERVATION_MODIFIER", 181, 196], ["Th2 balances", "OBSERVATION", 211, 223], ["respiratory tract", "ANATOMY", 231, 248]]], ["Orally administered L. rhamnosus CRL 1505 induces a mobilization of CD3 + CD4 + IFN-\u03b3 + T cells from the gut into the respiratory mucosa and improve local production of IFN-\u03b3 (Villena et al., 2012) .MECHANISMS OF ACTIONThere is also evidence that intranasally administrated probiotics protect against respiratory virus infection by stimulating innate immune responses directly in the respiratory epithelium .", [["CD3 + CD4 + IFN-\u03b3 + T cells", "ANATOMY", 68, 95], ["gut", "ANATOMY", 105, 108], ["respiratory mucosa", "ANATOMY", 118, 136], ["intranasally", "ANATOMY", 247, 259], ["respiratory epithelium", "ANATOMY", 384, 406], ["L. rhamnosus", "CHEMICAL", 20, 32], ["CRL 1505", "CHEMICAL", 33, 41], ["respiratory virus infection", "DISEASE", 301, 328], ["L. rhamnosus CRL 1505", "ORGANISM", 20, 41], ["CD3", "GENE_OR_GENE_PRODUCT", 68, 71], ["CD4", "GENE_OR_GENE_PRODUCT", 74, 77], ["gut", "ORGAN", 105, 108], ["respiratory mucosa", "MULTI-TISSUE_STRUCTURE", 118, 136], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 169, 174], ["respiratory virus", "ORGANISM", 301, 318], ["respiratory epithelium", "TISSUE", 384, 406], ["CD3", "PROTEIN", 68, 71], ["CD4", "PROTEIN", 74, 77], ["IFN", "PROTEIN", 80, 83], ["T cells", "CELL_TYPE", 88, 95], ["IFN", "PROTEIN", 169, 172], ["L. rhamnosus", "SPECIES", 20, 32], ["L. rhamnosus CRL 1505", "SPECIES", 20, 41], ["respiratory virus", "SPECIES", 301, 318], ["CD3", "TEST", 68, 71], ["CD4", "TEST", 74, 77], ["IFN", "PROBLEM", 80, 83], ["T cells", "PROBLEM", 88, 95], ["intranasally administrated probiotics", "TREATMENT", 247, 284], ["respiratory virus infection", "PROBLEM", 301, 328], ["respiratory mucosa", "ANATOMY", 118, 136], ["respiratory epithelium", "ANATOMY", 384, 406]]], ["Sublingual L. rhamnosus protected against influenza virus infection by enhancing mucosal secretory IgA production, T and NK cell activity, and lung IL-12 levels (Lee et al., 2013) (18) .MECHANISMS OF ACTIONStrains of lactobacilli and bifidobacteria provide protection against respiratory virus infections also by inducing the synthesis of virus-specific immunoglobulins in the respiratory secretions and in serum (Kobayashi et al., 2011) .", [["mucosal", "ANATOMY", 81, 88], ["NK cell", "ANATOMY", 121, 128], ["lung", "ANATOMY", 143, 147], ["respiratory secretions", "ANATOMY", 377, 399], ["serum", "ANATOMY", 407, 412], ["influenza virus infection", "DISEASE", 42, 67], ["lactobacilli", "CHEMICAL", 217, 229], ["bifidobacteria", "CHEMICAL", 234, 248], ["respiratory virus infections", "DISEASE", 276, 304], ["Sublingual L. rhamnosus", "ORGANISM", 0, 23], ["influenza virus", "ORGANISM", 42, 57], ["mucosal", "MULTI-TISSUE_STRUCTURE", 81, 88], ["IgA", "GENE_OR_GENE_PRODUCT", 99, 102], ["T", "CELL", 115, 116], ["NK cell", "CELL", 121, 128], ["lung", "ORGAN", 143, 147], ["IL-12", "GENE_OR_GENE_PRODUCT", 148, 153], ["lactobacilli", "SIMPLE_CHEMICAL", 217, 229], ["bifidobacteria", "SIMPLE_CHEMICAL", 234, 248], ["respiratory virus", "ORGANISM", 276, 293], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 354, 369], ["serum", "ORGANISM_SUBSTANCE", 407, 412], ["IgA", "PROTEIN", 99, 102], ["virus-specific immunoglobulins", "PROTEIN", 339, 369], ["L. rhamnosus", "SPECIES", 11, 23], ["influenza virus", "SPECIES", 42, 57], ["L. rhamnosus", "SPECIES", 11, 23], ["influenza virus", "SPECIES", 42, 57], ["Sublingual L. rhamnosus", "TREATMENT", 0, 23], ["influenza virus infection", "PROBLEM", 42, 67], ["enhancing mucosal secretory IgA production", "PROBLEM", 71, 113], ["NK cell activity", "TEST", 121, 137], ["lung IL", "TEST", 143, 150], ["lactobacilli", "TREATMENT", 217, 229], ["bifidobacteria", "TREATMENT", 234, 248], ["protection", "TREATMENT", 257, 267], ["respiratory virus infections", "PROBLEM", 276, 304], ["the synthesis of virus", "PROBLEM", 322, 344], ["specific immunoglobulins in the respiratory secretions", "PROBLEM", 345, 399], ["rhamnosus", "OBSERVATION", 14, 23], ["enhancing", "OBSERVATION_MODIFIER", 71, 80], ["mucosal", "ANATOMY_MODIFIER", 81, 88], ["secretory", "OBSERVATION", 89, 98], ["IgA production", "OBSERVATION", 99, 113], ["NK cell activity", "OBSERVATION", 121, 137], ["lung", "ANATOMY", 143, 147], ["IL", "ANATOMY_MODIFIER", 148, 150], ["respiratory secretions", "ANATOMY", 377, 399]]], ["It was reported that the oral administration of the Bifidobacterium breve YIT 4064 protected mice against influenza virus challenge through an enhancement of the humoral immune response (Yasui et al., 1999) .MECHANISMS OF ACTIONPrebiotics are defined as nondigestible, but fermentable, foods that beneficially affect the host by selectively stimulating the growth and activity of one species or a limited number of species of bacteria in the colon.", [["oral", "ANATOMY", 25, 29], ["colon", "ANATOMY", 442, 447], ["Bifidobacterium breve", "CHEMICAL", 52, 73], ["YIT 4064", "CHEMICAL", 74, 82], ["influenza virus", "DISEASE", 106, 121], ["oral", "ORGANISM_SUBDIVISION", 25, 29], ["Bifidobacterium breve YIT 4064", "ORGANISM", 52, 82], ["mice", "ORGANISM", 93, 97], ["influenza virus", "ORGANISM", 106, 121], ["colon", "ORGAN", 442, 447], ["Bifidobacterium breve", "SPECIES", 52, 73], ["mice", "SPECIES", 93, 97], ["influenza virus", "SPECIES", 106, 121], ["Bifidobacterium breve YIT 4064", "SPECIES", 52, 82], ["mice", "SPECIES", 93, 97], ["the Bifidobacterium breve YIT", "TREATMENT", 48, 77], ["influenza virus challenge", "TREATMENT", 106, 131], ["ACTIONPrebiotics", "TREATMENT", 222, 238], ["one species", "PROBLEM", 380, 391], ["bacteria in the colon", "PROBLEM", 426, 447], ["humoral immune", "OBSERVATION", 162, 176], ["growth", "OBSERVATION_MODIFIER", 357, 363], ["bacteria", "OBSERVATION", 426, 434], ["colon", "ANATOMY", 442, 447]]], ["Synbiotics, defined as a combination of a probiotic and a prebiotic, aim to increase the survival and activity of proven probiotics in vivo, as well as stimulating indigenous bifidobacteria and lactobacilli (Quigley, 2010) .", [["Synbiotics", "DISEASE", 0, 10], ["bifidobacteria", "SIMPLE_CHEMICAL", 175, 189], ["lactobacilli", "SIMPLE_CHEMICAL", 194, 206], ["Synbiotics", "TREATMENT", 0, 10], ["a probiotic", "TREATMENT", 40, 51], ["a prebiotic", "TREATMENT", 56, 67], ["the survival", "TREATMENT", 85, 97], ["probiotics", "TREATMENT", 121, 131], ["lactobacilli", "TREATMENT", 194, 206]]], ["The exact mechanism involved in systemic immune modulation by prebiotics is currently unknown.", [["systemic immune modulation", "TREATMENT", 32, 58], ["prebiotics", "TREATMENT", 62, 72]]], ["They may influence host innate and T-cell responses during a respiratory viral infection by modulation of the Th1/Th2 responses in the lungs.", [["T-cell", "ANATOMY", 35, 41], ["lungs", "ANATOMY", 135, 140], ["respiratory viral infection", "DISEASE", 61, 88], ["host", "CELL", 19, 23], ["T-cell", "CELL", 35, 41], ["Th1", "GENE_OR_GENE_PRODUCT", 110, 113], ["Th2", "GENE_OR_GENE_PRODUCT", 114, 117], ["lungs", "ORGAN", 135, 140], ["a respiratory viral infection", "PROBLEM", 59, 88], ["respiratory", "ANATOMY", 61, 72], ["viral infection", "OBSERVATION", 73, 88], ["Th2 responses", "OBSERVATION", 114, 127], ["lungs", "ANATOMY", 135, 140]]], ["The innate immune system of the gut may be improved by prebiotics.", [["gut", "ANATOMY", 32, 35], ["gut", "ORGANISM_SUBDIVISION", 32, 35], ["prebiotics", "TREATMENT", 55, 65], ["gut", "ANATOMY", 32, 35], ["may be", "UNCERTAINTY", 36, 42], ["improved", "OBSERVATION_MODIFIER", 43, 51]]], ["Several studies report an increase in intestinal mucosal surface IgA but not serum concentration of IgA, IgG, and IgM.", [["intestinal mucosal surface", "ANATOMY", 38, 64], ["serum", "ANATOMY", 77, 82], ["intestinal mucosal", "ORGAN", 38, 56], ["IgA", "GENE_OR_GENE_PRODUCT", 65, 68], ["serum", "ORGANISM_SUBSTANCE", 77, 82], ["IgA", "GENE_OR_GENE_PRODUCT", 100, 103], ["IgG", "GENE_OR_GENE_PRODUCT", 105, 108], ["IgA", "PROTEIN", 65, 68], ["IgA", "PROTEIN", 100, 103], ["IgG", "PROTEIN", 105, 108], ["Several studies", "TEST", 0, 15], ["intestinal mucosal surface IgA", "TEST", 38, 68], ["serum concentration", "TEST", 77, 96], ["IgA", "TEST", 100, 103], ["IgG", "TEST", 105, 108], ["increase", "OBSERVATION_MODIFIER", 26, 34], ["intestinal mucosal", "ANATOMY", 38, 56]]], ["Studies showed that changes in the microbiota induced by dietary oligosaccharides increased viral clearance and systemic Th1 responses (Schijf et al., 2012) .", [["Studies", "TEST", 0, 7], ["changes in the microbiota", "PROBLEM", 20, 45], ["dietary oligosaccharides", "PROBLEM", 57, 81], ["viral clearance", "PROBLEM", 92, 107], ["increased", "OBSERVATION_MODIFIER", 82, 91], ["viral clearance", "OBSERVATION", 92, 107]]], ["Binding directly to the virus and inhibiting virus attachment to the host cell receptor.2.Adhesion of probiotics on the epithelial surface may block viral receptor sites in a nonspecific manner, or by competing for specific carbohydrate receptors.", [["cell", "ANATOMY", 74, 78], ["epithelial surface", "ANATOMY", 120, 138], ["carbohydrate", "CHEMICAL", 224, 236], ["host cell receptor", "GENE_OR_GENE_PRODUCT", 69, 87], ["epithelial surface", "TISSUE", 120, 138], ["carbohydrate receptors", "GENE_OR_GENE_PRODUCT", 224, 246], ["host cell receptor", "PROTEIN", 69, 87], ["viral receptor sites", "DNA", 149, 169], ["carbohydrate receptors", "PROTEIN", 224, 246], ["the virus", "PROBLEM", 20, 29], ["inhibiting virus attachment", "PROBLEM", 34, 61], ["Adhesion of probiotics", "TREATMENT", 90, 112], ["the epithelial surface", "TREATMENT", 116, 138], ["viral receptor sites", "TREATMENT", 149, 169], ["host cell receptor", "OBSERVATION", 69, 87], ["probiotics", "OBSERVATION", 102, 112], ["epithelial", "ANATOMY_MODIFIER", 120, 130], ["viral receptor sites", "OBSERVATION", 149, 169]]], ["Probiotics may induce mucosal regeneration: intestinal mucins may bind to viruses and inhibit their adherence to epithelial cells.", [["mucosal", "ANATOMY", 22, 29], ["intestinal mucins", "ANATOMY", 44, 61], ["epithelial cells", "ANATOMY", 113, 129], ["mucosal", "TISSUE", 22, 29], ["intestinal mucins", "GENE_OR_GENE_PRODUCT", 44, 61], ["epithelial cells", "CELL", 113, 129], ["epithelial cells", "CELL_TYPE", 113, 129], ["Probiotics", "TREATMENT", 0, 10], ["mucosal regeneration", "PROBLEM", 22, 42], ["intestinal mucins", "PROBLEM", 44, 61], ["viruses", "PROBLEM", 74, 81], ["epithelial cells", "PROBLEM", 113, 129], ["mucosal regeneration", "OBSERVATION", 22, 42], ["intestinal", "ANATOMY", 44, 54], ["epithelial cells", "OBSERVATION", 113, 129]]], ["Probiotics also show direct antimicrobial activity against viruses by producing antimicrobial substances.", [["Probiotics", "TREATMENT", 0, 10], ["viruses", "PROBLEM", 59, 66], ["antimicrobial substances", "TREATMENT", 80, 104], ["antimicrobial activity", "OBSERVATION_MODIFIER", 28, 50], ["antimicrobial substances", "OBSERVATION", 80, 104]]], ["Induction of low-grade nitric oxide (NO) production may have antiviral activities.", [["nitric oxide", "CHEMICAL", 23, 35], ["NO", "CHEMICAL", 37, 39], ["nitric oxide", "CHEMICAL", 23, 35], ["NO", "CHEMICAL", 37, 39], ["nitric oxide", "SIMPLE_CHEMICAL", 23, 35], ["NO", "SIMPLE_CHEMICAL", 37, 39], ["low-grade nitric oxide", "TREATMENT", 13, 35], ["antiviral activities", "TREATMENT", 61, 81], ["nitric oxide", "OBSERVATION", 23, 35]]], ["Modulation of immune responses through epithelial cells, macrophages, and dendritic cells (DCs).", [["epithelial cells", "ANATOMY", 39, 55], ["macrophages", "ANATOMY", 57, 68], ["dendritic cells", "ANATOMY", 74, 89], ["DCs", "ANATOMY", 91, 94], ["epithelial cells", "CELL", 39, 55], ["macrophages", "CELL", 57, 68], ["dendritic cells", "CELL", 74, 89], ["DCs", "CELL", 91, 94], ["epithelial cells", "CELL_TYPE", 39, 55], ["macrophages", "CELL_TYPE", 57, 68], ["dendritic cells", "CELL_TYPE", 74, 89], ["DCs", "CELL_TYPE", 91, 94], ["epithelial cells", "PROBLEM", 39, 55], ["macrophages", "PROBLEM", 57, 68], ["dendritic cells", "PROBLEM", 74, 89], ["immune responses", "OBSERVATION", 14, 30], ["epithelial cells", "OBSERVATION", 39, 55], ["macrophages", "OBSERVATION_MODIFIER", 57, 68], ["dendritic cells", "OBSERVATION", 74, 89]]], ["After activation, CD8 + T lymphocytes differentiate into cytotoxic T lymphocytes, which destroy virus-infected cells.", [["CD8 + T lymphocytes", "ANATOMY", 18, 37], ["T lymphocytes", "ANATOMY", 67, 80], ["cells", "ANATOMY", 111, 116], ["CD8", "GENE_OR_GENE_PRODUCT", 18, 21], ["cytotoxic T lymphocytes", "CELL", 57, 80], ["cells", "CELL", 111, 116], ["CD8", "PROTEIN", 18, 21], ["T lymphocytes", "CELL_TYPE", 24, 37], ["cytotoxic T lymphocytes", "CELL_TYPE", 57, 80], ["virus-infected cells", "CELL_TYPE", 96, 116], ["CD8", "TEST", 18, 21], ["cytotoxic T lymphocytes", "PROBLEM", 57, 80], ["infected cells", "PROBLEM", 102, 116], ["cytotoxic T lymphocytes", "OBSERVATION", 57, 80], ["infected cells", "OBSERVATION", 102, 116]]], ["CD4 + T lymphocytes differentiate into Th1 and Th2 cells.", [["CD4 + T lymphocytes", "ANATOMY", 0, 19], ["Th2 cells", "ANATOMY", 47, 56], ["CD4", "GENE_OR_GENE_PRODUCT", 0, 3], ["Th1", "CELL", 39, 42], ["Th2 cells", "CELL", 47, 56], ["CD4", "PROTEIN", 0, 3], ["T lymphocytes", "CELL_TYPE", 6, 19], ["Th1 and Th2 cells", "CELL_TYPE", 39, 56], ["CD4", "TEST", 0, 3], ["T lymphocytes", "TEST", 6, 19], ["T lymphocytes", "OBSERVATION", 6, 19], ["Th1", "ANATOMY", 39, 42], ["Th2 cells", "OBSERVATION", 47, 56]]], ["T-helper cells type 1 (Th1) activates phagocytes, promoting virus killing.10.Th2 cells induce proliferation of B-cells, which travel to the secondary lymphatic organs in mucosa-associated lymphoid tissue (MALT) and differentiate into immunoglobulin (Ig)-producing plasma cells, which may migrate back to the infection site.", [["T-helper cells", "ANATOMY", 0, 14], ["phagocytes", "ANATOMY", 38, 48], ["Th2 cells", "ANATOMY", 77, 86], ["B-cells", "ANATOMY", 111, 118], ["lymphatic organs", "ANATOMY", 150, 166], ["mucosa-associated lymphoid tissue", "ANATOMY", 170, 203], ["MALT", "ANATOMY", 205, 209], ["plasma cells", "ANATOMY", 264, 276], ["infection", "DISEASE", 308, 317], ["T-helper cells type 1", "GENE_OR_GENE_PRODUCT", 0, 21], ["Th1", "GENE_OR_GENE_PRODUCT", 23, 26], ["phagocytes", "CELL", 38, 48], ["Th2 cells", "CELL", 77, 86], ["B-cells", "CELL", 111, 118], ["lymphatic organs", "MULTI-TISSUE_STRUCTURE", 150, 166], ["mucosa-associated lymphoid tissue", "TISSUE", 170, 203], ["MALT", "CANCER", 205, 209], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 234, 248], ["Ig", "GENE_OR_GENE_PRODUCT", 250, 252], ["plasma cells", "CELL", 264, 276], ["T-helper cells type 1 (Th1) activates phagocytes", "CELL_TYPE", 0, 48], ["Th2 cells", "CELL_LINE", 77, 86], ["B-cells", "CELL_TYPE", 111, 118], ["immunoglobulin (Ig)-producing plasma cells", "CELL_TYPE", 234, 276], ["promoting virus killing", "PROBLEM", 50, 73], ["Th2 cells", "PROBLEM", 77, 86], ["proliferation of B-cells", "PROBLEM", 94, 118], ["the secondary lymphatic organs", "PROBLEM", 136, 166], ["mucosa-associated lymphoid tissue", "PROBLEM", 170, 203], ["plasma cells", "PROBLEM", 264, 276], ["the infection site", "PROBLEM", 304, 322], ["virus killing", "OBSERVATION", 60, 73], ["proliferation", "OBSERVATION_MODIFIER", 94, 107], ["B-cells", "OBSERVATION", 111, 118], ["secondary", "ANATOMY_MODIFIER", 140, 149], ["lymphatic organs", "ANATOMY", 150, 166], ["mucosa-associated lymphoid tissue", "OBSERVATION", 170, 203], ["plasma cells", "OBSERVATION", 264, 276], ["infection", "OBSERVATION", 308, 317]]], ["Secretory antibodies neutralize the virus (Lehtoranta et al., 2014b) .ChildrenYoung children have an average of 6-8 episodes of common cold per year and 10-15% have at least 12 infections per year.", [["infections", "DISEASE", 177, 187], ["children", "ORGANISM", 84, 92], ["Secretory antibodies", "PROTEIN", 0, 20], ["children", "SPECIES", 84, 92], ["Secretory antibodies", "TEST", 0, 20]]], ["Children in day care centers have 50% more colds due to more exposure to the virus.", [["colds", "DISEASE", 43, 48], ["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8], ["the virus", "PROBLEM", 73, 82]]], ["Asthma and allergic rhinitis may also increase the risk of viral infections.", [["Asthma", "DISEASE", 0, 6], ["allergic rhinitis", "DISEASE", 11, 28], ["viral infections", "DISEASE", 59, 75], ["Asthma", "PROBLEM", 0, 6], ["allergic rhinitis", "PROBLEM", 11, 28], ["viral infections", "PROBLEM", 59, 75], ["allergic rhinitis", "OBSERVATION", 11, 28], ["viral", "OBSERVATION_MODIFIER", 59, 64], ["infections", "OBSERVATION", 65, 75]]], ["There are several trials using probiotics in different age groups of children with or without specific underlying disorders.Preterm InfantsPremature infants lack initial maturation signals as a result of their immature immune system and disturbed development of their gut microbiota.", [["immune system", "ANATOMY", 219, 232], ["gut microbiota", "ANATOMY", 268, 282], ["children", "ORGANISM", 69, 77], ["infants", "ORGANISM", 149, 156], ["immune system", "ANATOMICAL_SYSTEM", 219, 232], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 268, 282], ["children", "SPECIES", 69, 77], ["Infants", "SPECIES", 132, 139], ["infants", "SPECIES", 149, 156], ["probiotics", "TREATMENT", 31, 41], ["specific underlying disorders", "PROBLEM", 94, 123], ["Premature infants", "PROBLEM", 139, 156], ["initial maturation signals", "PROBLEM", 162, 188], ["several", "OBSERVATION_MODIFIER", 10, 17]]], ["The probable causes include delayed introduction of enteral feeding, lack of fresh breast milk, frequent antibiotic use, and the environment of the neonatal intensive care unit.", [["breast milk", "ANATOMY", 83, 94], ["breast milk", "DISEASE", 83, 94], ["breast", "ORGANISM_SUBDIVISION", 83, 89], ["milk", "ORGANISM_SUBSTANCE", 90, 94], ["enteral feeding", "TREATMENT", 52, 67], ["fresh breast milk", "TREATMENT", 77, 94], ["frequent antibiotic use", "TREATMENT", 96, 119], ["probable causes include", "UNCERTAINTY", 4, 27]]], ["Consequently, these infants have more susceptibility to infections.Preterm InfantsIdentifying safe and cost-effective strategies for the prevention of RTIs are essential.", [["infections", "DISEASE", 56, 66], ["RTIs", "DISEASE", 151, 155], ["infants", "ORGANISM", 20, 27], ["infants", "SPECIES", 20, 27], ["Infants", "SPECIES", 75, 82], ["infections", "PROBLEM", 56, 66], ["safe and cost-effective strategies", "TREATMENT", 94, 128], ["RTIs", "PROBLEM", 151, 155], ["infections", "OBSERVATION", 56, 66]]], ["A randomized trial by Lo Skiavo et al. indicated that preterm infants who were treated orally with a liquid probiotic based on E. faecium L3 in a dose of 0.5 ml (5 \u00d7 10 3 CFU) 3 times a day for 14 days had a significant decrease of the frequency of infectious complications: 20.7% against 53.9% in the control group patients (Lo Skiavo et al., 2014) .Preterm InfantsIn a recent randomized, double-blind, placebo-controlled trial, 94 preterm infants (gestational age >32 and <36 weeks) were allocated to receive oral prebiotics (galacto-oligosaccharide and polydextrose mixture, 1:1), a probiotic (L. rhamnosus GG, ATCC 53103), or placebo between days 3 and 60 of life.", [["oral", "ANATOMY", 511, 515], ["infectious complications", "DISEASE", 249, 273], ["galacto-oligosaccharide", "CHEMICAL", 528, 551], ["polydextrose", "CHEMICAL", 556, 568], ["L. rhamnosus GG", "CHEMICAL", 597, 612], ["ATCC 53103", "CHEMICAL", 614, 624], ["infants", "ORGANISM", 62, 69], ["E. faecium L3", "ORGANISM", 127, 140], ["patients", "ORGANISM", 316, 324], ["infants", "ORGANISM", 441, 448], ["oral", "ORGANISM_SUBDIVISION", 511, 515], ["galacto-oligosaccharide", "SIMPLE_CHEMICAL", 528, 551], ["polydextrose", "SIMPLE_CHEMICAL", 556, 568], ["L. rhamnosus GG", "ORGANISM", 597, 612], ["ATCC 53103", "CELL", 614, 624], ["infants", "SPECIES", 62, 69], ["E. faecium", "SPECIES", 127, 137], ["patients", "SPECIES", 316, 324], ["infants", "SPECIES", 441, 448], ["L. rhamnosus", "SPECIES", 597, 609], ["E. faecium", "SPECIES", 127, 137], ["L. rhamnosus GG, ATCC 53103", "SPECIES", 597, 624], ["A randomized trial", "TREATMENT", 0, 18], ["a liquid probiotic", "TREATMENT", 99, 117], ["E. faecium L3", "TREATMENT", 127, 140], ["infectious complications", "PROBLEM", 249, 273], ["double-blind", "TREATMENT", 390, 402], ["placebo", "TREATMENT", 404, 411], ["oral prebiotics", "TREATMENT", 511, 526], ["galacto-oligosaccharide", "TREATMENT", 528, 551], ["polydextrose mixture", "TREATMENT", 556, 576], ["ATCC", "TEST", 614, 618], ["significant", "OBSERVATION_MODIFIER", 208, 219], ["decrease", "OBSERVATION_MODIFIER", 220, 228], ["infectious", "OBSERVATION_MODIFIER", 249, 259]]], ["A significantly lower incidence of RTIs was detected in infants receiving prebiotics (rate ratio, 0.24; 95% CI, 0.12-0.49; P < 0.001) or probiotics (RR, 0.50; 95% CI, 0.28-0.90; P 5.022) compared with those receiving placebo.", [["RTIs", "DISEASE", 35, 39], ["infants", "ORGANISM", 56, 63], ["infants", "SPECIES", 56, 63], ["RTIs", "PROBLEM", 35, 39], ["prebiotics", "TREATMENT", 74, 84], ["rate ratio", "TEST", 86, 96], ["CI", "TEST", 108, 110], ["P", "TEST", 123, 124], ["probiotics", "TEST", 137, 147], ["RR", "TEST", 149, 151], ["CI", "TEST", 163, 165], ["P", "TEST", 178, 179], ["placebo", "TREATMENT", 217, 224], ["significantly", "OBSERVATION_MODIFIER", 2, 15], ["lower", "OBSERVATION_MODIFIER", 16, 21], ["RTIs", "OBSERVATION", 35, 39]]], ["Also, the incidence of rhinovirus-induced episodes, which comprised 80% of all RTI episodes, was found to be significantly lower in the prebiotic (RR, 0.31; 95% CI, 0.14-0.66; P 5.003) and probiotic (RR, 0.49; 95% CI, 0.24-1.00; P 5.051) groups compared with the placebo group (Luoto et al., 2014) .Term InfantsInfants are considered prone to infections as their immune system is not fully developed.", [["rhinovirus", "DISEASE", 23, 33], ["RTI", "DISEASE", 79, 82], ["infections", "DISEASE", 343, 353], ["rhinovirus", "ORGANISM", 23, 33], ["Infants", "ORGANISM", 311, 318], ["Infants", "SPECIES", 304, 311], ["Infants", "SPECIES", 311, 318], ["rhinovirus", "PROBLEM", 23, 33], ["induced episodes", "PROBLEM", 34, 50], ["all RTI episodes", "PROBLEM", 75, 91], ["RR", "TEST", 147, 149], ["CI", "TEST", 161, 163], ["P", "TEST", 176, 177], ["probiotic", "TEST", 189, 198], ["RR", "TEST", 200, 202], ["CI", "TEST", 214, 216], ["infections", "PROBLEM", 343, 353], ["rhinovirus", "OBSERVATION", 23, 33], ["significantly", "OBSERVATION_MODIFIER", 109, 122], ["lower", "OBSERVATION_MODIFIER", 123, 128], ["infections", "OBSERVATION", 343, 353], ["not fully", "UNCERTAINTY", 380, 389]]], ["Infections are considered one of the leading causes of death in this age group.", [["Infections", "DISEASE", 0, 10], ["death", "DISEASE", 55, 60], ["Infections", "PROBLEM", 0, 10], ["death", "PROBLEM", 55, 60]]], ["Available, safe, and cost-effective ways to prevent infection can reduce infant morbidity and mortality.", [["infection", "DISEASE", 52, 61], ["infection", "PROBLEM", 52, 61], ["infant morbidity", "PROBLEM", 73, 89], ["infection", "OBSERVATION", 52, 61]]], ["In a randomized trial, infants requiring formula before the age of 2 months were recruited, and a formula supplemented with the probiotics L. rhamnosus GG and Bifidobacterium lactis Bb-12 or placebo was administered daily until the age of 12 months.", [["L. rhamnosus", "CHEMICAL", 139, 151], ["GG", "CHEMICAL", 152, 154], ["Bifidobacterium lactis Bb-12", "CHEMICAL", 159, 187], ["infants", "ORGANISM", 23, 30], ["L. rhamnosus GG", "ORGANISM", 139, 154], ["Bifidobacterium lactis Bb-12", "ORGANISM", 159, 187], ["infants", "SPECIES", 23, 30], ["L. rhamnosus", "SPECIES", 139, 151], ["Bifidobacterium lactis Bb", "SPECIES", 159, 184], ["L. rhamnosus", "SPECIES", 139, 151], ["Bifidobacterium lactis Bb-12", "SPECIES", 159, 187], ["formula", "TREATMENT", 41, 48], ["a formula supplemented", "TREATMENT", 96, 118], ["the probiotics L. rhamnosus GG", "TREATMENT", 124, 154], ["Bifidobacterium lactis Bb", "TREATMENT", 159, 184], ["placebo", "TREATMENT", 191, 198]]], ["Antibiotics were prescribed for 10 out of 32 (31%) infants receiving probiotics and 24 out of 40 (60%) infants receiving placebo.", [["infants", "ORGANISM", 51, 58], ["infants", "ORGANISM", 103, 110], ["infants", "SPECIES", 51, 58], ["infants", "SPECIES", 103, 110], ["Antibiotics", "TREATMENT", 0, 11], ["probiotics", "TREATMENT", 69, 79], ["placebo", "TREATMENT", 121, 128]]], ["During the first year of life, 9 out of 32 (28%) infants receiving probiotics and 22 out of 40 (55%) infants receiving placebo encountered recurrent respiratory infections (RR 0.51 (95 % CI 0.27, 0.95); P\u00bc0.022) (Rautava et al., 2009) .Term InfantsIn another RCT, 109 newborn infants were assigned randomly to receive Bifidobacterium animalis ssp. lactis BB-12 or placebo until the 8th month of life.", [["respiratory", "ANATOMY", 149, 160], ["respiratory infections", "DISEASE", 149, 171], ["lactis BB-12", "CHEMICAL", 348, 360], ["infants", "ORGANISM", 49, 56], ["infants", "ORGANISM", 101, 108], ["infants", "ORGANISM", 276, 283], ["Bifidobacterium animalis ssp", "ORGANISM", 318, 346], ["infants", "SPECIES", 49, 56], ["infants", "SPECIES", 101, 108], ["infants", "SPECIES", 276, 283], ["Bifidobacterium animalis", "SPECIES", 318, 342], ["lactis", "SPECIES", 348, 354], ["Bifidobacterium animalis ssp", "SPECIES", 318, 346], ["lactis", "SPECIES", 348, 354], ["probiotics", "TREATMENT", 67, 77], ["placebo", "TREATMENT", 119, 126], ["recurrent respiratory infections", "PROBLEM", 139, 171], ["RR", "TEST", 173, 175], ["CI", "TEST", 187, 189], ["P\u00bc", "TEST", 203, 205], ["Bifidobacterium animalis ssp", "TREATMENT", 318, 346], ["lactis BB", "TEST", 348, 357], ["placebo", "TREATMENT", 364, 371], ["respiratory", "ANATOMY", 149, 160], ["infections", "OBSERVATION", 161, 171]]], ["At the age of 8 months, BB-12 was recovered in the feces of 62% of the infants receiving the BB-1.", [["feces", "ANATOMY", 51, 56], ["BB-12", "GENE_OR_GENE_PRODUCT", 24, 29], ["feces", "ORGANISM", 51, 56], ["infants", "ORGANISM", 71, 78], ["BB-1", "GENE_OR_GENE_PRODUCT", 93, 97], ["infants", "SPECIES", 71, 78], ["BB", "TEST", 24, 26], ["the BB", "TEST", 89, 95]]], ["The infants receiving BB-12 were reported to have experienced fewer respiratory infections (65% vs. 94%; risk ratio 0.69; 95% CI 0.53, 0.89; P\u00bc0.014) than the control infants (Taipale et al., 2011) .", [["respiratory", "ANATOMY", 68, 79], ["respiratory infections", "DISEASE", 68, 90], ["infants", "ORGANISM", 4, 11], ["infants", "ORGANISM", 167, 174], ["infants", "SPECIES", 4, 11], ["infants", "SPECIES", 167, 174], ["BB", "TEST", 22, 24], ["fewer respiratory infections", "PROBLEM", 62, 90], ["risk ratio", "TEST", 105, 115], ["CI", "TEST", 126, 128], ["P", "TEST", 141, 142], ["respiratory", "ANATOMY", 68, 79], ["infections", "OBSERVATION", 80, 90]]], ["A combination of L. rhamnosus GG and B. animalis ssp. lactis Bb12 in healthy newborns reduced the occurrence of recurrent RTIs, but not the incidence of acute otitis media (Rautava et al., 2009 ).Healthy Children in Day Care and SchoolsChildren who attend day care centers are at 2-3 times greater risk for developing a respiratory tract infection than children who stay at home.", [["respiratory tract", "ANATOMY", 320, 337], ["RTIs", "DISEASE", 122, 126], ["otitis", "DISEASE", 159, 165], ["respiratory tract infection", "DISEASE", 320, 347], ["L. rhamnosus GG", "ORGANISM", 17, 32], ["B. animalis ssp", "ORGANISM", 37, 52], ["lactis Bb12", "ORGANISM", 54, 65], ["newborns", "ORGANISM", 77, 85], ["respiratory tract", "ORGANISM_SUBDIVISION", 320, 337], ["children", "ORGANISM", 353, 361], ["L. rhamnosus", "SPECIES", 17, 29], ["B. animalis", "SPECIES", 37, 48], ["lactis", "SPECIES", 54, 60], ["Children", "SPECIES", 204, 212], ["Children", "SPECIES", 236, 244], ["children", "SPECIES", 353, 361], ["L. rhamnosus", "SPECIES", 17, 29], ["B. animalis ssp", "SPECIES", 37, 52], ["lactis", "SPECIES", 54, 60], ["L. rhamnosus GG", "TREATMENT", 17, 32], ["B. animalis ssp", "PROBLEM", 37, 52], ["lactis", "TEST", 54, 60], ["recurrent RTIs", "PROBLEM", 112, 126], ["acute otitis media", "PROBLEM", 153, 171], ["a respiratory tract infection", "PROBLEM", 318, 347], ["L.", "OBSERVATION_MODIFIER", 17, 19], ["rhamnosus GG", "OBSERVATION", 20, 32], ["recurrent", "OBSERVATION_MODIFIER", 112, 121], ["RTIs", "OBSERVATION", 122, 126], ["acute", "OBSERVATION_MODIFIER", 153, 158], ["otitis", "OBSERVATION", 159, 165], ["respiratory tract", "ANATOMY", 320, 337], ["infection", "OBSERVATION", 338, 347]]], ["This has a significant financial burden for both the family and society.", [["significant", "OBSERVATION_MODIFIER", 11, 22], ["financial", "OBSERVATION_MODIFIER", 23, 32], ["burden", "OBSERVATION", 33, 39]]], ["Providing a reliable strategy for the prevention of day care infections is required (Hojsak et al., 2010a) .", [["infections", "DISEASE", 61, 71], ["a reliable strategy", "TREATMENT", 10, 29]]], ["Hojsak et al. conducted a RCT in 281 children who attend day care centers to receive Lactobacillus GG at a dose of 10 9 colony-forming units in 100 ml of a fermented milk product or placebo.", [["milk", "ANATOMY", 166, 170], ["Lactobacillus GG", "CHEMICAL", 85, 101], ["children", "ORGANISM", 37, 45], ["milk", "ORGANISM_SUBSTANCE", 166, 170], ["children", "SPECIES", 37, 45], ["Lactobacillus GG", "TREATMENT", 85, 101], ["a fermented milk product", "TREATMENT", 154, 178], ["placebo", "TREATMENT", 182, 189]]], ["Compared to the placebo group, children in the LGG group had a significantly reduced risk of URTIs, a reduced risk of RTIs lasting longer than 3 days, and a significantly lower number of days with respiratory symptoms (Hojsak et al., 2010b) .Healthy Children in Day Care and SchoolsIn a similar study of long-term consumption of probiotic milk containing Lactobacillus GG, there was also a relative reduction of 17% in the number of children suffering from respiratory infections with complications and a 19% relative reduction in antibiotic treatments for respiratory infection in the Lactobacillus group than placebo (Hatakka et al., 2001) .Healthy Children in Day Care and SchoolsIn another study, no differences were reported between the L. rhamnosus GG and the control groups in the respiratory symptom episodes (Kumpu et al., 2013) .Healthy Children in Day Care and SchoolsA meta-analysis of RCTs investigating the role of L. rhamnosus GG in the prevention of respiratory infections in children showed that L. rhamnosus GG has the potential to reduce the risk of URTIs, incidence of acute otitis media, and antibiotic use.", [["respiratory", "ANATOMY", 197, 208], ["milk", "ANATOMY", 339, 343], ["respiratory", "ANATOMY", 457, 468], ["respiratory", "ANATOMY", 557, 568], ["respiratory", "ANATOMY", 788, 799], ["respiratory", "ANATOMY", 966, 977], ["URTIs", "DISEASE", 93, 98], ["RTIs", "DISEASE", 118, 122], ["respiratory symptoms", "DISEASE", 197, 217], ["Lactobacillus GG", "CHEMICAL", 355, 371], ["respiratory infections", "DISEASE", 457, 479], ["respiratory infection", "DISEASE", 557, 578], ["Lactobacillus", "CHEMICAL", 586, 599], ["respiratory symptom", "DISEASE", 788, 807], ["L. rhamnosus GG", "CHEMICAL", 929, 944], ["respiratory infections", "DISEASE", 966, 988], ["L. rhamnosus", "CHEMICAL", 1013, 1025], ["GG", "CHEMICAL", 1026, 1028], ["URTIs", "DISEASE", 1069, 1074], ["otitis", "DISEASE", 1095, 1101], ["children", "ORGANISM", 31, 39], ["milk", "ORGANISM_SUBSTANCE", 339, 343], ["Lactobacillus GG", "SIMPLE_CHEMICAL", 355, 371], ["children", "ORGANISM", 433, 441], ["Lactobacillus", "SIMPLE_CHEMICAL", 586, 599], ["L. rhamnosus GG", "ORGANISM", 742, 757], ["L. rhamnosus GG", "ORGANISM", 929, 944], ["children", "ORGANISM", 992, 1000], ["L. rhamnosus GG", "ORGANISM", 1013, 1028], ["children", "SPECIES", 31, 39], ["Children", "SPECIES", 250, 258], ["children", "SPECIES", 433, 441], ["Children", "SPECIES", 651, 659], ["L. rhamnosus", "SPECIES", 742, 754], ["Children", "SPECIES", 847, 855], ["L. rhamnosus", "SPECIES", 929, 941], ["children", "SPECIES", 992, 1000], ["L. rhamnosus", "SPECIES", 1013, 1025], ["Lactobacillus GG", "SPECIES", 355, 371], ["L. rhamnosus", "SPECIES", 742, 754], ["L. rhamnosus", "SPECIES", 929, 941], ["L. rhamnosus", "SPECIES", 1013, 1025], ["URTIs", "PROBLEM", 93, 98], ["RTIs", "PROBLEM", 118, 122], ["respiratory symptoms", "PROBLEM", 197, 217], ["a similar study", "TEST", 285, 300], ["probiotic milk containing Lactobacillus GG", "TREATMENT", 329, 371], ["respiratory infections", "PROBLEM", 457, 479], ["complications", "PROBLEM", 485, 498], ["a 19% relative reduction", "TREATMENT", 503, 527], ["antibiotic treatments", "TREATMENT", 531, 552], ["respiratory infection", "PROBLEM", 557, 578], ["another study", "TEST", 686, 699], ["the respiratory symptom episodes", "PROBLEM", 784, 816], ["RCTs", "TREATMENT", 898, 902], ["L. rhamnosus GG", "TREATMENT", 929, 944], ["respiratory infections", "PROBLEM", 966, 988], ["L. rhamnosus GG", "PROBLEM", 1013, 1028], ["URTIs", "PROBLEM", 1069, 1074], ["acute otitis media", "PROBLEM", 1089, 1107], ["antibiotic use", "TREATMENT", 1113, 1127], ["URTIs", "OBSERVATION", 93, 98], ["RTIs", "OBSERVATION", 118, 122], ["long-term", "OBSERVATION_MODIFIER", 304, 313], ["Lactobacillus GG", "OBSERVATION", 355, 371], ["relative", "OBSERVATION_MODIFIER", 390, 398], ["reduction", "OBSERVATION_MODIFIER", 399, 408], ["respiratory", "ANATOMY", 457, 468], ["infections", "OBSERVATION", 469, 479], ["reduction", "OBSERVATION_MODIFIER", 518, 527], ["infection", "OBSERVATION", 569, 578], ["rhamnosus GG", "OBSERVATION", 745, 757], ["respiratory", "ANATOMY", 788, 799], ["respiratory", "ANATOMY", 966, 977], ["infections", "OBSERVATION", 978, 988], ["URTIs", "OBSERVATION", 1069, 1074], ["acute", "OBSERVATION_MODIFIER", 1089, 1094], ["otitis", "OBSERVATION", 1095, 1101]]], ["There were no significant differences between the L. rhamnosus GG and the control groups in the incidence of lower RTIs (Liu et al., 2013) .Healthy Children in Day Care and SchoolsOther researchers used strains other than L. rhamnosus GG.", [["RTIs", "DISEASE", 115, 119], ["L. rhamnosus GG", "ORGANISM", 50, 65], ["L. rhamnosus GG", "ORGANISM", 222, 237], ["L. rhamnosus", "SPECIES", 50, 62], ["Children", "SPECIES", 148, 156], ["L. rhamnosus", "SPECIES", 222, 234], ["L. rhamnosus", "SPECIES", 50, 62], ["L. rhamnosus", "SPECIES", 222, 234], ["the L. rhamnosus GG", "TREATMENT", 46, 65], ["no", "UNCERTAINTY", 11, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["differences", "OBSERVATION_MODIFIER", 26, 37], ["rhamnosus GG", "OBSERVATION", 53, 65], ["lower RTIs", "ANATOMY", 109, 119], ["rhamnosus GG", "OBSERVATION", 225, 237]]], ["The preschoolers receiving the L. casei rhamnosus treatment had 0.30 times lower odds of doctor-diagnosed viral infection than the control group (Lin et al., 2009) .", [["L. casei rhamnosus", "CHEMICAL", 31, 49], ["viral infection", "DISEASE", 106, 121], ["L. casei rhamnosus", "ORGANISM", 31, 49], ["preschoolers", "SPECIES", 4, 16], ["L. casei rhamnosus", "SPECIES", 31, 49], ["L. casei rhamnosus", "SPECIES", 31, 49], ["the L. casei rhamnosus treatment", "TREATMENT", 27, 59], ["viral infection", "PROBLEM", 106, 121], ["viral infection", "OBSERVATION", 106, 121]]], ["In healthy infants, treatment with L. reuteri SD 112 or B. animalis ssp. lactis Bb12 was not effective in reducing the incidence or duration of RTIs.", [["RTIs", "DISEASE", 144, 148], ["infants", "ORGANISM", 11, 18], ["L. reuteri SD 112", "ORGANISM", 35, 52], ["B. animalis ssp", "ORGANISM", 56, 71], ["lactis Bb12", "ORGANISM", 73, 84], ["infants", "SPECIES", 11, 18], ["L. reuteri", "SPECIES", 35, 45], ["B. animalis", "SPECIES", 56, 67], ["lactis", "SPECIES", 73, 79], ["L. reuteri SD 112", "SPECIES", 35, 52], ["B. animalis ssp", "SPECIES", 56, 71], ["lactis", "SPECIES", 73, 79], ["lactis Bb12", "TEST", 73, 84], ["RTIs", "PROBLEM", 144, 148]]], ["L. reuteri SD 112 resulted in fewer days of absence from day care due to illness, lower number of days with fever, and fewer clinical visits (Niittynen et al., 2012; Weizman et al., 2005) .Healthy Children in Day Care and SchoolsSome trials investigated the effectiveness of combinations of probiotics or combinations of probiotics and prebiotics (synbiotics) on URTIs.", [["illness", "DISEASE", 73, 80], ["fever", "DISEASE", 108, 113], ["URTIs", "DISEASE", 363, 368], ["L. reuteri SD 112", "ORGANISM", 0, 17], ["synbiotics", "SIMPLE_CHEMICAL", 348, 358], ["L. reuteri", "SPECIES", 0, 10], ["Children", "SPECIES", 197, 205], ["L. reuteri SD 112", "SPECIES", 0, 17], ["illness", "PROBLEM", 73, 80], ["fever", "PROBLEM", 108, 113], ["probiotics", "TREATMENT", 291, 301], ["probiotics", "TREATMENT", 321, 331], ["prebiotics (synbiotics", "TREATMENT", 336, 358], ["URTIs", "PROBLEM", 363, 368]]], ["A combination of L. rhamnosus GG, L. rhamnosus LC 705, B. breve Bb99, and P. freudenreichii ssp. shermanii JS children reduced the occurrence of recurrent RTIs (Hatakka et al., 2007) .", [["RTIs", "DISEASE", 155, 159], ["L. rhamnosus GG", "ORGANISM", 17, 32], ["L. rhamnosus LC 705", "ORGANISM", 34, 53], ["B. breve Bb99", "ORGANISM", 55, 68], ["P. freudenreichii ssp", "ORGANISM", 74, 95], ["shermanii JS children", "ORGANISM", 97, 118], ["L. rhamnosus", "SPECIES", 17, 29], ["L. rhamnosus", "SPECIES", 34, 46], ["B. breve", "SPECIES", 55, 63], ["P. freudenreichii ssp", "SPECIES", 74, 95], ["shermanii", "SPECIES", 97, 106], ["children", "SPECIES", 110, 118], ["L. rhamnosus", "SPECIES", 17, 29], ["L. rhamnosus LC 705", "SPECIES", 34, 53], ["B. breve Bb99", "SPECIES", 55, 68], ["P. freudenreichii ssp", "SPECIES", 74, 95], ["P. freudenreichii ssp", "PROBLEM", 74, 95], ["recurrent RTIs", "PROBLEM", 145, 159], ["L.", "OBSERVATION_MODIFIER", 17, 19], ["rhamnosus GG", "OBSERVATION", 20, 32], ["freudenreichii ssp", "OBSERVATION", 77, 95]]], ["A combination of L. acidophilus and B. bifidum in healthy children reduced the duration of acute RTI symptoms and school absence (Liu et al., 2013) .Healthy Children in Day Care and SchoolsHowever, a combination of 12 bacteria including Lactobacillus, Bifidobacterium, Streptococcus, and Enterococcus was not able to reduce the number of RTIs (Lin et al., 2009) .", [["RTI", "DISEASE", 97, 100], ["Lactobacillus", "CHEMICAL", 237, 250], ["Enterococcus", "CHEMICAL", 288, 300], ["RTIs", "DISEASE", 338, 342], ["L. acidophilus", "ORGANISM", 17, 31], ["B. bifidum", "ORGANISM", 36, 46], ["children", "ORGANISM", 58, 66], ["Lactobacillus", "SIMPLE_CHEMICAL", 237, 250], ["L. acidophilus", "SPECIES", 17, 31], ["B. bifidum", "SPECIES", 36, 46], ["children", "SPECIES", 58, 66], ["Children", "SPECIES", 157, 165], ["L. acidophilus", "SPECIES", 17, 31], ["B. bifidum", "SPECIES", 36, 46], ["L. acidophilus", "TREATMENT", 17, 31], ["acute RTI symptoms", "PROBLEM", 91, 109], ["12 bacteria", "PROBLEM", 215, 226], ["Lactobacillus", "PROBLEM", 237, 250], ["Bifidobacterium", "PROBLEM", 252, 267], ["Streptococcus", "PROBLEM", 269, 282], ["Enterococcus", "PROBLEM", 288, 300], ["L. acidophilus", "OBSERVATION", 17, 31], ["Bifidobacterium", "ANATOMY", 252, 267], ["Enterococcus", "OBSERVATION", 288, 300]]], ["A mixture of four probiotic species (L. rhamnosus GG and LC 705, B. breve Bb99, and Propionibacterium freudenreichii ssp. shermanii) prescribed to pregnant mothers carrying infants at high risk for allergy for 4 weeks before delivery and infants received a synbiotic containing the same probiotics with 0.8 g of galacto-oligosaccharides, daily for 6 months after birth.", [["shermanii", "CHEMICAL", 122, 131], ["allergy", "DISEASE", 198, 205], ["galacto-oligosaccharides", "CHEMICAL", 312, 336], ["L. rhamnosus GG", "ORGANISM", 37, 52], ["LC 705", "ORGANISM", 57, 63], ["B. breve Bb99", "ORGANISM", 65, 78], ["Propionibacterium freudenreichii ssp", "ORGANISM", 84, 120], ["shermanii", "ORGANISM", 122, 131], ["mothers", "ORGANISM", 156, 163], ["infants", "ORGANISM", 173, 180], ["infants", "ORGANISM", 238, 245], ["galacto-oligosaccharides", "SIMPLE_CHEMICAL", 312, 336], ["L. rhamnosus", "SPECIES", 37, 49], ["B. breve Bb99", "SPECIES", 65, 78], ["Propionibacterium freudenreichii", "SPECIES", 84, 116], ["ssp", "SPECIES", 117, 120], ["shermanii", "SPECIES", 122, 131], ["infants", "SPECIES", 173, 180], ["infants", "SPECIES", 238, 245], ["L. rhamnosus", "SPECIES", 37, 49], ["B. breve Bb99", "SPECIES", 65, 78], ["Propionibacterium freudenreichii ssp", "SPECIES", 84, 120], ["shermanii", "SPECIES", 122, 131], ["LC", "TEST", 57, 59], ["B. breve Bb99", "TEST", 65, 78], ["Propionibacterium freudenreichii ssp", "PROBLEM", 84, 120], ["allergy", "PROBLEM", 198, 205], ["delivery", "TREATMENT", 225, 233], ["a synbiotic", "TREATMENT", 255, 266], ["the same probiotics", "TREATMENT", 278, 297], ["galacto-oligosaccharides", "TREATMENT", 312, 336]]], ["During the 6-month intervention, antibiotics were prescribed less often in the synbiotic group than in the placebo group (23% vs. 28%).", [["intervention", "TREATMENT", 19, 31], ["antibiotics", "TREATMENT", 33, 44]]], ["Throughout the 2 years of follow-up period, respiratory infections occurred less frequently in the synbiotic group than placebo (mean: 3.7 vs. 4.2 infections) (Kukkonen et al., 2008) .Healthy Children in Day Care and SchoolsSome studies showed that using a probiotic mixture might be more effective, although efficacy of the probiotic mixtures may be reduced by inhibitory effects between different probiotic strains (Kianifar et al., 2014) .", [["respiratory", "ANATOMY", 44, 55], ["respiratory infections", "DISEASE", 44, 66], ["infections", "DISEASE", 147, 157], ["Children", "SPECIES", 192, 200], ["respiratory infections", "PROBLEM", 44, 66], ["infections", "PROBLEM", 147, 157], ["Some studies", "TEST", 224, 236], ["a probiotic mixture", "TREATMENT", 255, 274], ["the probiotic mixtures", "TREATMENT", 321, 343], ["respiratory", "ANATOMY", 44, 55], ["infections", "OBSERVATION", 56, 66]]], ["Viral respiratory infections are the most common cause of recurrent wheezing episodes and asthma exacerbations in children.", [["respiratory", "ANATOMY", 6, 17], ["Viral respiratory infections", "DISEASE", 0, 28], ["wheezing", "DISEASE", 68, 76], ["asthma exacerbations", "DISEASE", 90, 110], ["children", "ORGANISM", 114, 122], ["children", "SPECIES", 114, 122], ["Viral respiratory infections", "PROBLEM", 0, 28], ["recurrent wheezing episodes", "PROBLEM", 58, 85], ["asthma exacerbations", "PROBLEM", 90, 110], ["respiratory", "ANATOMY", 6, 17], ["infections", "OBSERVATION", 18, 28], ["most common", "OBSERVATION_MODIFIER", 37, 48], ["recurrent", "OBSERVATION_MODIFIER", 58, 67], ["wheezing", "OBSERVATION", 68, 76], ["asthma", "OBSERVATION", 90, 96]]], ["Probiotics may be beneficial in these children by lowering the viral infections in addition to their antiinflammatory effects.", [["viral infections", "DISEASE", 63, 79], ["children", "ORGANISM", 38, 46], ["children", "SPECIES", 38, 46], ["Probiotics", "TREATMENT", 0, 10], ["the viral infections", "PROBLEM", 59, 79], ["their antiinflammatory effects", "TREATMENT", 95, 125], ["viral infections", "OBSERVATION", 63, 79]]], ["In a pilot study, the authors concluded that laser acupuncture and probiotics (a suspension of E. faecalis) has a beneficial clinical effect on bronchial hyperreactivity in school-age children with intermittent or mild persistent asthma and might be helpful in the prevention of acute respiratory exacerbations (Stockert et al., 2007) .Healthy Children in Day Care and SchoolsIn a double-blind, placebo-controlled, multicenter trial, 90 infants with atopic dermatitis, age <7 months, were randomized to receive an extensively hydrolyzed formula with B. breve M-16V and a galacto-/fructo-oligosaccharide mixture or the same formula without synbiotics during 12 weeks.", [["bronchial", "ANATOMY", 144, 153], ["respiratory", "ANATOMY", 285, 296], ["bronchial hyperreactivity", "DISEASE", 144, 169], ["asthma", "DISEASE", 230, 236], ["respiratory exacerbations", "DISEASE", 285, 310], ["atopic dermatitis", "DISEASE", 450, 467], ["B. breve M-16V", "CHEMICAL", 550, 564], ["galacto-/fructo-oligosaccharide", "CHEMICAL", 571, 602], ["E. faecalis", "ORGANISM", 95, 106], ["bronchial", "MULTI-TISSUE_STRUCTURE", 144, 153], ["children", "ORGANISM", 184, 192], ["infants", "ORGANISM", 437, 444], ["B. breve M-16V", "SIMPLE_CHEMICAL", 550, 564], ["galacto-", "SIMPLE_CHEMICAL", 571, 579], ["fructo-oligosaccharide", "SIMPLE_CHEMICAL", 580, 602], ["E. faecalis", "SPECIES", 95, 106], ["children", "SPECIES", 184, 192], ["Children", "SPECIES", 344, 352], ["infants", "SPECIES", 437, 444], ["B. breve", "SPECIES", 550, 558], ["E. faecalis", "SPECIES", 95, 106], ["B. breve M-16V", "SPECIES", 550, 564], ["a pilot study", "TEST", 3, 16], ["laser acupuncture", "TREATMENT", 45, 62], ["probiotics", "TREATMENT", 67, 77], ["a suspension of E. faecalis", "TREATMENT", 79, 106], ["bronchial hyperreactivity", "PROBLEM", 144, 169], ["intermittent or mild persistent asthma", "PROBLEM", 198, 236], ["acute respiratory exacerbations", "PROBLEM", 279, 310], ["atopic dermatitis", "PROBLEM", 450, 467], ["an extensively hydrolyzed formula", "TREATMENT", 511, 544], ["a galacto-/fructo-oligosaccharide mixture", "TREATMENT", 569, 610], ["synbiotics", "TREATMENT", 639, 649], ["bronchial", "ANATOMY", 144, 153], ["hyperreactivity", "OBSERVATION", 154, 169], ["mild", "OBSERVATION_MODIFIER", 214, 218], ["persistent", "OBSERVATION_MODIFIER", 219, 229], ["asthma", "OBSERVATION", 230, 236], ["acute", "OBSERVATION_MODIFIER", 279, 284], ["respiratory", "ANATOMY", 285, 296], ["exacerbations", "OBSERVATION", 297, 310]]], ["After 1 year, the prevalence of \"frequent wheezing\" and \"wheezing and/or noisy breathing apart from colds\" was significantly lower in the synbiotic than in the placebo group (13.9% vs. 34.2%).", [["wheezing", "DISEASE", 42, 50], ["wheezing", "DISEASE", 57, 65], ["colds", "DISEASE", 100, 105], ["\"frequent wheezing\"", "PROBLEM", 32, 51], ["\"wheezing", "PROBLEM", 56, 65], ["noisy breathing", "PROBLEM", 73, 88], ["colds", "PROBLEM", 100, 105], ["frequent", "OBSERVATION_MODIFIER", 33, 41], ["wheezing", "OBSERVATION", 42, 50], ["significantly", "OBSERVATION_MODIFIER", 111, 124], ["lower", "OBSERVATION_MODIFIER", 125, 130]]], ["Significantly less children in the synbiotic than in the placebo group (5.6% vs. 25.6%) had started to use asthma medication (van der Aa et al., 2011) .Healthy Children in Day Care and SchoolsOM-85 BV (Broncho-Vaxom) is an immunostimulant extracted from eight bacterial pathogens of the upper respiratory tract.", [["upper respiratory tract", "ANATOMY", 287, 310], ["asthma", "DISEASE", 107, 113], ["SchoolsOM-85 BV", "CHEMICAL", 185, 200], ["Broncho-Vaxom", "CHEMICAL", 202, 215], ["children", "ORGANISM", 19, 27], ["BV", "ORGANISM_SUBSTANCE", 198, 200], ["Broncho-Vaxom", "SIMPLE_CHEMICAL", 202, 215], ["upper respiratory", "ORGANISM_SUBDIVISION", 287, 304], ["tract", "ORGANISM_SUBDIVISION", 305, 310], ["children", "SPECIES", 19, 27], ["Children", "SPECIES", 160, 168], ["asthma medication", "TREATMENT", 107, 124], ["SchoolsOM", "TEST", 185, 194], ["Broncho-Vaxom", "TREATMENT", 202, 215], ["an immunostimulant", "TREATMENT", 220, 238], ["bacterial pathogens", "OBSERVATION", 260, 279], ["upper", "ANATOMY_MODIFIER", 287, 292], ["respiratory tract", "ANATOMY", 293, 310]]], ["Several randomized clinical trials have shown that OM-85 BV can reduce the number of URTIs by 25-50% compared with placebo in adults and children with a history of recurrence.", [["OM-85 BV", "CHEMICAL", 51, 59], ["URTIs", "DISEASE", 85, 90], ["BV", "ORGANISM_SUBSTANCE", 57, 59], ["children", "ORGANISM", 137, 145], ["children", "SPECIES", 137, 145], ["OM", "TEST", 51, 53], ["URTIs", "PROBLEM", 85, 90], ["recurrence", "PROBLEM", 164, 174], ["URTIs", "OBSERVATION", 85, 90], ["recurrence", "OBSERVATION", 164, 174]]], ["Razi et al. (2010) showed that after using 1 capsule of OM-85 per day for 10 days each month for 3 consecutive months caused a 37.9% reduction in wheezing attack in the group given OM-85 BV compared with the group given placebo.", [["wheezing", "DISEASE", 146, 154], ["OM-85 BV", "CHEMICAL", 181, 189], ["BV", "ORGANISM_SUBSTANCE", 187, 189], ["wheezing attack", "PROBLEM", 146, 161], ["placebo", "TREATMENT", 220, 227], ["wheezing", "OBSERVATION", 146, 154]]], ["A recent study on 62 children with asthma and recurrent respiratory infection showed that OM-85 reduces the occurrence of acute respiratory infection and improves serum levels of human beta-defensins 1(hBD-1), IgA, and IgG (Liao and Zhang, 2014) .Adults and the ElderlyDespite great advances in medicine, viral infections such as the common cold continue to cause a considerable economic burden, due to loss in productivity and high medical costs.", [["respiratory", "ANATOMY", 56, 67], ["respiratory", "ANATOMY", 128, 139], ["serum", "ANATOMY", 163, 168], ["asthma", "DISEASE", 35, 41], ["respiratory infection", "DISEASE", 56, 77], ["OM-85", "CHEMICAL", 90, 95], ["respiratory infection", "DISEASE", 128, 149], ["viral infections", "DISEASE", 305, 321], ["children", "ORGANISM", 21, 29], ["OM-85", "SIMPLE_CHEMICAL", 90, 95], ["serum", "ORGANISM_SUBSTANCE", 163, 168], ["human", "ORGANISM", 179, 184], ["beta-defensins 1", "GENE_OR_GENE_PRODUCT", 185, 201], ["hBD-1", "GENE_OR_GENE_PRODUCT", 202, 207], ["IgA", "GENE_OR_GENE_PRODUCT", 210, 213], ["IgG", "GENE_OR_GENE_PRODUCT", 219, 222], ["human beta-defensins 1", "PROTEIN", 179, 201], ["hBD", "PROTEIN", 202, 205], ["IgA", "PROTEIN", 210, 213], ["IgG", "PROTEIN", 219, 222], ["children", "SPECIES", 21, 29], ["human", "SPECIES", 179, 184], ["Adults", "SPECIES", 247, 253], ["human", "SPECIES", 179, 184], ["A recent study", "TEST", 0, 14], ["asthma", "PROBLEM", 35, 41], ["recurrent respiratory infection", "PROBLEM", 46, 77], ["OM", "TEST", 90, 92], ["acute respiratory infection", "PROBLEM", 122, 149], ["serum levels", "TEST", 163, 175], ["human beta-defensins", "TEST", 179, 199], ["hBD", "TEST", 202, 205], ["IgA", "TEST", 210, 213], ["medicine", "TREATMENT", 295, 303], ["viral infections", "PROBLEM", 305, 321], ["a considerable economic burden", "PROBLEM", 364, 394], ["loss in productivity", "PROBLEM", 403, 423], ["high medical costs", "PROBLEM", 428, 446], ["respiratory", "ANATOMY", 56, 67], ["infection", "OBSERVATION", 68, 77], ["acute", "OBSERVATION_MODIFIER", 122, 127], ["respiratory", "ANATOMY", 128, 139], ["infection", "OBSERVATION", 140, 149], ["viral infections", "OBSERVATION", 305, 321], ["considerable", "OBSERVATION_MODIFIER", 366, 378], ["economic", "OBSERVATION_MODIFIER", 379, 387], ["burden", "OBSERVATION", 388, 394], ["high", "OBSERVATION_MODIFIER", 428, 432]]], ["In a randomized trial, 479 healthy adults (aged 18-67) were supplemented daily with vitamins and minerals with or without the probiotic bacteria (Lactobacillus gasseri, Bifidobacterium longum, B. bifidum) for at least 3 months during two winter/spring periods.", [["vitamins and minerals", "CHEMICAL", 84, 105], ["Lactobacillus gasseri, Bifidobacterium longum", "CHEMICAL", 146, 191], ["vitamins", "CHEMICAL", 84, 92], ["adults", "ORGANISM", 35, 41], ["vitamins", "SIMPLE_CHEMICAL", 84, 92], ["minerals", "SIMPLE_CHEMICAL", 97, 105], ["Lactobacillus gasseri", "ORGANISM", 146, 167], ["Bifidobacterium longum", "ORGANISM", 169, 191], ["B. bifidum", "ORGANISM", 193, 203], ["Lactobacillus gasseri", "SPECIES", 146, 167], ["Bifidobacterium longum", "SPECIES", 169, 191], ["B. bifidum", "SPECIES", 193, 203], ["Lactobacillus gasseri", "SPECIES", 146, 167], ["Bifidobacterium longum", "SPECIES", 169, 191], ["B. bifidum", "SPECIES", 193, 203], ["vitamins and minerals", "TREATMENT", 84, 105], ["the probiotic bacteria", "PROBLEM", 122, 144], ["Lactobacillus gasseri", "TREATMENT", 146, 167], ["Bifidobacterium longum", "TREATMENT", 169, 191]]], ["The total symptom score, the duration of common cold episodes, and days with fever during an episode were lower in the probiotic-treated group than in the control group .", [["fever", "DISEASE", 77, 82], ["The total symptom score", "PROBLEM", 0, 23], ["common cold episodes", "PROBLEM", 41, 61], ["fever", "PROBLEM", 77, 82], ["an episode", "PROBLEM", 90, 100], ["lower", "OBSERVATION_MODIFIER", 106, 111]]], ["In another study, consumption of Lactobacillus plantarum and Lactobacillus paracasei reduced the incidence of acquiring one or more common cold episode from 67% in the control group to 55% in the probiotic group.", [["Lactobacillus plantarum", "CHEMICAL", 33, 56], ["Lactobacillus paracasei", "CHEMICAL", 61, 84], ["Lactobacillus plantarum", "ORGANISM", 33, 56], ["Lactobacillus paracasei", "ORGANISM", 61, 84], ["Lactobacillus plantarum", "SPECIES", 33, 56], ["Lactobacillus paracasei", "SPECIES", 61, 84], ["Lactobacillus plantarum", "SPECIES", 33, 56], ["Lactobacillus paracasei", "SPECIES", 61, 84], ["another study", "TEST", 3, 16], ["Lactobacillus plantarum", "TREATMENT", 33, 56], ["Lactobacillus paracasei", "TREATMENT", 61, 84]]], ["Also, the number of days with common cold symptoms was significantly reduced from 8.6 days in the control group to 6.2 days in the probiotic group, during the 12-week period (Berggren et al., 2011) .", [["common cold symptoms", "PROBLEM", 30, 50], ["reduced", "OBSERVATION_MODIFIER", 69, 76]]], ["In healthy adults, L. fermentum reduced the number of RTIs and increased antigen-specific IgA formation after influenza virus vaccination (Olivares et al., 2007) .", [["RTIs", "DISEASE", 54, 58], ["L. fermentum", "ORGANISM", 19, 31], ["antigen", "GENE_OR_GENE_PRODUCT", 73, 80], ["IgA", "GENE_OR_GENE_PRODUCT", 90, 93], ["influenza virus", "ORGANISM", 110, 125], ["IgA", "PROTEIN", 90, 93], ["L. fermentum", "SPECIES", 19, 31], ["influenza virus", "SPECIES", 110, 125], ["L. fermentum", "SPECIES", 19, 31], ["L. fermentum", "PROBLEM", 19, 31], ["RTIs", "PROBLEM", 54, 58], ["increased antigen", "PROBLEM", 63, 80], ["influenza virus vaccination", "TREATMENT", 110, 137], ["fermentum reduced", "OBSERVATION", 22, 39], ["increased", "OBSERVATION_MODIFIER", 63, 72]]], ["A combination of L. rhamnosus GG and B. animalis reduced both the duration and severity of upper respiratory infections (Smith et al., 2013) .Adults and the ElderlyIn Finnish conscripts who received a daily chewable probiotic tablet containing L. rhamnosus GG and B. animalis ssp. lactis or a control tablet, probiotics did not reduce nasopharyngeal viral occurrence.", [["respiratory", "ANATOMY", 97, 108], ["nasopharyngeal", "ANATOMY", 335, 349], ["L. rhamnosus", "CHEMICAL", 17, 29], ["upper respiratory infections", "DISEASE", 91, 119], ["L. rhamnosus", "CHEMICAL", 244, 256], ["L. rhamnosus GG", "ORGANISM", 17, 32], ["B. animalis", "ORGANISM", 37, 48], ["Adults", "ORGANISM", 142, 148], ["L. rhamnosus GG", "ORGANISM", 244, 259], ["B. animalis ssp", "ORGANISM", 264, 279], ["lactis", "ORGANISM", 281, 287], ["nasopharyngeal", "ORGAN", 335, 349], ["L. rhamnosus", "SPECIES", 17, 29], ["B. animalis", "SPECIES", 37, 48], ["Adults", "SPECIES", 142, 148], ["L. rhamnosus", "SPECIES", 244, 256], ["B. animalis", "SPECIES", 264, 275], ["lactis", "SPECIES", 281, 287], ["L. rhamnosus", "SPECIES", 17, 29], ["B. animalis", "SPECIES", 37, 48], ["L. rhamnosus", "SPECIES", 244, 256], ["B. animalis ssp", "SPECIES", 264, 279], ["lactis", "SPECIES", 281, 287], ["L. rhamnosus GG", "TREATMENT", 17, 32], ["B. animalis", "PROBLEM", 37, 48], ["upper respiratory infections", "PROBLEM", 91, 119], ["a daily chewable probiotic tablet", "TREATMENT", 199, 232], ["lactis", "TREATMENT", 281, 287], ["a control tablet", "TREATMENT", 291, 307], ["probiotics", "TREATMENT", 309, 319], ["nasopharyngeal viral occurrence", "PROBLEM", 335, 366], ["L.", "OBSERVATION_MODIFIER", 17, 19], ["rhamnosus GG", "OBSERVATION", 20, 32], ["upper", "ANATOMY_MODIFIER", 91, 96], ["respiratory", "ANATOMY", 97, 108], ["infections", "OBSERVATION", 109, 119], ["rhamnosus GG", "OBSERVATION", 247, 259], ["nasopharyngeal", "ANATOMY", 335, 349], ["viral", "OBSERVATION", 350, 355]]], ["However, probiotics decreased the presence of picornaviruses after 3 months, which may imply that probiotics play a role against viruses causing the common cold (Lehtoranta et al., 2014a) .", [["probiotics", "TREATMENT", 9, 19], ["picornaviruses", "PROBLEM", 46, 60], ["picornaviruses", "OBSERVATION", 46, 60]]], ["In male elite distance runners, L. fermentum reduced the duration of RTI symptoms, but not the incidence of RTIs or the severity of symptoms (Cox et al., 2010) .", [["RTI", "DISEASE", 69, 72], ["RTIs", "DISEASE", 108, 112], ["L. fermentum", "ORGANISM", 32, 44], ["L. fermentum", "SPECIES", 32, 44], ["L. fermentum", "SPECIES", 32, 44], ["RTI symptoms", "PROBLEM", 69, 81], ["RTIs", "PROBLEM", 108, 112], ["the severity of symptoms", "PROBLEM", 116, 140], ["fermentum reduced", "OBSERVATION", 35, 52]]], ["A recent systematic review performed by King et al. revealed significantly fewer numbers of days of illness per person, shorter illness episodes by almost a day, and fewer numbers of days absent from work in participants who received a probiotic intervention than in those who had taken a placebo (King et al., 2014) .Adults and the ElderlySome studies could not show any benefit of probiotics in prevention of incidence, duration, or severity of symptoms in adult individuals Gleeson et al., 2012; Tiollier et al., 2007; Winkler et al., 2005) .Adults and the ElderlyThe proportion and absolute number of individuals above the age of 65 years are increasing in most countries, particularly in industrialized nations.", [["illness", "DISEASE", 100, 107], ["illness", "DISEASE", 128, 135], ["Adults", "ORGANISM", 318, 324], ["Adults", "ORGANISM", 545, 551], ["person", "SPECIES", 112, 118], ["participants", "SPECIES", 208, 220], ["Adults", "SPECIES", 318, 324], ["Adults", "SPECIES", 545, 551], ["shorter illness episodes", "PROBLEM", 120, 144], ["a probiotic intervention", "TREATMENT", 234, 258], ["Some studies", "TEST", 340, 352], ["probiotics", "TREATMENT", 383, 393], ["symptoms", "PROBLEM", 447, 455], ["significantly", "OBSERVATION_MODIFIER", 61, 74], ["fewer", "OBSERVATION_MODIFIER", 75, 80], ["numbers", "OBSERVATION_MODIFIER", 81, 88], ["proportion", "OBSERVATION_MODIFIER", 571, 581], ["absolute", "OBSERVATION_MODIFIER", 586, 594], ["number", "OBSERVATION_MODIFIER", 595, 601], ["increasing", "OBSERVATION_MODIFIER", 647, 657], ["most countries", "OBSERVATION_MODIFIER", 661, 675]]], ["The human immune function undergoes adverse changes with aging including involution of the thymus, decline of naive T-cell numbers, reduction in T-cell repertoire diversity, and accumulation of specific memory T cells, which potentially leads to an increased risk of infections.", [["thymus", "ANATOMY", 91, 97], ["T-cell", "ANATOMY", 116, 122], ["T-cell", "ANATOMY", 145, 151], ["memory T cells", "ANATOMY", 203, 217], ["infections", "DISEASE", 267, 277], ["human", "ORGANISM", 4, 9], ["thymus", "ORGAN", 91, 97], ["T-cell", "CELL", 116, 122], ["T-cell", "CELL", 145, 151], ["memory T cells", "CELL", 203, 217], ["memory T cells", "CELL_TYPE", 203, 217], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9], ["The human immune function", "TEST", 0, 25], ["adverse changes", "PROBLEM", 36, 51], ["the thymus", "PROBLEM", 87, 97], ["T-cell repertoire diversity", "PROBLEM", 145, 172], ["accumulation of specific memory T cells", "PROBLEM", 178, 217], ["infections", "PROBLEM", 267, 277], ["thymus", "ANATOMY", 91, 97], ["reduction", "OBSERVATION_MODIFIER", 132, 141], ["T-cell repertoire diversity", "OBSERVATION", 145, 172], ["specific memory T cells", "OBSERVATION", 194, 217], ["increased", "OBSERVATION_MODIFIER", 249, 258], ["infections", "OBSERVATION", 267, 277]]], ["Achieving optimal success in preventing and controlling infections among the elderly requires new strategies to oppose the age-associated alterations of the immune system.Adults and the ElderlyA meta-analysis of the results of these two independent studies concluded that consumption of yogurt fermented with L. bulgaricus OLL1073R-1 augmented natural killer cell activity and reduced the risk of catching the common cold (about 2.6 times lower) in elderly individuals (Makino et al., 2010) .", [["immune system", "ANATOMY", 157, 170], ["killer cell", "ANATOMY", 352, 363], ["infections", "DISEASE", 56, 66], ["L. bulgaricus OLL1073R-1", "CHEMICAL", 309, 333], ["immune system", "ANATOMICAL_SYSTEM", 157, 170], ["Adults", "ORGANISM", 171, 177], ["yogurt", "ORGANISM_SUBDIVISION", 287, 293], ["L. bulgaricus", "ORGANISM", 309, 322], ["OLL1073R-1", "GENE_OR_GENE_PRODUCT", 323, 333], ["natural killer cell", "CELL", 344, 363], ["natural killer cell", "CELL_TYPE", 344, 363], ["Adults", "SPECIES", 171, 177], ["L. bulgaricus", "SPECIES", 309, 322], ["L. bulgaricus", "SPECIES", 309, 322], ["controlling infections", "PROBLEM", 44, 66], ["new strategies", "TREATMENT", 94, 108], ["associated alterations of the immune system", "PROBLEM", 127, 170], ["infections", "OBSERVATION", 56, 66], ["natural killer cell activity", "OBSERVATION", 344, 372]]], ["A multicentric, double-blind study, involving 1072 volunteers (median age = 76.0 years) randomized for consumption of either dairy products containing the probiotic strain Lactobacillus casei or without probiotics for 3 months.", [["Lactobacillus casei", "CHEMICAL", 172, 191], ["volunteers", "ORGANISM", 51, 61], ["Lactobacillus casei", "ORGANISM", 172, 191], ["Lactobacillus casei", "SPECIES", 172, 191], ["Lactobacillus casei", "SPECIES", 172, 191], ["blind study", "TEST", 23, 34], ["dairy products", "TREATMENT", 125, 139], ["the probiotic strain Lactobacillus casei", "TREATMENT", 151, 191], ["probiotics", "TREATMENT", 203, 213], ["multicentric", "OBSERVATION_MODIFIER", 2, 14]]], ["Reduction in both episode and cumulative durations was also significant for all URTIs and for rhinopharyngitis (Guillemard et al., 2010) .Adults and the ElderlyIn Japan, a multicenter study was conducted on 154 elderly persons who used day care at four facilities in Tokyo.", [["URTIs", "DISEASE", 80, 85], ["rhinopharyngitis", "DISEASE", 94, 110], ["persons", "ORGANISM", 219, 226], ["Adults", "SPECIES", 138, 144], ["persons", "SPECIES", 219, 226], ["Reduction", "TREATMENT", 0, 9], ["both episode", "PROBLEM", 13, 25], ["cumulative durations", "PROBLEM", 30, 50], ["all URTIs", "PROBLEM", 76, 85], ["rhinopharyngitis", "PROBLEM", 94, 110], ["a multicenter study", "TEST", 170, 189], ["both", "OBSERVATION_MODIFIER", 13, 17], ["URTIs", "OBSERVATION", 80, 85]]], ["They used fermented milk containing L. casei strain Shirota (LcS) and placebo drinks as control drinks and concluded that fermented milk containing LcS probably reduces the duration of acute URTIs (Fujita et al., 2013) .Adults and the ElderlyHowever, other studies using L. casei Shirota or a combination of L. rhamnosus GG, L. rhamnosus, B. breve, and P. freudenreichii had no effect on the number RTIs or the duration of RTI symptoms (Van Puyenbroeck et al., 2012) .SUMMARYAcute RTIs are the most common reason for people to seek medical help in developed countries and account for up to 75% of all antibiotic use in high-income countries.", [["milk", "ANATOMY", 20, 24], ["milk", "ANATOMY", 132, 136], ["Shirota", "CHEMICAL", 52, 59], ["LcS", "CHEMICAL", 61, 64], ["LcS", "CHEMICAL", 148, 151], ["URTIs", "DISEASE", 191, 196], ["Shirota", "CHEMICAL", 280, 287], ["L. rhamnosus", "CHEMICAL", 308, 320], ["RTIs", "DISEASE", 399, 403], ["RTI", "DISEASE", 423, 426], ["RTIs", "DISEASE", 481, 485], ["milk", "ORGANISM_SUBSTANCE", 20, 24], ["L. casei", "ORGANISM", 36, 44], ["Shirota", "SIMPLE_CHEMICAL", 52, 59], ["LcS", "SIMPLE_CHEMICAL", 61, 64], ["milk", "ORGANISM_SUBSTANCE", 132, 136], ["LcS", "SIMPLE_CHEMICAL", 148, 151], ["Adults", "ORGANISM", 220, 226], ["L. casei Shirota", "ORGANISM", 271, 287], ["L. rhamnosus GG", "ORGANISM", 308, 323], ["L. rhamnosus", "ORGANISM", 325, 337], ["B. breve", "ORGANISM", 339, 347], ["P. freudenreichii", "ORGANISM", 353, 370], ["people", "ORGANISM", 517, 523], ["milk", "SPECIES", 20, 24], ["L. casei", "SPECIES", 36, 44], ["Adults", "SPECIES", 220, 226], ["L. casei", "SPECIES", 271, 279], ["L. rhamnosus", "SPECIES", 308, 320], ["L. rhamnosus", "SPECIES", 325, 337], ["B. breve", "SPECIES", 339, 347], ["P. freudenreichii", "SPECIES", 353, 370], ["people", "SPECIES", 517, 523], ["L. casei", "SPECIES", 36, 44], ["L. casei", "SPECIES", 271, 279], ["L. rhamnosus", "SPECIES", 308, 320], ["L. rhamnosus", "SPECIES", 325, 337], ["B. breve", "SPECIES", 339, 347], ["P. freudenreichii", "SPECIES", 353, 370], ["fermented milk", "TREATMENT", 10, 24], ["acute URTIs", "PROBLEM", 185, 196], ["other studies", "TEST", 251, 264], ["L. casei Shirota", "TREATMENT", 271, 287], ["L. rhamnosus", "PROBLEM", 325, 337], ["P. freudenreichii", "PROBLEM", 353, 370], ["RTI symptoms", "PROBLEM", 423, 435], ["all antibiotic use", "TREATMENT", 597, 615], ["acute", "OBSERVATION_MODIFIER", 185, 190], ["URTIs", "OBSERVATION", 191, 196], ["rhamnosus GG", "OBSERVATION", 311, 323], ["L. rhamnosus", "ANATOMY", 325, 337]]], ["In low-income and middle-income countries, severe diarrhea and pneumonia are the leading causes of infections leading to death in children younger than 5 years of age.", [["diarrhea", "DISEASE", 50, 58], ["pneumonia", "DISEASE", 63, 72], ["infections", "DISEASE", 99, 109], ["death", "DISEASE", 121, 126], ["children", "ORGANISM", 130, 138], ["children", "SPECIES", 130, 138], ["severe diarrhea", "PROBLEM", 43, 58], ["pneumonia", "PROBLEM", 63, 72], ["infections", "PROBLEM", 99, 109], ["low", "OBSERVATION_MODIFIER", 3, 6], ["severe", "OBSERVATION_MODIFIER", 43, 49], ["diarrhea", "OBSERVATION", 50, 58], ["pneumonia", "OBSERVATION", 63, 72], ["infections", "OBSERVATION", 99, 109]]], ["Strategies that are most likely to prevent respiratory infections include hand hygiene, breast milk, the administration of different immunostimulants, probiotics, prebiotics, and synbiotics (Ahanchian et al., 2012) .SUMMARYMicrobiota is shaped by genetic and environmental factors including mode of delivery; breast feeding and diet; farm or urban living; vitamin D status; and antibiotic consumption.SUMMARYThis knowledge stimulated interest in the use of probiotics and prebiotics as the intentional introduction and encouragement of specific microbes to shape immune system development.", [["respiratory", "ANATOMY", 43, 54], ["hand", "ANATOMY", 74, 78], ["breast milk", "ANATOMY", 88, 99], ["breast", "ANATOMY", 309, 315], ["immune system", "ANATOMY", 563, 576], ["respiratory infections", "DISEASE", 43, 65], ["breast milk", "DISEASE", 88, 99], ["vitamin D", "CHEMICAL", 356, 365], ["vitamin D", "CHEMICAL", 356, 365], ["hand", "ORGANISM_SUBDIVISION", 74, 78], ["breast", "ORGANISM_SUBDIVISION", 88, 94], ["milk", "ORGANISM_SUBSTANCE", 95, 99], ["breast", "ORGANISM_SUBDIVISION", 309, 315], ["vitamin D", "SIMPLE_CHEMICAL", 356, 365], ["immune system", "ANATOMICAL_SYSTEM", 563, 576], ["Strategies", "TREATMENT", 0, 10], ["respiratory infections", "PROBLEM", 43, 65], ["hand hygiene", "TREATMENT", 74, 86], ["breast milk", "TREATMENT", 88, 99], ["different immunostimulants", "TREATMENT", 123, 149], ["probiotics", "TREATMENT", 151, 161], ["prebiotics", "TREATMENT", 163, 173], ["synbiotics", "TREATMENT", 179, 189], ["delivery", "TREATMENT", 299, 307], ["breast feeding", "TREATMENT", 309, 323], ["vitamin D status", "TREATMENT", 356, 372], ["antibiotic consumption", "TREATMENT", 378, 400], ["probiotics", "TREATMENT", 457, 467], ["prebiotics", "TREATMENT", 472, 482], ["the intentional introduction", "TREATMENT", 486, 514], ["most likely", "UNCERTAINTY", 20, 31], ["infections", "OBSERVATION", 55, 65], ["shaped", "OBSERVATION_MODIFIER", 237, 243], ["breast", "ANATOMY", 309, 315]]], ["Probiotics and synbiotics have been used successfully for different medical problems, and a growing number of clinical trials have shown the effectiveness of their usage for the prevention and management of respiratory infections.", [["respiratory", "ANATOMY", 207, 218], ["respiratory infections", "DISEASE", 207, 229], ["synbiotics", "SIMPLE_CHEMICAL", 15, 25], ["Probiotics", "TREATMENT", 0, 10], ["synbiotics", "TREATMENT", 15, 25], ["different medical problems", "PROBLEM", 58, 84], ["clinical trials", "TREATMENT", 110, 125], ["the prevention", "TREATMENT", 174, 188], ["management", "TREATMENT", 193, 203], ["respiratory infections", "PROBLEM", 207, 229], ["respiratory", "ANATOMY", 207, 218], ["infections", "OBSERVATION", 219, 229]]], ["Clinical trials in human subjects show promising data demonstrating that specific probiotic strains are able to shorten the duration or reduce the incidence of respiratory infections.", [["respiratory", "ANATOMY", 160, 171], ["respiratory infections", "DISEASE", 160, 182], ["human", "ORGANISM", 19, 24], ["human", "SPECIES", 19, 24], ["human", "SPECIES", 19, 24], ["Clinical trials in human subjects", "TEST", 0, 33], ["specific probiotic strains", "PROBLEM", 73, 99], ["respiratory infections", "PROBLEM", 160, 182], ["respiratory", "ANATOMY", 160, 171], ["infections", "OBSERVATION", 172, 182]]], ["However, only a few clinical studies have investigated the effects of probiotics on specific viruses.SUMMARYIt should be noted that the effects of probiotics are highly strain-specific and the adequate amount of bacteria transferred into the gut may be crucial.", [["gut", "ANATOMY", 242, 245], ["gut", "ORGANISM_SUBDIVISION", 242, 245], ["a few clinical studies", "TEST", 14, 36], ["probiotics", "TREATMENT", 70, 80], ["probiotics", "TREATMENT", 147, 157], ["highly strain", "PROBLEM", 162, 175], ["bacteria", "PROBLEM", 212, 220], ["bacteria", "OBSERVATION", 212, 220], ["gut", "ANATOMY", 242, 245], ["may be", "UNCERTAINTY", 246, 252], ["crucial", "OBSERVATION", 253, 260]]], ["It may be too soon to judge the role that probiotics may play in the prevention of the common cold because there are many strains of probiotics with established immunomodulatory effects yet to be tried with the particular goal of seeking their effects on respiratory infections.", [["respiratory", "ANATOMY", 255, 266], ["respiratory infections", "DISEASE", 255, 277], ["probiotics", "TREATMENT", 42, 52], ["probiotics", "TREATMENT", 133, 143], ["respiratory infections", "PROBLEM", 255, 277], ["respiratory", "ANATOMY", 255, 266], ["infections", "OBSERVATION", 267, 277]]], ["A better understanding of the effects of different probiotic strains and their combination, selection of the most beneficial strains, the dose and timing of supplementation for various age groups, and a deeper insight into their mechanisms of action are needed for the validation of specific strains carrying a potential to modify the frequency and severity of RTIs (Homayouni Rad et al., 2013) .", [["RTIs", "DISEASE", 361, 365], ["different probiotic strains", "TREATMENT", 41, 68], ["supplementation", "TREATMENT", 157, 172], ["various age groups", "TREATMENT", 177, 195], ["specific strains", "PROBLEM", 283, 299], ["RTIs", "PROBLEM", 361, 365]]], ["Functional foods such as probiotic milk or yogurt containing well-defined probiotic strains may reduce the risk of catching the common cold and represent a simple, safe, effective, and available method for preventing respiratory infections especially in developing countries.", [["milk", "ANATOMY", 35, 39], ["respiratory", "ANATOMY", 217, 228], ["respiratory infections", "DISEASE", 217, 239], ["milk", "ORGANISM_SUBSTANCE", 35, 39], ["yogurt", "ORGANISM_SUBDIVISION", 43, 49], ["milk", "SPECIES", 35, 39], ["probiotic milk", "TREATMENT", 25, 39], ["probiotic strains", "TREATMENT", 74, 91], ["method", "TREATMENT", 195, 201], ["respiratory infections", "PROBLEM", 217, 239], ["infections", "OBSERVATION", 229, 239]]], ["Further research to establish the role of probiotics and prebiotics in the treatment and prevention of RTIs is required and should also clarify if any susceptible subgroups of respiratory diseases exist, and how these subgroups benefit from supplementation with certain probiotic strains.", [["respiratory", "ANATOMY", 176, 187], ["RTIs", "DISEASE", 103, 107], ["respiratory diseases", "DISEASE", 176, 196], ["probiotics", "TREATMENT", 42, 52], ["prebiotics", "TREATMENT", 57, 67], ["the treatment", "TREATMENT", 71, 84], ["RTIs", "PROBLEM", 103, 107], ["respiratory diseases", "PROBLEM", 176, 196], ["supplementation", "TREATMENT", 241, 256], ["certain probiotic strains", "TREATMENT", 262, 287], ["respiratory diseases", "OBSERVATION", 176, 196]]]], "PMC4162001": [["METHODSFull-length HA sequences of 8712 pandemic A/H1N1 influenza viruses collected globally during 2009\u20132013 were downloaded from GISAID (www.gisaid.org).", [["influenza viruses", "DISEASE", 56, 73], ["8712 pandemic A/H1N1 influenza viruses", "ORGANISM", 35, 73], ["METHODSFull-length HA sequences", "DNA", 0, 31], ["H1N1 influenza viruses", "SPECIES", 51, 73], ["A/H1N1 influenza viruses", "SPECIES", 49, 73], ["METHODSFull-length HA sequences", "TEST", 0, 31], ["pandemic A/H1N1 influenza viruses", "PROBLEM", 40, 73]]], ["These data include 299 HA sequences from pandemic A/H1N1 influenza viruses collected in 18 African countries representing 4 African subregions: 3 nations in North Africa (Algeria, Morocco, and Egypt), 7 nations in West Africa (Burkina Faso, Cameroon, C\u00f4te d'Ivoire, Ghana, Niger, Nigeria, and Senegal), 7 nations in East Africa (Djibouti, Ethiopia, Kenya, Madagascar, Tanzania, Uganda, and Zambia), and 1 Southern African nation (South Africa) (Supplementary Table 1; GenBank accession numbers KJ026367\u2013KJ026452).", [["influenza viruses", "DISEASE", 57, 74], ["pandemic A/H1N1 influenza viruses", "ORGANISM", 41, 74], ["H1N1 influenza viruses", "SPECIES", 52, 74], ["A/H1N1 influenza viruses", "SPECIES", 50, 74], ["These data", "TEST", 0, 10], ["HA sequences", "TEST", 23, 35], ["pandemic", "PROBLEM", 41, 49], ["H1N1 influenza viruses", "PROBLEM", 52, 74], ["C\u00f4te d'Ivoire", "TREATMENT", 251, 264], ["Madagascar", "TREATMENT", 356, 366]]], ["Because Cameroon shares a long border with Nigeria and no other Central African countries had viral sequence data available that met the criteria for this study, for simplicity Cameroon was considered to be within West Africa in this analysis.METHODSThe entire data set of 8712 pH1N1 HA (H1) sequences was aligned using MUSCLE alignment software (version 3.3.81) [8], with manual correction.", [["8712 pH1N1 HA (H1) sequences", "DNA", 273, 301], ["viral sequence data", "TEST", 94, 113], ["this study", "TEST", 150, 160], ["this analysis", "TEST", 229, 242], ["METHODSThe entire data", "TEST", 243, 265], ["pH1N1 HA (H1) sequences", "TREATMENT", 278, 301], ["MUSCLE alignment software", "TEST", 320, 345], ["version", "TEST", 347, 354], ["manual correction", "TREATMENT", 373, 390], ["MUSCLE", "ANATOMY", 320, 326]]], ["A maximum likelihood (ML) tree of these data was inferred by using RAxML software (version 7.2.6) [9] and a general time-reversible (GTR) model of nucleotide substitution with a gamma-distributed (\u0393) rate variation among sites (data available on request).", [["nucleotide", "CHEMICAL", 147, 157], ["nucleotide", "CHEMICAL", 147, 157], ["these data", "TEST", 34, 44], ["version", "TEST", 83, 90], ["a general time-reversible (GTR", "PROBLEM", 106, 136], ["nucleotide substitution", "PROBLEM", 147, 170], ["a gamma-distributed (\u0393) rate variation among sites", "PROBLEM", 176, 226], ["maximum", "OBSERVATION_MODIFIER", 2, 9]]], ["Given the extremely large size of the data set, 100 bootstrap replicates were generated using RAxML software, with the same GTR + \u0393 model of nucleotide substitution, to assess the robustness of individual nodes.", [["nodes", "ANATOMY", 205, 210], ["nucleotide", "CHEMICAL", 141, 151], ["nucleotide", "CHEMICAL", 141, 151], ["nodes", "MULTI-TISSUE_STRUCTURE", 205, 210], ["RAxML software", "TEST", 94, 108], ["nucleotide substitution", "TREATMENT", 141, 164], ["individual nodes", "PROBLEM", 194, 210], ["large", "OBSERVATION_MODIFIER", 20, 25], ["size", "OBSERVATION_MODIFIER", 26, 30], ["nucleotide substitution", "OBSERVATION", 141, 164], ["individual", "OBSERVATION_MODIFIER", 194, 204], ["nodes", "OBSERVATION", 205, 210]]], ["The resulting phylogeny was visualized and midpoint rooted using FigTree software (version 1.4.0; available at: http://tree.bio.ed.ac.uk/software/figtree/), and amino acid substitutions were identified using a customized R script.", [["amino acid", "CHEMICAL", 161, 171], ["amino acid", "CHEMICAL", 161, 171], ["amino acid", "AMINO_ACID", 161, 171], ["amino acid substitutions", "TREATMENT", 161, 185], ["a customized R script", "TREATMENT", 208, 229]]], ["Similarly, an ML phylogeny also was inferred for 7644 full-length (1407 nt) pH1N1 NA (N1) sequences that were obtained and analyzed using identical methods (Supplementary Figure 1).", [["7644 full-length", "DNA", 49, 65], ["an ML phylogeny", "TEST", 11, 26], ["H1N1 NA (N1) sequences", "TEST", 77, 99]]], ["For the purposes of visualization (Figure 1), an ML tree also was inferred from a subset of the HA sequence data (1643 HA sequences) that included all 299 African viruses, 9 viruses identified within West African clades I and II (described below), and 300 HA sequences randomly sampled from each year during 2009\u20132013 (all sequences from 2013 were used because <300 sequences were available).", [["HA sequence", "DNA", 96, 107], ["HA sequences", "DNA", 256, 268], ["African viruses", "SPECIES", 155, 170], ["visualization", "TEST", 20, 33], ["the HA sequence data", "TEST", 92, 112], ["HA sequences", "TEST", 119, 131], ["9 viruses", "PROBLEM", 172, 181], ["HA sequences", "TEST", 256, 268]]]], "f63befc8a59e205df79cba28ea81a580d2737941": [["IntroductionNon-suppurative meningoencephalitis in cats and dogs is usually considered to be caused by viral infections (Summers et al., 1995) , and the histopathological \u00a2ndings consist mainly of perivascular and parenchymal in\u00a2ltration with lymphocytes, macrophages and plasma cells, usually associated with meningitis and occasionally with in\u00a3ammation of the plexus chorioideus and the ependyma (Braund, 1980; Luttgen, 1988) .", [["perivascular", "ANATOMY", 197, 209], ["parenchymal", "ANATOMY", 214, 225], ["lymphocytes", "ANATOMY", 243, 254], ["macrophages", "ANATOMY", 256, 267], ["plasma cells", "ANATOMY", 272, 284], ["plexus chorioideus", "ANATOMY", 362, 380], ["ependyma", "ANATOMY", 389, 397], ["meningoencephalitis", "DISEASE", 28, 47], ["viral infections", "DISEASE", 103, 119], ["meningitis", "DISEASE", 310, 320], ["in\u00a3ammation of the plexus chorioideus", "DISEASE", 343, 380], ["cats", "ORGANISM", 51, 55], ["dogs", "ORGANISM", 60, 64], ["perivascular", "IMMATERIAL_ANATOMICAL_ENTITY", 197, 209], ["lymphocytes", "CELL", 243, 254], ["macrophages", "CELL", 256, 267], ["plasma cells", "CELL", 272, 284], ["plexus chorioideus", "ORGANISM", 362, 380], ["ependyma", "ORGAN", 389, 397], ["lymphocytes", "CELL_TYPE", 243, 254], ["macrophages", "CELL_TYPE", 256, 267], ["plasma cells", "CELL_TYPE", 272, 284], ["cats", "SPECIES", 51, 55], ["dogs", "SPECIES", 60, 64], ["suppurative meningoencephalitis in cats", "PROBLEM", 16, 55], ["dogs", "PROBLEM", 60, 64], ["viral infections", "PROBLEM", 103, 119], ["the histopathological \u00a2ndings", "TEST", 149, 178], ["perivascular and parenchymal in\u00a2ltration", "PROBLEM", 197, 237], ["lymphocytes", "PROBLEM", 243, 254], ["macrophages", "PROBLEM", 256, 267], ["plasma cells", "PROBLEM", 272, 284], ["meningitis", "PROBLEM", 310, 320], ["in\u00a3ammation of the plexus chorioideus", "PROBLEM", 343, 380], ["suppurative", "OBSERVATION_MODIFIER", 16, 27], ["meningoencephalitis", "OBSERVATION", 28, 47], ["viral", "OBSERVATION_MODIFIER", 103, 108], ["infections", "OBSERVATION", 109, 119], ["perivascular", "ANATOMY_MODIFIER", 197, 209], ["parenchymal", "ANATOMY_MODIFIER", 214, 225], ["lymphocytes", "OBSERVATION", 243, 254], ["macrophages", "OBSERVATION_MODIFIER", 256, 267], ["plasma cells", "OBSERVATION", 272, 284], ["meningitis", "OBSERVATION", 310, 320], ["plexus chorioideus", "ANATOMY", 362, 380], ["ependyma", "ANATOMY_MODIFIER", 389, 397]]], ["Viruses, due to cell tropism and route of infection, often induce a typical pattern of in\u00a3ammation in the brain and spinal cord (Braund, 2001) .IntroductionIn newborn animals, infections of the central nervous system (CNS) with bacteria, including various strains of Escherichia coli, are a common sequel to septicaemia, whereas in adult dogs and cats bacteria may follow a neurogenic, otogenic or rhinogenic route to enter the CNS (Meric,1988; Summers et al.,1995) .", [["cell", "ANATOMY", 16, 20], ["brain", "ANATOMY", 106, 111], ["spinal cord", "ANATOMY", 116, 127], ["central nervous system", "ANATOMY", 194, 216], ["CNS", "ANATOMY", 218, 221], ["CNS", "ANATOMY", 428, 431], ["infection", "DISEASE", 42, 51], ["infections of the central nervous system", "DISEASE", 176, 216], ["Escherichia coli", "DISEASE", 267, 283], ["septicaemia", "DISEASE", 308, 319], ["cell", "CELL", 16, 20], ["brain", "ORGAN", 106, 111], ["spinal cord", "ORGAN", 116, 127], ["central nervous system", "ANATOMICAL_SYSTEM", 194, 216], ["CNS", "ANATOMICAL_SYSTEM", 218, 221], ["Escherichia coli", "ORGANISM", 267, 283], ["adult dogs", "ORGANISM", 332, 342], ["cats", "ORGANISM", 347, 351], ["CNS", "ANATOMICAL_SYSTEM", 428, 431], ["Escherichia coli", "SPECIES", 267, 283], ["dogs", "SPECIES", 338, 342], ["cats", "SPECIES", 347, 351], ["Escherichia coli", "SPECIES", 267, 283], ["Viruses", "PROBLEM", 0, 7], ["cell tropism", "PROBLEM", 16, 28], ["infection", "PROBLEM", 42, 51], ["in\u00a3ammation in the brain and spinal cord", "PROBLEM", 87, 127], ["infections of the central nervous system", "PROBLEM", 176, 216], ["bacteria", "PROBLEM", 228, 236], ["various strains of Escherichia coli", "PROBLEM", 248, 283], ["septicaemia", "PROBLEM", 308, 319], ["cats bacteria", "PROBLEM", 347, 360], ["a neurogenic", "PROBLEM", 372, 384], ["otogenic", "PROBLEM", 386, 394], ["cell tropism", "OBSERVATION", 16, 28], ["infection", "OBSERVATION", 42, 51], ["in\u00a3ammation", "OBSERVATION", 87, 98], ["brain", "ANATOMY", 106, 111], ["spinal cord", "ANATOMY", 116, 127], ["infections", "OBSERVATION", 176, 186], ["central", "ANATOMY_MODIFIER", 194, 201], ["nervous system", "ANATOMY", 202, 216], ["Escherichia coli", "OBSERVATION", 267, 283], ["septicaemia", "OBSERVATION", 308, 319], ["CNS", "ANATOMY", 428, 431]]], ["Whilst most bacterial CNS infections induce a purulent in-\u00a3ammation, some bacteria, particularly Listeria spp., as well as protozoa, fungi and algae, cause a non-suppurative, mainly granulomatous in\u00a3ammation of the CNS (Rand et al., 1994; Summers et al., 1995; Tipold, 1995; Quesnel et al., 1997) .", [["CNS", "ANATOMY", 22, 25], ["CNS", "ANATOMY", 215, 218], ["infections", "DISEASE", 26, 36], ["Listeria spp.", "ORGANISM", 97, 110], ["CNS", "ANATOMICAL_SYSTEM", 215, 218], ["Listeria spp.", "SPECIES", 97, 110], ["Listeria spp.", "SPECIES", 97, 110], ["most bacterial CNS infections", "PROBLEM", 7, 36], ["a purulent in-\u00a3ammation", "PROBLEM", 44, 67], ["some bacteria", "PROBLEM", 69, 82], ["Listeria spp.", "PROBLEM", 97, 110], ["protozoa", "PROBLEM", 123, 131], ["fungi", "PROBLEM", 133, 138], ["a non-suppurative", "PROBLEM", 156, 173], ["CNS", "ANATOMY", 22, 25], ["infections", "OBSERVATION", 26, 36], ["purulent", "OBSERVATION", 46, 54], ["bacteria", "OBSERVATION_MODIFIER", 74, 82], ["non-suppurative", "OBSERVATION_MODIFIER", 158, 173], ["granulomatous", "OBSERVATION", 182, 195], ["CNS", "ANATOMY", 215, 218]]], ["In the brains of beagles with granulomatous leptomeningitis, Maeda et al. www.elsevier.com/locate/jcpa (1993) demonstrated E. coli and considered it to be the causative agent.", [["brains", "ANATOMY", 7, 13], ["granulomatous leptomeningitis", "DISEASE", 30, 59], ["brains", "ORGAN", 7, 13], ["beagles", "ORGANISM", 17, 24], ["E. coli", "ORGANISM", 123, 130], ["E. coli", "SPECIES", 123, 130], ["E. coli", "SPECIES", 123, 130], ["granulomatous leptomeningitis", "PROBLEM", 30, 59], ["E. coli", "PROBLEM", 123, 130], ["brains", "ANATOMY", 7, 13], ["granulomatous", "OBSERVATION_MODIFIER", 30, 43], ["leptomeningitis", "OBSERVATION", 44, 59], ["coli", "OBSERVATION", 126, 130]]], ["If parasites enter the CNS, they often induce a granulomatous in\u00a3ammation (Summers et al., 1995) .", [["CNS", "ANATOMY", 23, 26], ["in\u00a3ammation", "DISEASE", 62, 73], ["CNS", "ANATOMICAL_SYSTEM", 23, 26], ["parasites", "PROBLEM", 3, 12], ["a granulomatous in\u00a3ammation", "PROBLEM", 46, 73], ["CNS", "ANATOMY", 23, 26], ["granulomatous", "OBSERVATION", 48, 61]]], ["In dogs, the most common parasite to cause infection of the CNS is Toxoplasma gondii, followed by Neospora caninum and, albeit rarely, Cuterebra spp.", [["CNS", "ANATOMY", 60, 63], ["infection", "DISEASE", 43, 52], ["Toxoplasma gondii", "DISEASE", 67, 84], ["Neospora caninum", "DISEASE", 98, 114], ["dogs", "ORGANISM", 3, 7], ["CNS", "ANATOMICAL_SYSTEM", 60, 63], ["Toxoplasma gondii", "ORGANISM", 67, 84], ["Neospora caninum", "ORGANISM", 98, 114], ["Cuterebra spp", "ORGANISM", 135, 148], ["dogs", "SPECIES", 3, 7], ["Toxoplasma gondii", "SPECIES", 67, 84], ["Neospora caninum", "SPECIES", 98, 114], ["Toxoplasma gondii", "SPECIES", 67, 84], ["Neospora caninum", "SPECIES", 98, 114], ["infection of the CNS", "PROBLEM", 43, 63], ["Toxoplasma gondii", "PROBLEM", 67, 84], ["most common", "OBSERVATION_MODIFIER", 13, 24], ["infection", "OBSERVATION", 43, 52], ["CNS", "ANATOMY", 60, 63], ["Toxoplasma gondii", "OBSERVATION", 67, 84]]], ["In cats, Cuterebra spp. are the most common parasites to be found in the CNS, followed by T. gondii in rare cases (Braund, 2001) .IntroductionThere would also seem to be non-infectious causes of non-suppurative meningoencephalitis.", [["CNS", "ANATOMY", 73, 76], ["meningoencephalitis", "DISEASE", 211, 230], ["cats", "ORGANISM", 3, 7], ["Cuterebra spp.", "ORGANISM", 9, 23], ["CNS", "ANATOMICAL_SYSTEM", 73, 76], ["T. gondii", "ORGANISM", 90, 99], ["cats", "SPECIES", 3, 7], ["Cuterebra spp.", "SPECIES", 9, 23], ["T. gondii", "SPECIES", 90, 99], ["Cuterebra spp.", "SPECIES", 9, 23], ["T. gondii", "SPECIES", 90, 99], ["Cuterebra spp.", "TREATMENT", 9, 23], ["non-suppurative meningoencephalitis", "PROBLEM", 195, 230], ["CNS", "ANATOMY", 73, 76], ["seem to be", "UNCERTAINTY", 159, 169], ["non-infectious", "OBSERVATION", 170, 184], ["non-suppurative", "OBSERVATION_MODIFIER", 195, 210], ["meningoencephalitis", "OBSERVATION", 211, 230]]], ["Thus, autoimmune and hereditary mechanisms are suspected to be the underlying cause of CNS disorders such as granulomatous meningoencephalitis (GME) in dogs (Harris et al., 1988; Kipar et al., 1998) , pug dog encephalitis and non-suppurative meningoencephalitis in greyhounds (Callanan et al., 2002) .", [["CNS", "ANATOMY", 87, 90], ["autoimmune and hereditary mechanisms", "DISEASE", 6, 42], ["CNS disorders", "DISEASE", 87, 100], ["granulomatous meningoencephalitis", "DISEASE", 109, 142], ["GME", "DISEASE", 144, 147], ["pug dog encephalitis", "DISEASE", 201, 221], ["meningoencephalitis", "DISEASE", 242, 261], ["CNS", "ANATOMICAL_SYSTEM", 87, 90], ["dogs", "ORGANISM", 152, 156], ["pug dog encephalitis", "ORGANISM", 201, 221], ["dogs", "SPECIES", 152, 156], ["dog", "SPECIES", 205, 208], ["autoimmune", "PROBLEM", 6, 16], ["hereditary mechanisms", "PROBLEM", 21, 42], ["CNS disorders", "PROBLEM", 87, 100], ["granulomatous meningoencephalitis", "PROBLEM", 109, 142], ["pug dog encephalitis", "PROBLEM", 201, 221], ["non-suppurative meningoencephalitis in greyhounds", "PROBLEM", 226, 275], ["CNS", "ANATOMY", 87, 90], ["granulomatous", "OBSERVATION_MODIFIER", 109, 122], ["meningoencephalitis", "OBSERVATION", 123, 142], ["dog encephalitis", "OBSERVATION", 205, 221], ["non-suppurative", "OBSERVATION_MODIFIER", 226, 241], ["meningoencephalitis", "OBSERVATION", 242, 261]]], ["So far no aetiological agent has been detected for feline ''staggering disease'' or so-called feline polioencephalomyelitis (Vandevelde and Braund, 1979; Nowotny and Weissenbo \u00ba ck, 1995; Braund, 2001) , although some suspect staggering disease to be due to Borna disease virus (BDV) infection (Lundgren et al.,1995) .", [["feline ''staggering disease", "DISEASE", 51, 78], ["feline polioencephalomyelitis", "DISEASE", 94, 123], ["Borna disease virus (BDV) infection", "DISEASE", 258, 293], ["feline", "ORGANISM", 51, 57], ["feline", "ORGANISM", 94, 100], ["Borna disease virus", "ORGANISM", 258, 277], ["BDV", "ORGANISM", 279, 282], ["feline", "SPECIES", 51, 57], ["feline", "SPECIES", 94, 100], ["Borna disease virus", "SPECIES", 258, 277], ["Borna disease virus", "SPECIES", 258, 277], ["BDV", "SPECIES", 279, 282], ["aetiological agent", "TREATMENT", 10, 28], ["feline ''staggering disease''", "PROBLEM", 51, 80], ["so-called feline polioencephalomyelitis", "PROBLEM", 84, 123], ["ck", "TEST", 178, 180], ["staggering disease", "PROBLEM", 226, 244], ["Borna disease virus (BDV) infection", "PROBLEM", 258, 293], ["Borna disease", "OBSERVATION", 258, 271]]], ["Paraneoplastic disorders of the CNS, well known in man, have not been reported in cats and dogs (Braund et al.,1987) .IntroductionRecent studies on a limited range of infectious agents failed to identify the cause of non-suppurative meningoencephalitis in 47% and 23% of dogs and cats, respectively (Rand et al., 1994; Tipold, 1995; Quesnel et al., 1997; K.Melzer, personal communication) .", [["CNS", "ANATOMY", 32, 35], ["Paraneoplastic disorders of the CNS", "DISEASE", 0, 35], ["meningoencephalitis", "DISEASE", 233, 252], ["CNS", "ANATOMICAL_SYSTEM", 32, 35], ["man", "ORGANISM", 51, 54], ["cats", "ORGANISM", 82, 86], ["dogs", "ORGANISM", 91, 95], ["dogs", "ORGANISM", 271, 275], ["cats", "ORGANISM", 280, 284], ["man", "SPECIES", 51, 54], ["cats", "SPECIES", 82, 86], ["dogs", "SPECIES", 91, 95], ["dogs", "SPECIES", 271, 275], ["cats", "SPECIES", 280, 284], ["Paraneoplastic disorders of the CNS", "PROBLEM", 0, 35], ["IntroductionRecent studies", "TEST", 118, 144], ["infectious agents", "TREATMENT", 167, 184], ["non-suppurative meningoencephalitis", "PROBLEM", 217, 252], ["CNS", "ANATOMY", 32, 35], ["non-suppurative", "OBSERVATION_MODIFIER", 217, 232], ["meningoencephalitis", "OBSERVATION", 233, 252]]], ["To provide further information, the present study sought to determine the cause of 86 cases of non-suppurative meningoencephalitis in dogs and cats by the immunohistochemical examination of formalin-\u00a2xed, para\u2044n wax-embedded tissue.", [["tissue", "ANATOMY", 225, 231], ["meningoencephalitis", "DISEASE", 111, 130], ["formalin-\u00a2xed", "CHEMICAL", 190, 203], ["formalin", "CHEMICAL", 190, 198], ["dogs", "ORGANISM", 134, 138], ["cats", "ORGANISM", 143, 147], ["formalin-\u00a2xed", "SIMPLE_CHEMICAL", 190, 203], ["tissue", "TISSUE", 225, 231], ["dogs", "SPECIES", 134, 138], ["cats", "SPECIES", 143, 147], ["the present study", "TEST", 32, 49], ["non-suppurative meningoencephalitis in dogs", "PROBLEM", 95, 138], ["the immunohistochemical examination", "TEST", 151, 186], ["formalin", "TEST", 190, 198], ["non-suppurative", "OBSERVATION_MODIFIER", 95, 110], ["meningoencephalitis", "OBSERVATION", 111, 130], ["embedded tissue", "OBSERVATION", 216, 231]]], ["In addition to examination for known viral and bacterial pathogens and prion protein Sc ,West Nile virus (WNV), a recently emerging cause of disease, was included in the present study (Komar, 2000; Lichtensteiger et al., 2003; Austgen et al., 2004) , together with encephalomyocarditis virus (EMCV), an agent so far demonstrated only in the CNS of pigs and rodents (Nowotny, 1996; Sue et al., 2003) .AnimalsFifty-three canine and 33 feline cases of non-suppurative meningoencephalitis of unknown origin, collected during the period 1998^2003 by the Department of Pathology of the University of Veterinary Medicine Hannover, Germany, were selected.", [["CNS", "ANATOMY", 341, 344], ["encephalomyocarditis virus", "DISEASE", 265, 291], ["meningoencephalitis", "DISEASE", 465, 484], ["prion protein Sc", "GENE_OR_GENE_PRODUCT", 71, 87], ["West Nile virus", "ORGANISM", 89, 104], ["WNV", "ORGANISM", 106, 109], ["encephalomyocarditis virus", "ORGANISM", 265, 291], ["EMCV", "ORGANISM", 293, 297], ["CNS", "ANATOMICAL_SYSTEM", 341, 344], ["pigs", "ORGANISM", 348, 352], ["canine", "ORGANISM", 419, 425], ["feline", "ORGANISM", 433, 439], ["prion protein Sc", "PROTEIN", 71, 87], ["West Nile virus", "SPECIES", 89, 104], ["encephalomyocarditis virus", "SPECIES", 265, 291], ["pigs", "SPECIES", 348, 352], ["canine", "SPECIES", 419, 425], ["West Nile virus", "SPECIES", 89, 104], ["WNV", "SPECIES", 106, 109], ["encephalomyocarditis virus", "SPECIES", 265, 291], ["EMCV", "SPECIES", 293, 297], ["pigs", "SPECIES", 348, 352], ["canine", "SPECIES", 419, 425], ["examination", "TEST", 15, 26], ["known viral and bacterial pathogens", "PROBLEM", 31, 66], ["prion protein Sc", "PROBLEM", 71, 87], ["disease", "PROBLEM", 141, 148], ["encephalomyocarditis virus", "PROBLEM", 265, 291], ["an agent", "TREATMENT", 300, 308], ["non-suppurative meningoencephalitis", "PROBLEM", 449, 484], ["viral", "OBSERVATION", 37, 42], ["bacterial pathogens", "OBSERVATION", 47, 66], ["disease", "OBSERVATION", 141, 148], ["CNS", "ANATOMY", 341, 344], ["non-suppurative", "OBSERVATION_MODIFIER", 449, 464], ["meningoencephalitis", "OBSERVATION", 465, 484], ["unknown origin", "OBSERVATION_MODIFIER", 488, 502]]], ["The case selection was made in the light of a preliminary investigation which revealed that 274 of 1209 (23%) dogs and 146 of 741 (20%) cats examined in a 5-year-period (1998^2002) displayed changes in the CNS.", [["CNS", "ANATOMY", 206, 209], ["dogs", "ORGANISM", 110, 114], ["cats", "ORGANISM", 136, 140], ["CNS", "ANATOMICAL_SYSTEM", 206, 209], ["dogs", "SPECIES", 110, 114], ["cats", "SPECIES", 136, 140], ["a preliminary investigation", "TEST", 44, 71], ["dogs", "TEST", 110, 114], ["cats", "TEST", 136, 140], ["changes in the CNS", "PROBLEM", 191, 209], ["CNS", "ANATOMY", 206, 209]]], ["Non-suppurative meningoencephalitis accounted for 22% and 49% of the CNS changes in dogs and cats, respectively.", [["CNS", "ANATOMY", 69, 72], ["meningoencephalitis", "DISEASE", 16, 35], ["CNS", "ANATOMICAL_SYSTEM", 69, 72], ["dogs", "ORGANISM", 84, 88], ["cats", "ORGANISM", 93, 97], ["dogs", "SPECIES", 84, 88], ["cats", "SPECIES", 93, 97], ["Non-suppurative meningoencephalitis", "PROBLEM", 0, 35], ["meningoencephalitis", "OBSERVATION", 16, 35], ["CNS", "ANATOMY", 69, 72]]], ["The cause of 49 canine and 32 feline cases remained undetermined after examination by routine diagnostic procedures.", [["canine", "ORGANISM", 16, 22], ["feline", "ORGANISM", 30, 36], ["canine", "SPECIES", 16, 22], ["examination", "TEST", 71, 82], ["routine diagnostic procedures", "TEST", 86, 115]]], ["These 81 animals, together with four dogs and one cat with undetermined non-suppurative meningoencephalitis encountered in 2003, were included in this study.AnimalsDue to the retrospective nature of the present study, clinical data were restricted to a short statement from the records of the Department of Pathology in most cases (46 dogs and 30 cats).", [["meningoencephalitis", "DISEASE", 88, 107], ["dogs", "ORGANISM", 37, 41], ["cat", "ORGANISM", 50, 53], ["dogs", "ORGANISM", 335, 339], ["cats", "ORGANISM", 347, 351], ["dogs", "SPECIES", 37, 41], ["cat", "SPECIES", 50, 53], ["dogs", "SPECIES", 335, 339], ["cats", "SPECIES", 347, 351], ["undetermined non-suppurative meningoencephalitis", "PROBLEM", 59, 107], ["this study", "TEST", 146, 156], ["the present study", "TEST", 199, 216], ["non-suppurative", "OBSERVATION_MODIFIER", 72, 87], ["meningoencephalitis", "OBSERVATION", 88, 107]]], ["In seven dogs and three cats, no clinical history was available.HistologyArchived CNS sections of each case, stained with haematoxylin and eosin (HE), were re-examined for in-\u00a3ammatory changes.", [["CNS sections", "ANATOMY", 82, 94], ["haematoxylin", "CHEMICAL", 122, 134], ["eosin", "CHEMICAL", 139, 144], ["dogs", "ORGANISM", 9, 13], ["cats", "ORGANISM", 24, 28], ["CNS sections", "CANCER", 82, 94], ["haematoxylin", "SIMPLE_CHEMICAL", 122, 134], ["dogs", "SPECIES", 9, 13], ["cats", "SPECIES", 24, 28], ["Histology", "TEST", 64, 73], ["haematoxylin", "TEST", 122, 134], ["eosin", "TEST", 139, 144]]], ["From each animal, one section of the cerebral cortex, the hippocampus (missing in three dogs and four cats), the midbrain (missing in \u00a2ve dogs and \u00a2ve cats), the cerebellum (missing in two dogs and two cats), the brain stem (missing in 17 dogs and 13 cats) and the spinal cord (available in only seven dogs and two cats) were examined.", [["cerebral cortex", "ANATOMY", 37, 52], ["hippocampus", "ANATOMY", 58, 69], ["midbrain", "ANATOMY", 113, 121], ["cerebellum", "ANATOMY", 162, 172], ["brain stem", "ANATOMY", 213, 223], ["spinal cord", "ANATOMY", 265, 276], ["cerebral cortex", "MULTI-TISSUE_STRUCTURE", 37, 52], ["hippocampus", "MULTI-TISSUE_STRUCTURE", 58, 69], ["cats", "ORGANISM", 102, 106], ["midbrain", "ORGAN", 113, 121], ["dogs", "ORGANISM", 138, 142], ["cats", "ORGANISM", 151, 155], ["cerebellum", "ORGAN", 162, 172], ["dogs", "ORGANISM", 189, 193], ["cats", "ORGANISM", 202, 206], ["brain stem", "TISSUE", 213, 223], ["dogs", "ORGANISM", 239, 243], ["cats", "ORGANISM", 251, 255], ["spinal cord", "ORGAN", 265, 276], ["dogs", "ORGANISM", 302, 306], ["cats", "ORGANISM", 315, 319], ["dogs", "SPECIES", 88, 92], ["cats", "SPECIES", 102, 106], ["dogs", "SPECIES", 138, 142], ["cats", "SPECIES", 151, 155], ["dogs", "SPECIES", 189, 193], ["cats", "SPECIES", 202, 206], ["dogs", "SPECIES", 239, 243], ["cats", "SPECIES", 251, 255], ["dogs", "SPECIES", 302, 306], ["cats", "SPECIES", 315, 319], ["cerebral cortex", "ANATOMY", 37, 52], ["hippocampus", "ANATOMY", 58, 69], ["midbrain", "ANATOMY", 113, 121], ["cerebellum", "ANATOMY", 162, 172], ["brain stem", "ANATOMY", 213, 223], ["spinal cord", "ANATOMY", 265, 276]]], ["In one canine section, a spinal cord ganglion was present.", [["spinal cord ganglion", "ANATOMY", 25, 45], ["canine", "ORGANISM", 7, 13], ["spinal cord ganglion", "MULTI-TISSUE_STRUCTURE", 25, 45], ["spinal cord", "ANATOMY", 25, 36], ["ganglion", "ANATOMY", 37, 45]]], ["The distribution of the lesions (e.g., polio-, leuco-, and panencephalitis) was categorized according to Summers et al. (1995) .", [["lesions", "ANATOMY", 24, 31], ["leuco-", "DISEASE", 47, 53], ["panencephalitis", "DISEASE", 59, 74], ["lesions", "PATHOLOGICAL_FORMATION", 24, 31], ["the lesions (e.g., polio-, leuco-, and panencephalitis)", "PROBLEM", 20, 75], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["lesions", "OBSERVATION", 24, 31]]], ["The type of in\u00a3ammation was de\u00a2ned as follows: lymphohistiocytic, if in\u00a2ltrates consisted mainly of lymphocytes and macrophages; granulomatous, if macrophages predominated; pyogranulomatous, if neutrophils and macrophages were the main cell types; and mixed, if macrophages, lymphocytes, plasma cells and neutrophils appeared in equal quantities.HistologyThe degree of histological changes were determined semiquantitatively.", [["lymphohistiocytic", "ANATOMY", 47, 64], ["lymphocytes", "ANATOMY", 100, 111], ["macrophages", "ANATOMY", 116, 127], ["granulomatous", "ANATOMY", 129, 142], ["macrophages", "ANATOMY", 147, 158], ["pyogranulomatous", "ANATOMY", 173, 189], ["neutrophils", "ANATOMY", 194, 205], ["macrophages", "ANATOMY", 210, 221], ["cell", "ANATOMY", 236, 240], ["macrophages", "ANATOMY", 262, 273], ["lymphocytes", "ANATOMY", 275, 286], ["plasma cells", "ANATOMY", 288, 300], ["neutrophils", "ANATOMY", 305, 316], ["lymphocytes", "CELL", 100, 111], ["macrophages", "CELL", 116, 127], ["macrophages", "CELL", 147, 158], ["neutrophils", "CELL", 194, 205], ["macrophages", "CELL", 210, 221], ["cell", "CELL", 236, 240], ["macrophages", "CELL", 262, 273], ["lymphocytes", "CELL", 275, 286], ["plasma cells", "CELL", 288, 300], ["neutrophils", "CELL", 305, 316], ["lymphocytes", "CELL_TYPE", 100, 111], ["macrophages", "CELL_TYPE", 116, 127], ["macrophages", "CELL_TYPE", 147, 158], ["neutrophils", "CELL_TYPE", 194, 205], ["macrophages", "CELL_TYPE", 210, 221], ["macrophages", "CELL_TYPE", 262, 273], ["lymphocytes", "CELL_TYPE", 275, 286], ["plasma cells", "CELL_TYPE", 288, 300], ["neutrophils", "CELL_TYPE", 305, 316], ["lymphohistiocytic", "PROBLEM", 47, 64], ["in\u00a2ltrates", "PROBLEM", 69, 79], ["lymphocytes", "PROBLEM", 100, 111], ["macrophages", "PROBLEM", 116, 127], ["granulomatous", "PROBLEM", 129, 142], ["macrophages", "PROBLEM", 147, 158], ["pyogranulomatous", "PROBLEM", 173, 189], ["neutrophils", "PROBLEM", 194, 205], ["macrophages", "PROBLEM", 210, 221], ["macrophages", "TEST", 262, 273], ["lymphocytes", "TEST", 275, 286], ["plasma cells", "TEST", 288, 300], ["neutrophils", "TEST", 305, 316], ["Histology", "TEST", 346, 355], ["histological changes", "PROBLEM", 369, 389], ["lymphohistiocytic", "OBSERVATION", 47, 64], ["lymphocytes", "ANATOMY", 100, 111], ["macrophages", "ANATOMY", 116, 127], ["granulomatous", "OBSERVATION_MODIFIER", 129, 142], ["main cell types", "OBSERVATION", 231, 246], ["lymphocytes", "ANATOMY", 275, 286], ["plasma cells", "OBSERVATION", 288, 300], ["equal quantities", "OBSERVATION_MODIFIER", 329, 345], ["degree", "OBSERVATION_MODIFIER", 359, 365], ["histological", "OBSERVATION", 369, 381]]], ["Perivascular in\u00a2ltrates were described as: mild (1^15 perivascular cells per \u00c2100 \u00a2eld, or 1^2 cell layers per vessel, or both); moderate (16^30 perivascular cells per \u00c2100 \u00a2eld or 2^3 cell layers per vessel, or both); and severe (430 perivascular cells per \u00c2 100 \u00a2eld or X3 cell layers per vessel, or both).", [["Perivascular in\u00a2ltrates", "ANATOMY", 0, 23], ["perivascular cells", "ANATOMY", 54, 72], ["\u00c2100 \u00a2eld", "ANATOMY", 77, 86], ["1^2 cell layers", "ANATOMY", 91, 106], ["vessel", "ANATOMY", 111, 117], ["perivascular cells", "ANATOMY", 145, 163], ["\u00c2100 \u00a2eld", "ANATOMY", 168, 177], ["2^3 cell layers", "ANATOMY", 181, 196], ["vessel", "ANATOMY", 201, 207], ["perivascular cells", "ANATOMY", 235, 253], ["\u00a2eld", "ANATOMY", 264, 268], ["X3 cell layers", "ANATOMY", 272, 286], ["vessel", "ANATOMY", 291, 297], ["Perivascular in\u00a2ltrates", "CELL", 0, 23], ["perivascular cells", "CELL", 54, 72], ["1^2 cell layers", "TISSUE", 91, 106], ["vessel", "MULTI-TISSUE_STRUCTURE", 111, 117], ["perivascular cells", "CELL", 145, 163], ["2^3 cell layers", "TISSUE", 181, 196], ["vessel", "MULTI-TISSUE_STRUCTURE", 201, 207], ["perivascular cells", "CELL", 235, 253], ["vessel", "MULTI-TISSUE_STRUCTURE", 291, 297], ["Perivascular in\u00a2ltrates", "PROBLEM", 0, 23], ["mild (1^15 perivascular cells", "PROBLEM", 43, 72], ["moderate (16^30 perivascular cells", "PROBLEM", 129, 163], ["perivascular cells", "TEST", 235, 253], ["mild", "OBSERVATION_MODIFIER", 43, 47], ["vessel", "ANATOMY", 111, 117], ["moderate", "OBSERVATION_MODIFIER", 129, 137], ["vessel", "ANATOMY", 201, 207], ["severe", "OBSERVATION_MODIFIER", 223, 229], ["perivascular cells", "OBSERVATION", 235, 253], ["vessel", "ANATOMY", 291, 297]]], ["Meningeal in\u00a2ltrates were described as mild (one or no more than a few mild in\u00a2ltrates), moderate (one moderate in\u00a2ltrate or several mild in\u00a2ltrates), or severe (several moderate in\u00a2ltrates or con\u00a3uent in\u00a2ltrates).HistologyIf suggested by histological results, slides were additionally stained with periodic acid^Schi\u00a1 (16 dogs, six cats), Ziehl^Neelsen (11dogs, one cat), Grocott (10 dogs, four cats), luxol-fast blue (nine dogs, one cat), cresylecht-violet (two dogs, one cat), alcian-blue (one cat) or Congo-red (one cat), as described by Romeis (1994) .Immunohistochemistry (IHC)For the detection of 18 infectious agents (Table 1) , the avidin^biotin-peroxidase complex (ABC) method was performed, as previously described (Hsu et al., 1981; Wu \u00ba nschmann et al.,1997) .", [["Meningeal in\u00a2ltrates", "ANATOMY", 0, 20], ["in\u00a2ltrates", "DISEASE", 76, 86], ["in\u00a2ltrates", "DISEASE", 138, 148], ["cresylecht-violet", "CHEMICAL", 441, 458], ["alcian-blue", "CHEMICAL", 480, 491], ["biotin", "CHEMICAL", 648, 654], ["alcian-blue", "CHEMICAL", 480, 491], ["biotin", "CHEMICAL", 648, 654], ["dogs", "ORGANISM", 323, 327], ["cats", "ORGANISM", 333, 337], ["cat", "ORGANISM", 367, 370], ["dogs", "ORGANISM", 385, 389], ["cats", "ORGANISM", 396, 400], ["luxol", "SIMPLE_CHEMICAL", 403, 408], ["dogs", "ORGANISM", 425, 429], ["cat", "ORGANISM", 435, 438], ["dogs", "ORGANISM", 464, 468], ["cat", "ORGANISM", 474, 477], ["cat", "ORGANISM", 497, 500], ["cat", "ORGANISM", 520, 523], ["avidin^biotin-peroxidase complex", "GENE_OR_GENE_PRODUCT", 641, 673], ["avidin^biotin-peroxidase complex", "PROTEIN", 641, 673], ["ABC", "PROTEIN", 675, 678], ["dogs", "SPECIES", 323, 327], ["cats", "SPECIES", 333, 337], ["cat", "SPECIES", 367, 370], ["dogs", "SPECIES", 385, 389], ["cats", "SPECIES", 396, 400], ["dogs", "SPECIES", 425, 429], ["cat", "SPECIES", 435, 438], ["dogs", "SPECIES", 464, 468], ["cat", "SPECIES", 474, 477], ["cat", "SPECIES", 497, 500], ["Meningeal in\u00a2ltrates", "PROBLEM", 0, 20], ["a few mild in\u00a2ltrates)", "PROBLEM", 65, 87], ["moderate (one moderate in\u00a2ltrate", "PROBLEM", 89, 121], ["several mild in\u00a2ltrates)", "PROBLEM", 125, 149], ["severe (several moderate in\u00a2ltrates", "PROBLEM", 154, 189], ["periodic acid", "TEST", 299, 312], ["luxol", "TREATMENT", 403, 408], ["cresylecht-violet", "TREATMENT", 441, 458], ["alcian-blue", "TREATMENT", 480, 491], ["Immunohistochemistry", "TEST", 557, 577], ["the detection", "TEST", 587, 600], ["the avidin^biotin", "TREATMENT", 637, 654], ["in\u00a2ltrates", "OBSERVATION", 10, 20], ["mild", "OBSERVATION_MODIFIER", 39, 43], ["mild", "OBSERVATION_MODIFIER", 71, 75], ["in\u00a2ltrates", "OBSERVATION", 76, 86], ["moderate", "OBSERVATION_MODIFIER", 89, 97], ["one moderate", "OBSERVATION_MODIFIER", 99, 111], ["several", "OBSERVATION_MODIFIER", 125, 132], ["mild", "OBSERVATION_MODIFIER", 133, 137], ["in\u00a2ltrates", "OBSERVATION", 138, 148], ["severe", "OBSERVATION_MODIFIER", 154, 160], ["several", "OBSERVATION_MODIFIER", 162, 169], ["moderate", "OBSERVATION_MODIFIER", 170, 178]]], ["Due to their known cross-reactivity for the detection of canine and feline herpesvirus, parvovirus and coronavirus antigen, the same antibodies were used for both species.", [["canine", "ORGANISM", 57, 63], ["feline herpesvirus", "ORGANISM", 68, 86], ["parvovirus", "ORGANISM", 88, 98], ["coronavirus antigen", "ORGANISM", 103, 122], ["parvovirus and coronavirus antigen", "PROTEIN", 88, 122], ["antibodies", "PROTEIN", 133, 143], ["canine", "SPECIES", 57, 63], ["feline herpesvirus", "SPECIES", 68, 86], ["parvovirus and coronavirus", "SPECIES", 88, 114], ["canine", "SPECIES", 57, 63], ["feline herpesvirus", "SPECIES", 68, 86], ["coronavirus", "SPECIES", 103, 114], ["the detection", "TEST", 40, 53], ["canine and feline herpesvirus", "PROBLEM", 57, 86], ["parvovirus", "PROBLEM", 88, 98], ["coronavirus antigen", "PROBLEM", 103, 122], ["the same antibodies", "TEST", 124, 143]]], ["Feline tissue was not examined for canine adenovirus 1and canine tissue was not examined for feline leukaemia virus (FeLV).", [["tissue", "ANATOMY", 7, 13], ["tissue", "ANATOMY", 65, 71], ["feline leukaemia virus", "DISEASE", 93, 115], ["Feline", "ORGANISM", 0, 6], ["tissue", "TISSUE", 7, 13], ["canine", "ORGANISM", 35, 41], ["adenovirus", "ORGANISM", 42, 52], ["canine", "ORGANISM", 58, 64], ["tissue", "TISSUE", 65, 71], ["feline leukaemia virus", "ORGANISM", 93, 115], ["FeLV", "ORGANISM", 117, 121], ["canine", "SPECIES", 35, 41], ["canine", "SPECIES", 58, 64], ["feline leukaemia virus", "SPECIES", 93, 115], ["canine", "SPECIES", 35, 41], ["canine", "SPECIES", 58, 64], ["feline leukaemia virus", "SPECIES", 93, 115], ["FeLV", "SPECIES", 117, 121], ["canine adenovirus", "PROBLEM", 35, 52], ["feline leukaemia virus", "PROBLEM", 93, 115]]], ["IHC for the detection of FeLVantigen was additionally performed on lymphoid tissue; however, such tissue was available from only 20 of the 33 cats.", [["lymphoid tissue", "ANATOMY", 67, 82], ["tissue", "ANATOMY", 98, 104], ["FeLVantigen", "GENE_OR_GENE_PRODUCT", 25, 36], ["lymphoid tissue", "TISSUE", 67, 82], ["tissue", "TISSUE", 98, 104], ["cats", "ORGANISM", 142, 146], ["FeLVantigen", "PROTEIN", 25, 36], ["cats", "SPECIES", 142, 146], ["IHC", "TEST", 0, 3], ["the detection", "TEST", 8, 21], ["FeLVantigen", "TREATMENT", 25, 36], ["lymphoid tissue", "OBSERVATION", 67, 82]]], ["In one dog that showed immunoreactivity for porcine herpesvirus 1, tissue from the gastrointestinal tract was also examined, and in one dog and two cats showing immunoreactivity for EMCV, myocardial tissue was examined.Immunohistochemistry (IHC)Brie\u00a3y, specimens were dewaxed in graded alcohols and endogenous peroxidase was quenched with H 2 O 2 0.5% in ethanol.The pre-treatments applied to sections (Table 2 ) depended on the primary antibody and were performed as previously described (see below).", [["tissue", "ANATOMY", 67, 73], ["gastrointestinal tract", "ANATOMY", 83, 105], ["myocardial tissue", "ANATOMY", 188, 205], ["specimens", "ANATOMY", 253, 262], ["sections", "ANATOMY", 393, 401], ["H 2 O", "CHEMICAL", 339, 344], ["ethanol", "CHEMICAL", 355, 362], ["alcohols", "CHEMICAL", 286, 294], ["H 2 O 2", "CHEMICAL", 339, 346], ["ethanol", "CHEMICAL", 355, 362], ["dog", "ORGANISM", 7, 10], ["porcine herpesvirus 1", "ORGANISM", 44, 65], ["tissue", "TISSUE", 67, 73], ["gastrointestinal tract", "ORGAN", 83, 105], ["dog", "ORGANISM", 136, 139], ["cats", "ORGANISM", 148, 152], ["EMCV", "ORGANISM", 182, 186], ["myocardial tissue", "TISSUE", 188, 205], ["peroxidase", "GENE_OR_GENE_PRODUCT", 310, 320], ["ethanol", "SIMPLE_CHEMICAL", 355, 362], ["endogenous peroxidase", "PROTEIN", 299, 320], ["primary antibody", "PROTEIN", 429, 445], ["dog", "SPECIES", 7, 10], ["porcine herpesvirus", "SPECIES", 44, 63], ["dog", "SPECIES", 136, 139], ["porcine herpesvirus 1", "SPECIES", 44, 65], ["EMCV", "SPECIES", 182, 186], ["immunoreactivity", "PROBLEM", 23, 39], ["porcine herpesvirus", "PROBLEM", 44, 63], ["EMCV", "PROBLEM", 182, 186], ["myocardial tissue", "TEST", 188, 205], ["Immunohistochemistry", "TEST", 219, 239], ["specimens", "TEST", 253, 262], ["endogenous peroxidase", "TEST", 299, 320], ["The pre-treatments", "TREATMENT", 363, 381], ["the primary antibody", "TEST", 425, 445], ["gastrointestinal tract", "ANATOMY", 83, 105], ["myocardial tissue", "ANATOMY", 188, 205]]], ["The various pre-treatments were as follows: Pronase E (Merck, Darmstadt, Germany; Bahn, 1988) ; trypsin (Fluka, Neu Ulm, Germany; Nietfeld et al., 1989) ; Kovacevic et al., 1997) ; pepsin (Dako, Hamburg, Germany; Bahn, 1988) , proteinase K and formic acid (Merck, Darmstadt, Germany; Hardt et al., 2000) ; and microwave pre-treatment (Kahveci et al., 2003) .", [["K", "CHEMICAL", 238, 239], ["formic acid", "CHEMICAL", 244, 255], ["formic acid", "CHEMICAL", 244, 255], ["Pronase E", "SIMPLE_CHEMICAL", 44, 53], ["trypsin", "GENE_OR_GENE_PRODUCT", 96, 103], ["pepsin", "GENE_OR_GENE_PRODUCT", 181, 187], ["proteinase K", "SIMPLE_CHEMICAL", 227, 239], ["formic acid", "SIMPLE_CHEMICAL", 244, 255], ["Merck", "SIMPLE_CHEMICAL", 257, 262], ["proteinase K", "TEST", 227, 239], ["formic acid", "TEST", 244, 255]]], ["Goat serum, diluted 1 in 5 in phosphate-bu\u00a1ered saline (PBS), served as a blocking serum.", [["serum", "ANATOMY", 5, 10], ["serum", "ANATOMY", 83, 88], ["phosphate-bu\u00a1ered", "CHEMICAL", 30, 47], ["phosphate", "CHEMICAL", 30, 39], ["Goat", "ORGANISM", 0, 4], ["serum", "ORGANISM_SUBSTANCE", 5, 10], ["phosphate-bu\u00a1ered saline", "SIMPLE_CHEMICAL", 30, 54], ["PBS", "SIMPLE_CHEMICAL", 56, 59], ["serum", "ORGANISM_SUBSTANCE", 83, 88], ["Goat", "SPECIES", 0, 4], ["Goat", "SPECIES", 0, 4], ["Goat serum", "TEST", 0, 10], ["phosphate-bu\u00a1ered saline (PBS", "TREATMENT", 30, 59], ["a blocking serum", "TEST", 72, 88]]], ["Primary antibodies were, unless stated otherwise, diluted in PBS containing bovine serum albumin (BSA) 1%, and incubated overnight (12^16 h) at 4 1C ( Table 2) .", [["serum", "ANATOMY", 83, 88], ["bovine", "ORGANISM", 76, 82], ["serum", "ORGANISM_SUBSTANCE", 83, 88], ["albumin", "SIMPLE_CHEMICAL", 89, 96], ["BSA", "SIMPLE_CHEMICAL", 98, 101], ["antibodies", "PROTEIN", 8, 18], ["bovine", "SPECIES", 76, 82], ["bovine", "SPECIES", 76, 82], ["Primary antibodies", "TEST", 0, 18], ["bovine serum albumin (BSA)", "TEST", 76, 102]]], ["Biotinylated goat-anti-mouse (gam-b), goatanti-rabbit (gar-b) and goat-anti-\u00a3uorescein-isothiocyanate (ga-FITC-b; directed against the FITCligated anti-feline infectious peritonitis [FIP] virus antibody) antibodies served as secondary antibodies (Vector Laboratories, Burlingame, CA, USA) and were all diluted 1 in 200 in PBS.", [["goat-anti-\u00a3uorescein-isothiocyanate", "CHEMICAL", 66, 101], ["ga-FITC-b", "CHEMICAL", 103, 112], ["infectious peritonitis", "DISEASE", 159, 181], ["FIP", "DISEASE", 183, 186], ["isothiocyanate", "CHEMICAL", 87, 101], ["FITC", "CHEMICAL", 106, 110], ["gam-b", "GENE_OR_GENE_PRODUCT", 30, 35], ["goatanti-rabbit", "ORGANISM", 38, 53], ["gar-b", "SIMPLE_CHEMICAL", 55, 60], ["goat-anti-\u00a3uorescein-isothiocyanate", "SIMPLE_CHEMICAL", 66, 101], ["ga-FITC-b", "SIMPLE_CHEMICAL", 103, 112], ["FITCligated", "ORGANISM", 135, 146], ["anti-feline infectious peritonitis [FIP] virus", "ORGANISM", 147, 193], ["Biotinylated goat-anti-mouse", "PROTEIN", 0, 28], ["gam", "PROTEIN", 30, 33], ["goatanti", "PROTEIN", 38, 46], ["FITCligated anti-feline infectious peritonitis [FIP] virus antibody) antibodies", "PROTEIN", 135, 214], ["secondary antibodies", "PROTEIN", 225, 245], ["goat", "SPECIES", 13, 17], ["anti-mouse", "SPECIES", 18, 28], ["rabbit", "SPECIES", 47, 53], ["goat", "SPECIES", 66, 70], ["rabbit", "SPECIES", 47, 53], ["goat", "SPECIES", 66, 70], ["FITCligated anti-feline infectious peritonitis [FIP] virus", "SPECIES", 135, 193], ["Biotinylated goat", "TEST", 0, 17], ["goatanti", "TEST", 38, 46], ["goat", "TEST", 66, 70], ["anti-\u00a3uorescein", "TREATMENT", 71, 86], ["isothiocyanate", "TREATMENT", 87, 101], ["the FITCligated anti-feline infectious peritonitis", "PROBLEM", 131, 181], ["FIP] virus antibody", "TEST", 183, 202], ["antibodies", "TEST", 204, 214], ["secondary antibodies", "TEST", 225, 245], ["Vector Laboratories", "TEST", 247, 266], ["Burlingame", "TEST", 268, 278], ["infectious", "OBSERVATION_MODIFIER", 159, 169], ["peritonitis", "OBSERVATION", 170, 181]]], ["Finally, sections were incubated with ABC (Vector) for 30 min at room temperature.", [["sections", "ANATOMY", 9, 17], ["ABC", "GENE_OR_GENE_PRODUCT", 38, 41], ["ABC", "PROTEIN", 38, 41]]], ["Between the incubation steps, sections were thoroughly rinsed with PBS.", [["sections", "ANATOMY", 30, 38], ["PBS", "TREATMENT", 67, 70]]], ["Positive antigen\u00e2 ntibody reactions were ''visualized'' by incubation with 3,3 0 -diaminobenzidine-tetrahydrochloride (DAB) with H 2 O 2 0.5% for 10 min followed by mild counterstaining with haematoxylin.", [["3,3 0 -diaminobenzidine-tetrahydrochloride", "CHEMICAL", 75, 117], ["DAB", "CHEMICAL", 119, 122], ["H 2 O", "CHEMICAL", 129, 134], ["3,3 0 -diaminobenzidine-tetrahydrochloride", "CHEMICAL", 75, 117], ["DAB", "CHEMICAL", 119, 122], ["H 2 O 2", "CHEMICAL", 129, 136], ["haematoxylin", "CHEMICAL", 191, 203], ["3,3 0 -diaminobenzidine-tetrahydrochloride", "SIMPLE_CHEMICAL", 75, 117], ["DAB", "SIMPLE_CHEMICAL", 119, 122], ["H 2 O 2", "SIMPLE_CHEMICAL", 129, 136], ["haematoxylin", "SIMPLE_CHEMICAL", 191, 203], ["Positive antigen\u00e2 ntibody reactions", "PROBLEM", 0, 35], ["diaminobenzidine", "TREATMENT", 82, 98], ["tetrahydrochloride", "TREATMENT", 99, 117], ["haematoxylin", "TREATMENT", 191, 203], ["mild", "OBSERVATION_MODIFIER", 165, 169]]], ["In control sections the primary and secondary antibodies were replaced by PBS, control serum or isotype-speci\u00a2c antibodies directed against irrelevant antigens.AnimalsToy breeds constituted 27% (14) ).", [["sections", "ANATOMY", 11, 19], ["primary", "ANATOMY", 24, 31], ["serum", "ANATOMY", 87, 92], ["PBS", "SIMPLE_CHEMICAL", 74, 77], ["serum", "ORGANISM_SUBSTANCE", 87, 92], ["isotype-speci\u00a2c antibodies", "PROTEIN", 96, 122], ["secondary antibodies", "TREATMENT", 36, 56], ["PBS", "TREATMENT", 74, 77], ["control serum", "TEST", 79, 92], ["isotype-speci\u00a2c antibodies", "TREATMENT", 96, 122], ["irrelevant antigens", "PROBLEM", 140, 159]]], ["Animals aged less than 1 year accounted for 38% of a\u00a1ected dogs,37% were1^5 years old, and 21% were aged45 years.", [["Animals", "ORGANISM", 0, 7], ["dogs", "ORGANISM", 59, 63], ["dogs", "SPECIES", 59, 63]]], ["In 4% of dogs the age was unknown.", [["dogs", "ORGANISM", 9, 13], ["dogs", "SPECIES", 9, 13]]], ["The domestic shorthair breed accounted for 52% of affected cats.", [["cats", "ORGANISM", 59, 63], ["cats", "SPECIES", 59, 63], ["affected cats", "PROBLEM", 50, 63]]], ["In 11 cats the breed was unknown.", [["cats", "ORGANISM", 6, 10], ["cats", "SPECIES", 6, 10]]], ["The sexes were represented equally in both species.Clinical SignsNeurological signs, including ataxia, seizures and central blindness, were reported in 35 dogs (68%).", [["ataxia", "DISEASE", 95, 101], ["seizures", "DISEASE", 103, 111], ["central blindness", "DISEASE", 116, 133], ["dogs", "SPECIES", 155, 159], ["Clinical SignsNeurological signs", "TEST", 51, 83], ["ataxia", "PROBLEM", 95, 101], ["seizures", "PROBLEM", 103, 111], ["central blindness", "PROBLEM", 116, 133], ["central", "ANATOMY_MODIFIER", 116, 123], ["blindness", "OBSERVATION", 124, 133]]], ["Nine dogs (17%) showed other symptoms such as vomiting and diarrhoea but lacked neurological signs.", [["neurological", "ANATOMY", 80, 92], ["vomiting", "DISEASE", 46, 54], ["diarrhoea", "DISEASE", 59, 68], ["neurological signs", "DISEASE", 80, 98], ["dogs", "ORGANISM", 5, 9], ["dogs", "SPECIES", 5, 9], ["other symptoms", "PROBLEM", 23, 37], ["vomiting", "PROBLEM", 46, 54], ["diarrhoea", "PROBLEM", 59, 68], ["lacked neurological signs", "PROBLEM", 73, 98]]], ["One dog died spontaneously and one under anaesthesia during routine surgery, no clinical signs having been reported before death.", [["death", "DISEASE", 123, 128], ["dog", "ORGANISM", 4, 7], ["dog", "SPECIES", 4, 7], ["routine surgery", "TREATMENT", 60, 75], ["clinical signs", "PROBLEM", 80, 94]]], ["In seven dogs no clinical data were available.Clinical SignsNeurological signs were reported in 17 cats (52%).", [["dogs", "ORGANISM", 9, 13], ["cats", "ORGANISM", 99, 103], ["dogs", "SPECIES", 9, 13], ["clinical data", "TEST", 17, 30], ["Clinical SignsNeurological signs", "TEST", 46, 78]]], ["Thirteen (39%) showed gastrointestinal or respiratory signs but not neurological signs.", [["gastrointestinal", "ANATOMY", 22, 38], ["respiratory", "ANATOMY", 42, 53], ["neurological", "ANATOMY", 68, 80], ["gastrointestinal or respiratory signs", "DISEASE", 22, 59], ["gastrointestinal", "ORGAN", 22, 38], ["gastrointestinal or respiratory signs", "PROBLEM", 22, 59], ["neurological signs", "PROBLEM", 68, 86], ["gastrointestinal", "ANATOMY", 22, 38], ["respiratory signs", "OBSERVATION", 42, 59]]], ["In three cats, one of which died spontaneously, no clinical data were available.HistopathologyLymphohistiocytic, perivascular in\u00a2ltrates were found in 40 dogs (75%) and 23 cats (70%).", [["perivascular in\u00a2ltrates", "ANATOMY", 113, 136], ["cats", "ORGANISM", 9, 13], ["perivascular in\u00a2ltrates", "CANCER", 113, 136], ["dogs", "ORGANISM", 154, 158], ["cats", "ORGANISM", 172, 176], ["cats", "SPECIES", 9, 13], ["dogs", "SPECIES", 154, 158], ["cats", "SPECIES", 172, 176], ["clinical data", "TEST", 51, 64], ["perivascular in\u00a2ltrates", "TEST", 113, 136], ["23 cats", "TEST", 169, 176], ["perivascular", "ANATOMY", 113, 125]]], ["Predominantly granulomatous in\u00a2ltrates were found in 10 dogs and two cats.", [["granulomatous in\u00a2ltrates", "ANATOMY", 14, 38], ["granulomatous in\u00a2ltrates", "CANCER", 14, 38], ["dogs", "ORGANISM", 56, 60], ["cats", "ORGANISM", 69, 73], ["dogs", "SPECIES", 56, 60], ["cats", "SPECIES", 69, 73], ["Predominantly granulomatous in\u00a2ltrates", "PROBLEM", 0, 38], ["granulomatous", "OBSERVATION", 14, 27]]], ["Mixed in\u00a3ammatory in\u00a2ltrates appeared more often in cats (six animals) than in dogs (two animals).", [["cats", "ORGANISM", 52, 56], ["dogs", "ORGANISM", 79, 83], ["cats", "SPECIES", 52, 56], ["dogs", "SPECIES", 79, 83], ["Mixed in\u00a3ammatory in\u00a2ltrates", "PROBLEM", 0, 28], ["more often", "OBSERVATION_MODIFIER", 38, 48]]], ["Two cats and one dog exhibited pyogranulomatous in\u00a3ammation.", [["in\u00a3ammation", "DISEASE", 48, 59], ["cats", "ORGANISM", 4, 8], ["dog", "ORGANISM", 17, 20], ["cats", "SPECIES", 4, 8], ["dog", "SPECIES", 17, 20], ["pyogranulomatous in\u00a3ammation", "PROBLEM", 31, 59], ["pyogranulomatous in\u00a3ammation", "OBSERVATION", 31, 59]]], ["In 39 dogs (74%), encephalitis was the most prominent \u00a2nding.", [["encephalitis", "DISEASE", 18, 30], ["dogs", "ORGANISM", 6, 10], ["dogs", "SPECIES", 6, 10], ["encephalitis", "PROBLEM", 18, 30], ["encephalitis", "OBSERVATION", 18, 30], ["most prominent", "OBSERVATION_MODIFIER", 39, 53]]], ["In 13 dogs (25%), in\u00a2ltrates were restricted to the meninx and a ganglioneuritis without encephalitis or meningitis was found in one animal.", [["meninx", "ANATOMY", 52, 58], ["meninx", "DISEASE", 52, 58], ["ganglioneuritis", "DISEASE", 65, 80], ["encephalitis", "DISEASE", 89, 101], ["meningitis", "DISEASE", 105, 115], ["dogs", "ORGANISM", 6, 10], ["meninx", "CANCER", 52, 58], ["dogs", "SPECIES", 6, 10], ["a ganglioneuritis", "PROBLEM", 63, 80], ["encephalitis", "PROBLEM", 89, 101], ["meningitis", "PROBLEM", 105, 115], ["without", "UNCERTAINTY", 81, 88], ["encephalitis", "OBSERVATION", 89, 101], ["meningitis", "OBSERVATION", 105, 115]]], ["In 26 cats (79%), encephalitis was observed.", [["encephalitis", "DISEASE", 18, 30], ["cats", "ORGANISM", 6, 10], ["cats", "SPECIES", 6, 10], ["encephalitis", "PROBLEM", 18, 30], ["encephalitis", "OBSERVATION", 18, 30]]], ["In six cats (18%), in\u00a2ltrates were restricted to the meninx and a chorioiditis without encephalitis was found in one animal.", [["meninx", "ANATOMY", 53, 59], ["chorioiditis", "DISEASE", 66, 78], ["encephalitis", "DISEASE", 87, 99], ["cats", "ORGANISM", 7, 11], ["meninx", "CANCER", 53, 59], ["chorioiditis", "CANCER", 66, 78], ["cats", "SPECIES", 7, 11], ["a chorioiditis", "PROBLEM", 64, 78], ["encephalitis", "PROBLEM", 87, 99], ["without", "UNCERTAINTY", 79, 86], ["encephalitis", "OBSERVATION", 87, 99]]], ["Six dogs showed, in addition to the in\u00a3ammatory changes in the CNS, mild-to-moderate vacuolation of the white matter of the cerebrum (three animals) or cerebellum (one animal) or both (two animals).", [["CNS", "ANATOMY", 63, 66], ["white matter", "ANATOMY", 104, 116], ["cerebrum", "ANATOMY", 124, 132], ["cerebellum", "ANATOMY", 152, 162], ["dogs", "ORGANISM", 4, 8], ["CNS", "ANATOMICAL_SYSTEM", 63, 66], ["cerebrum", "ORGAN", 124, 132], ["cerebellum", "ORGAN", 152, 162], ["dogs", "SPECIES", 4, 8], ["the in\u00a3ammatory changes in the CNS", "PROBLEM", 32, 66], ["mild-to-moderate vacuolation of the white matter", "PROBLEM", 68, 116], ["CNS", "ANATOMY", 63, 66], ["mild", "OBSERVATION_MODIFIER", 68, 72], ["-to-moderate", "OBSERVATION_MODIFIER", 72, 84], ["vacuolation", "OBSERVATION", 85, 96], ["white matter", "ANATOMY_MODIFIER", 104, 116], ["cerebrum", "ANATOMY", 124, 132], ["cerebellum", "ANATOMY", 152, 162]]], ["Luxol-fast-blue staining revealed demyelination in two of these dogs.", [["Luxol", "CHEMICAL", 0, 5], ["demyelination", "DISEASE", 34, 47], ["Luxol", "CHEMICAL", 0, 5], ["Luxol", "SIMPLE_CHEMICAL", 0, 5], ["dogs", "ORGANISM", 64, 68], ["dogs", "SPECIES", 64, 68], ["Luxol", "TEST", 0, 5], ["blue staining", "TEST", 11, 24], ["demyelination", "PROBLEM", 34, 47], ["demyelination", "OBSERVATION", 34, 47]]], ["Only one of these six dogs showed an in-\u00a3ammatory in\u00a2ltrate within the areas of vacuolation.HistopathologyTwo cats showed in addition to the in\u00a3ammatory changes in the CNS, mild vacuolation of the white matter of the cerebellum (one animal; severe) or both cerebrum and cerebellum (one animal; mild).", [["CNS", "ANATOMY", 168, 171], ["white matter", "ANATOMY", 197, 209], ["cerebellum", "ANATOMY", 217, 227], ["cerebrum", "ANATOMY", 257, 265], ["cerebellum", "ANATOMY", 270, 280], ["dogs", "ORGANISM", 22, 26], ["cats", "ORGANISM", 110, 114], ["CNS", "ANATOMICAL_SYSTEM", 168, 171], ["cerebellum", "ORGAN", 217, 227], ["cerebrum", "ORGAN", 257, 265], ["cerebellum", "ORGAN", 270, 280], ["dogs", "SPECIES", 22, 26], ["vacuolation", "PROBLEM", 80, 91], ["HistopathologyTwo cats", "TEST", 92, 114], ["the in\u00a3ammatory changes in the CNS", "PROBLEM", 137, 171], ["mild vacuolation of the white matter of the cerebellum", "PROBLEM", 173, 227], ["severe) or both cerebrum and cerebellum", "PROBLEM", 241, 280], ["areas", "OBSERVATION_MODIFIER", 71, 76], ["vacuolation", "OBSERVATION", 80, 91], ["CNS", "ANATOMY", 168, 171], ["mild", "OBSERVATION_MODIFIER", 173, 177], ["vacuolation", "OBSERVATION", 178, 189], ["white matter", "ANATOMY_MODIFIER", 197, 209], ["cerebellum", "ANATOMY", 217, 227], ["severe", "OBSERVATION_MODIFIER", 241, 247], ["both", "ANATOMY_MODIFIER", 252, 256], ["cerebrum", "ANATOMY", 257, 265], ["cerebellum", "ANATOMY", 270, 280], ["mild", "OBSERVATION_MODIFIER", 294, 298]]], ["Luxol-fastblue staining did not reveal demyelination.HistopathologyOf the nine dogs without neurological signs, one showed mild, focal meningitis and two showed mild, multifocal meningitis.", [["neurological", "ANATOMY", 92, 104], ["Luxol-fastblue", "CHEMICAL", 0, 14], ["demyelination", "DISEASE", 39, 52], ["neurological signs", "DISEASE", 92, 110], ["meningitis", "DISEASE", 135, 145], ["meningitis", "DISEASE", 178, 188], ["Luxol", "SIMPLE_CHEMICAL", 0, 5], ["dogs", "ORGANISM", 79, 83], ["dogs", "SPECIES", 79, 83], ["Luxol-fastblue staining", "TEST", 0, 23], ["demyelination", "PROBLEM", 39, 52], ["neurological signs", "TEST", 92, 110], ["mild, focal meningitis", "PROBLEM", 123, 145], ["mild, multifocal meningitis", "PROBLEM", 161, 188], ["demyelination", "OBSERVATION", 39, 52], ["mild", "OBSERVATION_MODIFIER", 123, 127], ["focal", "OBSERVATION_MODIFIER", 129, 134], ["meningitis", "OBSERVATION", 135, 145], ["mild", "OBSERVATION_MODIFIER", 161, 165], ["multifocal", "OBSERVATION_MODIFIER", 167, 177], ["meningitis", "OBSERVATION", 178, 188]]], ["Moderate in\u00a3ammation, consisting of multifocal or focal in\u00a2ltrations in various brain regions (midbrain, cerebellum, meninges, choroid plexus) was observed in six dogs.", [["brain", "ANATOMY", 80, 85], ["midbrain", "ANATOMY", 95, 103], ["cerebellum", "ANATOMY", 105, 115], ["meninges", "ANATOMY", 117, 125], ["choroid plexus", "ANATOMY", 127, 141], ["in\u00a3ammation", "DISEASE", 9, 20], ["brain regions", "MULTI-TISSUE_STRUCTURE", 80, 93], ["midbrain", "MULTI-TISSUE_STRUCTURE", 95, 103], ["cerebellum", "MULTI-TISSUE_STRUCTURE", 105, 115], ["meninges", "MULTI-TISSUE_STRUCTURE", 117, 125], ["choroid plexus", "MULTI-TISSUE_STRUCTURE", 127, 141], ["dogs", "ORGANISM", 163, 167], ["dogs", "SPECIES", 163, 167], ["Moderate in\u00a3ammation", "PROBLEM", 0, 20], ["multifocal or focal in\u00a2ltrations in various brain regions (midbrain, cerebellum, meninges, choroid plexus)", "PROBLEM", 36, 142], ["in\u00a3ammation", "OBSERVATION", 9, 20], ["multifocal", "OBSERVATION_MODIFIER", 36, 46], ["focal", "OBSERVATION_MODIFIER", 50, 55], ["in\u00a2ltrations", "OBSERVATION", 56, 68], ["various", "ANATOMY_MODIFIER", 72, 79], ["brain", "ANATOMY", 80, 85], ["regions", "ANATOMY_MODIFIER", 86, 93], ["midbrain", "ANATOMY_MODIFIER", 95, 103], ["cerebellum", "ANATOMY", 105, 115], ["meninges", "ANATOMY", 117, 125], ["choroid plexus", "ANATOMY", 127, 141]]], ["In\u00a3ammatory changes were lymphohistiocytic (six cases), mixed (two cases) or granulomatous (one case).HistopathologyThe 13 cats without neurological signs showed mild, multifocal in\u00a3ammation of the meninx (two cases), meninx and cerebellum (two), meninx and cerebrum (one), meninx, cerebrum and brainstem (one), meninxARTICLE IN PRESS8000 (PBS contained 20% NSS but no BSA), adsorbed to rat brain powderARTICLE IN PRESSMicrowave gam-b Anti-prion protein Sc 400 (PBS contained 10% goat serum but no BSA); no further blocking with goat serum necessary Formic acid, proteinase K, microwaveARTICLE IN PRESSAnti-E. coli 1600 None gar-b NSS, normal swine serum; TUF, target unmasking \u00a3uid; gam-b, biotinylated goat-anti-mouse antibody; gar-b, biotinylated goat-anti-rabbit antibody; ga-FITC-b, biotinylated goat-anti-FITC antibody (see Materials and Methods).", [["lymphohistiocytic", "ANATOMY", 25, 42], ["granulomatous", "ANATOMY", 77, 90], ["neurological", "ANATOMY", 136, 148], ["meninx", "ANATOMY", 198, 204], ["meninx", "ANATOMY", 218, 224], ["cerebellum", "ANATOMY", 229, 239], ["meninx", "ANATOMY", 247, 253], ["cerebrum", "ANATOMY", 258, 266], ["meninx", "ANATOMY", 274, 280], ["cerebrum", "ANATOMY", 282, 290], ["brainstem", "ANATOMY", 295, 304], ["brain", "ANATOMY", 391, 396], ["serum", "ANATOMY", 485, 490], ["serum", "ANATOMY", 534, 539], ["serum", "ANATOMY", 649, 654], ["Formic acid", "CHEMICAL", 550, 561], ["K", "CHEMICAL", 574, 575], ["Formic acid", "CHEMICAL", 550, 561], ["FITC", "CHEMICAL", 780, 784], ["FITC", "CHEMICAL", 811, 815], ["cats", "ORGANISM", 123, 127], ["meninx", "CANCER", 198, 204], ["meninx", "CANCER", 218, 224], ["cerebellum", "ORGAN", 229, 239], ["meninx", "CANCER", 247, 253], ["cerebrum", "ORGAN", 258, 266], ["meninx", "CANCER", 274, 280], ["cerebrum", "ORGAN", 282, 290], ["brainstem", "ORGAN", 295, 304], ["BSA", "SIMPLE_CHEMICAL", 369, 372], ["rat", "ORGANISM", 387, 390], ["brain", "ORGAN", 391, 396], ["gam-b Anti-prion protein Sc 400", "GENE_OR_GENE_PRODUCT", 429, 460], ["goat", "ORGANISM", 480, 484], ["serum", "ORGANISM_SUBSTANCE", 485, 490], ["BSA", "SIMPLE_CHEMICAL", 498, 501], ["goat", "ORGANISM", 529, 533], ["serum", "ORGANISM_SUBSTANCE", 534, 539], ["Formic acid", "SIMPLE_CHEMICAL", 550, 561], ["proteinase K", "SIMPLE_CHEMICAL", 563, 575], ["E. coli", "ORGANISM", 607, 614], ["swine", "ORGANISM", 643, 648], ["serum", "ORGANISM_SUBSTANCE", 649, 654], ["TUF", "SIMPLE_CHEMICAL", 656, 659], ["gam-b", "SIMPLE_CHEMICAL", 684, 689], ["goat", "ORGANISM", 704, 708], ["mouse", "ORGANISM", 714, 719], ["gar-b", "SIMPLE_CHEMICAL", 730, 735], ["goat", "ORGANISM", 750, 754], ["ga-FITC-b", "SIMPLE_CHEMICAL", 777, 786], ["goat", "ORGANISM", 801, 805], ["FITC antibody", "SIMPLE_CHEMICAL", 811, 824], ["target unmasking \u00a3uid; gam-b", "PROTEIN", 661, 689], ["biotinylated goat", "PROTEIN", 691, 708], ["anti-mouse antibody", "PROTEIN", 709, 728], ["gar-b", "PROTEIN", 730, 735], ["biotinylated goat", "PROTEIN", 737, 754], ["anti-rabbit antibody", "PROTEIN", 755, 775], ["ga-FITC-b", "PROTEIN", 777, 786], ["biotinylated goat", "PROTEIN", 788, 805], ["FITC antibody", "PROTEIN", 811, 824], ["cats", "SPECIES", 123, 127], ["rat", "SPECIES", 387, 390], ["goat", "SPECIES", 480, 484], ["goat", "SPECIES", 529, 533], ["E. coli", "SPECIES", 607, 614], ["swine", "SPECIES", 643, 648], ["goat", "SPECIES", 704, 708], ["mouse", "SPECIES", 714, 719], ["goat", "SPECIES", 750, 754], ["anti-rabbit", "SPECIES", 755, 766], ["goat", "SPECIES", 801, 805], ["rat", "SPECIES", 387, 390], ["goat", "SPECIES", 480, 484], ["goat", "SPECIES", 529, 533], ["E. coli", "SPECIES", 607, 614], ["swine", "SPECIES", 643, 648], ["goat", "SPECIES", 704, 708], ["mouse", "SPECIES", 714, 719], ["goat", "SPECIES", 750, 754], ["goat", "SPECIES", 801, 805], ["In\u00a3ammatory changes", "PROBLEM", 0, 19], ["lymphohistiocytic", "PROBLEM", 25, 42], ["mixed (two cases)", "PROBLEM", 56, 73], ["granulomatous", "PROBLEM", 77, 90], ["Histopathology", "TEST", 102, 116], ["neurological signs", "TEST", 136, 154], ["mild, multifocal in\u00a3ammation of the meninx (two cases), meninx and cerebellum (two), meninx and cerebrum (one), meninx, cerebrum and brainstem", "PROBLEM", 162, 304], ["meninxARTICLE IN PRESS8000 (PBS", "TREATMENT", 312, 343], ["20% NSS", "TREATMENT", 354, 361], ["PRESSMicrowave gam", "TEST", 414, 432], ["Anti-prion protein Sc", "TREATMENT", 435, 456], ["PBS", "TEST", 462, 465], ["serum", "TEST", 485, 490], ["BSA", "TEST", 498, 501], ["further blocking", "PROBLEM", 507, 523], ["goat serum", "TEST", 529, 539], ["Formic acid", "TEST", 550, 561], ["proteinase K", "TEST", 563, 575], ["microwaveARTICLE", "TEST", 577, 593], ["PRESSAnti", "TEST", 597, 606], ["E. coli", "TEST", 607, 614], ["gar", "TEST", 625, 628], ["NSS", "TEST", 631, 634], ["serum", "TEST", 649, 654], ["TUF", "TEST", 656, 659], ["\u00a3uid", "TEST", 678, 682], ["gam", "TEST", 684, 687], ["biotinylated goat", "TEST", 691, 708], ["anti-mouse antibody", "TEST", 709, 728], ["gar", "TEST", 730, 733], ["biotinylated goat", "TEST", 737, 754], ["anti-rabbit antibody", "TEST", 755, 775], ["ga-FITC", "TEST", 777, 784], ["biotinylated goat", "TEST", 788, 805], ["anti-FITC antibody", "TEST", 806, 824], ["lymphohistiocytic", "OBSERVATION_MODIFIER", 25, 42], ["mixed", "OBSERVATION_MODIFIER", 56, 61], ["granulomatous", "OBSERVATION_MODIFIER", 77, 90], ["mild", "OBSERVATION_MODIFIER", 162, 166], ["multifocal", "OBSERVATION_MODIFIER", 168, 178], ["meninx", "ANATOMY", 198, 204], ["cerebellum", "ANATOMY", 229, 239], ["cerebrum", "ANATOMY", 258, 266], ["cerebrum", "ANATOMY", 282, 290], ["brainstem", "ANATOMY", 295, 304]]], ["\u00c3 Against agents listed inTable 1. y In phosphate-bu\u00a1ered saline (PBS) containing bovine serum albumin (BSA) 1%. and brainstem (one) or choroid plexus (one).", [["serum", "ANATOMY", 89, 94], ["brainstem", "ANATOMY", 117, 126], ["choroid plexus", "ANATOMY", 136, 150], ["phosphate-bu\u00a1ered", "CHEMICAL", 40, 57], ["phosphate", "CHEMICAL", 40, 49], ["phosphate-bu\u00a1ered saline", "SIMPLE_CHEMICAL", 40, 64], ["PBS", "SIMPLE_CHEMICAL", 66, 69], ["bovine", "ORGANISM", 82, 88], ["serum", "ORGANISM_SUBSTANCE", 89, 94], ["albumin", "SIMPLE_CHEMICAL", 95, 102], ["BSA", "SIMPLE_CHEMICAL", 104, 107], ["brainstem", "CANCER", 117, 126], ["choroid plexus", "MULTI-TISSUE_STRUCTURE", 136, 150], ["bovine", "SPECIES", 82, 88], ["bovine", "SPECIES", 82, 88], ["phosphate-bu\u00a1ered saline (PBS)", "TREATMENT", 40, 70], ["bovine serum albumin (BSA)", "TEST", 82, 108], ["brainstem", "ANATOMY", 117, 126], ["choroid plexus", "ANATOMY", 136, 150]]], ["Also seen were mild-to-moderate in\u00a3ammation of the brainstem (one) and of the meninx and cerebral cortex in addition (one).", [["brainstem", "ANATOMY", 51, 60], ["meninx", "ANATOMY", 78, 84], ["cerebral cortex", "ANATOMY", 89, 104], ["brainstem", "ORGAN", 51, 60], ["meninx", "CANCER", 78, 84], ["cerebral cortex", "CANCER", 89, 104], ["mild-to-moderate in\u00a3ammation of the brainstem", "PROBLEM", 15, 60], ["mild", "OBSERVATION_MODIFIER", 15, 19], ["-to-", "OBSERVATION_MODIFIER", 19, 23], ["moderate", "OBSERVATION_MODIFIER", 23, 31], ["in\u00a3ammation", "OBSERVATION", 32, 43], ["brainstem", "ANATOMY", 51, 60], ["meninx", "ANATOMY", 78, 84], ["cerebral cortex", "ANATOMY", 89, 104]]], ["One cat showed moderate, focal meningitis, one a moderate multifocal meningoencephalitis and one a severe, generalized choroiditis.", [["meningitis", "DISEASE", 31, 41], ["meningoencephalitis", "DISEASE", 69, 88], ["choroiditis", "DISEASE", 119, 130], ["cat", "ORGANISM", 4, 7], ["One cat", "TEST", 0, 7], ["moderate, focal meningitis", "PROBLEM", 15, 41], ["a moderate multifocal meningoencephalitis", "PROBLEM", 47, 88], ["a severe, generalized choroiditis", "PROBLEM", 97, 130], ["moderate", "OBSERVATION_MODIFIER", 15, 23], ["focal", "OBSERVATION_MODIFIER", 25, 30], ["meningitis", "OBSERVATION", 31, 41], ["moderate", "OBSERVATION_MODIFIER", 49, 57], ["multifocal", "OBSERVATION_MODIFIER", 58, 68], ["meningoencephalitis", "OBSERVATION", 69, 88], ["severe", "OBSERVATION_MODIFIER", 99, 105], ["generalized", "OBSERVATION_MODIFIER", 107, 118], ["choroiditis", "OBSERVATION", 119, 130]]], ["The type of in\u00a3ammation was lymphohistiocytic in six cases, mixed in three, granulomatous in two, and pyogranulomatous in two.", [["granulomatous", "ANATOMY", 76, 89], ["pyogranulomatous", "ANATOMY", 102, 118], ["in\u00a3ammation", "DISEASE", 12, 23], ["granulomatous", "DISEASE", 76, 89], ["lymphohistiocytic", "PROBLEM", 28, 45], ["granulomatous", "PROBLEM", 76, 89], ["lymphohistiocytic", "OBSERVATION", 28, 45], ["mixed", "OBSERVATION_MODIFIER", 60, 65], ["granulomatous", "OBSERVATION_MODIFIER", 76, 89], ["pyogranulomatous", "OBSERVATION_MODIFIER", 102, 118]]], ["The gastrointestinal tissue examined in one dog, and the myocardial tissue examined in one dog and two cats, showed no signi\u00a2cant histological changes.Aetiological DiagnosisIn 14 dogs (26%) and 13 cats (39%), viral or bacterial antigens were detected by IHC (Table 3) , two dogs and one cat giving positive results for two infectious agents simultaneously.", [["gastrointestinal tissue", "ANATOMY", 4, 27], ["myocardial tissue", "ANATOMY", 57, 74], ["gastrointestinal tissue", "TISSUE", 4, 27], ["dog", "ORGANISM", 44, 47], ["myocardial tissue", "TISSUE", 57, 74], ["dog", "ORGANISM", 91, 94], ["cats", "ORGANISM", 103, 107], ["dogs", "ORGANISM", 179, 183], ["cats", "ORGANISM", 197, 201], ["dogs", "ORGANISM", 274, 278], ["cat", "ORGANISM", 287, 290], ["dog", "SPECIES", 44, 47], ["dog", "SPECIES", 91, 94], ["cats", "SPECIES", 103, 107], ["dogs", "SPECIES", 179, 183], ["cats", "SPECIES", 197, 201], ["dogs", "SPECIES", 274, 278], ["the myocardial tissue", "PROBLEM", 53, 74], ["two cats", "TEST", 99, 107], ["signi\u00a2cant histological changes", "PROBLEM", 119, 150], ["viral or bacterial antigens", "PROBLEM", 209, 236], ["two infectious agents", "TREATMENT", 319, 340], ["gastrointestinal tissue", "ANATOMY", 4, 27], ["myocardial tissue", "ANATOMY", 57, 74], ["no", "UNCERTAINTY", 116, 118]]], ["Control sections containing the appropriate antigens gave positive signals, in contrast to negative controls.", [["sections", "ANATOMY", 8, 16]]], ["Special histochemical stains invariably gave negative results.Aetiological DiagnosisIn12 of the14 positive dogs and nine of the13 positive cats, reactions were found only in CNS regions in\u00a2ltrated with in\u00a3ammatory cells.", [["CNS", "ANATOMY", 174, 177], ["in\u00a3ammatory cells", "ANATOMY", 202, 219], ["dogs", "ORGANISM", 107, 111], ["cats", "ORGANISM", 139, 143], ["in\u00a3ammatory cells", "CELL", 202, 219], ["in\u00a3ammatory cells", "CELL_TYPE", 202, 219], ["dogs", "SPECIES", 107, 111], ["cats", "SPECIES", 139, 143], ["Special histochemical stains", "TEST", 0, 28], ["the13 positive cats", "PROBLEM", 124, 143], ["in\u00a3ammatory cells", "PROBLEM", 202, 219], ["CNS", "ANATOMY", 174, 177], ["in\u00a3ammatory cells", "OBSERVATION", 202, 219]]], ["The remaining two dogs and four cats showed immunoreactivity only in CNS regions without in\u00a3ammatory in\u00a2ltration.Aetiological DiagnosisOf the 14 positive dogs,12 (94%), had shown neurological signs, almost always said to be severe.", [["CNS", "ANATOMY", 69, 72], ["neurological", "ANATOMY", 179, 191], ["dogs", "ORGANISM", 18, 22], ["cats", "ORGANISM", 32, 36], ["CNS", "ANATOMICAL_SYSTEM", 69, 72], ["dogs", "ORGANISM", 154, 158], ["dogs", "SPECIES", 18, 22], ["dogs", "SPECIES", 154, 158], ["immunoreactivity", "PROBLEM", 44, 60], ["in\u00a3ammatory in\u00a2ltration", "PROBLEM", 89, 112], ["neurological signs", "PROBLEM", 179, 197], ["CNS", "ANATOMY", 69, 72], ["severe", "OBSERVATION", 224, 230]]], ["It was not possible, however, to relate the histological or IHC results to the clinical signs.", [["the clinical signs", "TEST", 75, 93], ["not possible", "UNCERTAINTY", 7, 19]]], ["One dog positive for EMCV antigen did not show neurological signs, and for one dog positive for WNV antigen no clinical data were available.Aetiological DiagnosisOf the 13 positive cats, eight had shown neurological signs (severe in three cases).", [["neurological", "ANATOMY", 47, 59], ["neurological", "ANATOMY", 203, 215], ["neurological signs", "DISEASE", 203, 221], ["dog", "ORGANISM", 4, 7], ["EMCV", "ORGANISM", 21, 25], ["dog", "ORGANISM", 79, 82], ["WNV", "ORGANISM", 96, 99], ["cats", "ORGANISM", 181, 185], ["EMCV antigen", "PROTEIN", 21, 33], ["WNV antigen", "PROTEIN", 96, 107], ["cats", "SPECIES", 181, 185], ["EMCV", "SPECIES", 21, 25], ["WNV", "SPECIES", 96, 99], ["EMCV antigen", "TEST", 21, 33], ["neurological signs", "PROBLEM", 47, 65], ["WNV antigen", "TEST", 96, 107], ["clinical data", "TEST", 111, 124], ["neurological signs (severe in three cases", "PROBLEM", 203, 244], ["severe", "OBSERVATION_MODIFIER", 223, 229]]], ["In the remaining \u00a2ve cats, no statement regarding the severity of signs was recorded.", [["cats", "ORGANISM", 21, 25], ["cats", "SPECIES", 21, 25], ["signs", "PROBLEM", 66, 71]]], ["Four cats with a positive immunoreaction showed no neurological signs.", [["neurological", "ANATOMY", 51, 63], ["cats", "ORGANISM", 5, 9], ["cats", "SPECIES", 5, 9], ["a positive immunoreaction", "TEST", 15, 40], ["neurological signs", "PROBLEM", 51, 69], ["no", "UNCERTAINTY", 48, 50]]], ["For one positive cat, no clinical data were available.Clinical and Light Microscopical Findings in Aetiologically Diagnosed CasesIn a 2-year-old male Canadian shepherd dog with diarrhoea and progressive convulsions, porcine herpesvirus-1 (PHV-1) antigen was demonstrated in neuronal perikarya of the gyrus parahippocampalis.", [["neuronal perikarya", "ANATOMY", 274, 292], ["gyrus parahippocampalis", "ANATOMY", 300, 323], ["diarrhoea", "DISEASE", 177, 186], ["convulsions", "DISEASE", 203, 214], ["cat", "ORGANISM", 17, 20], ["dog", "ORGANISM", 168, 171], ["porcine herpesvirus-1", "ORGANISM", 216, 237], ["PHV-1) antigen", "GENE_OR_GENE_PRODUCT", 239, 253], ["neuronal perikarya", "CELL", 274, 292], ["gyrus parahippocampalis", "ORGANISM", 300, 323], ["dog", "SPECIES", 168, 171], ["porcine herpesvirus-1", "SPECIES", 216, 237], ["Canadian shepherd dog", "SPECIES", 150, 171], ["porcine herpesvirus-1 (PHV-1", "SPECIES", 216, 244], ["gyrus parahippocampalis", "SPECIES", 300, 323], ["clinical data", "TEST", 25, 38], ["diarrhoea", "PROBLEM", 177, 186], ["progressive convulsions", "PROBLEM", 191, 214], ["porcine herpesvirus", "PROBLEM", 216, 235], ["PHV", "TEST", 239, 242], ["progressive", "OBSERVATION_MODIFIER", 191, 202], ["convulsions", "OBSERVATION", 203, 214], ["neuronal", "ANATOMY_MODIFIER", 274, 282], ["perikarya", "ANATOMY_MODIFIER", 283, 292], ["gyrus", "ANATOMY", 300, 305], ["parahippocampalis", "ANATOMY_MODIFIER", 306, 323]]], ["No PHV-1 antigen was detected in the hippocampus, cerebellum, brain stem, spinal cord, remaining part of the cerebrum, or the gastrointestinal tract.", [["hippocampus", "ANATOMY", 37, 48], ["cerebellum", "ANATOMY", 50, 60], ["brain stem", "ANATOMY", 62, 72], ["spinal cord", "ANATOMY", 74, 85], ["cerebrum", "ANATOMY", 109, 117], ["gastrointestinal tract", "ANATOMY", 126, 148], ["PHV-1 antigen", "GENE_OR_GENE_PRODUCT", 3, 16], ["hippocampus", "MULTI-TISSUE_STRUCTURE", 37, 48], ["cerebellum", "ORGAN", 50, 60], ["brain stem", "TISSUE", 62, 72], ["spinal cord", "ORGAN", 74, 85], ["cerebrum", "ORGAN", 109, 117], ["gastrointestinal tract", "ORGAN", 126, 148], ["PHV-1 antigen", "PROTEIN", 3, 16], ["PHV", "TEST", 3, 6], ["hippocampus", "ANATOMY", 37, 48], ["cerebellum", "ANATOMY", 50, 60], ["brain stem", "ANATOMY", 62, 72], ["spinal cord", "ANATOMY", 74, 85], ["remaining", "ANATOMY_MODIFIER", 87, 96], ["cerebrum", "ANATOMY", 109, 117], ["gastrointestinal tract", "ANATOMY", 126, 148]]], ["Histologically, there was mild, lymphohistiocytic polioencephalitis in the gyrus parahippocampalis and occasional neuronal necrosis in the CA1 and CA2 regions of the hippocampus.Clinical and Light Microscopical Findings in Aetiologically Diagnosed CasesParvovirus antigen was demonstrated in the CNS of \u00a2ve Greek hunting dog puppies from two litters originating from the same breeder, and in a 2-week-old cat.", [["gyrus parahippocampalis", "ANATOMY", 75, 98], ["neuronal", "ANATOMY", 114, 122], ["CA1", "ANATOMY", 139, 142], ["CA2 regions", "ANATOMY", 147, 158], ["hippocampus", "ANATOMY", 166, 177], ["CNS", "ANATOMY", 296, 299], ["polioencephalitis", "DISEASE", 50, 67], ["neuronal necrosis", "DISEASE", 114, 131], ["gyrus parahippocampalis", "CANCER", 75, 98], ["neuronal", "CELL", 114, 122], ["CA1", "MULTI-TISSUE_STRUCTURE", 139, 142], ["hippocampus", "MULTI-TISSUE_STRUCTURE", 166, 177], ["CasesParvovirus antigen", "GENE_OR_GENE_PRODUCT", 248, 271], ["CNS", "ANATOMICAL_SYSTEM", 296, 299], ["dog", "ORGANISM", 321, 324], ["puppies", "ORGANISM_SUBDIVISION", 325, 332], ["cat", "ORGANISM", 405, 408], ["CA1 and CA2 regions", "DNA", 139, 158], ["CasesParvovirus antigen", "PROTEIN", 248, 271], ["dog", "SPECIES", 321, 324], ["cat", "SPECIES", 405, 408], ["mild, lymphohistiocytic polioencephalitis in the gyrus parahippocampalis", "PROBLEM", 26, 98], ["occasional neuronal necrosis in the CA1 and CA2 regions of the hippocampus", "PROBLEM", 103, 177], ["CasesParvovirus antigen", "TEST", 248, 271], ["mild", "OBSERVATION_MODIFIER", 26, 30], ["lymphohistiocytic polioencephalitis", "OBSERVATION", 32, 67], ["gyrus", "ANATOMY", 75, 80], ["parahippocampalis", "ANATOMY_MODIFIER", 81, 98], ["occasional", "OBSERVATION_MODIFIER", 103, 113], ["neuronal necrosis", "OBSERVATION", 114, 131], ["CA1", "ANATOMY", 139, 142], ["CA2", "ANATOMY_MODIFIER", 147, 150], ["regions", "ANATOMY_MODIFIER", 151, 158], ["hippocampus", "ANATOMY", 166, 177], ["CNS", "ANATOMY", 296, 299]]], ["Clinically, the dogs had shown generalized tremor and jumping movements in the hind limbs, and the neurological signs in the cat were characterized by severe ataxia, opisthotonus and convulsions.", [["hind limbs", "ANATOMY", 79, 89], ["neurological", "ANATOMY", 99, 111], ["tremor", "DISEASE", 43, 49], ["jumping movements", "DISEASE", 54, 71], ["ataxia", "DISEASE", 158, 164], ["opisthotonus", "DISEASE", 166, 178], ["convulsions", "DISEASE", 183, 194], ["dogs", "ORGANISM", 16, 20], ["hind limbs", "ORGANISM_SUBDIVISION", 79, 89], ["cat", "ORGANISM", 125, 128], ["dogs", "SPECIES", 16, 20], ["generalized tremor", "PROBLEM", 31, 49], ["jumping movements in the hind limbs", "PROBLEM", 54, 89], ["the neurological signs", "TEST", 95, 117], ["severe ataxia", "PROBLEM", 151, 164], ["opisthotonus", "PROBLEM", 166, 178], ["convulsions", "PROBLEM", 183, 194], ["generalized", "OBSERVATION_MODIFIER", 31, 42], ["tremor", "OBSERVATION", 43, 49], ["jumping movements", "OBSERVATION", 54, 71], ["hind limbs", "ANATOMY", 79, 89], ["severe", "OBSERVATION_MODIFIER", 151, 157], ["ataxia", "OBSERVATION", 158, 164]]], ["Neither in the dogs nor in the cat were cerebellar hypoplasia or necrotic Purkinje cells observed.", [["cerebellar", "ANATOMY", 40, 50], ["necrotic Purkinje cells", "ANATOMY", 65, 88], ["cerebellar hypoplasia", "DISEASE", 40, 61], ["necrotic", "DISEASE", 65, 73], ["dogs", "ORGANISM", 15, 19], ["cat", "ORGANISM", 31, 34], ["necrotic Purkinje cells", "CELL", 65, 88], ["necrotic Purkinje cells", "CELL_TYPE", 65, 88], ["dogs", "SPECIES", 15, 19], ["cerebellar hypoplasia", "PROBLEM", 40, 61], ["necrotic Purkinje cells", "PROBLEM", 65, 88], ["cerebellar", "ANATOMY", 40, 50], ["hypoplasia", "OBSERVATION", 51, 61], ["necrotic", "OBSERVATION_MODIFIER", 65, 73], ["Purkinje cells", "OBSERVATION", 74, 88]]], ["Histopathologically, all affected dogs showed mild to moderate lymphohistiocytic meningitis or leucoencephalitis (or both) as well as mild to moderate, and in one case severe, vacuolation in the white matter of cerebrum and cerebellum.", [["white matter", "ANATOMY", 195, 207], ["cerebrum", "ANATOMY", 211, 219], ["cerebellum", "ANATOMY", 224, 234], ["meningitis", "DISEASE", 81, 91], ["leucoencephalitis", "DISEASE", 95, 112], ["dogs", "ORGANISM", 34, 38], ["cerebrum", "ORGAN", 211, 219], ["cerebellum", "ORGAN", 224, 234], ["dogs", "SPECIES", 34, 38], ["all affected dogs", "PROBLEM", 21, 38], ["mild to moderate lymphohistiocytic meningitis", "PROBLEM", 46, 91], ["leucoencephalitis", "PROBLEM", 95, 112], ["vacuolation in the white matter of cerebrum and cerebellum", "PROBLEM", 176, 234], ["mild", "OBSERVATION_MODIFIER", 46, 50], ["moderate", "OBSERVATION_MODIFIER", 54, 62], ["lymphohistiocytic", "OBSERVATION_MODIFIER", 63, 80], ["meningitis", "OBSERVATION", 81, 91], ["leucoencephalitis", "OBSERVATION", 95, 112], ["mild", "OBSERVATION_MODIFIER", 134, 138], ["moderate", "OBSERVATION_MODIFIER", 142, 150], ["severe", "OBSERVATION_MODIFIER", 168, 174], ["vacuolation", "OBSERVATION", 176, 187], ["white matter", "ANATOMY_MODIFIER", 195, 207], ["cerebrum", "ANATOMY", 211, 219], ["cerebellum", "ANATOMY", 224, 234]]], ["Parvovirus antigen was demonstrated in periventricular cells resembling spongioblasts, in macrophages, microglia and astrocytes, and in cells of the outer granular layer of the cerebellum (Fig. 1) .", [["periventricular cells", "ANATOMY", 39, 60], ["spongioblasts", "ANATOMY", 72, 85], ["macrophages", "ANATOMY", 90, 101], ["microglia", "ANATOMY", 103, 112], ["astrocytes", "ANATOMY", 117, 127], ["cells", "ANATOMY", 136, 141], ["outer granular layer", "ANATOMY", 149, 169], ["cerebellum", "ANATOMY", 177, 187], ["periventricular cells", "CELL", 39, 60], ["spongioblasts", "CELL", 72, 85], ["macrophages", "CELL", 90, 101], ["microglia", "CELL", 103, 112], ["astrocytes", "CELL", 117, 127], ["cells", "CELL", 136, 141], ["outer granular layer", "TISSUE", 149, 169], ["cerebellum", "ORGAN", 177, 187], ["Parvovirus antigen", "PROTEIN", 0, 18], ["periventricular cells", "CELL_TYPE", 39, 60], ["spongioblasts", "CELL_TYPE", 72, 85], ["macrophages", "CELL_TYPE", 90, 101], ["microglia", "CELL_TYPE", 103, 112], ["astrocytes", "CELL_TYPE", 117, 127], ["Parvovirus antigen", "TEST", 0, 18], ["periventricular cells", "PROBLEM", 39, 60], ["spongioblasts", "PROBLEM", 72, 85], ["macrophages, microglia and astrocytes", "PROBLEM", 90, 127], ["periventricular cells", "ANATOMY", 39, 60], ["macrophages", "ANATOMY", 90, 101], ["microglia", "ANATOMY", 103, 112], ["astrocytes", "ANATOMY", 117, 127], ["outer", "ANATOMY_MODIFIER", 149, 154], ["granular", "ANATOMY_MODIFIER", 155, 163], ["layer", "ANATOMY_MODIFIER", 164, 169], ["cerebellum", "ANATOMY", 177, 187], ["Fig", "OBSERVATION_MODIFIER", 189, 192]]], ["The histopathological changes in the cat consisted of mild, lymphohistiocytic in\u00a3ammation of the meninges and cerebellum, without vacuolation.", [["meninges", "ANATOMY", 97, 105], ["cerebellum", "ANATOMY", 110, 120], ["cat", "ORGANISM", 37, 40], ["meninges", "MULTI-TISSUE_STRUCTURE", 97, 105], ["cerebellum", "ORGAN", 110, 120], ["The histopathological changes", "PROBLEM", 0, 29], ["mild, lymphohistiocytic in\u00a3ammation of the meninges and cerebellum", "PROBLEM", 54, 120], ["vacuolation", "PROBLEM", 130, 141], ["histopathological", "OBSERVATION", 4, 21], ["mild", "OBSERVATION_MODIFIER", 54, 58], ["lymphohistiocytic in\u00a3ammation", "OBSERVATION", 60, 89], ["meninges", "ANATOMY", 97, 105], ["cerebellum", "ANATOMY", 110, 120], ["without", "UNCERTAINTY", 122, 129], ["vacuolation", "OBSERVATION", 130, 141]]], ["Parvovirus antigen was detected in the cytoplasm and nucleus of numerous small and large neurons, mainly in the granular layer and outer granular layer of the cerebellum, in the grey matter of the spinal cord, and multifocally in most other brain regions (Fig. 2) .", [["cytoplasm", "ANATOMY", 39, 48], ["nucleus", "ANATOMY", 53, 60], ["neurons", "ANATOMY", 89, 96], ["granular layer", "ANATOMY", 112, 126], ["outer granular layer", "ANATOMY", 131, 151], ["cerebellum", "ANATOMY", 159, 169], ["grey matter", "ANATOMY", 178, 189], ["spinal cord", "ANATOMY", 197, 208], ["brain", "ANATOMY", 241, 246], ["Parvovirus antigen", "GENE_OR_GENE_PRODUCT", 0, 18], ["cytoplasm", "ORGANISM_SUBSTANCE", 39, 48], ["nucleus", "CELLULAR_COMPONENT", 53, 60], ["neurons", "CELL", 89, 96], ["granular layer", "TISSUE", 112, 126], ["outer granular layer", "TISSUE", 131, 151], ["cerebellum", "ORGAN", 159, 169], ["spinal cord", "ORGAN", 197, 208], ["brain", "ORGAN", 241, 246], ["Parvovirus antigen", "PROTEIN", 0, 18], ["small and large neurons", "CELL_TYPE", 73, 96], ["Parvovirus antigen", "TEST", 0, 18], ["numerous small and large neurons", "PROBLEM", 64, 96], ["cytoplasm", "ANATOMY_MODIFIER", 39, 48], ["nucleus", "ANATOMY_MODIFIER", 53, 60], ["numerous", "OBSERVATION_MODIFIER", 64, 72], ["small", "OBSERVATION_MODIFIER", 73, 78], ["large", "OBSERVATION_MODIFIER", 83, 88], ["neurons", "OBSERVATION", 89, 96], ["granular", "ANATOMY_MODIFIER", 112, 120], ["layer", "ANATOMY_MODIFIER", 121, 126], ["outer", "ANATOMY_MODIFIER", 131, 136], ["granular", "ANATOMY_MODIFIER", 137, 145], ["layer", "ANATOMY_MODIFIER", 146, 151], ["cerebellum", "ANATOMY", 159, 169], ["grey", "ANATOMY_MODIFIER", 178, 182], ["matter", "ANATOMY_MODIFIER", 183, 189], ["spinal cord", "ANATOMY", 197, 208], ["most", "ANATOMY_MODIFIER", 230, 234], ["brain", "ANATOMY", 241, 246], ["regions", "ANATOMY_MODIFIER", 247, 254], ["Fig", "OBSERVATION_MODIFIER", 256, 259]]], ["In addition, parvovirus antigen was observed in macrophages, microglia, astrocytes and ependymal cells.Clinical and Light Microscopical Findings in Aetiologically Diagnosed CasesFIP virus antigen was detected in three cats aged 6,18 and 36 months.Two a\u00a1ected cats had shown increasing apathy and recurrent fever attacks (one animal) or diarrhoea and dyspnoea (one).", [["macrophages", "ANATOMY", 48, 59], ["microglia", "ANATOMY", 61, 70], ["astrocytes", "ANATOMY", 72, 82], ["ependymal cells", "ANATOMY", 87, 102], ["apathy", "DISEASE", 285, 291], ["fever", "DISEASE", 306, 311], ["diarrhoea", "DISEASE", 336, 345], ["dyspnoea", "DISEASE", 350, 358], ["parvovirus", "ORGANISM", 13, 23], ["antigen", "GENE_OR_GENE_PRODUCT", 24, 31], ["macrophages", "CELL", 48, 59], ["microglia", "CELL", 61, 70], ["astrocytes", "CELL", 72, 82], ["ependymal cells", "CELL", 87, 102], ["cats", "ORGANISM", 218, 222], ["cats", "ORGANISM", 259, 263], ["parvovirus antigen", "PROTEIN", 13, 31], ["macrophages", "CELL_TYPE", 48, 59], ["microglia", "CELL_TYPE", 61, 70], ["astrocytes", "CELL_TYPE", 72, 82], ["ependymal cells", "CELL_TYPE", 87, 102], ["cats", "SPECIES", 218, 222], ["cats", "SPECIES", 259, 263], ["parvovirus", "SPECIES", 13, 23], ["CasesFIP virus", "SPECIES", 173, 187], ["parvovirus antigen", "TEST", 13, 31], ["macrophages", "PROBLEM", 48, 59], ["CasesFIP virus antigen", "TEST", 173, 195], ["increasing apathy", "PROBLEM", 274, 291], ["recurrent fever attacks", "PROBLEM", 296, 319], ["diarrhoea", "PROBLEM", 336, 345], ["dyspnoea", "PROBLEM", 350, 358], ["parvovirus", "OBSERVATION", 13, 23], ["macrophages", "ANATOMY", 48, 59], ["microglia", "ANATOMY", 61, 70], ["astrocytes", "ANATOMY", 72, 82], ["ependymal cells", "OBSERVATION", 87, 102], ["increasing", "OBSERVATION_MODIFIER", 274, 284], ["apathy", "OBSERVATION_MODIFIER", 285, 291], ["recurrent", "OBSERVATION_MODIFIER", 296, 305], ["fever", "OBSERVATION", 306, 311]]], ["No clinical data were available for the third cat.", [["cat", "ORGANISM", 46, 49], ["clinical data", "TEST", 3, 16], ["the third cat", "TEST", 36, 49]]], ["Viral antigen was demonstrated in the cytoplasm of macrophages within the in-\u00a3amed brain regions in all three cases.", [["cytoplasm", "ANATOMY", 38, 47], ["macrophages", "ANATOMY", 51, 62], ["brain", "ANATOMY", 83, 88], ["Viral", "ORGANISM", 0, 5], ["cytoplasm", "ORGANISM_SUBSTANCE", 38, 47], ["macrophages", "CELL", 51, 62], ["brain", "ORGAN", 83, 88], ["Viral antigen", "PROTEIN", 0, 13], ["macrophages", "CELL_TYPE", 51, 62], ["Viral antigen", "TEST", 0, 13], ["cytoplasm", "OBSERVATION_MODIFIER", 38, 47], ["macrophages", "OBSERVATION", 51, 62], ["brain", "ANATOMY", 83, 88], ["regions", "ANATOMY_MODIFIER", 89, 96], ["all three", "ANATOMY_MODIFIER", 100, 109]]], ["Histologically, lesions consisted of pyogranulomatous and mixed in\u00a2ltrates in the plexus chorioideus and the meninges.", [["lesions", "ANATOMY", 16, 23], ["pyogranulomatous", "ANATOMY", 37, 53], ["plexus chorioideus", "ANATOMY", 82, 100], ["meninges", "ANATOMY", 109, 117], ["lesions", "PATHOLOGICAL_FORMATION", 16, 23], ["plexus chorioideus", "MULTI-TISSUE_STRUCTURE", 82, 100], ["meninges", "ORGAN", 109, 117], ["lesions", "PROBLEM", 16, 23], ["pyogranulomatous and mixed in\u00a2ltrates in the plexus chorioideus and the meninges", "PROBLEM", 37, 117], ["lesions", "OBSERVATION", 16, 23], ["pyogranulomatous", "OBSERVATION_MODIFIER", 37, 53], ["mixed in\u00a2ltrates", "OBSERVATION", 58, 74], ["plexus", "ANATOMY", 82, 88], ["chorioideus", "ANATOMY_MODIFIER", 89, 100], ["meninges", "ANATOMY", 109, 117]]], ["The third cat showed moderate lymphohistiocytic leucoencephalitis in the caudal regions of the cerebrum.Non-suppurative MeningoencephalitisWeak immunolabelling for feline leukaemia virus antigen was seen in microglia and astrocytes in the hypothalamus of a 9.5-year-old European shorthair cat with progressive apathy and increased salivation (Fig. 3) .", [["caudal regions", "ANATOMY", 73, 87], ["cerebrum", "ANATOMY", 95, 103], ["microglia", "ANATOMY", 207, 216], ["astrocytes", "ANATOMY", 221, 231], ["hypothalamus", "ANATOMY", 239, 251], ["leucoencephalitis", "DISEASE", 48, 65], ["feline leukaemia", "DISEASE", 164, 180], ["apathy", "DISEASE", 310, 316], ["cat", "ORGANISM", 10, 13], ["caudal regions", "MULTI-TISSUE_STRUCTURE", 73, 87], ["cerebrum", "ORGAN", 95, 103], ["MeningoencephalitisWeak", "GENE_OR_GENE_PRODUCT", 120, 143], ["feline leukaemia virus", "ORGANISM", 164, 186], ["microglia", "CELL", 207, 216], ["astrocytes", "CELL", 221, 231], ["hypothalamus", "ORGAN", 239, 251], ["cat", "ORGANISM", 289, 292], ["feline leukaemia virus antigen", "PROTEIN", 164, 194], ["microglia", "CELL_TYPE", 207, 216], ["astrocytes", "CELL_TYPE", 221, 231], ["feline leukaemia virus", "SPECIES", 164, 186], ["cat", "SPECIES", 289, 292], ["feline leukaemia virus", "SPECIES", 164, 186], ["The third cat", "TEST", 0, 13], ["moderate lymphohistiocytic leucoencephalitis in the caudal regions of the cerebrum", "PROBLEM", 21, 103], ["Non-suppurative MeningoencephalitisWeak immunolabelling", "PROBLEM", 104, 159], ["feline leukaemia virus antigen", "PROBLEM", 164, 194], ["progressive apathy", "PROBLEM", 298, 316], ["increased salivation", "PROBLEM", 321, 341], ["moderate", "OBSERVATION_MODIFIER", 21, 29], ["lymphohistiocytic leucoencephalitis", "OBSERVATION", 30, 65], ["caudal", "ANATOMY_MODIFIER", 73, 79], ["regions", "ANATOMY_MODIFIER", 80, 87], ["cerebrum", "ANATOMY", 95, 103], ["feline leukaemia virus", "OBSERVATION", 164, 186], ["microglia", "ANATOMY", 207, 216], ["hypothalamus", "ANATOMY", 239, 251], ["progressive", "OBSERVATION_MODIFIER", 298, 309], ["apathy", "OBSERVATION", 310, 316], ["increased", "OBSERVATION_MODIFIER", 321, 330], ["salivation", "OBSERVATION", 331, 341]]], ["Histopathological changes consisted of mild multifocal lymphohistiocytic meningitis and severe satellitosis in the cerebral cortex.", [["cerebral cortex", "ANATOMY", 115, 130], ["meningitis", "DISEASE", 73, 83], ["satellitosis", "DISEASE", 95, 107], ["cerebral cortex", "MULTI-TISSUE_STRUCTURE", 115, 130], ["Histopathological changes", "PROBLEM", 0, 25], ["mild multifocal lymphohistiocytic meningitis", "PROBLEM", 39, 83], ["severe satellitosis in the cerebral cortex", "PROBLEM", 88, 130], ["mild", "OBSERVATION_MODIFIER", 39, 43], ["multifocal", "OBSERVATION_MODIFIER", 44, 54], ["lymphohistiocytic meningitis", "OBSERVATION", 55, 83], ["severe", "OBSERVATION_MODIFIER", 88, 94], ["satellitosis", "OBSERVATION", 95, 107], ["cerebral cortex", "ANATOMY", 115, 130]]], ["No lymphoid tissues or other organs were available for further investigations.Non-suppurative MeningoencephalitisFive dogs (8.9%) and four cats (11.8%) showed immunoreactivity for West Nile virus (WNV) antigen.", [["lymphoid tissues", "ANATOMY", 3, 19], ["organs", "ANATOMY", 29, 35], ["Meningoencephalitis", "DISEASE", 94, 113], ["lymphoid tissues", "TISSUE", 3, 19], ["organs", "ORGAN", 29, 35], ["dogs", "ORGANISM", 118, 122], ["cats", "ORGANISM", 139, 143], ["West Nile virus", "ORGANISM", 180, 195], ["WNV", "ORGANISM", 197, 200], ["West Nile virus (WNV) antigen", "PROTEIN", 180, 209], ["dogs", "SPECIES", 118, 122], ["cats", "SPECIES", 139, 143], ["West Nile virus", "SPECIES", 180, 195], ["West Nile virus", "SPECIES", 180, 195], ["WNV", "SPECIES", 197, 200], ["lymphoid tissues", "PROBLEM", 3, 19], ["further investigations", "TEST", 55, 77], ["Non-suppurative Meningoencephalitis", "PROBLEM", 78, 113], ["four cats", "TEST", 134, 143], ["immunoreactivity", "PROBLEM", 159, 175], ["West Nile virus", "PROBLEM", 180, 195], ["lymphoid tissues", "OBSERVATION", 3, 19], ["Meningoencephalitis", "OBSERVATION", 94, 113]]], ["In one dog, canine parain\u00a3uenza virus (CPIV) antigen was also detected in the same brain region (see also below).", [["brain", "ANATOMY", 83, 88], ["dog", "ORGANISM", 7, 10], ["canine parain\u00a3uenza virus", "ORGANISM", 12, 37], ["CPIV) antigen", "GENE_OR_GENE_PRODUCT", 39, 52], ["brain", "ORGAN", 83, 88], ["canine parain\u00a3uenza virus (CPIV) antigen", "PROTEIN", 12, 52], ["dog", "SPECIES", 7, 10], ["canine parain\u00a3uenza virus", "SPECIES", 12, 37], ["canine parain\u00a3uenza virus", "SPECIES", 12, 37], ["CPIV", "SPECIES", 39, 43], ["canine parain\u00a3uenza virus (CPIV) antigen", "PROBLEM", 12, 52], ["brain", "ANATOMY", 83, 88], ["region", "ANATOMY_MODIFIER", 89, 95]]], ["One of these dogs, and one cat also gave positive reactions with EMCV-speci\u00a2c antibodies (see also below).", [["dogs", "ORGANISM", 13, 17], ["cat", "ORGANISM", 27, 30], ["EMCV", "ORGANISM", 65, 69], ["EMCV-speci\u00a2c antibodies", "PROTEIN", 65, 88], ["dogs", "SPECIES", 13, 17], ["EMCV", "SPECIES", 65, 69], ["positive reactions", "PROBLEM", 41, 59], ["EMCV", "PROBLEM", 65, 69], ["speci\u00a2c antibodies", "PROBLEM", 70, 88], ["dogs", "OBSERVATION", 13, 17]]], ["In four of the \u00a2ve dogs, severe neurological signs, including ataxia, convulsions and central blindness, had been recorded.", [["neurological", "ANATOMY", 32, 44], ["neurological signs", "DISEASE", 32, 50], ["ataxia", "DISEASE", 62, 68], ["convulsions", "DISEASE", 70, 81], ["central blindness", "DISEASE", 86, 103], ["dogs", "ORGANISM", 19, 23], ["dogs", "SPECIES", 19, 23], ["severe neurological signs", "PROBLEM", 25, 50], ["ataxia", "PROBLEM", 62, 68], ["convulsions", "PROBLEM", 70, 81], ["central blindness", "PROBLEM", 86, 103], ["severe", "OBSERVATION_MODIFIER", 25, 31], ["central", "OBSERVATION_MODIFIER", 86, 93], ["blindness", "OBSERVATION", 94, 103]]], ["No clinical data were avail-able for the \u00a2fth dog.", [["dog", "ORGANISM", 46, 49], ["clinical data", "TEST", 3, 16]]], ["All four cats had shown neurological signs, reported in one case to consist of severe circling, hypermetria and blindness.", [["neurological", "ANATOMY", 24, 36], ["neurological signs", "DISEASE", 24, 42], ["circling", "DISEASE", 86, 94], ["hypermetria", "DISEASE", 96, 107], ["blindness", "DISEASE", 112, 121], ["cats", "ORGANISM", 9, 13], ["neurological signs", "PROBLEM", 24, 42], ["severe circling", "PROBLEM", 79, 94], ["hypermetria", "PROBLEM", 96, 107], ["blindness", "PROBLEM", 112, 121], ["severe", "OBSERVATION_MODIFIER", 79, 85], ["circling", "OBSERVATION", 86, 94], ["blindness", "OBSERVATION", 112, 121]]], ["In four of the \u00a2ve dogs and two of the four cats a moderate to severe meningoencephalitis a\u00a1ecting the grey and white matter was observed; this varied from granulomatous, pyogranulomatous, lymphohistiocytic to \u00a2brinopurulent, occasionally associated with neuronal necrosis or malacia.", [["white matter", "ANATOMY", 112, 124], ["granulomatous", "ANATOMY", 156, 169], ["pyogranulomatous", "ANATOMY", 171, 187], ["lymphohistiocytic", "ANATOMY", 189, 206], ["neuronal", "ANATOMY", 255, 263], ["meningoencephalitis", "DISEASE", 70, 89], ["\u00a2brinopurulent", "DISEASE", 210, 224], ["neuronal necrosis", "DISEASE", 255, 272], ["malacia", "DISEASE", 276, 283], ["dogs", "ORGANISM", 19, 23], ["cats", "ORGANISM", 44, 48], ["neuronal", "CELL", 255, 263], ["dogs", "SPECIES", 19, 23], ["cats", "SPECIES", 44, 48], ["a moderate to severe meningoencephalitis a\u00a1ecting the grey and white matter", "PROBLEM", 49, 124], ["granulomatous", "PROBLEM", 156, 169], ["pyogranulomatous", "PROBLEM", 171, 187], ["lymphohistiocytic to \u00a2brinopurulent", "PROBLEM", 189, 224], ["neuronal necrosis", "PROBLEM", 255, 272], ["malacia", "PROBLEM", 276, 283], ["moderate", "OBSERVATION_MODIFIER", 51, 59], ["severe", "OBSERVATION_MODIFIER", 63, 69], ["meningoencephalitis", "OBSERVATION", 70, 89], ["grey", "ANATOMY", 103, 107], ["white matter", "OBSERVATION_MODIFIER", 112, 124], ["granulomatous", "OBSERVATION_MODIFIER", 156, 169], ["pyogranulomatous", "OBSERVATION_MODIFIER", 171, 187], ["lymphohistiocytic", "OBSERVATION_MODIFIER", 189, 206], ["neuronal", "OBSERVATION_MODIFIER", 255, 263], ["necrosis", "OBSERVATION", 264, 272], ["malacia", "OBSERVATION", 276, 283]]], ["In the remaining dog, in\u00a3ammation was restricted to the grey matter of the cerebrum and cerebellum, being associated with severe malacia in the hippocampus.", [["grey matter", "ANATOMY", 56, 67], ["cerebrum", "ANATOMY", 75, 83], ["cerebellum", "ANATOMY", 88, 98], ["hippocampus", "ANATOMY", 144, 155], ["malacia", "DISEASE", 129, 136], ["dog", "ORGANISM", 17, 20], ["cerebrum", "ORGAN", 75, 83], ["cerebellum", "ORGAN", 88, 98], ["hippocampus", "ORGAN", 144, 155], ["severe malacia in the hippocampus", "PROBLEM", 122, 155], ["grey matter", "ANATOMY_MODIFIER", 56, 67], ["cerebrum", "ANATOMY", 75, 83], ["cerebellum", "ANATOMY", 88, 98], ["severe", "OBSERVATION_MODIFIER", 122, 128], ["malacia", "OBSERVATION", 129, 136], ["hippocampus", "ANATOMY", 144, 155]]], ["One cat showed mild focal, lymphocytic polioencephalitis and moderate focal, lymphohistiocytic meningitis, as well as severe vacuolation of the cerebral white matter and severe generalized neuronal necrosis.", [["lymphocytic", "ANATOMY", 27, 38], ["cerebral white matter", "ANATOMY", 144, 165], ["neuronal", "ANATOMY", 189, 197], ["polioencephalitis", "DISEASE", 39, 56], ["meningitis", "DISEASE", 95, 105], ["neuronal necrosis", "DISEASE", 189, 206], ["cat", "ORGANISM", 4, 7], ["cerebral", "ORGAN", 144, 152], ["neuronal", "CELL", 189, 197], ["One cat", "TEST", 0, 7], ["mild focal, lymphocytic polioencephalitis", "PROBLEM", 15, 56], ["moderate focal, lymphohistiocytic meningitis", "PROBLEM", 61, 105], ["severe vacuolation of the cerebral white matter", "PROBLEM", 118, 165], ["severe generalized neuronal necrosis", "PROBLEM", 170, 206], ["mild", "OBSERVATION_MODIFIER", 15, 19], ["focal", "OBSERVATION_MODIFIER", 20, 25], ["lymphocytic polioencephalitis", "OBSERVATION", 27, 56], ["moderate", "OBSERVATION_MODIFIER", 61, 69], ["focal", "OBSERVATION_MODIFIER", 70, 75], ["lymphohistiocytic", "OBSERVATION_MODIFIER", 77, 94], ["meningitis", "OBSERVATION", 95, 105], ["severe", "OBSERVATION_MODIFIER", 118, 124], ["vacuolation", "OBSERVATION", 125, 136], ["cerebral white matter", "ANATOMY", 144, 165], ["severe", "OBSERVATION_MODIFIER", 170, 176], ["generalized", "OBSERVATION_MODIFIER", 177, 188], ["neuronal necrosis", "OBSERVATION", 189, 206]]], ["In another cat, severe, focal, \u00a2brinopurulent meningitis and severe, acute neuronal necrosis in the hippocampus were observed.Non-suppurative MeningoencephalitisWNV immunolabelling was seen in the cytoplasm of various types of neurons, macrophages, astrocytes and microglia (Fig. 4) .", [["neuronal", "ANATOMY", 75, 83], ["hippocampus", "ANATOMY", 100, 111], ["cytoplasm", "ANATOMY", 197, 206], ["neurons", "ANATOMY", 227, 234], ["macrophages", "ANATOMY", 236, 247], ["astrocytes", "ANATOMY", 249, 259], ["microglia", "ANATOMY", 264, 273], ["meningitis", "DISEASE", 46, 56], ["necrosis", "DISEASE", 84, 92], ["cat", "ORGANISM", 11, 14], ["neuronal", "CELL", 75, 83], ["hippocampus", "ORGAN", 100, 111], ["MeningoencephalitisWNV", "GENE_OR_GENE_PRODUCT", 142, 164], ["cytoplasm", "ORGANISM_SUBSTANCE", 197, 206], ["neurons", "CELL", 227, 234], ["macrophages", "CELL", 236, 247], ["astrocytes", "CELL", 249, 259], ["microglia", "CELL", 264, 273], ["neurons", "CELL_TYPE", 227, 234], ["macrophages", "CELL_TYPE", 236, 247], ["astrocytes", "CELL_TYPE", 249, 259], ["microglia", "CELL_TYPE", 264, 273], ["cat", "SPECIES", 11, 14], ["severe, focal, \u00a2brinopurulent meningitis", "PROBLEM", 16, 56], ["severe, acute neuronal necrosis in the hippocampus", "PROBLEM", 61, 111], ["Non-suppurative MeningoencephalitisWNV immunolabelling", "PROBLEM", 126, 180], ["astrocytes", "PROBLEM", 249, 259], ["severe", "OBSERVATION_MODIFIER", 16, 22], ["focal", "OBSERVATION_MODIFIER", 24, 29], ["\u00a2brinopurulent", "OBSERVATION_MODIFIER", 31, 45], ["meningitis", "OBSERVATION", 46, 56], ["severe", "OBSERVATION_MODIFIER", 61, 67], ["acute", "OBSERVATION_MODIFIER", 69, 74], ["neuronal", "OBSERVATION_MODIFIER", 75, 83], ["necrosis", "OBSERVATION", 84, 92], ["hippocampus", "ANATOMY", 100, 111], ["various types", "OBSERVATION_MODIFIER", 210, 223], ["neurons", "ANATOMY", 227, 234], ["macrophages", "OBSERVATION", 236, 247], ["astrocytes", "ANATOMY", 249, 259]]], ["Strong immunolabelling of neutrophils was observed in two cats with pyogranulomatous in\u00a3ammation (Fig. 5) .", [["neutrophils", "ANATOMY", 26, 37], ["neutrophils", "CELL", 26, 37], ["cats", "ORGANISM", 58, 62], ["neutrophils", "CELL_TYPE", 26, 37], ["cats", "SPECIES", 58, 62], ["Strong immunolabelling of neutrophils", "PROBLEM", 0, 37], ["pyogranulomatous in\u00a3ammation", "TREATMENT", 68, 96], ["neutrophils", "OBSERVATION", 26, 37], ["pyogranulomatous in\u00a3ammation", "OBSERVATION", 68, 96]]], ["These immunohistochemical reactions were in general more intense with the anti-NSP-1WNVantibody than with the anti-MEP-E WNVantibody.", [["anti-NSP-1WNVantibody", "GENE_OR_GENE_PRODUCT", 74, 95], ["anti-MEP-E WNVantibody", "SIMPLE_CHEMICAL", 110, 132], ["anti-NSP", "PROTEIN", 74, 82], ["anti-MEP", "PROTEIN", 110, 118], ["E WNVantibody", "DNA", 119, 132], ["These immunohistochemical reactions", "PROBLEM", 0, 35]]], ["In some cases, immunoreactivity was observed with only one of these two WNV monoclonal antibodies.", [["WNV", "ORGANISM", 72, 75], ["WNV monoclonal antibodies", "PROTEIN", 72, 97], ["WNV", "SPECIES", 72, 75]]], ["One dog showed immunoreactivity in pyramidal cells of the CA1 and CA2 sector of the hippocampus, and another in the frontal cortex, respectively.", [["pyramidal cells", "ANATOMY", 35, 50], ["CA1", "ANATOMY", 58, 61], ["CA2 sector", "ANATOMY", 66, 76], ["hippocampus", "ANATOMY", 84, 95], ["frontal cortex", "ANATOMY", 116, 130], ["dog", "ORGANISM", 4, 7], ["pyramidal cells", "CELL", 35, 50], ["CA1", "MULTI-TISSUE_STRUCTURE", 58, 61], ["CA2 sector", "MULTI-TISSUE_STRUCTURE", 66, 76], ["hippocampus", "ORGAN", 84, 95], ["frontal cortex", "MULTI-TISSUE_STRUCTURE", 116, 130], ["pyramidal cells", "CELL_TYPE", 35, 50], ["immunoreactivity", "OBSERVATION", 15, 31], ["pyramidal cells", "OBSERVATION", 35, 50], ["CA1", "ANATOMY", 58, 61], ["CA2", "ANATOMY_MODIFIER", 66, 69], ["hippocampus", "ANATOMY", 84, 95], ["frontal", "ANATOMY_MODIFIER", 116, 123], ["cortex", "ANATOMY_MODIFIER", 124, 130]]], ["A positive reaction in numerous macrophages and microglial cells in the midbrain, pons and frontal cerebrum was detected only with the anti-NSP-1 antibody.", [["macrophages", "ANATOMY", 32, 43], ["microglial cells", "ANATOMY", 48, 64], ["midbrain", "ANATOMY", 72, 80], ["pons", "ANATOMY", 82, 86], ["frontal cerebrum", "ANATOMY", 91, 107], ["macrophages", "CELL", 32, 43], ["microglial cells", "CELL", 48, 64], ["midbrain", "MULTI-TISSUE_STRUCTURE", 72, 80], ["pons", "MULTI-TISSUE_STRUCTURE", 82, 86], ["frontal cerebrum", "ORGAN", 91, 107], ["anti-NSP-1 antibody", "GENE_OR_GENE_PRODUCT", 135, 154], ["macrophages", "CELL_TYPE", 32, 43], ["microglial cells", "CELL_TYPE", 48, 64], ["anti-NSP-1 antibody", "PROTEIN", 135, 154], ["A positive reaction in numerous macrophages and microglial cells in the midbrain, pons and frontal cerebrum", "PROBLEM", 0, 107], ["the anti-NSP", "TEST", 131, 143], ["positive", "OBSERVATION_MODIFIER", 2, 10], ["reaction", "OBSERVATION", 11, 19], ["numerous", "OBSERVATION_MODIFIER", 23, 31], ["macrophages", "OBSERVATION", 32, 43], ["microglial cells", "OBSERVATION", 48, 64], ["midbrain", "ANATOMY", 72, 80], ["pons", "ANATOMY", 82, 86], ["frontal cerebrum", "ANATOMY", 91, 107]]], ["One dog showed WNV immunolabelling in numerous macrophages and microglial cells, and pyramidal cells in the cerebrum, hippocampus and midbrain, but only with the anti-NSP-1 antibody.", [["macrophages", "ANATOMY", 47, 58], ["microglial cells", "ANATOMY", 63, 79], ["pyramidal cells", "ANATOMY", 85, 100], ["cerebrum", "ANATOMY", 108, 116], ["hippocampus", "ANATOMY", 118, 129], ["midbrain", "ANATOMY", 134, 142], ["dog", "ORGANISM", 4, 7], ["WNV", "ORGANISM", 15, 18], ["macrophages", "CELL", 47, 58], ["microglial cells", "CELL", 63, 79], ["pyramidal cells", "CELL", 85, 100], ["cerebrum", "ORGAN", 108, 116], ["hippocampus", "MULTI-TISSUE_STRUCTURE", 118, 129], ["midbrain", "ORGAN", 134, 142], ["anti-NSP-1 antibody", "GENE_OR_GENE_PRODUCT", 162, 181], ["macrophages", "CELL_TYPE", 47, 58], ["microglial cells", "CELL_TYPE", 63, 79], ["pyramidal cells", "CELL_TYPE", 85, 100], ["anti-NSP-1 antibody", "PROTEIN", 162, 181], ["dog", "SPECIES", 4, 7], ["WNV", "SPECIES", 15, 18], ["WNV immunolabelling", "TEST", 15, 34], ["microglial cells", "TEST", 63, 79], ["pyramidal cells in the cerebrum, hippocampus and midbrain", "PROBLEM", 85, 142], ["the anti-NSP", "TEST", 158, 170], ["WNV", "OBSERVATION", 15, 18], ["numerous macrophages", "OBSERVATION", 38, 58], ["microglial cells", "OBSERVATION", 63, 79], ["pyramidal cells", "OBSERVATION", 85, 100], ["cerebrum", "ANATOMY", 108, 116], ["hippocampus", "ANATOMY", 118, 129], ["midbrain", "ANATOMY", 134, 142]]], ["Another dog, in contrast, showed immunoreactivity in a few neurons and macrophages in an in\u00a3amed part of the midbrain, but only with the anti-MEP-E antibody.", [["neurons", "ANATOMY", 59, 66], ["macrophages", "ANATOMY", 71, 82], ["midbrain", "ANATOMY", 109, 117], ["dog", "ORGANISM", 8, 11], ["neurons", "CELL", 59, 66], ["macrophages", "CELL", 71, 82], ["midbrain", "ORGAN", 109, 117], ["anti-MEP-E antibody", "GENE_OR_GENE_PRODUCT", 137, 156], ["macrophages", "CELL_TYPE", 71, 82], ["anti-MEP-E antibody", "PROTEIN", 137, 156], ["Another dog, in contrast", "TEST", 0, 24], ["immunoreactivity in a few neurons", "PROBLEM", 33, 66], ["the anti-MEP-E antibody", "TEST", 133, 156], ["immunoreactivity", "OBSERVATION", 33, 49], ["macrophages", "OBSERVATION", 71, 82], ["midbrain", "ANATOMY", 109, 117]]], ["One cat showed immunolabelling with both WNV antibodies in numerous neutrophils and occasional macrophages in the plexus chorioideus and laterally to the third ventricle.", [["neutrophils", "ANATOMY", 68, 79], ["macrophages", "ANATOMY", 95, 106], ["plexus chorioideus", "ANATOMY", 114, 132], ["third ventricle", "ANATOMY", 154, 169], ["cat", "ORGANISM", 4, 7], ["WNV", "ORGANISM", 41, 44], ["neutrophils", "CELL", 68, 79], ["macrophages", "CELL", 95, 106], ["plexus chorioideus", "MULTI-TISSUE_STRUCTURE", 114, 132], ["third ventricle", "MULTI-TISSUE_STRUCTURE", 154, 169], ["WNV antibodies", "PROTEIN", 41, 55], ["neutrophils", "CELL_TYPE", 68, 79], ["macrophages", "CELL_TYPE", 95, 106], ["WNV", "SPECIES", 41, 44], ["immunolabelling", "PROBLEM", 15, 30], ["both WNV antibodies in numerous neutrophils", "PROBLEM", 36, 79], ["occasional macrophages in the plexus chorioideus", "PROBLEM", 84, 132], ["WNV antibodies", "OBSERVATION", 41, 55], ["numerous neutrophils", "OBSERVATION", 59, 79], ["occasional", "OBSERVATION_MODIFIER", 84, 94], ["macrophages", "OBSERVATION", 95, 106], ["plexus chorioideus", "ANATOMY", 114, 132], ["laterally", "ANATOMY_MODIFIER", 137, 146], ["third ventricle", "ANATOMY", 154, 169]]], ["In this cat, small neurons, macrophages and microglial cells in the same brain region reacted only with the anti-NSP-1 antibody.", [["small neurons", "ANATOMY", 13, 26], ["macrophages", "ANATOMY", 28, 39], ["microglial cells", "ANATOMY", 44, 60], ["brain", "ANATOMY", 73, 78], ["cat", "ORGANISM", 8, 11], ["small neurons", "CELL", 13, 26], ["macrophages", "CELL", 28, 39], ["microglial cells", "CELL", 44, 60], ["brain", "ORGAN", 73, 78], ["anti-NSP-1 antibody", "GENE_OR_GENE_PRODUCT", 108, 127], ["small neurons", "CELL_TYPE", 13, 26], ["macrophages", "CELL_TYPE", 28, 39], ["microglial cells", "CELL_TYPE", 44, 60], ["anti-NSP-1 antibody", "PROTEIN", 108, 127], ["microglial cells in the same brain region", "PROBLEM", 44, 85], ["the anti-NSP", "TEST", 104, 116], ["small neurons", "ANATOMY", 13, 26], ["macrophages", "OBSERVATION", 28, 39], ["microglial cells", "OBSERVATION", 44, 60], ["brain", "ANATOMY", 73, 78], ["region", "ANATOMY_MODIFIER", 79, 85]]], ["In another cat, astrocytes and perivascular macrophages in the lobus parietalis reacted with both antibodies, whereas the anti-NSP-1 antibody additionally labelled pyramidal cells in the same brain region.", [["astrocytes", "ANATOMY", 16, 26], ["perivascular macrophages", "ANATOMY", 31, 55], ["lobus parietalis", "ANATOMY", 63, 79], ["pyramidal cells", "ANATOMY", 164, 179], ["brain", "ANATOMY", 192, 197], ["cat", "ORGANISM", 11, 14], ["astrocytes", "CELL", 16, 26], ["perivascular macrophages", "CELL", 31, 55], ["lobus parietalis", "CELL", 63, 79], ["anti-NSP-1 antibody", "GENE_OR_GENE_PRODUCT", 122, 141], ["pyramidal cells", "CELL", 164, 179], ["brain", "ORGAN", 192, 197], ["astrocytes", "CELL_TYPE", 16, 26], ["perivascular macrophages", "CELL_TYPE", 31, 55], ["antibodies", "PROTEIN", 98, 108], ["anti-NSP-1 antibody", "PROTEIN", 122, 141], ["pyramidal cells", "CELL_TYPE", 164, 179], ["cat", "SPECIES", 11, 14], ["lobus parietalis", "SPECIES", 63, 79], ["lobus parietalis", "SPECIES", 63, 79], ["both antibodies", "TEST", 93, 108], ["the anti-NSP-1 antibody", "TEST", 118, 141], ["astrocytes", "ANATOMY", 16, 26], ["perivascular", "ANATOMY_MODIFIER", 31, 43], ["macrophages", "OBSERVATION", 44, 55], ["lobus parietalis", "ANATOMY", 63, 79], ["labelled pyramidal cells", "OBSERVATION", 155, 179], ["same", "ANATOMY_MODIFIER", 187, 191], ["brain", "ANATOMY", 192, 197], ["region", "ANATOMY_MODIFIER", 198, 204]]], ["In one cat, astrocytes and oligodendrocytes of the medulla oblongata displayed more abundant positive signals with the anti-NSP-1 antibody than with anti-MEP-E.", [["astrocytes", "ANATOMY", 12, 22], ["oligodendrocytes", "ANATOMY", 27, 43], ["medulla oblongata", "ANATOMY", 51, 68], ["cat", "ORGANISM", 7, 10], ["astrocytes", "CELL", 12, 22], ["oligodendrocytes", "CELL", 27, 43], ["medulla oblongata", "MULTI-TISSUE_STRUCTURE", 51, 68], ["anti-NSP-1", "GENE_OR_GENE_PRODUCT", 119, 129], ["astrocytes", "CELL_TYPE", 12, 22], ["oligodendrocytes", "CELL_TYPE", 27, 43], ["anti-NSP-1 antibody", "PROTEIN", 119, 138], ["anti-MEP", "PROTEIN", 149, 157], ["cat", "SPECIES", 7, 10], ["the anti-NSP", "TEST", 115, 127], ["anti-MEP", "TEST", 149, 157], ["astrocytes", "ANATOMY", 12, 22], ["oligodendrocytes", "OBSERVATION", 27, 43], ["medulla oblongata", "ANATOMY", 51, 68], ["abundant", "OBSERVATION_MODIFIER", 84, 92], ["positive signals", "OBSERVATION", 93, 109]]], ["Additionally, in this animal, the anti-NSP-1 antibody labelled large neurons in the medulla oblongata which failed to react with the anti-MEP-E antibody.", [["neurons", "ANATOMY", 69, 76], ["medulla oblongata", "ANATOMY", 84, 101], ["anti-NSP-1 antibody", "GENE_OR_GENE_PRODUCT", 34, 53], ["neurons", "CELL", 69, 76], ["medulla oblongata", "MULTI-TISSUE_STRUCTURE", 84, 101], ["anti-MEP-E antibody", "GENE_OR_GENE_PRODUCT", 133, 152], ["anti-NSP-1 antibody", "PROTEIN", 34, 53], ["anti-MEP-E antibody", "PROTEIN", 133, 152], ["the anti-NSP-1 antibody", "TEST", 30, 53], ["large neurons in the medulla oblongata", "PROBLEM", 63, 101], ["the anti-MEP-E antibody", "TEST", 129, 152], ["neurons", "ANATOMY", 69, 76], ["medulla oblongata", "ANATOMY", 84, 101]]], ["Canine parain\u00a3uenza virus (CPIV) antigen was detected in the brain of a 9-year-old male collie that was also positive forWest Nile virus antigen (see alsoWNV, above).", [["brain", "ANATOMY", 61, 66], ["Canine parain\u00a3uenza virus", "ORGANISM", 0, 25], ["CPIV", "GENE_OR_GENE_PRODUCT", 27, 31], ["brain", "ORGAN", 61, 66], ["male", "ORGANISM", 83, 87], ["collie", "ORGANISM", 88, 94], ["forWest Nile virus", "ORGANISM", 118, 136], ["Canine parain\u00a3uenza virus (CPIV) antigen", "PROTEIN", 0, 40], ["forWest Nile virus antigen", "PROTEIN", 118, 144], ["alsoWNV", "PROTEIN", 150, 157], ["Canine parain\u00a3uenza virus", "SPECIES", 0, 25], ["forWest Nile virus", "SPECIES", 118, 136], ["Canine parain\u00a3uenza virus", "SPECIES", 0, 25], ["CPIV", "SPECIES", 27, 31], ["forWest Nile virus", "SPECIES", 118, 136], ["Canine parain\u00a3uenza virus (CPIV) antigen", "TEST", 0, 40], ["positive forWest Nile virus antigen", "PROBLEM", 109, 144], ["parain\u00a3uenza virus", "OBSERVATION", 7, 25], ["brain", "ANATOMY", 61, 66]]], ["This dog had exhibited changed behaviour and was generally weak.", [["dog", "ORGANISM", 5, 8], ["generally weak", "PROBLEM", 49, 63], ["weak", "OBSERVATION", 59, 63]]], ["Histopathologically, severe periventricular granulomatous meningoencephalitis was found.", [["periventricular granulomatous", "ANATOMY", 28, 57], ["periventricular granulomatous meningoencephalitis", "DISEASE", 28, 77], ["periventricular granulomatous", "PATHOLOGICAL_FORMATION", 28, 57], ["severe periventricular granulomatous meningoencephalitis", "PROBLEM", 21, 77], ["severe", "OBSERVATION_MODIFIER", 21, 27], ["periventricular", "OBSERVATION_MODIFIER", 28, 43], ["granulomatous", "OBSERVATION_MODIFIER", 44, 57], ["meningoencephalitis", "OBSERVATION", 58, 77]]], ["Viral antigen was demonstrated in the cytoplasm of occasional macrophages in the hypothalamus (Fig. 6) .ARTICLE IN PRESSIHC revealed encephalomyocarditis virus (EMCV) antigen in the brains of four dogs (7.1%) and four cats (11.8%).", [["cytoplasm", "ANATOMY", 38, 47], ["macrophages", "ANATOMY", 62, 73], ["hypothalamus", "ANATOMY", 81, 93], ["brains", "ANATOMY", 182, 188], ["encephalomyocarditis virus", "DISEASE", 133, 159], ["Viral", "ORGANISM", 0, 5], ["cytoplasm", "ORGANISM_SUBSTANCE", 38, 47], ["macrophages", "CELL", 62, 73], ["hypothalamus", "ORGAN", 81, 93], ["encephalomyocarditis virus", "ORGANISM", 133, 159], ["EMCV", "ORGANISM", 161, 165], ["brains", "ORGAN", 182, 188], ["dogs", "ORGANISM", 197, 201], ["cats", "ORGANISM", 218, 222], ["Viral antigen", "PROTEIN", 0, 13], ["occasional macrophages", "CELL_TYPE", 51, 73], ["encephalomyocarditis virus (EMCV) antigen", "PROTEIN", 133, 174], ["encephalomyocarditis virus", "SPECIES", 133, 159], ["dogs", "SPECIES", 197, 201], ["cats", "SPECIES", 218, 222], ["encephalomyocarditis virus", "SPECIES", 133, 159], ["EMCV", "SPECIES", 161, 165], ["Viral antigen", "TEST", 0, 13], ["occasional macrophages in the hypothalamus", "PROBLEM", 51, 93], ["encephalomyocarditis virus", "PROBLEM", 133, 159], ["four cats", "TEST", 213, 222], ["cytoplasm", "OBSERVATION_MODIFIER", 38, 47], ["occasional macrophages", "OBSERVATION", 51, 73], ["hypothalamus", "ANATOMY", 81, 93], ["encephalomyocarditis virus", "OBSERVATION", 133, 159]]], ["In one dog and one cat, WNV-antigen was detected in addition (see also WNV, above).", [["dog", "ORGANISM", 7, 10], ["cat", "ORGANISM", 19, 22], ["WNV", "ORGANISM", 24, 27], ["-antigen", "GENE_OR_GENE_PRODUCT", 27, 35], ["WNV-antigen", "PROTEIN", 24, 35], ["dog", "SPECIES", 7, 10], ["cat", "SPECIES", 19, 22], ["WNV", "SPECIES", 24, 27], ["WNV-antigen", "TEST", 24, 35]]], ["The dogs were aged 0.3^8 years and the cats 0.2^10 years.", [["dogs", "ORGANISM", 4, 8], ["dogs", "SPECIES", 4, 8]]], ["Two domestic shorthairs, one Persian and one cat of unknown breed as well as a Landseer, a West Highland white terrier, a Bordeaux Dogge and an Entlebucher Sennenhund were a\u00a1ected.", [["cat", "ORGANISM", 45, 48], ["cat", "SPECIES", 45, 48], ["domestic", "OBSERVATION_MODIFIER", 4, 12], ["shorthairs", "OBSERVATION", 13, 23]]], ["A granulomatous immune response was found in three of the four dogs.", [["dogs", "ORGANISM", 63, 67], ["dogs", "SPECIES", 63, 67], ["A granulomatous immune response", "PROBLEM", 0, 31], ["granulomatous", "OBSERVATION_MODIFIER", 2, 15], ["immune response", "OBSERVATION", 16, 31]]], ["The remaining dog displayed a lymphohistiocytic chorioiditis and meningitis.", [["lymphohistiocytic", "ANATOMY", 30, 47], ["chorioiditis", "DISEASE", 48, 60], ["meningitis", "DISEASE", 65, 75], ["dog", "ORGANISM", 14, 17], ["dog", "SPECIES", 14, 17], ["a lymphohistiocytic chorioiditis", "PROBLEM", 28, 60], ["meningitis", "PROBLEM", 65, 75], ["lymphohistiocytic chorioiditis", "OBSERVATION", 30, 60], ["meningitis", "OBSERVATION", 65, 75]]], ["In\u00a2ltration with macrophages, neutrophils, lymphocytes and plasma cells or pyogranulomatous in\u00a3ammation was present in two of the four cats, and lymphohistiocytic in\u00a3ammation in the remaining two cats.", [["macrophages", "ANATOMY", 17, 28], ["neutrophils", "ANATOMY", 30, 41], ["lymphocytes", "ANATOMY", 43, 54], ["plasma cells", "ANATOMY", 59, 71], ["pyogranulomatous in\u00a3ammation", "ANATOMY", 75, 103], ["macrophages", "CELL", 17, 28], ["neutrophils", "CELL", 30, 41], ["lymphocytes", "CELL", 43, 54], ["plasma cells", "CELL", 59, 71], ["pyogranulomatous in\u00a3ammation", "CELL", 75, 103], ["cats", "ORGANISM", 135, 139], ["cats", "ORGANISM", 196, 200], ["macrophages", "CELL_TYPE", 17, 28], ["neutrophils", "CELL_TYPE", 30, 41], ["lymphocytes", "CELL_TYPE", 43, 54], ["plasma cells", "CELL_TYPE", 59, 71], ["cats", "SPECIES", 135, 139], ["cats", "SPECIES", 196, 200], ["macrophages", "TEST", 17, 28], ["neutrophils", "TEST", 30, 41], ["lymphocytes", "TEST", 43, 54], ["plasma cells", "PROBLEM", 59, 71], ["pyogranulomatous in\u00a3ammation", "PROBLEM", 75, 103], ["lymphohistiocytic in\u00a3ammation", "PROBLEM", 145, 174], ["macrophages", "OBSERVATION", 17, 28], ["neutrophils", "ANATOMY", 30, 41], ["lymphocytes", "ANATOMY", 43, 54], ["plasma cells", "OBSERVATION", 59, 71], ["pyogranulomatous in\u00a3ammation", "OBSERVATION", 75, 103], ["lymphohistiocytic in\u00a3ammation", "OBSERVATION", 145, 174]]], ["In three of these four dogs, severe neurological signs had been recorded; the fourth dog had shown dyspnoea and anaemia but no neurological signs.", [["neurological", "ANATOMY", 36, 48], ["neurological", "ANATOMY", 127, 139], ["dyspnoea", "DISEASE", 99, 107], ["anaemia", "DISEASE", 112, 119], ["neurological signs", "DISEASE", 127, 145], ["dogs", "ORGANISM", 23, 27], ["dog", "ORGANISM", 85, 88], ["dogs", "SPECIES", 23, 27], ["dog", "SPECIES", 85, 88], ["severe neurological signs", "PROBLEM", 29, 54], ["dyspnoea", "PROBLEM", 99, 107], ["anaemia", "PROBLEM", 112, 119], ["neurological signs", "PROBLEM", 127, 145], ["severe", "OBSERVATION_MODIFIER", 29, 35], ["dyspnoea", "OBSERVATION", 99, 107], ["anaemia", "OBSERVATION", 112, 119], ["no", "UNCERTAINTY", 124, 126]]], ["In three of the cats, neurological signs were recorded without reference to their severity.", [["neurological", "ANATOMY", 22, 34], ["cats", "ORGANISM", 16, 20], ["cats", "SPECIES", 16, 20], ["neurological signs", "TEST", 22, 40]]], ["The fourth cat showed respiratory signs only.", [["respiratory", "ANATOMY", 22, 33], ["respiratory signs", "DISEASE", 22, 39], ["cat", "ORGANISM", 11, 14], ["The fourth cat", "TEST", 0, 14], ["respiratory signs", "PROBLEM", 22, 39], ["respiratory signs", "OBSERVATION", 22, 39]]], ["The eight animals showed di\u00a1erent patterns of immunoreactivity.", [["di\u00a1erent patterns of immunoreactivity", "PROBLEM", 25, 62], ["immunoreactivity", "OBSERVATION", 46, 62]]], ["DAB precipitates were observed in the cytoplasm of perivascular and parenchymal macrophages, in the perikarya and processes of various neurons distant Non-suppurative Meningoencephalitis from or within the in\u00a3ammatory lesions (Fig.7) , and in periventricular and submeningeal astrocytic foot processes (Fig. 8) .", [["cytoplasm", "ANATOMY", 38, 47], ["perivascular", "ANATOMY", 51, 63], ["parenchymal macrophages", "ANATOMY", 68, 91], ["perikarya", "ANATOMY", 100, 109], ["neurons", "ANATOMY", 135, 142], ["in\u00a3ammatory lesions", "ANATOMY", 206, 225], ["periventricular", "ANATOMY", 243, 258], ["submeningeal astrocytic foot", "ANATOMY", 263, 291], ["Meningoencephalitis", "DISEASE", 167, 186], ["DAB", "CHEMICAL", 0, 3], ["DAB", "GENE_OR_GENE_PRODUCT", 0, 3], ["cytoplasm", "ORGANISM_SUBSTANCE", 38, 47], ["perivascular", "CELL", 51, 63], ["parenchymal macrophages", "CELL", 68, 91], ["perikarya", "CELLULAR_COMPONENT", 100, 109], ["neurons", "CELL", 135, 142], ["in\u00a3ammatory lesions", "CANCER", 206, 225], ["perivascular and parenchymal macrophages", "CELL_TYPE", 51, 91], ["DAB precipitates", "PROBLEM", 0, 16], ["perivascular and parenchymal macrophages", "PROBLEM", 51, 91], ["various neurons distant Non-suppurative Meningoencephalitis", "PROBLEM", 127, 186], ["the in\u00a3ammatory lesions", "PROBLEM", 202, 225], ["periventricular and submeningeal astrocytic foot processes", "PROBLEM", 243, 301], ["perivascular", "ANATOMY_MODIFIER", 51, 63], ["parenchymal", "ANATOMY_MODIFIER", 68, 79], ["macrophages", "OBSERVATION", 80, 91], ["perikarya", "ANATOMY", 100, 109], ["various", "OBSERVATION_MODIFIER", 127, 134], ["neurons", "OBSERVATION_MODIFIER", 135, 142], ["distant", "OBSERVATION_MODIFIER", 143, 150], ["Non-suppurative", "OBSERVATION_MODIFIER", 151, 166], ["Meningoencephalitis", "OBSERVATION", 167, 186], ["in\u00a3ammatory", "OBSERVATION_MODIFIER", 206, 217], ["lesions", "OBSERVATION", 218, 225], ["periventricular", "ANATOMY_MODIFIER", 243, 258], ["submeningeal", "ANATOMY_MODIFIER", 263, 275], ["astrocytic foot", "ANATOMY", 276, 291], ["Fig", "OBSERVATION_MODIFIER", 303, 306]]], ["In one dog and two cats, vessel-associated cells, probably pericytes or endothelial cells, showed immunolabelling (Fig. 9) .", [["vessel", "ANATOMY", 25, 31], ["cells", "ANATOMY", 43, 48], ["pericytes", "ANATOMY", 59, 68], ["endothelial cells", "ANATOMY", 72, 89], ["dog", "ORGANISM", 7, 10], ["cats", "ORGANISM", 19, 23], ["vessel", "MULTI-TISSUE_STRUCTURE", 25, 31], ["cells", "CELL", 43, 48], ["pericytes", "CELL", 59, 68], ["endothelial cells", "CELL", 72, 89], ["vessel-associated cells", "CELL_TYPE", 25, 48], ["pericytes", "CELL_TYPE", 59, 68], ["endothelial cells", "CELL_TYPE", 72, 89], ["dog", "SPECIES", 7, 10], ["cats", "SPECIES", 19, 23], ["associated cells", "PROBLEM", 32, 48], ["pericytes or endothelial cells", "PROBLEM", 59, 89], ["immunolabelling", "TEST", 98, 113], ["vessel", "ANATOMY", 25, 31], ["probably", "UNCERTAINTY", 50, 58], ["pericytes", "OBSERVATION", 59, 68], ["endothelial cells", "OBSERVATION", 72, 89]]], ["Seven of the eight animals showed immunolabelling with the EMCV-speci-\u00a2c monoclonal antibody (mab) 4F3; mab 3E5 gave results in selected cases only.", [["animals", "ORGANISM", 19, 26], ["EMCV", "ORGANISM", 59, 63], ["mab 3E5", "SIMPLE_CHEMICAL", 104, 111], ["EMCV-speci-\u00a2c monoclonal antibody", "PROTEIN", 59, 92], ["mab", "PROTEIN", 94, 97], ["4F3", "PROTEIN", 99, 102], ["mab 3E5", "PROTEIN", 104, 111], ["the EMCV", "TEST", 55, 63], ["speci", "TEST", 64, 69], ["monoclonal antibody", "TEST", 73, 92], ["mab", "TEST", 104, 107]]], ["One cat which was negative with the 4F3 antibody gave EMCV-speci\u00a2c reactions with mab 3E5.", [["cat", "ORGANISM", 4, 7], ["EMCV", "ORGANISM", 54, 58], ["mab 3E5", "SIMPLE_CHEMICAL", 82, 89], ["4F3 antibody", "PROTEIN", 36, 48], ["mab 3E5", "PROTEIN", 82, 89], ["the 4F3 antibody", "TEST", 32, 48], ["EMCV", "PROBLEM", 54, 58], ["speci\u00a2c reactions", "PROBLEM", 59, 76], ["mab", "TREATMENT", 82, 85]]], ["In one dog the results with mab 4F3 were con\u00a2rmed with the mab 3E5.", [["dog", "ORGANISM", 7, 10], ["mab 4F3", "PROTEIN", 28, 35], ["mab 3E5", "PROTEIN", 59, 66], ["dog", "SPECIES", 7, 10], ["mab 4F3", "TEST", 28, 35]]], ["The mab 4E4, which was applied only in one cat, con\u00a2rmed the reactions observed with the 4F3 antibody in numerous cells of the medulla oblongata and in perivascular macrophages and occasional neurons of the mediocaudal thalamus.", [["cells", "ANATOMY", 114, 119], ["medulla oblongata", "ANATOMY", 127, 144], ["perivascular macrophages", "ANATOMY", 152, 176], ["neurons", "ANATOMY", 192, 199], ["mediocaudal thalamus", "ANATOMY", 207, 227], ["mab 4E4", "GENE_OR_GENE_PRODUCT", 4, 11], ["cat", "ORGANISM", 43, 46], ["cells", "CELL", 114, 119], ["medulla oblongata", "MULTI-TISSUE_STRUCTURE", 127, 144], ["perivascular macrophages", "CELL", 152, 176], ["neurons", "CELL", 192, 199], ["mediocaudal thalamus", "MULTI-TISSUE_STRUCTURE", 207, 227], ["mab 4E4", "PROTEIN", 4, 11], ["4F3 antibody", "PROTEIN", 89, 101], ["perivascular macrophages", "CELL_TYPE", 152, 176], ["occasional neurons", "CELL_TYPE", 181, 199], ["The mab", "TREATMENT", 0, 7], ["the reactions", "PROBLEM", 57, 70], ["the 4F3 antibody", "TEST", 85, 101], ["numerous cells", "OBSERVATION", 105, 119], ["medulla oblongata", "ANATOMY", 127, 144], ["perivascular macrophages", "ANATOMY", 152, 176], ["occasional", "OBSERVATION_MODIFIER", 181, 191], ["neurons", "ANATOMY_MODIFIER", 192, 199], ["mediocaudal thalamus", "ANATOMY", 207, 227]]], ["The histologically intact myocardial tissue available from one dog and two cats was not immunolabelled with the mab 4F3.ARTICLE IN PRESSE. coli antigen was demonstrated in the brain of a 5-month old male cat.", [["myocardial tissue", "ANATOMY", 26, 43], ["brain", "ANATOMY", 176, 181], ["myocardial tissue", "TISSUE", 26, 43], ["dog", "ORGANISM", 63, 66], ["cats", "ORGANISM", 75, 79], ["coli antigen", "GENE_OR_GENE_PRODUCT", 139, 151], ["brain", "ORGAN", 176, 181], ["cat", "ORGANISM", 204, 207], ["mab 4F3", "PROTEIN", 112, 119], ["dog", "SPECIES", 63, 66], ["coli", "SPECIES", 139, 143], ["cat", "SPECIES", 204, 207], ["coli", "SPECIES", 139, 143], ["the mab", "TREATMENT", 108, 115], ["coli antigen", "TEST", 139, 151], ["histologically", "OBSERVATION_MODIFIER", 4, 18], ["intact", "OBSERVATION", 19, 25], ["myocardial tissue", "ANATOMY", 26, 43], ["brain", "ANATOMY", 176, 181]]], ["Histopathologically, mild to moderate, multifocal, perivascular in\u00a2ltration with lymphocytes, plasma cells, macrophages and neutrophilic granulocytes was observed in the cerebellum and meninges.", [["perivascular in\u00a2ltration", "ANATOMY", 51, 75], ["lymphocytes", "ANATOMY", 81, 92], ["plasma cells", "ANATOMY", 94, 106], ["macrophages", "ANATOMY", 108, 119], ["neutrophilic granulocytes", "ANATOMY", 124, 149], ["cerebellum", "ANATOMY", 170, 180], ["meninges", "ANATOMY", 185, 193], ["lymphocytes", "CELL", 81, 92], ["plasma cells", "CELL", 94, 106], ["macrophages", "CELL", 108, 119], ["neutrophilic granulocytes", "CELL", 124, 149], ["cerebellum", "ORGAN", 170, 180], ["meninges", "ORGAN", 185, 193], ["lymphocytes", "CELL_TYPE", 81, 92], ["plasma cells", "CELL_TYPE", 94, 106], ["macrophages", "CELL_TYPE", 108, 119], ["neutrophilic granulocytes", "CELL_TYPE", 124, 149], ["mild to moderate, multifocal, perivascular in\u00a2ltration", "PROBLEM", 21, 75], ["lymphocytes", "PROBLEM", 81, 92], ["plasma cells", "PROBLEM", 94, 106], ["macrophages", "PROBLEM", 108, 119], ["neutrophilic granulocytes", "PROBLEM", 124, 149], ["mild", "OBSERVATION_MODIFIER", 21, 25], ["moderate", "OBSERVATION_MODIFIER", 29, 37], ["multifocal", "OBSERVATION_MODIFIER", 39, 49], ["perivascular", "ANATOMY_MODIFIER", 51, 63], ["lymphocytes", "ANATOMY", 81, 92], ["plasma cells", "OBSERVATION", 94, 106], ["macrophages", "OBSERVATION_MODIFIER", 108, 119], ["neutrophilic granulocytes", "OBSERVATION", 124, 149], ["cerebellum", "ANATOMY", 170, 180], ["meninges", "ANATOMY", 185, 193]]], ["Moderate numbers of bacterial emboli in various vessels were visible in HE-stained sections.", [["emboli", "ANATOMY", 30, 36], ["vessels", "ANATOMY", 48, 55], ["sections", "ANATOMY", 83, 91], ["bacterial emboli", "DISEASE", 20, 36], ["bacterial emboli", "PATHOLOGICAL_FORMATION", 20, 36], ["vessels", "MULTI-TISSUE_STRUCTURE", 48, 55], ["bacterial emboli in various vessels", "PROBLEM", 20, 55], ["bacterial", "OBSERVATION_MODIFIER", 20, 29], ["emboli", "OBSERVATION", 30, 36], ["various", "ANATOMY_MODIFIER", 40, 47], ["vessels", "ANATOMY", 48, 55], ["visible", "OBSERVATION_MODIFIER", 61, 68]]], ["E. coli antigen was demonstrated immunohistochemically in the cytoplasm of numerous perivascular, meningeal and periventricular macrophages, and in intravascular bacteria.ARTICLE IN PRESSCases remaining unclear included 39 (74%) dogs and 20 (61%) cats, no infectious agent being identi\u00a2ed as the underlying cause of the observed non-suppurative meningoencephalitis.DiscussionIn the present study, CNS tissue of 53 dogs and 33 cats with non-suppurative meningoencephalitis of unknown cause was investigated for the presence of 18 different infectious agents.", [["cytoplasm", "ANATOMY", 62, 71], ["perivascular", "ANATOMY", 84, 96], ["meningeal", "ANATOMY", 98, 107], ["periventricular macrophages", "ANATOMY", 112, 139], ["intravascular bacteria", "ANATOMY", 148, 170], ["CNS tissue", "ANATOMY", 397, 407], ["meningoencephalitis", "DISEASE", 345, 364], ["meningoencephalitis", "DISEASE", 452, 471], ["E. coli antigen", "GENE_OR_GENE_PRODUCT", 0, 15], ["cytoplasm", "ORGANISM_SUBSTANCE", 62, 71], ["perivascular", "CELL", 84, 96], ["meningeal", "CELL", 98, 107], ["periventricular macrophages", "CELL", 112, 139], ["dogs", "ORGANISM", 229, 233], ["cats", "ORGANISM", 247, 251], ["CNS tissue", "TISSUE", 397, 407], ["dogs", "ORGANISM", 414, 418], ["cats", "ORGANISM", 426, 430], ["E. coli antigen", "PROTEIN", 0, 15], ["perivascular, meningeal and periventricular macrophages", "CELL_TYPE", 84, 139], ["E. coli", "SPECIES", 0, 7], ["dogs", "SPECIES", 229, 233], ["cats", "SPECIES", 247, 251], ["dogs", "SPECIES", 414, 418], ["cats", "SPECIES", 426, 430], ["E. coli", "SPECIES", 0, 7], ["E. coli antigen", "TEST", 0, 15], ["numerous perivascular, meningeal and periventricular macrophages", "PROBLEM", 75, 139], ["intravascular bacteria", "PROBLEM", 148, 170], ["PRESSCases", "TEST", 182, 192], ["dogs", "TEST", 229, 233], ["infectious agent", "PROBLEM", 256, 272], ["the observed non-suppurative meningoencephalitis", "PROBLEM", 316, 364], ["the present study", "TEST", 378, 395], ["non-suppurative meningoencephalitis", "PROBLEM", 436, 471], ["coli", "OBSERVATION", 3, 7], ["numerous", "OBSERVATION_MODIFIER", 75, 83], ["perivascular", "ANATOMY_MODIFIER", 84, 96], ["meningeal", "ANATOMY", 98, 107], ["periventricular macrophages", "OBSERVATION", 112, 139], ["intravascular bacteria", "OBSERVATION", 148, 170], ["no", "UNCERTAINTY", 253, 255], ["infectious", "OBSERVATION_MODIFIER", 256, 266], ["non-suppurative", "OBSERVATION_MODIFIER", 329, 344], ["meningoencephalitis", "OBSERVATION", 345, 364], ["non-suppurative", "OBSERVATION_MODIFIER", 436, 451], ["meningoencephalitis", "OBSERVATION", 452, 471], ["infectious", "OBSERVATION", 539, 549]]], ["Former studies either investigated at most six agents or were based on cases selected only on the presence of neurological signs (Tipold, 1995; Quesnel et al., 1997; Bradshaw et al., 2004; K. Melzer, personal communication) .DiscussionAs in other studies (Sorjonen, 1992; Tipold, 1995) , no speci\u00a2c canine breed predisposition was observed.", [["neurological", "ANATOMY", 110, 122], ["neurological signs", "DISEASE", 110, 128], ["canine", "ORGANISM", 299, 305], ["canine", "SPECIES", 299, 305], ["speci\u00a2c canine breed predisposition", "PROBLEM", 291, 326]]], ["Cases were seen more often in toy breeds than in other breeds, but this may merely have re\u00a3ected the normal distribution of dog breeds in Germany.", [["dog", "ORGANISM", 124, 127], ["normal", "OBSERVATION", 101, 107], ["dog breeds", "OBSERVATION", 124, 134]]], ["So far, no breed predisposition for non-suppurative meningoencephalitis has been described in respect of the cat (Sorjonen, 1992) .", [["meningoencephalitis", "DISEASE", 52, 71], ["cat", "ORGANISM", 109, 112], ["breed predisposition", "PROBLEM", 11, 31], ["non-suppurative meningoencephalitis", "PROBLEM", 36, 71], ["no", "UNCERTAINTY", 8, 10], ["non-suppurative", "OBSERVATION_MODIFIER", 36, 51], ["meningoencephalitis", "OBSERVATION", 52, 71]]], ["In the present study, domestic shorthair cats accounted for more than half of the feline cases, probably due to the normal feline breed distribution in Germany.DiscussionThe CNS of the majority of dogs (40/53) and cats (23/ 33) examined showed lymphohistiocytic perivascular in\u00a2ltrates.", [["CNS", "ANATOMY", 174, 177], ["perivascular", "ANATOMY", 262, 274], ["cats", "ORGANISM", 41, 45], ["feline", "ORGANISM", 82, 88], ["feline", "ORGANISM", 123, 129], ["CNS", "ANATOMICAL_SYSTEM", 174, 177], ["dogs", "ORGANISM", 197, 201], ["cats", "ORGANISM", 214, 218], ["cats", "SPECIES", 41, 45], ["dogs", "SPECIES", 197, 201], ["cats", "SPECIES", 214, 218], ["the present study", "TEST", 3, 20], ["cats", "TEST", 214, 218], ["lymphohistiocytic perivascular in\u00a2ltrates", "PROBLEM", 244, 285], ["probably due to", "UNCERTAINTY", 96, 111], ["normal", "OBSERVATION", 116, 122], ["feline breed", "OBSERVATION", 123, 135], ["distribution", "OBSERVATION_MODIFIER", 136, 148], ["lymphohistiocytic", "OBSERVATION_MODIFIER", 244, 261], ["perivascular in\u00a2ltrates", "OBSERVATION", 262, 285]]], ["This is generally suggestive of a viral aetiology (Summers et al., 1995) but has also been reported following hypoxic or toxic damage, which also sometimes produces demyelinating lesions (Braund, 1980; Lee et al., 2002) .", [["demyelinating lesions", "ANATOMY", 165, 186], ["toxic damage", "DISEASE", 121, 133], ["demyelinating lesions", "DISEASE", 165, 186], ["lesions", "PATHOLOGICAL_FORMATION", 179, 186], ["a viral aetiology", "PROBLEM", 32, 49], ["hypoxic or toxic damage", "PROBLEM", 110, 133], ["demyelinating lesions", "PROBLEM", 165, 186], ["generally suggestive of", "UNCERTAINTY", 8, 31], ["viral", "OBSERVATION", 34, 39], ["hypoxic", "OBSERVATION_MODIFIER", 110, 117], ["toxic", "OBSERVATION_MODIFIER", 121, 126], ["damage", "OBSERVATION", 127, 133], ["demyelinating", "OBSERVATION_MODIFIER", 165, 178], ["lesions", "OBSERVATION", 179, 186]]], ["Granulomatous CNS in\u00a2ltrates, observed in 10 dogs and two cats, are often considered to be associated with fungal, parasitic or bacterial infections.", [["Granulomatous CNS in\u00a2ltrates", "ANATOMY", 0, 28], ["fungal, parasitic or bacterial infections", "DISEASE", 107, 148], ["cats", "ORGANISM", 58, 62], ["dogs", "SPECIES", 45, 49], ["cats", "SPECIES", 58, 62], ["Granulomatous CNS in\u00a2ltrates", "PROBLEM", 0, 28], ["fungal, parasitic or bacterial infections", "PROBLEM", 107, 148], ["fungal", "OBSERVATION", 107, 113], ["parasitic", "OBSERVATION_MODIFIER", 115, 124], ["bacterial", "OBSERVATION_MODIFIER", 128, 137], ["infections", "OBSERVATION", 138, 148]]], ["Fungal infections occur mainly in warmer climates (Gerds-Grogan and Dayrell-Hart, 1997 ) and, like parasitic infections, were not detected in the present study.", [["Fungal infections", "DISEASE", 0, 17], ["parasitic infections", "DISEASE", 99, 119], ["Fungal infections", "PROBLEM", 0, 17], ["parasitic infections", "PROBLEM", 99, 119], ["the present study", "TEST", 142, 159], ["infections", "OBSERVATION", 7, 17], ["parasitic", "OBSERVATION_MODIFIER", 99, 108], ["infections", "OBSERVATION", 109, 119]]], ["In the 10 dogs referred to above, granulomatous meningoencephalitis (GME) was suggested by the histopathological \u00a2ndings and distribution of lesions.", [["lesions", "ANATOMY", 141, 148], ["meningoencephalitis", "DISEASE", 48, 67], ["dogs", "ORGANISM", 10, 14], ["lesions", "PATHOLOGICAL_FORMATION", 141, 148], ["dogs", "SPECIES", 10, 14], ["granulomatous meningoencephalitis", "PROBLEM", 34, 67], ["lesions", "PROBLEM", 141, 148], ["granulomatous", "OBSERVATION_MODIFIER", 34, 47], ["meningoencephalitis", "OBSERVATION", 48, 67], ["lesions", "OBSERVATION", 141, 148]]], ["Interestingly, three of the a\u00a1ected dogs belonged to large breeds (Landseer, Bordeaux Dogge and collie), in which GME is only rarely reported (Braund, 1985) .", [["dogs", "ORGANISM", 36, 40], ["dogs", "SPECIES", 36, 40], ["the a\u00a1ected dogs", "PROBLEM", 24, 40], ["large breeds", "PROBLEM", 53, 65], ["large", "OBSERVATION_MODIFIER", 53, 58], ["breeds", "OBSERVATION", 59, 65]]], ["GME has been thought to be associated with viral infections including canine distemper, but no viral agent has been demonstrated in the CNS so far (Thomas and Eger,1989; Kipar et al.,1998) .", [["CNS", "ANATOMY", 136, 139], ["GME", "CHEMICAL", 0, 3], ["viral infections", "DISEASE", 43, 59], ["canine distemper", "DISEASE", 70, 86], ["canine distemper", "ORGANISM", 70, 86], ["CNS", "ANATOMICAL_SYSTEM", 136, 139], ["canine distemper", "SPECIES", 70, 86], ["canine distemper", "SPECIES", 70, 86], ["viral infections", "PROBLEM", 43, 59], ["canine distemper", "PROBLEM", 70, 86], ["viral agent", "PROBLEM", 95, 106], ["thought to be associated with", "UNCERTAINTY", 13, 42], ["viral", "OBSERVATION_MODIFIER", 43, 48], ["infections", "OBSERVATION", 49, 59], ["distemper", "OBSERVATION", 77, 86], ["no", "UNCERTAINTY", 92, 94]]], ["E. coli antigen, as found in the brains of beagles with granulomatous leptomeningitis (Maeda et al., 1993) or in association with human cases of granulomatous encephalitis (Rickert et al., 2000) , was not observed in the present cases with suspected GME.", [["brains", "ANATOMY", 33, 39], ["granulomatous leptomeningitis", "DISEASE", 56, 85], ["granulomatous encephalitis", "DISEASE", 145, 171], ["E. coli antigen", "GENE_OR_GENE_PRODUCT", 0, 15], ["brains", "ORGAN", 33, 39], ["beagles", "ORGANISM", 43, 50], ["human", "ORGANISM", 130, 135], ["E. coli antigen", "PROTEIN", 0, 15], ["E. coli", "SPECIES", 0, 7], ["human", "SPECIES", 130, 135], ["E. coli", "SPECIES", 0, 7], ["human", "SPECIES", 130, 135], ["E. coli antigen", "TEST", 0, 15], ["granulomatous leptomeningitis", "PROBLEM", 56, 85], ["granulomatous encephalitis", "PROBLEM", 145, 171], ["coli antigen", "OBSERVATION", 3, 15], ["brains", "ANATOMY", 33, 39], ["beagles", "OBSERVATION_MODIFIER", 43, 50], ["granulomatous", "OBSERVATION_MODIFIER", 56, 69], ["leptomeningitis", "OBSERVATION", 70, 85], ["granulomatous", "OBSERVATION_MODIFIER", 145, 158], ["encephalitis", "OBSERVATION", 159, 171]]], ["The cat with abundant E. coli antigen in the brain in the present study showed perivascular in-\u00a2ltrations, indicating septicaemia.ARTICLE IN PRESSPyogranulomatous and mixed in\u00a3ammatory in\u00a2ltration in the CNS occurred less often in dogs than in cats.", [["brain", "ANATOMY", 45, 50], ["perivascular", "ANATOMY", 79, 91], ["CNS", "ANATOMY", 204, 207], ["septicaemia", "DISEASE", 118, 129], ["cat", "ORGANISM", 4, 7], ["E. coli antigen", "GENE_OR_GENE_PRODUCT", 22, 37], ["brain", "ORGAN", 45, 50], ["perivascular", "IMMATERIAL_ANATOMICAL_ENTITY", 79, 91], ["CNS", "ANATOMICAL_SYSTEM", 204, 207], ["dogs", "ORGANISM", 231, 235], ["cats", "ORGANISM", 244, 248], ["E. coli antigen", "PROTEIN", 22, 37], ["E. coli", "SPECIES", 22, 29], ["dogs", "SPECIES", 231, 235], ["cats", "SPECIES", 244, 248], ["E. coli", "SPECIES", 22, 29], ["abundant E. coli antigen in the brain", "PROBLEM", 13, 50], ["perivascular in-\u00a2ltrations", "PROBLEM", 79, 105], ["septicaemia", "PROBLEM", 118, 129], ["mixed in\u00a3ammatory in\u00a2ltration", "PROBLEM", 167, 196], ["the CNS", "PROBLEM", 200, 207], ["abundant", "OBSERVATION_MODIFIER", 13, 21], ["E. coli antigen", "OBSERVATION", 22, 37], ["brain", "ANATOMY", 45, 50], ["perivascular", "ANATOMY", 79, 91], ["septicaemia", "OBSERVATION", 118, 129], ["mixed", "OBSERVATION_MODIFIER", 167, 172], ["in\u00a3ammatory in\u00a2ltration", "OBSERVATION", 173, 196], ["CNS", "ANATOMY", 204, 207]]], ["In cats, this type of change is reminiscent of FIP (Rand et al.,1994) .", [["FIP", "DISEASE", 47, 50], ["cats", "ORGANISM", 3, 7], ["cats", "SPECIES", 3, 7], ["FIP", "PROBLEM", 47, 50], ["FIP", "OBSERVATION", 47, 50]]], ["In the present study, FIP virus antigen was also detected in a cat showing lymphohistiocytic leucoencephalitis, a rare consequence of FIP (Summers et al.,1995; Braund, 2001) .", [["lymphohistiocytic leucoencephalitis", "ANATOMY", 75, 110], ["lymphohistiocytic leucoencephalitis", "DISEASE", 75, 110], ["FIP", "DISEASE", 134, 137], ["FIP virus", "ORGANISM", 22, 31], ["cat", "ORGANISM", 63, 66], ["FIP virus antigen", "PROTEIN", 22, 39], ["FIP virus", "SPECIES", 22, 31], ["the present study", "TEST", 3, 20], ["FIP virus antigen", "TEST", 22, 39], ["lymphohistiocytic leucoencephalitis", "PROBLEM", 75, 110], ["FIP virus", "OBSERVATION", 22, 31], ["lymphohistiocytic leucoencephalitis", "OBSERVATION", 75, 110], ["FIP", "OBSERVATION", 134, 137]]], ["In dogs, pyogranulomatous or mixed in\u00a3ammatory changes in the CNS are occasionally described, but no infectious agents have so far been detected (Meric,1988) .ARTICLE IN PRESSIt cannot be ruled out that aetiologically undetermined feline cases were due to feline immunode\u00a2ciency virus (FIV), which leads to lymphocytic encephalitis in 30% of naturally infected cats (Gunn-Moore et al., 1996) .", [["pyogranulomatous", "ANATOMY", 9, 25], ["CNS", "ANATOMY", 62, 65], ["feline immunode\u00a2ciency virus (FIV)", "DISEASE", 256, 290], ["lymphocytic encephalitis", "DISEASE", 307, 331], ["dogs", "ORGANISM", 3, 7], ["CNS", "ANATOMICAL_SYSTEM", 62, 65], ["feline", "ORGANISM", 231, 237], ["feline immunode\u00a2ciency virus", "ORGANISM", 256, 284], ["FIV", "ORGANISM", 286, 289], ["cats", "ORGANISM", 361, 365], ["dogs", "SPECIES", 3, 7], ["feline immunode\u00a2ciency virus", "SPECIES", 256, 284], ["cats", "SPECIES", 361, 365], ["feline immunode\u00a2ciency virus", "SPECIES", 256, 284], ["FIV", "SPECIES", 286, 289], ["pyogranulomatous", "PROBLEM", 9, 25], ["mixed in\u00a3ammatory changes in the CNS", "PROBLEM", 29, 65], ["infectious agents", "PROBLEM", 101, 118], ["feline immunode\u00a2ciency virus", "PROBLEM", 256, 284], ["lymphocytic encephalitis", "PROBLEM", 307, 331], ["dogs", "OBSERVATION", 3, 7], ["pyogranulomatous", "OBSERVATION_MODIFIER", 9, 25], ["mixed", "OBSERVATION_MODIFIER", 29, 34], ["in\u00a3ammatory", "OBSERVATION", 35, 46], ["CNS", "ANATOMY", 62, 65], ["no", "UNCERTAINTY", 98, 100], ["infectious", "OBSERVATION", 101, 111], ["lymphocytic encephalitis", "OBSERVATION", 307, 331]]], ["Only \u00a2ve of the 33 cats had been examined serologically for FIV, a positive result having being obtained in one animal.ARTICLE IN PRESSIn a Canadian shepherd dog, porcine herpesvirus 1 (PHV 1) antigen was detected in neurons of the gyrus parahippocampalis.", [["neurons", "ANATOMY", 217, 224], ["gyrus parahippocampalis", "ANATOMY", 232, 255], ["cats", "ORGANISM", 19, 23], ["FIV", "ORGANISM", 60, 63], ["shepherd dog", "ORGANISM", 149, 161], ["porcine herpesvirus 1", "ORGANISM", 163, 184], ["PHV 1) antigen", "GENE_OR_GENE_PRODUCT", 186, 200], ["neurons", "CELL", 217, 224], ["gyrus parahippocampalis", "ORGANISM", 232, 255], ["cats", "SPECIES", 19, 23], ["dog", "SPECIES", 158, 161], ["porcine herpesvirus 1", "SPECIES", 163, 184], ["FIV", "SPECIES", 60, 63], ["Canadian shepherd dog", "SPECIES", 140, 161], ["porcine herpesvirus 1 (PHV 1", "SPECIES", 163, 191], ["gyrus parahippocampalis", "SPECIES", 232, 255], ["porcine herpesvirus", "TEST", 163, 182], ["PHV 1) antigen", "TEST", 186, 200], ["gyrus", "ANATOMY", 232, 237]]], ["Due to a retrograde neural route of infection, PHV 1 antigen usually occurs in the brain stem or spinal cord ganglions (Quiroga et al., 1998; Honavar and Meldrum, 2002) .", [["neural", "ANATOMY", 20, 26], ["brain stem", "ANATOMY", 83, 93], ["spinal cord ganglions", "ANATOMY", 97, 118], ["infection", "DISEASE", 36, 45], ["PHV 1 antigen", "GENE_OR_GENE_PRODUCT", 47, 60], ["brain stem", "TISSUE", 83, 93], ["spinal cord ganglions", "TISSUE", 97, 118], ["PHV 1 antigen", "PROTEIN", 47, 60], ["infection", "PROBLEM", 36, 45], ["PHV 1 antigen", "TEST", 47, 60], ["spinal cord ganglions", "PROBLEM", 97, 118], ["infection", "OBSERVATION", 36, 45], ["brain stem", "ANATOMY", 83, 93], ["spinal cord", "ANATOMY", 97, 108], ["ganglions", "ANATOMY", 109, 118]]], ["The dog in this study showed diarrhoea for 3 weeks, reminiscent of the rare alimentary form of Aujeszky disease (Pensaert and Maes, 1987) ; however, no PHV 1 antigen was detected in the gastrointestinal tract.", [["gastrointestinal tract", "ANATOMY", 186, 208], ["diarrhoea", "DISEASE", 29, 38], ["Aujeszky disease", "DISEASE", 95, 111], ["dog", "ORGANISM", 4, 7], ["Aujeszky", "ORGANISM", 95, 103], ["PHV 1 antigen", "GENE_OR_GENE_PRODUCT", 152, 165], ["gastrointestinal tract", "ORGAN", 186, 208], ["PHV 1 antigen", "PROTEIN", 152, 165], ["dog", "SPECIES", 4, 7], ["Aujeszky", "SPECIES", 95, 103], ["Aujeszky", "SPECIES", 95, 103], ["this study", "TEST", 11, 21], ["diarrhoea", "PROBLEM", 29, 38], ["Aujeszky disease", "PROBLEM", 95, 111], ["PHV 1 antigen", "PROBLEM", 152, 165], ["diarrhoea", "OBSERVATION", 29, 38], ["Aujeszky disease", "OBSERVATION", 95, 111], ["gastrointestinal tract", "ANATOMY", 186, 208]]], ["Only later did the animal develop neurological signs, and an unusual portal of entry of the virus to the brain remains a possibility.ARTICLE IN PRESSNeither the \u00a2ve dogs nor the cat with parvovirus infection of the brain showed typical CNS manifestations, such as cerebellar hypoplasia or death of Purkinje cells (Sharp et al., 1999) , or encephalomalacia (Johnson and Castro, 1984; Agungpriyono et al., 1999) .", [["neurological", "ANATOMY", 34, 46], ["brain", "ANATOMY", 105, 110], ["brain", "ANATOMY", 215, 220], ["CNS", "ANATOMY", 236, 239], ["cerebellar", "ANATOMY", 264, 274], ["Purkinje cells", "ANATOMY", 298, 312], ["neurological signs", "DISEASE", 34, 52], ["parvovirus infection of the brain", "DISEASE", 187, 220], ["cerebellar hypoplasia", "DISEASE", 264, 285], ["death", "DISEASE", 289, 294], ["encephalomalacia", "DISEASE", 339, 355], ["brain", "ORGAN", 105, 110], ["dogs", "ORGANISM", 165, 169], ["cat", "ORGANISM", 178, 181], ["parvovirus", "ORGANISM", 187, 197], ["brain", "ORGAN", 215, 220], ["CNS", "ANATOMICAL_SYSTEM", 236, 239], ["cerebellar", "ORGAN", 264, 274], ["Purkinje cells", "CELL", 298, 312], ["Purkinje cells", "CELL_TYPE", 298, 312], ["dogs", "SPECIES", 165, 169], ["cat", "SPECIES", 178, 181], ["neurological signs", "PROBLEM", 34, 52], ["parvovirus infection of the brain", "PROBLEM", 187, 220], ["typical CNS manifestations", "PROBLEM", 228, 254], ["cerebellar hypoplasia", "PROBLEM", 264, 285], ["death of Purkinje cells", "PROBLEM", 289, 312], ["encephalomalacia", "PROBLEM", 339, 355], ["portal", "ANATOMY", 69, 75], ["entry", "OBSERVATION", 79, 84], ["virus", "OBSERVATION", 92, 97], ["brain", "ANATOMY", 105, 110], ["remains a possibility", "UNCERTAINTY", 111, 132], ["parvovirus", "OBSERVATION", 187, 197], ["brain", "ANATOMY", 215, 220], ["typical", "OBSERVATION_MODIFIER", 228, 235], ["CNS manifestations", "OBSERVATION", 236, 254], ["cerebellar", "ANATOMY", 264, 274], ["hypoplasia", "OBSERVATION", 275, 285], ["Purkinje cells", "OBSERVATION", 298, 312], ["Sharp", "OBSERVATION_MODIFIER", 314, 319], ["encephalomalacia", "OBSERVATION", 339, 355]]], ["The \u00a2ndings indicated, however, a potential association between parvovirus and spongiform lesions in the CNS.ARTICLE IN PRESSIn chronic feline leukaemia virus (FeLV) infection, lymphocytic in\u00a2ltration of peripheral nerves of the spinal cord has been reported occasionally (Pedersen, 1987) .", [["spongiform lesions", "ANATOMY", 79, 97], ["CNS", "ANATOMY", 105, 108], ["lymphocytic", "ANATOMY", 177, 188], ["peripheral nerves", "ANATOMY", 204, 221], ["spinal cord", "ANATOMY", 229, 240], ["parvovirus and spongiform lesions", "DISEASE", 64, 97], ["feline leukaemia virus (FeLV) infection", "DISEASE", 136, 175], ["parvovirus", "ORGANISM", 64, 74], ["spongiform lesions", "PATHOLOGICAL_FORMATION", 79, 97], ["CNS", "ANATOMICAL_SYSTEM", 105, 108], ["IN PRESSIn chronic feline leukaemia virus", "ORGANISM", 117, 158], ["FeLV", "ORGANISM", 160, 164], ["peripheral nerves", "MULTI-TISSUE_STRUCTURE", 204, 221], ["spinal cord", "ORGAN", 229, 240], ["feline leukaemia virus", "SPECIES", 136, 158], ["feline leukaemia virus", "SPECIES", 136, 158], ["FeLV", "SPECIES", 160, 164], ["parvovirus and spongiform lesions in the CNS", "PROBLEM", 64, 108], ["PRESSIn chronic feline leukaemia virus (FeLV) infection", "PROBLEM", 120, 175], ["lymphocytic in\u00a2ltration of peripheral nerves of the spinal cord", "PROBLEM", 177, 240], ["parvovirus", "OBSERVATION", 64, 74], ["spongiform", "OBSERVATION_MODIFIER", 79, 89], ["lesions", "OBSERVATION", 90, 97], ["CNS", "ANATOMY", 105, 108], ["chronic", "OBSERVATION_MODIFIER", 128, 135], ["feline leukaemia virus", "OBSERVATION", 136, 158], ["infection", "OBSERVATION", 166, 175], ["lymphocytic in\u00a2ltration", "OBSERVATION", 177, 200], ["peripheral", "ANATOMY_MODIFIER", 204, 214], ["nerves", "ANATOMY_MODIFIER", 215, 221], ["spinal cord", "ANATOMY", 229, 240]]], ["In the brain, however, FeLV infection has been associated only with degenerative CNS disease (Carmichael et al., 2002) .", [["brain", "ANATOMY", 7, 12], ["CNS", "ANATOMY", 81, 84], ["FeLV infection", "DISEASE", 23, 37], ["degenerative CNS disease", "DISEASE", 68, 92], ["brain", "ORGAN", 7, 12], ["FeLV", "ORGANISM", 23, 27], ["CNS", "ORGAN", 81, 84], ["FeLV infection", "PROBLEM", 23, 37], ["degenerative CNS disease", "PROBLEM", 68, 92], ["brain", "ANATOMY", 7, 12], ["FeLV infection", "OBSERVATION", 23, 37], ["degenerative", "OBSERVATION_MODIFIER", 68, 80], ["CNS", "ANATOMY", 81, 84], ["disease", "OBSERVATION", 85, 92]]], ["In one cat, FeLV infection of microglia and astrocytes was detected.", [["microglia", "ANATOMY", 30, 39], ["astrocytes", "ANATOMY", 44, 54], ["FeLV infection", "DISEASE", 12, 26], ["cat", "ORGANISM", 7, 10], ["FeLV", "ORGANISM", 12, 16], ["microglia", "CELL", 30, 39], ["astrocytes", "CELL", 44, 54], ["microglia", "CELL_TYPE", 30, 39], ["astrocytes", "CELL_TYPE", 44, 54], ["cat", "SPECIES", 7, 10], ["FeLV", "SPECIES", 12, 16], ["FeLV infection of microglia and astrocytes", "PROBLEM", 12, 54], ["FeLV", "OBSERVATION_MODIFIER", 12, 16], ["infection", "OBSERVATION", 17, 26], ["microglia", "OBSERVATION", 30, 39]]], ["Histologically, this animal showed mild, multifocal, lymphohistiocytic meningitis.", [["meningitis", "DISEASE", 71, 81], ["mild, multifocal, lymphohistiocytic meningitis", "PROBLEM", 35, 81], ["mild", "OBSERVATION_MODIFIER", 35, 39], ["multifocal", "OBSERVATION_MODIFIER", 41, 51], ["lymphohistiocytic meningitis", "OBSERVATION", 53, 81]]], ["Since FeLV regularly persists for years in lymphocytes and macrophages (Rohn and Overbaugh,1999) , a persistent infection of glial cells seemed possible but unfortunately no lymphoid tissue, including bone marrow (in which FeLV-antigen can typically be demonstrated), was available.ARTICLE IN PRESSSurprisingly, \u00a2ve (9.4%) dogs and four (12%) cats showed immunolabelling for WNV.", [["lymphocytes", "ANATOMY", 43, 54], ["macrophages", "ANATOMY", 59, 70], ["glial cells", "ANATOMY", 125, 136], ["lymphoid tissue", "ANATOMY", 174, 189], ["bone marrow", "ANATOMY", 201, 212], ["infection", "DISEASE", 112, 121], ["WNV", "DISEASE", 375, 378], ["FeLV", "ORGANISM", 6, 10], ["lymphocytes", "CELL", 43, 54], ["macrophages", "CELL", 59, 70], ["Rohn", "CELL", 72, 76], ["glial cells", "CELL", 125, 136], ["lymphoid tissue", "TISSUE", 174, 189], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 201, 212], ["FeLV", "ORGANISM", 223, 227], ["antigen", "GENE_OR_GENE_PRODUCT", 228, 235], ["dogs", "ORGANISM", 323, 327], ["cats", "ORGANISM", 343, 347], ["WNV", "ORGANISM", 375, 378], ["lymphocytes", "CELL_TYPE", 43, 54], ["macrophages", "CELL_TYPE", 59, 70], ["glial cells", "CELL_TYPE", 125, 136], ["FeLV-antigen", "PROTEIN", 223, 235], ["dogs", "SPECIES", 323, 327], ["cats", "SPECIES", 343, 347], ["WNV", "SPECIES", 375, 378], ["FeLV", "PROBLEM", 6, 10], ["lymphocytes", "PROBLEM", 43, 54], ["macrophages", "PROBLEM", 59, 70], ["a persistent infection of glial cells", "PROBLEM", 99, 136], ["lymphoid tissue", "PROBLEM", 174, 189], ["bone marrow", "PROBLEM", 201, 212], ["PRESSSurprisingly", "TEST", 293, 310], ["WNV", "PROBLEM", 375, 378], ["FeLV", "OBSERVATION", 6, 10], ["lymphocytes", "ANATOMY", 43, 54], ["macrophages", "OBSERVATION_MODIFIER", 59, 70], ["persistent", "OBSERVATION_MODIFIER", 101, 111], ["infection", "OBSERVATION", 112, 121], ["glial cells", "OBSERVATION", 125, 136], ["lymphoid tissue", "OBSERVATION", 174, 189], ["bone marrow", "ANATOMY", 201, 212]]], ["Histopathologically, these animals showed mild to moderate meningoencephalitis in the grey and white matter, mostly with granulomatous or pyogranulomatous in\u00a3ammation.", [["white matter", "ANATOMY", 95, 107], ["granulomatous", "ANATOMY", 121, 134], ["meningoencephalitis", "DISEASE", 59, 78], ["in\u00a3ammation", "DISEASE", 155, 166], ["mild to moderate meningoencephalitis in the grey and white matter", "PROBLEM", 42, 107], ["granulomatous or pyogranulomatous in\u00a3ammation", "PROBLEM", 121, 166], ["mild", "OBSERVATION_MODIFIER", 42, 46], ["moderate", "OBSERVATION_MODIFIER", 50, 58], ["meningoencephalitis", "OBSERVATION", 59, 78], ["grey", "ANATOMY_MODIFIER", 86, 90], ["white matter", "ANATOMY", 95, 107], ["granulomatous", "OBSERVATION", 121, 134], ["pyogranulomatous in\u00a3ammation", "OBSERVATION", 138, 166]]], ["In contrast, previous reports of WNV infection in birds and in mammals indicated that the grey matter was mainly a\u00a1ected and that the histopathology was characterized by lymphoplasmahistiocytic in\u00a3ammation with small numbers of neutrophils (Steele et al., 2000; Cantile et al., 2001; Buchweitz et al., 2003; Kelly et al., 2003; Lichtensteiger et al., 2003) .", [["grey matter", "ANATOMY", 90, 101], ["neutrophils", "ANATOMY", 228, 239], ["WNV infection", "DISEASE", 33, 46], ["WNV", "ORGANISM", 33, 36], ["birds", "ORGANISM", 50, 55], ["neutrophils", "CELL", 228, 239], ["neutrophils", "CELL_TYPE", 228, 239], ["WNV", "SPECIES", 33, 36], ["WNV infection", "PROBLEM", 33, 46], ["the grey matter", "PROBLEM", 86, 101], ["the histopathology", "TEST", 130, 148], ["lymphoplasmahistiocytic in\u00a3ammation", "PROBLEM", 170, 205], ["WNV", "OBSERVATION_MODIFIER", 33, 36], ["infection", "OBSERVATION", 37, 46], ["small", "OBSERVATION_MODIFIER", 211, 216], ["numbers", "OBSERVATION_MODIFIER", 217, 224]]], ["Polyclonal WNV-speci\u00a2c antibodies used for immunolabelling often cross-react with other \u00a3aviviruses (Steele et al., 2000; Kelly et al., 2003; Chvala et al., 2004) .", [["WNV-speci\u00a2c antibodies", "GENE_OR_GENE_PRODUCT", 11, 33], ["Polyclonal WNV-speci\u00a2c antibodies", "PROTEIN", 0, 33], ["WNV", "SPECIES", 11, 14], ["Polyclonal WNV", "TEST", 0, 14], ["speci\u00a2c antibodies", "TEST", 15, 33]]], ["The monoclonal antibodies speci\u00a2c for the major envelope protein E (anti-MEP) and non-structural protein 1 (anti-NSP-1) used in this study (Tables 1 and 2 ) crossreact with Kunjin virus, also a member of the Flaviviridae (Scherret et al., 2001) .", [["E", "GENE_OR_GENE_PRODUCT", 65, 66], ["anti-MEP", "GENE_OR_GENE_PRODUCT", 68, 76], ["non-structural protein 1", "GENE_OR_GENE_PRODUCT", 82, 106], ["anti-NSP-1", "GENE_OR_GENE_PRODUCT", 108, 118], ["Kunjin virus", "ORGANISM", 173, 185], ["Flaviviridae", "ORGANISM", 208, 220], ["monoclonal antibodies", "PROTEIN", 4, 25], ["speci\u00a2c", "PROTEIN", 26, 33], ["major envelope protein E", "PROTEIN", 42, 66], ["anti", "PROTEIN", 68, 72], ["MEP", "PROTEIN", 73, 76], ["non-structural protein 1", "PROTEIN", 82, 106], ["anti", "PROTEIN", 108, 112], ["NSP", "PROTEIN", 113, 116], ["Kunjin virus", "SPECIES", 173, 185], ["The monoclonal antibodies", "TEST", 0, 25], ["the major envelope protein E", "TEST", 38, 66], ["non-structural protein", "TREATMENT", 82, 104], ["anti-NSP", "TREATMENT", 108, 116], ["this study", "TEST", 128, 138], ["Kunjin virus", "TREATMENT", 173, 185]]], ["Presumably, the anti-NSP-1 antibody is more speci\u00a2c than the anti-MEP antibody (Hall, 2000) .", [["anti-NSP-1", "GENE_OR_GENE_PRODUCT", 16, 26], ["anti-NSP-1 antibody", "PROTEIN", 16, 35], ["anti-MEP antibody", "PROTEIN", 61, 78], ["the anti-NSP-1 antibody", "TEST", 12, 35]]], ["This might explain its stronger immunoreactivity in the present study and might support the identi\u00a2cation of a WNV infection.", [["WNV infection", "DISEASE", 111, 124], ["WNV", "ORGANISM", 111, 114], ["WNV", "SPECIES", 111, 114], ["its stronger immunoreactivity", "PROBLEM", 19, 48], ["the present study", "TEST", 52, 69], ["a WNV infection", "PROBLEM", 109, 124], ["stronger", "OBSERVATION_MODIFIER", 23, 31], ["immunoreactivity", "OBSERVATION", 32, 48], ["WNV", "OBSERVATION_MODIFIER", 111, 114], ["infection", "OBSERVATION", 115, 124]]], ["The a\u00a1ected animals did not react positively for tick-borne encephalitis (TBE) virus antigen with a polyclonal speci\u00a2c antibody that may cross-react with other \u00a3aviviruses (H. Weissenbo \u00ba ck, personal communication).", [["encephalitis", "DISEASE", 60, 72], ["tick-borne encephalitis", "ORGANISM", 49, 72], ["tick-borne encephalitis (TBE) virus antigen", "PROTEIN", 49, 92], ["polyclonal speci\u00a2c antibody", "PROTEIN", 100, 127], ["tick-borne encephalitis", "SPECIES", 49, 72], ["tick-borne encephalitis (TBE) virus", "SPECIES", 49, 84], ["H. Weissenbo \u00ba ck", "SPECIES", 173, 190], ["tick-borne encephalitis", "PROBLEM", 49, 72], ["TBE) virus antigen", "TEST", 74, 92], ["a polyclonal speci\u00a2c antibody", "TEST", 98, 127]]], ["However, it is still possible that the positive WNV reaction was due to infection with other cross-reactive agents or represented molecular mimicry of host-derived antigens (Oldstone, 1998) .", [["infection", "DISEASE", 72, 81], ["WNV", "ORGANISM", 48, 51], ["WNV", "SPECIES", 48, 51], ["the positive WNV reaction", "PROBLEM", 35, 60], ["infection", "PROBLEM", 72, 81], ["other cross-reactive agents", "TREATMENT", 87, 114], ["still possible", "UNCERTAINTY", 15, 29], ["positive", "OBSERVATION_MODIFIER", 39, 47], ["WNV", "OBSERVATION", 48, 51], ["infection", "OBSERVATION", 72, 81]]], ["The latter possibility receives some support from studies indicating that dogs and cats can be infected with WNV but usually develop only a low viraemia, without clinical signs or histopathological changes in the brain (Blackburn et al.,1989; Lichtensteiger et al., 2003; Austgen et al., 2004) .", [["brain", "ANATOMY", 213, 218], ["WNV", "DISEASE", 109, 112], ["viraemia", "DISEASE", 144, 152], ["dogs", "ORGANISM", 74, 78], ["cats", "ORGANISM", 83, 87], ["WNV", "ORGANISM", 109, 112], ["brain", "ORGAN", 213, 218], ["dogs", "SPECIES", 74, 78], ["cats", "SPECIES", 83, 87], ["WNV", "SPECIES", 109, 112], ["some support", "TREATMENT", 32, 44], ["studies", "TEST", 50, 57], ["dogs and cats", "PROBLEM", 74, 87], ["WNV", "PROBLEM", 109, 112], ["a low viraemia", "PROBLEM", 138, 152], ["clinical signs", "PROBLEM", 162, 176], ["histopathological changes in the brain", "PROBLEM", 180, 218], ["low", "OBSERVATION_MODIFIER", 140, 143], ["viraemia", "OBSERVATION", 144, 152], ["brain", "ANATOMY", 213, 218]]], ["Furthermore, no evidence of WNV infections in domestic animals has so far been detected in Germany.", [["WNV infections", "DISEASE", 28, 42], ["WNV", "ORGANISM", 28, 31], ["WNV", "SPECIES", 28, 31], ["WNV infections", "PROBLEM", 28, 42], ["no evidence of", "UNCERTAINTY", 13, 27], ["WNV", "OBSERVATION_MODIFIER", 28, 31], ["infections", "OBSERVATION", 32, 42]]], ["Therefore, the signi\u00a2cance of the present \u00a2ndings requires further studies.ARTICLE IN PRESSNatural infections of dogs with canine parain\u00a3uenza virus (CPIV) are typically associated with hydrocephalus and necrotizing periventricular encephalitis, but neither viral antigen nor RNA has been detected so far in spontaneous cases (Baumg\u00ccrtner et al., 1982b; Vieler et al.,1994; Cantile et al.,1997) .", [["PRESSNatural infections", "DISEASE", 86, 109], ["canine parain\u00a3uenza virus", "DISEASE", 123, 148], ["hydrocephalus", "DISEASE", 186, 199], ["periventricular encephalitis", "DISEASE", 216, 244], ["dogs", "ORGANISM", 113, 117], ["canine parain\u00a3uenza virus", "ORGANISM", 123, 148], ["CPIV", "CANCER", 150, 154], ["viral antigen", "PROTEIN", 258, 271], ["dogs", "SPECIES", 113, 117], ["canine parain\u00a3uenza virus", "SPECIES", 123, 148], ["canine parain\u00a3uenza virus", "SPECIES", 123, 148], ["CPIV", "SPECIES", 150, 154], ["further studies", "TEST", 59, 74], ["dogs", "PROBLEM", 113, 117], ["canine parain\u00a3uenza virus", "PROBLEM", 123, 148], ["hydrocephalus", "PROBLEM", 186, 199], ["necrotizing periventricular encephalitis", "PROBLEM", 204, 244], ["neither viral antigen nor RNA", "PROBLEM", 250, 279], ["infections", "OBSERVATION", 99, 109], ["typically associated with", "UNCERTAINTY", 160, 185], ["hydrocephalus", "OBSERVATION", 186, 199], ["necrotizing", "OBSERVATION_MODIFIER", 204, 215], ["periventricular", "ANATOMY_MODIFIER", 216, 231], ["encephalitis", "OBSERVATION", 232, 244]]], ["After experimental infection with CPIV, viral antigen was detected in ependymal cells and neurons and in macrophages, in ferrets and dogs respectively (Baumg\u00ccrtner et al., 1982a (Baumg\u00ccrtner et al., , b, 1989a W. Baumg\u00ccrtner, unpublished) .", [["ependymal cells", "ANATOMY", 70, 85], ["neurons", "ANATOMY", 90, 97], ["macrophages", "ANATOMY", 105, 116], ["infection", "DISEASE", 19, 28], ["ependymal cells", "CELL", 70, 85], ["neurons", "CELL", 90, 97], ["macrophages", "CELL", 105, 116], ["ferrets", "ORGANISM", 121, 128], ["dogs", "ORGANISM", 133, 137], ["CPIV", "PROTEIN", 34, 38], ["viral antigen", "PROTEIN", 40, 53], ["ependymal cells", "CELL_TYPE", 70, 85], ["neurons", "CELL_TYPE", 90, 97], ["macrophages", "CELL_TYPE", 105, 116], ["ferrets", "SPECIES", 121, 128], ["dogs", "SPECIES", 133, 137], ["CPIV", "SPECIES", 34, 38], ["experimental infection", "PROBLEM", 6, 28], ["CPIV", "PROBLEM", 34, 38], ["viral antigen", "PROBLEM", 40, 53], ["infection", "OBSERVATION", 19, 28], ["ependymal cells", "OBSERVATION", 70, 85], ["neurons", "ANATOMY", 90, 97], ["macrophages", "ANATOMY", 105, 116]]], ["CPIV infection of brain macrophages was also observed in the present study in a collie with granulomatous encephalitis characteristic of GME.", [["brain macrophages", "ANATOMY", 18, 35], ["infection", "DISEASE", 5, 14], ["granulomatous encephalitis", "DISEASE", 92, 118], ["brain macrophages", "CELL", 18, 35], ["brain macrophages", "CELL_TYPE", 18, 35], ["CPIV", "SPECIES", 0, 4], ["CPIV infection of brain macrophages", "PROBLEM", 0, 35], ["the present study", "TEST", 57, 74], ["granulomatous encephalitis", "PROBLEM", 92, 118], ["infection", "OBSERVATION", 5, 14], ["brain", "ANATOMY", 18, 23], ["macrophages", "OBSERVATION", 24, 35], ["granulomatous", "OBSERVATION_MODIFIER", 92, 105], ["encephalitis", "OBSERVATION", 106, 118], ["GME", "OBSERVATION_MODIFIER", 137, 140]]], ["Interestingly, this dog also showed immunolabelling of WNV antigen.", [["dog", "ORGANISM", 20, 23], ["WNV antigen", "GENE_OR_GENE_PRODUCT", 55, 66], ["WNV antigen", "PROTEIN", 55, 66], ["dog", "SPECIES", 20, 23], ["WNV", "SPECIES", 55, 58], ["immunolabelling of WNV antigen", "PROBLEM", 36, 66], ["WNV", "OBSERVATION", 55, 58]]], ["It remains unclear, therefore, whether the detection of CPIVantigen represented a true infection, or whether immunoreactivity was due to a cross-reaction of the antibody with degraded cellular antigens, or to molecular mimicry (Oldstone,1998) .ARTICLE IN PRESSA further surprising \u00a2nding was the detection of EMCVantigen in the CNS of four dogs and four cats.", [["cellular", "ANATOMY", 184, 192], ["CNS", "ANATOMY", 328, 331], ["infection", "DISEASE", 87, 96], ["CPIVantigen", "GENE_OR_GENE_PRODUCT", 56, 67], ["cellular", "CELL", 184, 192], ["EMCVantigen", "GENE_OR_GENE_PRODUCT", 309, 320], ["CNS", "ANATOMICAL_SYSTEM", 328, 331], ["dogs", "ORGANISM", 340, 344], ["cats", "ORGANISM", 354, 358], ["CPIVantigen", "PROTEIN", 56, 67], ["cellular antigens", "PROTEIN", 184, 201], ["EMCVantigen", "PROTEIN", 309, 320], ["dogs", "SPECIES", 340, 344], ["cats", "SPECIES", 354, 358], ["CPIVantigen", "PROBLEM", 56, 67], ["a true infection", "PROBLEM", 80, 96], ["immunoreactivity", "PROBLEM", 109, 125], ["a cross-reaction of the antibody", "PROBLEM", 137, 169], ["degraded cellular antigens", "PROBLEM", 175, 201], ["true", "OBSERVATION_MODIFIER", 82, 86], ["infection", "OBSERVATION", 87, 96], ["CNS", "ANATOMY", 328, 331]]], ["EMCV-speci\u00a2c antibodies have been detected in primates, mice, rats, horses and elephants in various parts of the world, the rat being the natural host (Nowotny et al.,1993; Nowotny,1996; Psalla et al., 2006) .", [["EMCV-speci\u00a2c antibodies", "GENE_OR_GENE_PRODUCT", 0, 23], ["primates", "ORGANISM", 46, 54], ["mice", "ORGANISM", 56, 60], ["rats", "ORGANISM", 62, 66], ["horses", "ORGANISM", 68, 74], ["rat", "ORGANISM", 124, 127], ["EMCV-speci\u00a2c antibodies", "PROTEIN", 0, 23], ["mice", "SPECIES", 56, 60], ["rats", "SPECIES", 62, 66], ["horses", "SPECIES", 68, 74], ["rat", "SPECIES", 124, 127], ["EMCV", "SPECIES", 0, 4], ["mice", "SPECIES", 56, 60], ["rat", "SPECIES", 124, 127], ["EMCV", "TEST", 0, 4], ["speci\u00a2c antibodies", "TEST", 5, 23]]], ["In Austria, a low seroprevalence has been reported in cats (Nowotny,1996) , but not dogs.", [["cats", "ORGANISM", 54, 58], ["dogs", "ORGANISM", 84, 88], ["cats", "SPECIES", 54, 58], ["dogs", "SPECIES", 84, 88]]], ["In Germany, EMCV-associated non-suppurative meningoencephalitis is reported occasionally in man, but the virus has been isolated from the CNS in only a few cases (Nowotny et al., 1993; LaRue et al., 2003) .", [["CNS", "ANATOMY", 138, 141], ["meningoencephalitis", "DISEASE", 44, 63], ["EMCV", "ORGANISM", 12, 16], ["man", "ORGANISM", 92, 95], ["CNS", "ANATOMICAL_SYSTEM", 138, 141], ["man", "SPECIES", 92, 95], ["EMCV", "PROBLEM", 12, 16], ["non-suppurative meningoencephalitis", "PROBLEM", 28, 63], ["the virus", "PROBLEM", 101, 110], ["EMCV", "OBSERVATION", 12, 16], ["non-suppurative", "OBSERVATION_MODIFIER", 28, 43], ["meningoencephalitis", "OBSERVATION", 44, 63], ["CNS", "ANATOMY", 138, 141]]], ["The histopathological changes reported here varied (neuronal necrosis, mild lymphohistiocytic meningitis, severe generalized granulomatous or pyogranulomatous meningoencephalitis).", [["neuronal", "ANATOMY", 52, 60], ["granulomatous", "ANATOMY", 125, 138], ["neuronal necrosis", "DISEASE", 52, 69], ["meningitis", "DISEASE", 94, 104], ["meningoencephalitis", "DISEASE", 159, 178], ["neuronal", "CELL", 52, 60], ["The histopathological changes", "PROBLEM", 0, 29], ["neuronal necrosis", "PROBLEM", 52, 69], ["mild lymphohistiocytic meningitis", "PROBLEM", 71, 104], ["severe generalized granulomatous", "PROBLEM", 106, 138], ["pyogranulomatous meningoencephalitis", "PROBLEM", 142, 178], ["neuronal necrosis", "OBSERVATION", 52, 69], ["mild", "OBSERVATION_MODIFIER", 71, 75], ["lymphohistiocytic", "OBSERVATION_MODIFIER", 76, 93], ["meningitis", "OBSERVATION", 94, 104], ["severe", "OBSERVATION_MODIFIER", 106, 112], ["generalized", "OBSERVATION_MODIFIER", 113, 124], ["granulomatous", "OBSERVATION", 125, 138], ["pyogranulomatous meningoencephalitis", "OBSERVATION", 142, 178]]], ["In pigs with natural EMCV infections, lymphohistiocytic in\u00a2ltrates in the CNS have been described (Gainer et al., 1968) .", [["CNS", "ANATOMY", 74, 77], ["EMCV infections", "DISEASE", 21, 36], ["pigs", "ORGANISM", 3, 7], ["EMCV", "ORGANISM", 21, 25], ["CNS", "ANATOMICAL_SYSTEM", 74, 77], ["pigs", "SPECIES", 3, 7], ["pigs", "SPECIES", 3, 7], ["EMCV", "SPECIES", 21, 25], ["natural EMCV infections", "PROBLEM", 13, 36], ["lymphohistiocytic in\u00a2ltrates", "PROBLEM", 38, 66], ["natural EMCV infections", "OBSERVATION", 13, 36], ["lymphohistiocytic in\u00a2ltrates", "OBSERVATION", 38, 66], ["CNS", "ANATOMY", 74, 77]]], ["Experimentally infected mice and pigs also develop lymphohistiocytic, perivascular in\u00a2ltrates in the CNS, poliomeningoencephalomyelitis being the predominant feature in mice (Topham et al., 1991; LaRue et al., 2003) .", [["lymphohistiocytic", "ANATOMY", 51, 68], ["perivascular in\u00a2ltrates", "ANATOMY", 70, 93], ["CNS", "ANATOMY", 101, 104], ["poliomeningoencephalomyelitis", "DISEASE", 106, 135], ["mice", "ORGANISM", 24, 28], ["pigs", "ORGANISM", 33, 37], ["perivascular in\u00a2ltrates", "PATHOLOGICAL_FORMATION", 70, 93], ["CNS", "ANATOMICAL_SYSTEM", 101, 104], ["mice", "ORGANISM", 169, 173], ["mice", "SPECIES", 24, 28], ["pigs", "SPECIES", 33, 37], ["mice", "SPECIES", 169, 173], ["mice", "SPECIES", 24, 28], ["pigs", "SPECIES", 33, 37], ["mice", "SPECIES", 169, 173], ["lymphohistiocytic, perivascular in\u00a2ltrates", "PROBLEM", 51, 93], ["the CNS", "PROBLEM", 97, 104], ["poliomeningoencephalomyelitis", "PROBLEM", 106, 135], ["infected", "OBSERVATION", 15, 23], ["lymphohistiocytic", "OBSERVATION", 51, 68], ["perivascular", "ANATOMY_MODIFIER", 70, 82], ["in\u00a2ltrates", "OBSERVATION", 83, 93], ["CNS", "ANATOMY", 101, 104]]], ["In the present study, EMCV immunolabelling was observed in perikarya and processes of neurons in some animals, indicating neurotropism similar to that observed in experimental EMCV infection.", [["perikarya", "ANATOMY", 59, 68], ["neurons", "ANATOMY", 86, 93], ["EMCV infection", "DISEASE", 176, 190], ["EMCV", "ORGANISM", 22, 26], ["perikarya", "CELLULAR_COMPONENT", 59, 68], ["neurons", "CELL", 86, 93], ["EMCV", "ORGANISM", 176, 180], ["EMCV", "SPECIES", 22, 26], ["EMCV", "SPECIES", 176, 180], ["the present study", "TEST", 3, 20], ["EMCV immunolabelling", "TEST", 22, 42], ["neurotropism", "PROBLEM", 122, 134], ["experimental EMCV infection", "PROBLEM", 163, 190], ["neurons", "ANATOMY", 86, 93], ["neurotropism", "OBSERVATION", 122, 134], ["EMCV", "OBSERVATION_MODIFIER", 176, 180], ["infection", "OBSERVATION", 181, 190]]], ["The EMCV-positive cells, associated with cerebral vessels, may have been endothelial cells or pericytes.", [["cells", "ANATOMY", 18, 23], ["cerebral vessels", "ANATOMY", 41, 57], ["endothelial cells", "ANATOMY", 73, 90], ["pericytes", "ANATOMY", 94, 103], ["EMCV", "ORGANISM", 4, 8], ["cells", "CELL", 18, 23], ["cerebral vessels", "MULTI-TISSUE_STRUCTURE", 41, 57], ["endothelial cells", "CELL", 73, 90], ["pericytes", "CELL", 94, 103], ["EMCV-positive cells", "CELL_LINE", 4, 23], ["endothelial cells", "CELL_TYPE", 73, 90], ["pericytes", "CELL_TYPE", 94, 103], ["EMCV", "SPECIES", 4, 8], ["The EMCV", "TEST", 0, 8], ["positive cells", "PROBLEM", 9, 23], ["cerebral vessels", "PROBLEM", 41, 57], ["endothelial cells", "PROBLEM", 73, 90], ["pericytes", "PROBLEM", 94, 103], ["EMCV", "OBSERVATION", 4, 8], ["positive cells", "OBSERVATION", 9, 23], ["cerebral vessels", "ANATOMY", 41, 57], ["endothelial cells", "OBSERVATION", 73, 90], ["pericytes", "OBSERVATION", 94, 103]]], ["Neither cell type has been reported to be susceptible to EMCV, but endothelial and mesenchymal cells in organs other than the CNS are regularly infected with EMCV, as shown by Papaioannou et al. (2003) in pigs.", [["cell", "ANATOMY", 8, 12], ["endothelial", "ANATOMY", 67, 78], ["mesenchymal cells", "ANATOMY", 83, 100], ["organs", "ANATOMY", 104, 110], ["CNS", "ANATOMY", 126, 129], ["cell type", "CELL", 8, 17], ["EMCV", "ORGANISM", 57, 61], ["endothelial", "CELL", 67, 78], ["mesenchymal cells", "CELL", 83, 100], ["organs", "ORGAN", 104, 110], ["CNS", "ANATOMICAL_SYSTEM", 126, 129], ["EMCV", "ORGANISM", 158, 162], ["pigs", "ORGANISM", 205, 209], ["endothelial and mesenchymal cells", "CELL_TYPE", 67, 100], ["pigs", "SPECIES", 205, 209], ["EMCV", "SPECIES", 57, 61], ["EMCV", "SPECIES", 158, 162], ["pigs", "SPECIES", 205, 209], ["EMCV", "PROBLEM", 57, 61], ["endothelial and mesenchymal cells in organs", "PROBLEM", 67, 110], ["EMCV", "TREATMENT", 158, 162], ["cell type", "OBSERVATION", 8, 17], ["EMCV", "OBSERVATION", 57, 61], ["endothelial", "ANATOMY", 67, 78], ["mesenchymal cells", "OBSERVATION", 83, 100], ["CNS", "ANATOMY", 126, 129]]], ["The detection of EMCV antigen in macrophages in the CNS of dogs and cats may support their role in viral replication and distribution, as proposed by Papaioannou et al. (2003) .", [["macrophages", "ANATOMY", 33, 44], ["CNS", "ANATOMY", 52, 55], ["EMCV", "ORGANISM", 17, 21], ["antigen", "GENE_OR_GENE_PRODUCT", 22, 29], ["macrophages", "CELL", 33, 44], ["CNS", "ANATOMICAL_SYSTEM", 52, 55], ["dogs", "ORGANISM", 59, 63], ["cats", "ORGANISM", 68, 72], ["EMCV antigen", "PROTEIN", 17, 29], ["macrophages", "CELL_TYPE", 33, 44], ["dogs", "SPECIES", 59, 63], ["cats", "SPECIES", 68, 72], ["EMCV", "SPECIES", 17, 21], ["The detection", "TEST", 0, 13], ["EMCV antigen", "TEST", 17, 29], ["EMCV", "OBSERVATION", 17, 21], ["CNS", "ANATOMY", 52, 55], ["viral replication", "OBSERVATION", 99, 116]]], ["In natural EMCV infection of pigs, interstitial myocarditis and myocardial degeneration represent the main features (Papaioannou et al., 2003) .", [["interstitial", "ANATOMY", 35, 47], ["myocardial", "ANATOMY", 64, 74], ["EMCV infection", "DISEASE", 11, 25], ["interstitial myocarditis", "DISEASE", 35, 59], ["myocardial degeneration", "DISEASE", 64, 87], ["EMCV", "ORGANISM", 11, 15], ["pigs", "ORGANISM", 29, 33], ["myocardial", "MULTI-TISSUE_STRUCTURE", 64, 74], ["pigs", "SPECIES", 29, 33], ["EMCV", "SPECIES", 11, 15], ["pigs", "SPECIES", 29, 33], ["interstitial myocarditis", "PROBLEM", 35, 59], ["myocardial degeneration", "PROBLEM", 64, 87], ["natural EMCV", "OBSERVATION", 3, 15], ["infection", "OBSERVATION_MODIFIER", 16, 25], ["interstitial", "ANATOMY_MODIFIER", 35, 47], ["myocarditis", "OBSERVATION", 48, 59], ["myocardial", "ANATOMY", 64, 74], ["degeneration", "OBSERVATION", 75, 87], ["main", "OBSERVATION_MODIFIER", 102, 106]]], ["Neither change was observed in any of the present cases, but myocardial tissue was available from only one dog and two cats.ARTICLE IN PRESSDespite the broad spectrum of antibodies used, the aetiology of the CNS lesions could be determined in only 26% and 39% of the cases in dogs and cats, respectively.", [["myocardial tissue", "ANATOMY", 61, 78], ["CNS lesions", "ANATOMY", 208, 219], ["myocardial tissue", "TISSUE", 61, 78], ["dog", "ORGANISM", 107, 110], ["cats", "ORGANISM", 119, 123], ["CNS lesions", "PATHOLOGICAL_FORMATION", 208, 219], ["dogs", "ORGANISM", 276, 280], ["cats", "ORGANISM", 285, 289], ["antibodies", "PROTEIN", 170, 180], ["dog", "SPECIES", 107, 110], ["dogs", "SPECIES", 276, 280], ["cats", "SPECIES", 285, 289], ["myocardial tissue", "PROBLEM", 61, 78], ["antibodies", "TREATMENT", 170, 180], ["the CNS lesions", "PROBLEM", 204, 219], ["change", "OBSERVATION", 8, 14], ["myocardial tissue", "ANATOMY", 61, 78], ["CNS", "ANATOMY", 208, 211], ["lesions", "OBSERVATION", 212, 219]]], ["Due to the retrospective character of the study, a standardized clinical and neurological investigation and serum and CSF laboratory procedures were not possible.", [["serum", "ANATOMY", 108, 113], ["serum", "ORGANISM_SUBSTANCE", 108, 113], ["the study", "TEST", 38, 47], ["a standardized clinical and neurological investigation", "TEST", 49, 103], ["serum", "TEST", 108, 113], ["CSF laboratory procedures", "TEST", 118, 143]]], ["In the remaining cases, infection cannot be ruled out.", [["infection", "DISEASE", 24, 33], ["infection", "PROBLEM", 24, 33], ["infection", "OBSERVATION", 24, 33], ["cannot be ruled", "UNCERTAINTY", 34, 49]]], ["Other agents that might have caused the observed histopathological changes in dogs include Ehrlichia spp.", [["Ehrlichia spp", "DISEASE", 91, 104], ["dogs", "ORGANISM", 78, 82], ["Ehrlichia spp", "ORGANISM", 91, 104], ["dogs", "SPECIES", 78, 82], ["Other agents", "TREATMENT", 0, 12], ["the observed histopathological changes in dogs", "PROBLEM", 36, 82], ["Ehrlichia spp", "PROBLEM", 91, 104], ["Ehrlichia spp", "OBSERVATION", 91, 104]]], ["(Glaus and Jaggy, 1992; Maretzki et al., 1994) , Leptospira spp.", [["Leptospira spp", "DISEASE", 49, 63], ["Leptospira spp", "ORGANISM", 49, 63], ["Leptospira spp", "SPECIES", 49, 63], ["Leptospira spp", "TEST", 49, 63]]], ["(Rentko et al., 1992) and Borrelia spp.", [["Borrelia spp", "DISEASE", 26, 38], ["Borrelia spp", "ORGANISM", 26, 38]]], ["(Mandel et al.,1993; Chang et al., 2001) , and in cats Bartonella henselae (Breitschwerdt et al., 1999) cannot be excluded.", [["Bartonella henselae", "DISEASE", 55, 74], ["cats", "ORGANISM", 50, 54], ["Bartonella henselae", "ORGANISM", 55, 74], ["cats", "SPECIES", 50, 54], ["Bartonella henselae", "SPECIES", 55, 74], ["Bartonella henselae", "SPECIES", 55, 74], ["not be excluded", "UNCERTAINTY", 107, 122]]], ["However, the high percentage of cases in which no infectious agent was identi\u00a2ed suggests that non-infectious causes are more common than anticipated.", [["infectious agent", "PROBLEM", 50, 66], ["non-infectious causes", "PROBLEM", 95, 116], ["high", "OBSERVATION_MODIFIER", 13, 17], ["percentage", "OBSERVATION_MODIFIER", 18, 28], ["no", "UNCERTAINTY", 47, 49], ["infectious", "OBSERVATION_MODIFIER", 50, 60], ["non-infectious", "OBSERVATION", 95, 109]]], ["Various factors, ranging from autoimmune processes to intoxication, have already been suggested as causes of non-suppurative changes in the CNS (Kipar et al.,1998; , Lee et al., 2002 .ARTICLE IN PRESSThe immunohistochemical reactions for WNV, CPIVand EMCV, which were unexpected, were possibly due to molecular mimicry, a phenomenon reported for various paramyxoviruses and forJapanese encephalitis virus (JPEV; Shesberadaran and Norrby, 1984) , which belongs to the Flaviviridae.", [["CNS", "ANATOMY", 140, 143], ["forJapanese encephalitis", "DISEASE", 374, 398], ["CNS", "ANATOMICAL_SYSTEM", 140, 143], ["WNV", "ORGANISM", 238, 241], ["CPIVand EMCV", "ORGANISM", 243, 255], ["forJapanese encephalitis virus", "ORGANISM", 374, 404], ["forJapanese encephalitis virus", "SPECIES", 374, 404], ["WNV", "SPECIES", 238, 241], ["EMCV", "SPECIES", 251, 255], ["forJapanese encephalitis virus", "SPECIES", 374, 404], ["JPEV", "SPECIES", 406, 410], ["Various factors", "PROBLEM", 0, 15], ["autoimmune processes", "PROBLEM", 30, 50], ["intoxication", "PROBLEM", 54, 66], ["non-suppurative changes", "PROBLEM", 109, 132], ["WNV", "PROBLEM", 238, 241], ["CPIVand EMCV", "PROBLEM", 243, 255], ["molecular mimicry", "PROBLEM", 301, 318], ["a phenomenon", "PROBLEM", 320, 332], ["various paramyxoviruses", "PROBLEM", 346, 369], ["forJapanese encephalitis virus", "PROBLEM", 374, 404], ["non-suppurative", "OBSERVATION", 109, 124], ["CNS", "ANATOMY", 140, 143]]], ["In most of the cases showing these unexpected reactions the histopathological changes were severe and often resembled GME.", [["these unexpected reactions", "PROBLEM", 29, 55], ["the histopathological changes", "PROBLEM", 56, 85]]], ["Autoimmune mechanisms have already been discussed as a possible cause of canine GME and pug dog encephalitis (Kipar et al., 1998; .", [["pug dog encephalitis", "DISEASE", 88, 108], ["canine", "ORGANISM", 73, 79], ["pug dog", "ORGANISM", 88, 95], ["dog", "SPECIES", 92, 95], ["canine", "SPECIES", 73, 79], ["Autoimmune mechanisms", "PROBLEM", 0, 21], ["canine GME", "PROBLEM", 73, 83], ["pug dog encephalitis", "PROBLEM", 88, 108]]], ["Other factors that may have played a role in the \u00a2ndings described include the following: epitope spreading Vanderlugt et al., 1998) ; hereditary factors, as already suspected in pug dog encephalitis and non-suppurative meningoencephalitis in greyhounds (Hinrichs et al., 1996; Callanan et al., 2002) ; intoxication (Lee et al., 2002) ; increased permeability of the blood-brain barrier in systemic illness, due to prostaglandins and interleukin (IL)-1, IL-6 or tumour necrosis factor (TNF)-a, leading to in\u00a2ltration of the CNS by in\u00a3ammatory cells (Reiss et al., 2000) .", [["blood", "ANATOMY", 367, 372], ["brain", "ANATOMY", 373, 378], ["CNS", "ANATOMY", 524, 527], ["in\u00a3ammatory cells", "ANATOMY", 531, 548], ["hereditary factors", "DISEASE", 135, 153], ["pug dog encephalitis", "DISEASE", 179, 199], ["meningoencephalitis", "DISEASE", 220, 239], ["systemic illness", "DISEASE", 390, 406], ["prostaglandins", "CHEMICAL", 415, 429], ["necrosis", "DISEASE", 469, 477], ["prostaglandins", "CHEMICAL", 415, 429], ["pug dog", "ORGANISM", 179, 186], ["blood", "ORGANISM_SUBSTANCE", 367, 372], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 373, 386], ["prostaglandins", "SIMPLE_CHEMICAL", 415, 429], ["interleukin (IL)-1", "GENE_OR_GENE_PRODUCT", 434, 452], ["IL-6", "GENE_OR_GENE_PRODUCT", 454, 458], ["tumour necrosis factor", "GENE_OR_GENE_PRODUCT", 462, 484], ["TNF", "GENE_OR_GENE_PRODUCT", 486, 489], ["CNS", "ANATOMICAL_SYSTEM", 524, 527], ["in\u00a3ammatory cells", "CELL", 531, 548], ["interleukin (IL)-1, IL-6", "PROTEIN", 434, 458], ["TNF", "PROTEIN", 486, 489], ["in\u00a3ammatory cells", "CELL_TYPE", 531, 548], ["dog", "SPECIES", 183, 186], ["hereditary factors", "PROBLEM", 135, 153], ["pug dog encephalitis", "PROBLEM", 179, 199], ["non-suppurative meningoencephalitis in greyhounds", "PROBLEM", 204, 253], ["intoxication", "PROBLEM", 303, 315], ["increased permeability", "PROBLEM", 337, 359], ["the blood", "PROBLEM", 363, 372], ["systemic illness", "PROBLEM", 390, 406], ["prostaglandins", "TREATMENT", 415, 429], ["interleukin (IL)", "TREATMENT", 434, 450], ["IL", "TEST", 454, 456], ["tumour necrosis factor", "PROBLEM", 462, 484], ["TNF", "TEST", 486, 489], ["non-suppurative", "OBSERVATION_MODIFIER", 204, 219], ["meningoencephalitis", "OBSERVATION", 220, 239], ["blood", "ANATOMY", 367, 372], ["brain", "ANATOMY", 373, 378], ["systemic", "ANATOMY", 390, 398], ["illness", "OBSERVATION", 399, 406], ["tumour", "OBSERVATION_MODIFIER", 462, 468], ["necrosis", "OBSERVATION", 469, 477], ["CNS", "ANATOMY", 524, 527]]], ["In addition, it should be mentioned that, unlike paraneoplastic encephalitis, which has been described in man but not in dogs or cats (Scaravilli et al., 1999) , paraneoplastic polyneuropathy has been described in dogs (Braund, 1990; Wagner, 2002) .", [["paraneoplastic encephalitis", "DISEASE", 49, 76], ["paraneoplastic polyneuropathy", "DISEASE", 162, 191], ["man", "ORGANISM", 106, 109], ["dogs", "ORGANISM", 121, 125], ["cats", "ORGANISM", 129, 133], ["dogs", "ORGANISM", 214, 218], ["man", "SPECIES", 106, 109], ["dogs", "SPECIES", 121, 125], ["cats", "SPECIES", 129, 133], ["dogs", "SPECIES", 214, 218], ["paraneoplastic encephalitis", "PROBLEM", 49, 76], ["paraneoplastic polyneuropathy", "PROBLEM", 162, 191], ["paraneoplastic encephalitis", "OBSERVATION", 49, 76], ["paraneoplastic polyneuropathy", "OBSERVATION", 162, 191]]], ["As tumours in the CNS or other organs were present in only one of the cases examined, paraneoplastic encephalitis seemed unlikely to have played any role in the \u00a2ndings.ARTICLE IN PRESSIn conclusion, in a high proportion of dogs and cats with non-suppurative meningoencephalitis, immunohistochemical examination with antibodies against 18 di\u00a1erent infectious agents failed to reveal a cause.", [["tumours", "ANATOMY", 3, 10], ["CNS", "ANATOMY", 18, 21], ["organs", "ANATOMY", 31, 37], ["tumours", "DISEASE", 3, 10], ["paraneoplastic encephalitis", "DISEASE", 86, 113], ["meningoencephalitis", "DISEASE", 259, 278], ["tumours", "CANCER", 3, 10], ["CNS", "ANATOMICAL_SYSTEM", 18, 21], ["organs", "ORGAN", 31, 37], ["dogs", "ORGANISM", 224, 228], ["cats", "ORGANISM", 233, 237], ["antibodies", "PROTEIN", 317, 327], ["dogs", "SPECIES", 224, 228], ["cats", "SPECIES", 233, 237], ["paraneoplastic encephalitis", "PROBLEM", 86, 113], ["non-suppurative meningoencephalitis", "PROBLEM", 243, 278], ["immunohistochemical examination", "TEST", 280, 311], ["antibodies", "TREATMENT", 317, 327], ["18 di\u00a1erent infectious agents", "PROBLEM", 336, 365], ["CNS", "ANATOMY", 18, 21], ["paraneoplastic encephalitis", "OBSERVATION", 86, 113], ["non-suppurative", "OBSERVATION_MODIFIER", 243, 258], ["meningoencephalitis", "OBSERVATION", 259, 278]]], ["The signi\u00a2cance of positive immunoreactions obtained with WNV and EMCV antibodies requires further investigation.", [["WNV", "ORGANISM", 58, 61], ["EMCV", "ORGANISM", 66, 70], ["EMCV antibodies", "PROTEIN", 66, 81], ["WNV", "SPECIES", 58, 61], ["EMCV", "SPECIES", 66, 70], ["positive immunoreactions", "PROBLEM", 19, 43], ["WNV", "PROBLEM", 58, 61], ["EMCV antibodies", "TEST", 66, 81], ["further investigation", "TEST", 91, 112], ["positive immunoreactions", "OBSERVATION", 19, 43]]], ["In addition, primary or virus-triggered secondary immune-mediated mechanisms should be considered in many in\u00a3ammatory CNS disorders of dogs and cats.", [["CNS", "ANATOMY", 118, 121], ["CNS", "ANATOMICAL_SYSTEM", 118, 121], ["dogs", "ORGANISM", 135, 139], ["cats", "ORGANISM", 144, 148], ["dogs", "SPECIES", 135, 139], ["cats", "SPECIES", 144, 148], ["primary or virus", "PROBLEM", 13, 29], ["immune-mediated mechanisms", "TREATMENT", 50, 76], ["virus", "OBSERVATION", 24, 29]]]], "8d11ad8459100f406b9881b316e48b7d242fdb60": [["thickened, and multifocally lytic, indicating osteomyelitis and otitis interna.", [["otitis interna", "ANATOMY", 64, 78], ["osteomyelitis", "DISEASE", 46, 59], ["otitis interna", "DISEASE", 64, 78], ["thickened, and multifocally lytic", "PROBLEM", 0, 33], ["osteomyelitis", "PROBLEM", 46, 59], ["otitis interna", "PROBLEM", 64, 78], ["multifocally", "OBSERVATION_MODIFIER", 15, 27], ["lytic", "OBSERVATION_MODIFIER", 28, 33], ["indicating", "UNCERTAINTY", 35, 45], ["osteomyelitis", "OBSERVATION", 46, 59], ["otitis", "OBSERVATION", 64, 70]]], ["Additionally, in both tympanic cavities and external ear canals there was an increased soft tissue density, indicative of bilateral otitis media (Fig 1) .", [["tympanic cavities", "ANATOMY", 22, 39], ["ear canals", "ANATOMY", 53, 63], ["soft tissue", "ANATOMY", 87, 98], ["otitis", "DISEASE", 132, 138], ["tympanic cavities", "MULTI-TISSUE_STRUCTURE", 22, 39], ["ear canals", "MULTI-TISSUE_STRUCTURE", 53, 63], ["soft tissue", "TISSUE", 87, 98], ["an increased soft tissue density", "PROBLEM", 74, 106], ["bilateral otitis media", "PROBLEM", 122, 144], ["both", "ANATOMY_MODIFIER", 17, 21], ["tympanic", "ANATOMY", 22, 30], ["cavities", "ANATOMY_MODIFIER", 31, 39], ["external ear canals", "ANATOMY", 44, 63], ["increased", "OBSERVATION_MODIFIER", 77, 86], ["soft tissue", "OBSERVATION_MODIFIER", 87, 98], ["density", "OBSERVATION", 99, 106], ["indicative of", "UNCERTAINTY", 108, 121], ["bilateral", "ANATOMY_MODIFIER", 122, 131], ["otitis", "OBSERVATION", 132, 138]]], ["An atlanto-occipital CSF fluid sample provided evidence of meningitis (36 nucleated cells/L, mostly macrophages with moderate lymphocytes and moderate neutrophils, no bacteria, total protein concentration 31 mg/dL).", [["CSF fluid sample", "ANATOMY", 21, 37], ["nucleated cells", "ANATOMY", 74, 89], ["L", "ANATOMY", 90, 91], ["macrophages", "ANATOMY", 100, 111], ["lymphocytes", "ANATOMY", 126, 137], ["neutrophils", "ANATOMY", 151, 162], ["meningitis", "DISEASE", 59, 69], ["cells", "CELL", 84, 89], ["L", "CELL", 90, 91], ["macrophages", "CELL", 100, 111], ["lymphocytes", "CELL", 126, 137], ["neutrophils", "CELL", 151, 162], ["macrophages", "CELL_TYPE", 100, 111], ["moderate lymphocytes", "CELL_TYPE", 117, 137], ["neutrophils", "CELL_TYPE", 151, 162], ["An atlanto-occipital CSF fluid sample", "TEST", 0, 37], ["meningitis", "PROBLEM", 59, 69], ["nucleated cells", "TEST", 74, 89], ["mostly macrophages", "PROBLEM", 93, 111], ["moderate lymphocytes", "PROBLEM", 117, 137], ["moderate neutrophils", "PROBLEM", 142, 162], ["bacteria", "PROBLEM", 167, 175], ["total protein concentration", "TEST", 177, 204], ["occipital", "ANATOMY_MODIFIER", 11, 20], ["CSF", "ANATOMY", 21, 24], ["fluid", "OBSERVATION", 25, 30], ["evidence of", "UNCERTAINTY", 47, 58], ["meningitis", "OBSERVATION", 59, 69], ["L", "ANATOMY_MODIFIER", 90, 91], ["macrophages", "ANATOMY", 100, 111], ["moderate", "OBSERVATION_MODIFIER", 117, 125], ["lymphocytes", "OBSERVATION", 126, 137], ["moderate", "OBSERVATION_MODIFIER", 142, 150], ["neutrophils", "OBSERVATION", 151, 162], ["no", "UNCERTAINTY", 164, 166], ["bacteria", "OBSERVATION_MODIFIER", 167, 175]]], ["The calf was treated with fluids intravenously, nonsteroidal anti-inflammatory drugs, topical nonantibiotic eye ointment, vitamin E and selenium (204 IU vitamin E, 3 mg IM once sodium selenite), and oxytetracycline (6.6 mg/kg IV q12h for a total for 14 days).", [["calf", "ANATOMY", 4, 8], ["intravenously", "ANATOMY", 33, 46], ["nonsteroidal", "ANATOMY", 48, 60], ["eye", "ANATOMY", 108, 111], ["vitamin E", "CHEMICAL", 122, 131], ["selenium", "CHEMICAL", 136, 144], ["vitamin E", "CHEMICAL", 153, 162], ["sodium selenite", "CHEMICAL", 177, 192], ["oxytetracycline", "CHEMICAL", 199, 214], ["vitamin E", "CHEMICAL", 122, 131], ["selenium", "CHEMICAL", 136, 144], ["vitamin E", "CHEMICAL", 153, 162], ["sodium selenite", "CHEMICAL", 177, 192], ["oxytetracycline", "CHEMICAL", 199, 214], ["calf", "ORGANISM", 4, 8], ["eye", "ORGAN", 108, 111], ["vitamin E", "SIMPLE_CHEMICAL", 122, 131], ["selenium", "SIMPLE_CHEMICAL", 136, 144], ["vitamin E", "SIMPLE_CHEMICAL", 153, 162], ["sodium", "SIMPLE_CHEMICAL", 177, 183], ["selenite", "SIMPLE_CHEMICAL", 184, 192], ["oxytetracycline", "SIMPLE_CHEMICAL", 199, 214], ["calf", "SPECIES", 4, 8], ["fluids intravenously", "TREATMENT", 26, 46], ["nonsteroidal anti-inflammatory drugs", "TREATMENT", 48, 84], ["topical nonantibiotic eye ointment", "TREATMENT", 86, 120], ["vitamin E", "TREATMENT", 122, 131], ["selenium", "TREATMENT", 136, 144], ["vitamin E", "TREATMENT", 153, 162], ["sodium selenite", "TREATMENT", 177, 192], ["oxytetracycline", "TREATMENT", 199, 214], ["calf", "ANATOMY", 4, 8]]], ["Otitis externa was treated with instillation of diluted vinegar solution in both ears (50% distilled vinegar : 50% water q12h).", [["Otitis externa", "ANATOMY", 0, 14], ["ears", "ANATOMY", 81, 85], ["Otitis externa", "DISEASE", 0, 14], ["ears", "ORGAN", 81, 85], ["Otitis externa", "PROBLEM", 0, 14], ["instillation of diluted vinegar solution", "TREATMENT", 32, 72], ["externa", "OBSERVATION", 7, 14]]], ["The calf was able to pan-feed from the ground safely and was given small volumes of milk replacer multiple times per day.", [["calf", "ORGANISM", 4, 8], ["milk", "ORGANISM", 84, 88], ["calf", "SPECIES", 4, 8], ["small volumes of milk replacer", "TREATMENT", 67, 97], ["calf", "ANATOMY", 4, 8]]], ["Slow but gradual improvement was noticed in all her clinical signs.", [["gradual", "OBSERVATION_MODIFIER", 9, 16], ["improvement", "OBSERVATION_MODIFIER", 17, 28]]], ["Endoscopy after 12 days was normal.", [["Endoscopy", "TEST", 0, 9], ["normal", "OBSERVATION", 28, 34]]], ["The calf was continued on oxytetracycline (20 mg/kg IM q48h) and procaine-penicillin (22,000 IU/kg IM q12h) for an additional 10 days after discharge.", [["oxytetracycline", "CHEMICAL", 26, 41], ["procaine", "CHEMICAL", 65, 73], ["penicillin", "CHEMICAL", 74, 84], ["oxytetracycline", "CHEMICAL", 26, 41], ["procaine", "CHEMICAL", 65, 73], ["penicillin", "CHEMICAL", 74, 84], ["calf", "ORGANISM", 4, 8], ["oxytetracycline", "SIMPLE_CHEMICAL", 26, 41], ["procaine-penicillin", "SIMPLE_CHEMICAL", 65, 84], ["calf", "SPECIES", 4, 8], ["oxytetracycline", "TREATMENT", 26, 41], ["procaine", "TREATMENT", 65, 73], ["penicillin", "TREATMENT", 74, 84], ["calf", "ANATOMY", 4, 8]]], ["All clinical signs resolved completely and she became a productive animal in the herd.", [["herd", "ORGANISM_SUBDIVISION", 81, 85], ["All clinical signs", "TEST", 0, 18], ["productive", "OBSERVATION_MODIFIER", 56, 66]]]], "7ee0743d5eb754406f3b4c8cd0a46764650314f2": [["changes that result in virus-cell membrane fusion and viral entry.", [["cell membrane", "ANATOMY", 29, 42], ["cell membrane", "CELLULAR_COMPONENT", 29, 42], ["virus-cell membrane fusion", "TREATMENT", 23, 49], ["viral entry", "PROBLEM", 54, 65], ["virus", "OBSERVATION", 23, 28], ["cell membrane fusion", "OBSERVATION", 29, 49], ["viral entry", "OBSERVATION", 54, 65]]], ["Several endosomal, 70 cell surface, and exogenous proteases, including furin, select cathepsins and 71", [["endosomal", "ANATOMY", 8, 17], ["cell surface", "ANATOMY", 22, 34], ["endosomal", "CELLULAR_COMPONENT", 8, 17], ["cell surface", "CELLULAR_COMPONENT", 22, 34], ["furin", "GENE_OR_GENE_PRODUCT", 71, 76], ["cathepsins", "GENE_OR_GENE_PRODUCT", 85, 95], ["exogenous proteases", "PROTEIN", 40, 59], ["furin", "PROTEIN", 71, 76], ["cathepsins", "PROTEIN", 85, 95], ["70 cell surface", "TREATMENT", 19, 34], ["exogenous proteases", "TREATMENT", 40, 59], ["endosomal", "OBSERVATION_MODIFIER", 8, 17], ["70 cell", "OBSERVATION_MODIFIER", 19, 26], ["surface", "OBSERVATION_MODIFIER", 27, 34], ["exogenous proteases", "OBSERVATION", 40, 59]]]], "d0b020db06836ca663b554b802af338f97d62a4d": [["The Impact of Coronavirus Disease 2019 on Bariatric Surgery: Redefining Psychosocial Care Sanjeev Sockalingam 1, 2, 3, 4 , Samantha E. Leung 1, 2 , and Stephanie E. Cassin 1, 3, 5 The global outbreak of the 2019 novel coronavirus disease has had a tremendous psychological impact on individuals around the world.", [["Coronavirus Disease", "DISEASE", 14, 33], ["coronavirus disease", "DISEASE", 218, 237], ["coronavirus", "ORGANISM", 218, 229], ["coronavirus", "SPECIES", 218, 229], ["Coronavirus Disease", "PROBLEM", 14, 33], ["Bariatric Surgery", "TREATMENT", 42, 59], ["novel coronavirus disease", "PROBLEM", 212, 237], ["Coronavirus Disease", "OBSERVATION", 14, 33], ["coronavirus disease", "OBSERVATION", 218, 237]]], ["Individuals with obesity are susceptible to distress and psychological sequalae secondary to this pandemic, which can have detrimental effects on obesity management.", [["obesity", "DISEASE", 17, 24], ["distress and psychological sequalae", "DISEASE", 44, 79], ["obesity", "DISEASE", 146, 153], ["obesity", "PROBLEM", 17, 24], ["distress", "PROBLEM", 44, 52], ["psychological sequalae", "PROBLEM", 57, 79], ["this pandemic", "PROBLEM", 93, 106], ["obesity management", "TREATMENT", 146, 164], ["obesity", "OBSERVATION", 17, 24], ["obesity", "OBSERVATION", 146, 153]]], ["In particular, individuals undergoing bariatric surgery could experience increased emotional distress, resulting in increased eating psychopathology, mental health exacerbation, and difficulties with self-management.", [["emotional distress", "DISEASE", 83, 101], ["eating psychopathology", "DISEASE", 126, 148], ["bariatric surgery", "TREATMENT", 38, 55], ["increased emotional distress", "PROBLEM", 73, 101], ["increased eating psychopathology", "PROBLEM", 116, 148], ["mental health exacerbation", "PROBLEM", 150, 176], ["self-management", "TREATMENT", 200, 215], ["increased", "OBSERVATION_MODIFIER", 116, 125]]], ["Addressing these challenges requires novel approaches to redefining psychosocial care before and after bariatric surgery.", [["bariatric surgery", "TREATMENT", 103, 120]]], ["Emerging evidence suggests that the remote delivery of care using virtual care models, including mobile and online modalities, could extend the reach of psychosocial services to individuals after bariatric surgery and mitigate weight regain or impairment in quality of life.", [["weight regain", "DISEASE", 227, 240], ["virtual care models", "TREATMENT", 66, 85], ["bariatric surgery", "TREATMENT", 196, 213], ["impairment in quality of life", "PROBLEM", 244, 273]]], ["Because of this pandemic, the rapid integration of virtual psychosocial care in bariatric surgery programs to address patients' needs will create new opportunities for clinical and implementational scientific research.", [["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["this pandemic", "PROBLEM", 11, 24], ["virtual psychosocial care", "TREATMENT", 51, 76], ["bariatric surgery programs", "TREATMENT", 80, 106]]]], "PMC3127449": [["IntroductionTo understand the dynamics of infectious diseases it is crucial to understand the structure and interactions within the host population.", [["infectious diseases", "DISEASE", 42, 61], ["infectious diseases", "PROBLEM", 42, 61], ["infectious", "OBSERVATION", 42, 52]]], ["Conversely, it is possible to learn something about host population structure by observing the pattern of pathogen spread within it.", [["pathogen spread", "PROBLEM", 106, 121], ["pathogen", "OBSERVATION_MODIFIER", 106, 114], ["spread", "OBSERVATION_MODIFIER", 115, 121]]], ["Networks, where nodes of the network represent hosts and edges between nodes represent contacts across which pathogens may be transmitted, are now regularly used to model host interactions [1\u20133].", [["nodes", "ANATOMY", 71, 76], ["nodes", "OBSERVATION", 71, 76]]], ["While many models have been proposed to describe the structure of these contact networks for different populations and different modes of transmission, it is not yet understood how different features of networks affect the spread of pathogens.IntroductionOne promising development in this field is the use of statistical techniques which aim to model a contact network based on data relating to the passage of a pathogen through a population.", [["pathogens", "PROBLEM", 233, 242], ["statistical techniques", "TREATMENT", 309, 331]]], ["Such data includes infection times [4\u20136] and genetic sequences that are collected from an epidemic present in the population of interest [7\u20139].", [["infection", "DISEASE", 19, 28], ["infection", "PROBLEM", 19, 28], ["genetic sequences", "TEST", 45, 62]]], ["Infection times can be used to crudely reconstruct transmission histories by examining which individuals were infectious at the time that any particular individual was infected [10].", [["individuals", "ORGANISM", 93, 104], ["Infection", "PROBLEM", 0, 9], ["infectious", "PROBLEM", 110, 120]]], ["Genetic sequences from viruses are informative about who infected whom by comparing the similarity between sequences.", [["Genetic sequences", "TEST", 0, 17]]], ["Due to the random accumulation of mutations in the sequences, we expect sequences from an infector/infectee pair to be much closer to each other than sequences from a randomly selected pair in the population (see [11] for a review of modern approaches to analysing viral genetic data).", [["infector/infectee pair", "DNA", 90, 112], ["the random accumulation of mutations in the sequences", "PROBLEM", 7, 60], ["an infector/infectee pair", "TREATMENT", 87, 112]]], ["In theory, these statistical methods could settle arguments about which features of the network are important in the transmission of the disease and which are simply artifacts of the physical system.IntroductionIn this article, we focus on clustering in networks and ask whether or not networks which differ only in their level of clustering could be distinguished if all we observed was transmission data from an epidemic outbreak.", [["the disease", "PROBLEM", 133, 144], ["artifacts of the physical system", "PROBLEM", 166, 198], ["an epidemic outbreak", "PROBLEM", 411, 431], ["disease", "OBSERVATION", 137, 144]]], ["This population and its interactions are fully described by a undirected random network, denoted Y, on N nodes.", [["N nodes", "ANATOMY", 103, 110], ["N nodes", "MULTI-TISSUE_STRUCTURE", 103, 110], ["nodes", "OBSERVATION", 105, 110]]], ["An simple example of a network is shown in Figure 1 with illustrations of some of the terms we use in this article.", [["simple", "OBSERVATION_MODIFIER", 3, 9]]], ["Y can be represented by the symmetric binary matrix [Yij] where Yij = Yji = 1 if an edge is present between nodes i and j, otherwise Yij = 0.", [["edge", "OBSERVATION_MODIFIER", 84, 88], ["nodes", "OBSERVATION", 108, 113]]], ["We stipulate that there no loops in the network, so Yii = 0 for all i.", [["no", "UNCERTAINTY", 24, 26], ["loops", "OBSERVATION", 27, 32]]], ["The degree of the ith node, denoted di is the number of edges connected to i, so di = \u2211j:j>i Yij.IntroductionClustering is one of the central features of observed social networks [12,13].", [["node", "ANATOMY", 22, 26], ["node", "MULTI-TISSUE_STRUCTURE", 22, 26], ["Yij", "PROTEIN", 93, 96], ["the ith node", "PROBLEM", 14, 26], ["degree", "OBSERVATION_MODIFIER", 4, 10], ["ith", "OBSERVATION_MODIFIER", 18, 21], ["node", "OBSERVATION", 22, 26], ["edges", "OBSERVATION_MODIFIER", 56, 61]]], ["Intuitively, clustering is the propensity for triangles or other small cycles to form, so that, for example, a friend of my friend is also likely to be my friend.", [["triangles", "TREATMENT", 46, 55]]], ["Where there is a positive clustering effect, the existence of edges (i, j) and (i, k) increases the propensity for the edge (j, k) to exist, while a negative clustering effect implies that (j, k) is less likely to exist given the presence of (i, j) and (i, k).", [["a positive clustering effect", "PROBLEM", 15, 43], ["positive", "OBSERVATION_MODIFIER", 17, 25], ["clustering", "OBSERVATION_MODIFIER", 26, 36], ["effect", "OBSERVATION_MODIFIER", 37, 43], ["edges", "OBSERVATION_MODIFIER", 62, 67], ["less likely", "UNCERTAINTY", 199, 210]]], ["When there is no clustering effect, the presence or absence of (i, j) and (i, k) has no bearing on that of (j, k).", [["no", "UNCERTAINTY", 14, 16], ["clustering effect", "OBSERVATION", 17, 34]]], ["Thus clustering is one of the most basic of the true network effects\u2014when it is present, the relationship between two nodes depends not only on properties of the nodes themselves but the presence or absence of other relationships in the network.IntroductionThe effect of clustering on the dynamics of stochastic epidemics that run over networks remains largely unknown, though it has been studied in a few special cases.", [["stochastic epidemics", "PROBLEM", 301, 321], ["one of the most", "OBSERVATION_MODIFIER", 19, 34], ["nodes", "OBSERVATION", 118, 123], ["nodes", "OBSERVATION", 162, 167]]], ["In simulations we study here, we focus on holding the degree sequence of a network constant\u2014that is, each node maintains the same number of contacts\u2014while varying the level of clustering.", [["node", "OBSERVATION", 106, 110]]], ["Intuition suggests that clustering will have some effect on epidemic dynamics since, in a graph with no cycles, if an infection is introduced to a population at node i and there is a path leading to j then k, k can only become infected if j does first.", [["node", "ANATOMY", 161, 165], ["infection", "DISEASE", 118, 127], ["node i", "MULTI-TISSUE_STRUCTURE", 161, 167], ["epidemic dynamics", "PROBLEM", 60, 77], ["an infection", "PROBLEM", 115, 127], ["infection", "OBSERVATION", 118, 127], ["infected", "OBSERVATION", 227, 235]]], ["However, where cycles are present, there may be multiple paths leading from i to k that do not include j, so giving a different probability that k becomes infected and a different expected time to infection for k.IntroductionPrevious work on the effect of clustering on epidemic dynamics has produced a variety of results which are largely specific to particular types of networks.", [["infection", "DISEASE", 197, 206], ["infected", "PROBLEM", 155, 163], ["infection", "PROBLEM", 197, 206], ["epidemic dynamics", "PROBLEM", 270, 287], ["may be", "UNCERTAINTY", 41, 47], ["multiple", "OBSERVATION_MODIFIER", 48, 56], ["paths", "OBSERVATION", 57, 62], ["infected", "OBSERVATION", 155, 163], ["infection", "OBSERVATION", 197, 206]]], ["Newman [14] and Britton et al. [15] show that for a class of networks known as random intersection graphs in which individuals belong to one or more overlapping groups and groups form fully connected cliques, an increase in clustering reduces the epidemic threshold, that is, major outbreaks may occur at lower levels of transmissibility in highly clustered networks.", [["increase", "OBSERVATION_MODIFIER", 212, 220]]], ["Newman [14], using heuristic methods and simulations, suggests that for sufficiently high levels of transmissibility the expected size of an outbreak is smaller in a highly clustered network than it would be in a similar network with lower clustering.", [["size", "OBSERVATION_MODIFIER", 130, 134], ["outbreak", "OBSERVATION", 141, 149], ["smaller", "OBSERVATION_MODIFIER", 153, 160]]], ["These articles show that graphs with different levels of clustering do, at least in some cases, have different outbreak probabilities and final size distributions for epidemic outbreaks.IntroductionKiss and Green [16] provide a succinct rebuttal to the suggestion that the effects found by [14] and [15] are solely due to clustering.", [["[15]", "SIMPLE_CHEMICAL", 299, 303], ["different outbreak probabilities", "PROBLEM", 101, 133], ["epidemic outbreaks", "PROBLEM", 167, 185], ["different", "OBSERVATION_MODIFIER", 101, 110], ["outbreak", "OBSERVATION_MODIFIER", 111, 119], ["final", "OBSERVATION_MODIFIER", 138, 143], ["size", "OBSERVATION_MODIFIER", 144, 148], ["epidemic", "OBSERVATION_MODIFIER", 167, 175]]], ["They show that, while the mean degree of the network is preserved in the random intersection graph, the degree distribution varies greatly (in particular, there are many zero-degree nodes) and variance of this distribution increases with clustering.", [["many zero-degree nodes", "PROBLEM", 165, 187], ["preserved", "OBSERVATION", 56, 65], ["degree", "OBSERVATION_MODIFIER", 104, 110], ["distribution", "OBSERVATION_MODIFIER", 111, 123], ["varies", "OBSERVATION_MODIFIER", 124, 130], ["greatly", "OBSERVATION_MODIFIER", 131, 138], ["many", "OBSERVATION_MODIFIER", 165, 169], ["zero-degree", "OBSERVATION_MODIFIER", 170, 181], ["nodes", "OBSERVATION", 182, 187], ["distribution", "OBSERVATION_MODIFIER", 210, 222], ["increases", "OBSERVATION_MODIFIER", 223, 232]]], ["An increase in the variance of the degree distribution has previously been shown to lower the epidemic threshold.", [["increase", "OBSERVATION_MODIFIER", 3, 11], ["variance", "OBSERVATION_MODIFIER", 19, 27], ["degree", "OBSERVATION_MODIFIER", 35, 41], ["distribution", "OBSERVATION_MODIFIER", 42, 54], ["lower", "OBSERVATION_MODIFIER", 84, 89]]], ["They demonstrate that a rewiring of random intersection graphs that preserves the degree sequence but decreases clustering produces networks with similarly lowered epidemic thresholds and even smaller mean outbreak sizes.", [["random intersection graphs", "TEST", 36, 62], ["similarly lowered epidemic thresholds", "PROBLEM", 146, 183], ["smaller", "OBSERVATION_MODIFIER", 193, 200], ["mean", "OBSERVATION_MODIFIER", 201, 205], ["outbreak", "OBSERVATION_MODIFIER", 206, 214], ["sizes", "OBSERVATION_MODIFIER", 215, 220]]], ["Our experiments, reported below, are similar in spirit to those of [16] but look at networks with different degree distributions and study in detail how epidemic data from networks with varying levels of clustering might vary.IntroductionBall et al. [17] show, using analytical techniques, that clustering induced by household structure in a population (where individuals have many contacts with individuals in the same household and fewer global contacts with those outside of the household) has an effect on probability of an outbreak and the expected size of any outbreak.", [["analytical techniques", "TREATMENT", 267, 288], ["an outbreak", "PROBLEM", 525, 536], ["size", "OBSERVATION_MODIFIER", 554, 558]]], ["The probability of an outbreak, in some special cases, is shown to be monotonically decreasing with clustering coefficient and the expected outbreak size also decreases with clustering.", [["an outbreak", "PROBLEM", 19, 30], ["outbreak", "OBSERVATION", 22, 30], ["monotonically", "OBSERVATION_MODIFIER", 70, 83], ["decreasing", "OBSERVATION_MODIFIER", 84, 94], ["outbreak", "OBSERVATION_MODIFIER", 140, 148], ["size", "OBSERVATION_MODIFIER", 149, 153], ["decreases", "OBSERVATION_MODIFIER", 159, 168]]], ["There is no suggestion that these results will apply to clustered networks outside of this specific type of network or that they apply when degree distributions are held constant.IntroductionEames [18] also studies networks with two types of contacts: regular contacts (between people who live or work together, for example) and random contacts (sharing a train ride, for example).", [["people", "SPECIES", 278, 284], ["no suggestion", "UNCERTAINTY", 9, 22]]], ["Using simulations of a stochastic epidemic model and deterministic approximations, it is shown that both outbreak final size and probability of an outbreak are reduced with increased clustering, particularly when regular contacts dominate.", [["a stochastic epidemic model", "TREATMENT", 21, 48], ["an outbreak", "PROBLEM", 144, 155], ["increased clustering", "PROBLEM", 173, 193], ["size", "OBSERVATION_MODIFIER", 120, 124], ["reduced", "OBSERVATION_MODIFIER", 160, 167], ["increased", "OBSERVATION_MODIFIER", 173, 182]]], ["As the number of random contacts increases, the effect of clustering reduces to almost zero.", [["number", "OBSERVATION_MODIFIER", 7, 13]]], ["Strong effects on the expected outbreak size in networks with no random contacts are observed for values of the clustering coefficient above about 0.4, however, no indication of the magnitude of the variance of these effects is given.IntroductionKeeling [19] reports similar results, introducing clustering to a network using a spatial technique\u2014nodes live in a two-dimensional space and two nodes are connected by an edge with a probability inversely proportional to their distance.", [["outbreak", "OBSERVATION_MODIFIER", 31, 39], ["size", "OBSERVATION_MODIFIER", 40, 44], ["two", "OBSERVATION_MODIFIER", 388, 391], ["nodes", "OBSERVATION", 392, 397], ["edge", "OBSERVATION_MODIFIER", 418, 422]]], ["The clustering comes about by randomly choosing positions in space to which nodes are attracted before connections are made.", [["nodes", "ANATOMY", 76, 81], ["nodes", "OBSERVATION", 76, 81]]], ["The results suggest that changes in clustering at lower levels has little effect on the probability of an outbreak, but as the clustering coefficient reaches about 0.45, the chance of an outbreak reduces significantly.", [["changes in clustering at lower levels", "PROBLEM", 25, 62], ["an outbreak", "PROBLEM", 103, 114], ["outbreak", "OBSERVATION", 106, 114], ["outbreak", "OBSERVATION", 187, 195]]], ["As in [14] and [15], while the mean degree of network nodes is held constant here, nothing is said about the degree distribution as clustering varies.IntroductionSerrano and Bogu\u00f1\u00e1 [20] look specifically at infinite power-law networks and shows that the probability of an outbreak increases as clustering increases but the expected size of an outbreak decreases.IntroductionSome more recent papers seek to distinguish the effects of clustering from confounding factors such as assortativity and degree sequence.", [["network nodes", "ANATOMY", 46, 59], ["[15]", "SIMPLE_CHEMICAL", 15, 19], ["network nodes", "MULTI-TISSUE_STRUCTURE", 46, 59], ["confounding factors", "PROBLEM", 449, 468], ["network nodes", "OBSERVATION", 46, 59], ["size", "OBSERVATION_MODIFIER", 332, 336], ["outbreak", "OBSERVATION_MODIFIER", 343, 351], ["decreases", "OBSERVATION_MODIFIER", 352, 361]]], ["Miller [21] develops analytic approximations to study the interplay of various effects such as clustering, heterogeneity in host infectiousness and susceptibility and the weighting of contacts on the spread of disease over a network.", [["analytic approximations", "PROBLEM", 21, 44], ["heterogeneity in host infectiousness", "PROBLEM", 107, 143], ["susceptibility", "PROBLEM", 148, 162], ["host infectiousness", "OBSERVATION", 124, 143]]], ["The impact of clustering on the probability and size of an outbreak is found to be small on \u201creasonable\u201d networks so long as the average degree of the network is not too low.", [["size", "OBSERVATION_MODIFIER", 48, 52], ["outbreak", "OBSERVATION", 59, 67], ["small", "OBSERVATION_MODIFIER", 83, 88], ["too low", "OBSERVATION_MODIFIER", 166, 173]]], ["The rate at which the epidemic spreads, measured by the reproduction number, R0, is found to reduce with increased clustering in such networks.", [["The rate", "TEST", 0, 8], ["increased clustering in such networks", "PROBLEM", 105, 142], ["epidemic", "OBSERVATION_MODIFIER", 22, 30], ["spreads", "OBSERVATION_MODIFIER", 31, 38], ["increased", "OBSERVATION_MODIFIER", 105, 114], ["clustering", "OBSERVATION", 115, 125]]], ["In networks with low mean degree, R0 may be reduced to point of affecting the probability and size of an outbreak.IntroductionMiller [22] points out that studies of the effects of clustering should take into account assortativity in the network, that is, the correlations in node degree between connected nodes.", [["node", "ANATOMY", 275, 279], ["nodes", "ANATOMY", 305, 310], ["connected nodes", "MULTI-TISSUE_STRUCTURE", 295, 310], ["an outbreak", "PROBLEM", 102, 113], ["connected nodes", "PROBLEM", 295, 310], ["low mean degree", "OBSERVATION_MODIFIER", 17, 32], ["size", "OBSERVATION_MODIFIER", 94, 98], ["outbreak", "OBSERVATION", 105, 113], ["node", "OBSERVATION", 275, 279], ["nodes", "OBSERVATION", 305, 310]]], ["To distinguish between the effects of assortativity and clustering, a method of producing networks with arbitrary degree distributions and arbitrary levels of clustering with or without correlated degrees is presented and studied using percolation methods.", [["arbitrary degree distributions", "PROBLEM", 104, 134], ["percolation methods", "TREATMENT", 236, 255]]], ["The effect of increasing clustering in these models is to reduce the probability of outbreaks and reduce the expected size of an epidemic.", [["increasing clustering in these models", "PROBLEM", 14, 51], ["outbreaks", "PROBLEM", 84, 93], ["an epidemic", "PROBLEM", 126, 137], ["increasing", "OBSERVATION_MODIFIER", 14, 24], ["size", "OBSERVATION_MODIFIER", 118, 122], ["epidemic", "OBSERVATION", 129, 137]]], ["Their results suggest that increased clustering diminished the final size of the epidemic, while the effect of clustering on probability of outbreak was not very clear.", [["increased clustering diminished", "PROBLEM", 27, 58], ["outbreak", "PROBLEM", 140, 148], ["increased", "OBSERVATION_MODIFIER", 27, 36], ["clustering", "OBSERVATION_MODIFIER", 37, 47], ["diminished", "OBSERVATION_MODIFIER", 48, 58], ["final", "OBSERVATION_MODIFIER", 63, 68], ["size", "OBSERVATION_MODIFIER", 69, 73], ["epidemic", "OBSERVATION_MODIFIER", 81, 89], ["clear", "OBSERVATION", 162, 167]]], ["Like [23], Moslonka-Lefebvre et al. [24] use simulations to try to distinguish the effects of clustering and assortativity but look at directed graphs.", [["Moslonka", "TEST", 11, 19], ["simulations", "TREATMENT", 45, 56], ["clustering and assortativity", "PROBLEM", 94, 122]]], ["Here, they find that clustering has little effect on epidemic behaviour.IntroductionMelnik et al. [25] propose that the theory developed for epidemics on unclustered (tree-like) networks applies with a high degree of accuracy to networks with clustering so long as the network has a small-world property [12].", [["epidemics", "PROBLEM", 141, 150], ["small", "OBSERVATION_MODIFIER", 283, 288]]], ["That is, if the mean length of the shortest path between vertices of the clustered network is sufficiently small, quantities such as the probability of an outbreak on the network can be estimated using known results that require only the degree distribution and degree correlations.", [["network", "MULTI-TISSUE_STRUCTURE", 83, 90], ["small", "OBSERVATION_MODIFIER", 107, 112]]], ["The theory is tested using simulations on various empirical networks from a wide range of domains and synthetic networks simulated from theoretical models.IntroductionTaken together, these studies show that clustering can have significant effects on crucial properties of epidemics on networks such as the probability, size and speed of an outbreak.", [["various empirical networks", "TREATMENT", 42, 68], ["a wide range of domains", "TREATMENT", 74, 97], ["these studies", "TEST", 183, 196], ["size", "OBSERVATION_MODIFIER", 319, 323], ["outbreak", "OBSERVATION", 340, 348]]], ["These results primarily relate to the final outcome and mean behaviour of epidemics.", [["epidemics", "PROBLEM", 74, 83]]], ["However, if we can obtain a transmission tree for an outbreak then we have information from the start to the finish of a particular epidemic including times of infection and who infected whom.", [["infection", "DISEASE", 160, 169], ["infection", "PROBLEM", 160, 169], ["infection", "OBSERVATION", 160, 169]]], ["Since epidemics are stochastic processes, data from a particular epidemic may differ considerably from the predicted mean.", [["epidemics", "PROBLEM", 6, 15]]], ["Whether or not such data contains information about clustering in the underlying network is the question we seek to address here.IntroductionWe simulate epidemics over networks with fixed degree distributions and varying levels of clustering and inspect various summary statistics of the resulting epidemic data, comparing the summaries for epidemics run over networks with the same degree distribution but different levels of clustering.", [["fixed degree distributions", "PROBLEM", 182, 208], ["epidemics", "PROBLEM", 341, 350], ["fixed degree", "OBSERVATION_MODIFIER", 182, 194]]], ["The results of the simulations, presented in Section 3, show that there is likely little to no signal of clustering in a contact network to be found in a single realisation of an epidemic process over that network.IntroductionWe conclude that it is unlikely that clustering parameters can be inferred solely from epidemiological data that relates to the transmission tree and suggest that further work in parameter estimation for contact networks would be best focused on other properties of contact networks such as degree distribution or broader notions of population structure.Simulating Networks and Measuring Clustering ::: MethodsWe simulate multiple networks from two network models: a Bernoulli model [26] and a power-law model [27].", [["the simulations", "TEST", 15, 30], ["an epidemic process", "PROBLEM", 176, 195], ["a power-law model", "TREATMENT", 718, 735], ["epidemic", "OBSERVATION", 179, 187], ["population structure", "OBSERVATION", 559, 579]]], ["Under the Bernoulli model (also called the Erd\u0151s-R\u00e9nyi or binomial model), an edge between nodes i and j is present with some fixed probability 0 \u2264 p \u2264 1 and absent with probability 1 \u2013 p, independently of all other edges.", [["some fixed probability", "PROBLEM", 121, 143], ["Bernoulli model", "OBSERVATION", 10, 25], ["edge", "OBSERVATION_MODIFIER", 78, 82], ["nodes", "OBSERVATION", 91, 96]]], ["Due to their simplicity, Bernoulli networks are well-studied and commonly used in disease modeling but are not generally thought to be accurate models of social systems.", [["Bernoulli networks", "MULTI-TISSUE_STRUCTURE", 25, 43]]], ["A Bernoulli network is trivial to construct by sampling first the total number of edges in a the graph |Y | = \u2211i>j Yij \u223c Binomial(N(N \u2013 1)/2, p), where N is the number of nodes in the network, and then sampling |Y | edges uniformly at random without replacement.", [["Bernoulli network", "MULTI-TISSUE_STRUCTURE", 2, 19], ["sampling", "TEST", 47, 55], ["\u2211i", "TEST", 110, 112], ["Yij", "TEST", 115, 118], ["Binomial", "TEST", 121, 129], ["nodes", "TEST", 171, 176], ["the network", "TEST", 180, 191], ["replacement", "TREATMENT", 250, 261], ["trivial", "OBSERVATION", 23, 30], ["nodes", "OBSERVATION", 171, 176]]], ["We set N = 500 and p = 7/N = 0.014 in the simulations reported below.Simulating Networks and Measuring Clustering ::: MethodsA power-law network is defined as having a power-law degree distribution, that is, for nodes i = 1, \u2026, N, P (di = k) \u221e k\u2212\u03b1 for some \u03b1 > 0.", [["N", "CHEMICAL", 228, 229], ["\u03b1", "PROTEIN", 257, 258], ["p", "TEST", 19, 20], ["nodes i", "TEST", 212, 219], ["\u2026", "TEST", 225, 226], ["P", "TEST", 231, 232], ["di", "TEST", 234, 236], ["k\u2212\u03b1", "TEST", 244, 247], ["law degree", "OBSERVATION_MODIFIER", 174, 184]]], ["Power-law networks are commonly used to model social interactions and various estimates of \u03b1 in the range 1.5\u20132.5 have been claimed for observed social networks.", [["social networks", "MULTI-TISSUE_STRUCTURE", 145, 160]]], ["We simulate power-law using a Reed-Molloy type algorithm [28].", [["a Reed-Molloy type algorithm", "TREATMENT", 28, 56]]], ["That is, the degree of each node, di, i = 1, \u2026, N, is sampled from the appropriate distribution.", [["node", "ANATOMY", 28, 32], ["each node", "PROBLEM", 23, 32], ["degree", "OBSERVATION_MODIFIER", 13, 19], ["each", "OBSERVATION_MODIFIER", 23, 27], ["node", "OBSERVATION", 28, 32], ["distribution", "OBSERVATION_MODIFIER", 83, 95]]], ["Node i is then assigned di \u201cedge stubs\u201d and pairs of stubs are sampled uniformly without replacement to be joined and become edges.", [["replacement", "TREATMENT", 89, 100], ["edges", "OBSERVATION_MODIFIER", 125, 130]]], ["When all stubs have been paired, loops are removed and multiple edges between the same nodes are collapsed to single edges.", [["nodes", "ANATOMY", 87, 92], ["nodes", "MULTI-TISSUE_STRUCTURE", 87, 92], ["loops", "OBSERVATION_MODIFIER", 33, 38], ["removed", "OBSERVATION_MODIFIER", 43, 50], ["multiple", "OBSERVATION_MODIFIER", 55, 63], ["edges", "OBSERVATION_MODIFIER", 64, 69], ["same", "OBSERVATION_MODIFIER", 82, 86], ["nodes", "OBSERVATION", 87, 92], ["collapsed", "OBSERVATION", 97, 106], ["single", "OBSERVATION_MODIFIER", 110, 116], ["edges", "OBSERVATION_MODIFIER", 117, 122]]], ["This last step of removing loops and multiple edges causes the resulting graph to be only an approximation of a power law graph but the approximation is good for even moderately large N. We set N = 600 and consider only the largest connected component of the network in the simulation reported below.Simulating Networks and Measuring Clustering ::: MethodsThe size of the networks considered here is smaller than some considered in simulation studies though on a par with others (see, for example, [25] who looks a a wide range of network sizes).", [["removing loops and multiple edges", "PROBLEM", 18, 51], ["Methods", "TREATMENT", 349, 356], ["simulation studies", "TEST", 432, 450], ["loops", "OBSERVATION", 27, 32], ["multiple", "OBSERVATION_MODIFIER", 37, 45], ["edges", "OBSERVATION_MODIFIER", 46, 51], ["size", "OBSERVATION_MODIFIER", 360, 364], ["smaller", "OBSERVATION_MODIFIER", 400, 407], ["sizes", "OBSERVATION_MODIFIER", 539, 544]]], ["We choose these network sizes partly for convenience and partly because the current computational methods for statistical fitting of epidemic data to network models would struggle with networks much larger than a few hundred nodes [6] so our interest is in networks around this size.Simulating Networks and Measuring Clustering ::: MethodsFrom each sampled network, Y, we generate two further networks, Yhi and Ylo that preserve the degrees of all nodes in Y but have, respectively, high and low levels of clustering.", [["Methods", "TREATMENT", 332, 339], ["high and low levels of clustering", "PROBLEM", 483, 516], ["nodes", "OBSERVATION", 225, 230], ["size", "OBSERVATION_MODIFIER", 278, 282], ["nodes", "OBSERVATION", 448, 453], ["high", "OBSERVATION_MODIFIER", 483, 487], ["low levels", "OBSERVATION_MODIFIER", 492, 502]]], ["We achieve this using a Monte Carlo algorithm implemented in the ERGM package [29] in R [30] that randomly rewires the input network while preserving the degree distribution.", [["input network", "MULTI-TISSUE_STRUCTURE", 119, 132], ["a Monte Carlo algorithm", "TREATMENT", 22, 45]]], ["For details of the ERGM model and implementation of this algorithm, we refer the reader the package manual [32] and note that the two commands used to simulate our networks areSimulating Networks and Measuring Clustering ::: Methodsy_hi = simulate(y \u223c gwesp (0.2, fixed=T), theta0 = 5,...Simulating Networks and Measuring Clustering ::: Methodsconstraints = \u223c degreedist, burnin=5e+5)Simulating Networks and Measuring Clustering ::: MethodsandSimulating Networks and Measuring Clustering ::: Methodsy_lo = simulate(y \u223c gwesp(0.2, fixed=T), theta0 = \u22125,...Simulating Networks and Measuring Clustering ::: Methodsconstraints = \u223c degreedist, burnin=5e+5)Simulating Networks and Measuring Clustering ::: MethodsWe measure clustering in the resulting networks using the clustering coefficient [12], defined as follows.", [["Methodsy_hi", "TEST", 225, 236], ["theta0", "TEST", 274, 280], ["Methodsy_lo", "TEST", 492, 503], ["theta0", "TEST", 540, 546]]], ["Let Ni = {j|Yij = 1} be the neighbourhood of vertex i and di = |Ni| be the degree of i.", [["Ni", "CHEMICAL", 4, 6], ["Ni", "CHEMICAL", 64, 66], ["vertex", "ANATOMY_MODIFIER", 45, 51]]], ["Let ni = \u2211j 1, the local clustering coefficient is Ci = 2ni/di(di \u2013 1), which is the ratio of extant edges between neighbours of i to possible edges.", [["Let ni = \u2211j 1", "GENE_OR_GENE_PRODUCT", 0, 13], ["Ci", "TEST", 51, 53], ["extant edges", "OBSERVATION", 94, 106], ["possible", "UNCERTAINTY", 134, 142], ["edges", "OBSERVATION_MODIFIER", 143, 148]]], ["For di \u2208 {0, 1}, let Ci = 0.", [["let Ci = 0", "SIMPLE_CHEMICAL", 17, 27], ["let Ci", "TEST", 17, 23]]], ["The (global) clustering coefficient is the mean of the local coefficients,C=\u2211i=1NCi/N. The choice of Ci = 0 for di \u2208 {0, 1} is somewhat arbitrary, though other possible choices, such as Ci = 1 or excluding those statistics from the mean, give similar qualitative results in our experiments.Simulating Epidemics ::: MethodsOver each simulated network, we simulate a stochastic susceptible-exposed-infectious-removed (SEIR) epidemic.", [["di \u2208 {0, 1}", "SIMPLE_CHEMICAL", 112, 123], ["C", "TEST", 74, 75], ["Ci", "TEST", 101, 103], ["somewhat arbitrary", "PROBLEM", 127, 145], ["Ci", "TEST", 186, 188], ["epidemic", "PROBLEM", 422, 430], ["infectious", "OBSERVATION", 396, 406]]], ["All nodes are initially susceptible to the infection.", [["nodes", "ANATOMY", 4, 9], ["infection", "DISEASE", 43, 52], ["nodes", "MULTI-TISSUE_STRUCTURE", 4, 9], ["All nodes", "PROBLEM", 0, 9], ["the infection", "PROBLEM", 39, 52], ["nodes", "OBSERVATION", 4, 9], ["infection", "OBSERVATION", 43, 52]]], ["The outbreak starts when a single node is chosen uniformly at random and exposed to a disease.", [["node", "ANATOMY", 34, 38], ["node", "MULTI-TISSUE_STRUCTURE", 34, 38], ["a single node", "PROBLEM", 25, 38], ["a disease", "PROBLEM", 84, 93], ["node", "OBSERVATION", 34, 38], ["disease", "OBSERVATION", 86, 93]]], ["After a gamma-distributed waiting period with mean kE\u03b8E and variancekE\u03b8E2, the node becomes infectious.", [["node", "ANATOMY", 79, 83], ["node", "MULTI-TISSUE_STRUCTURE", 79, 83], ["kE\u03b8E", "DNA", 51, 55], ["variancekE\u03b8E2", "DNA", 60, 73], ["mean kE\u03b8E", "TEST", 46, 55], ["infectious", "PROBLEM", 92, 102], ["node", "OBSERVATION", 79, 83], ["infectious", "OBSERVATION", 92, 102]]], ["The infection may spread across the edges of the network, from infectious nodes to susceptible nodes according to a Poisson process with rate \u03b2.", [["nodes", "ANATOMY", 95, 100], ["infection", "DISEASE", 4, 13], ["infectious nodes", "MULTI-TISSUE_STRUCTURE", 63, 79], ["nodes", "MULTI-TISSUE_STRUCTURE", 95, 100], ["The infection", "PROBLEM", 0, 13], ["infectious nodes", "PROBLEM", 63, 79], ["susceptible nodes", "PROBLEM", 83, 100], ["infection", "OBSERVATION", 4, 13], ["edges", "OBSERVATION_MODIFIER", 36, 41], ["infectious", "OBSERVATION_MODIFIER", 63, 73], ["susceptible nodes", "OBSERVATION", 83, 100]]], ["Infected nodes recover after an infectious period with a gamma distributed waiting time with mean kI\u03b8I and variancekI\u03b8I2.", [["nodes", "ANATOMY", 9, 14], ["nodes", "MULTI-TISSUE_STRUCTURE", 9, 14], ["Infected nodes", "PROBLEM", 0, 14], ["nodes", "OBSERVATION", 9, 14], ["infectious", "OBSERVATION_MODIFIER", 32, 42]]], ["Once a node is recovered, it plays no further part in the spread of the infection.", [["node", "ANATOMY", 7, 11], ["infection", "DISEASE", 72, 81], ["node", "MULTI-TISSUE_STRUCTURE", 7, 11], ["the infection", "PROBLEM", 68, 81], ["node", "OBSERVATION", 7, 11], ["no further", "UNCERTAINTY", 35, 45], ["infection", "OBSERVATION", 72, 81]]], ["The process stops when there are no longer any exposed or infectious nodes.", [["nodes", "ANATOMY", 69, 74], ["nodes", "MULTI-TISSUE_STRUCTURE", 69, 74], ["any exposed or infectious nodes", "PROBLEM", 43, 74], ["no longer", "UNCERTAINTY", 33, 42], ["infectious", "OBSERVATION_MODIFIER", 58, 68], ["nodes", "OBSERVATION", 69, 74]]], ["For each pair, Yhi and Ylo, we start the infection from the same node.", [["node", "ANATOMY", 65, 69], ["infection", "DISEASE", 41, 50], ["node", "MULTI-TISSUE_STRUCTURE", 65, 69], ["the infection", "PROBLEM", 37, 50], ["infection", "OBSERVATION", 41, 50], ["node", "OBSERVATION", 65, 69]]], ["We condition on the outbreak infecting at least 20 nodes.", [["nodes", "OBSERVATION", 51, 56]]], ["The parameter values are set at \u03b2 = 0.1, kE = kI = 1 and \u03b8E = \u03b2I = 3 in the simulations reported below.Summarising Epidemic Data ::: MethodsA transmission tree encodes all information about the epidemic outbreak it describes.", [["The parameter values", "TEST", 0, 20], ["kE", "TEST", 41, 43], ["kI", "TEST", 46, 48], ["\u03b8E", "TEST", 57, 59], ["I", "TEST", 63, 64], ["the simulations", "TEST", 72, 87]]], ["As such, it is a very complicated object.", [["a very complicated object", "PROBLEM", 15, 40]]], ["The summaries we use can be divided into two groups, those relating solely to the number of infected through time and those relating to topology of the tree.Summarising Epidemic Data ::: MethodsThe first group of summaries can all be derived from the epidemic curves, that is, the number infected as a function of time.", [["Methods", "TREATMENT", 187, 194], ["infected", "OBSERVATION", 92, 100], ["tree", "ANATOMY_MODIFIER", 152, 156]]], ["From this, we derive scalar summaries being the total number of individuals infected, the length of the epidemic (measured from the time of the first infection to the last recovery), the maximum of the epidemic curve and the time of that maximum.Summarising Epidemic Data ::: MethodsWe label each individual in the population (equivalently, each node in the contact network) with labels 1, \u2026, N. A transmission tree, a distinct graph from the contact network, has a time component and can be defined as follows; an example of a transmission tree and the notation is given in Figure 2.", [["node", "ANATOMY", 346, 350], ["infection", "DISEASE", 150, 159], ["contact network", "MULTI-TISSUE_STRUCTURE", 358, 373], ["the epidemic", "PROBLEM", 100, 112], ["Methods", "TREATMENT", 276, 283], ["infection", "OBSERVATION", 150, 159], ["node", "OBSERVATION", 346, 350]]], ["There are three types of nodes in a transmission tree (not to be confused with nodes in the contact network): the root node corresponding to the initial infection, transmission or internal nodes corresponding to transmission events, and leaf or external nodes corresponding to recovery events.", [["nodes", "ANATOMY", 25, 30], ["nodes", "ANATOMY", 79, 84], ["root node", "ANATOMY", 114, 123], ["internal nodes", "ANATOMY", 180, 194], ["leaf", "ANATOMY", 237, 241], ["nodes", "ANATOMY", 254, 259], ["infection", "DISEASE", 153, 162], ["nodes", "MULTI-TISSUE_STRUCTURE", 25, 30], ["contact network", "MULTI-TISSUE_STRUCTURE", 92, 107], ["root node", "MULTI-TISSUE_STRUCTURE", 114, 123], ["leaf", "ORGAN", 237, 241], ["external nodes", "MULTI-TISSUE_STRUCTURE", 245, 259], ["confused", "PROBLEM", 65, 73], ["the root node", "PROBLEM", 110, 123], ["the initial infection", "PROBLEM", 141, 162], ["internal nodes", "PROBLEM", 180, 194], ["transmission events", "PROBLEM", 212, 231], ["leaf or external nodes", "PROBLEM", 237, 259], ["recovery events", "PROBLEM", 277, 292], ["three", "OBSERVATION_MODIFIER", 10, 15], ["types", "OBSERVATION_MODIFIER", 16, 21], ["nodes", "OBSERVATION", 25, 30], ["not to be", "UNCERTAINTY", 55, 64], ["nodes", "OBSERVATION", 79, 84], ["root", "ANATOMY", 114, 118], ["node", "OBSERVATION", 119, 123], ["initial", "OBSERVATION_MODIFIER", 145, 152], ["infection", "OBSERVATION", 153, 162], ["internal", "OBSERVATION_MODIFIER", 180, 188], ["nodes", "OBSERVATION", 189, 194], ["leaf", "OBSERVATION_MODIFIER", 237, 241], ["external nodes", "OBSERVATION", 245, 259]]], ["Leaf nodes are defined by the time and label pair (ti, ui) where t \u2265 0 is the time of the recovery event and ui is the label of individual that recovered.", [["Leaf nodes", "ANATOMY", 0, 10], ["Leaf nodes", "MULTI-TISSUE_STRUCTURE", 0, 10], ["Leaf nodes", "PROBLEM", 0, 10], ["nodes", "OBSERVATION", 5, 10]]], ["The internal nodes are associated with the triple (ti, ui, vi) being the time of the event, ti, the label ui of the exposed individual and vi that is the transmitter or \u201cparent\u201d of the infection.", [["internal nodes", "ANATOMY", 4, 18], ["infection", "DISEASE", 185, 194], ["internal nodes", "MULTI-TISSUE_STRUCTURE", 4, 18], ["the infection", "PROBLEM", 181, 194], ["internal", "OBSERVATION_MODIFIER", 4, 12], ["nodes", "OBSERVATION", 13, 18], ["infection", "OBSERVATION", 185, 194]]], ["The root node is like an internal node but the infection parent is given as 0, so is denoted (t0, u0, 0).", [["root node", "ANATOMY", 4, 13], ["node", "ANATOMY", 34, 38], ["infection", "DISEASE", 47, 56], ["root node", "MULTI-TISSUE_STRUCTURE", 4, 13], ["internal node", "MULTI-TISSUE_STRUCTURE", 25, 38], ["an internal node", "PROBLEM", 22, 38], ["the infection parent", "PROBLEM", 43, 63], ["root", "ANATOMY", 4, 8], ["node", "OBSERVATION", 9, 13], ["internal", "OBSERVATION_MODIFIER", 25, 33], ["node", "OBSERVATION", 34, 38], ["infection", "OBSERVATION", 47, 56]]], ["The branches of the tree are times between infection, transmission and recovery events for a particular vertex.", [["infection", "DISEASE", 43, 52], ["infection", "PROBLEM", 43, 52], ["branches", "ANATOMY_MODIFIER", 4, 12], ["tree", "ANATOMY_MODIFIER", 20, 24], ["infection", "OBSERVATION", 43, 52]]], ["For example, if the individual labelled u is infected at event (t1, u, v1), is involved in transmission events (tk, vk, u), k = 2, \u2026, m \u2013 1, and recovers at (tm, u) where ti < tj for i < j and {v1, \u2026, um\u22121} are other individuals in the population, there are m \u2013 1 branches of the transmission tree at u defined by the intervals (ti, ti+1], for i = 1, \u2026, m \u2013 1.Summarising Epidemic Data ::: MethodsWe summarise the transmission tree using the following statistics: the mean branch length between internal nodes (corresponding to the mean time between secondary infections for each individual); the mean branch length of those branches adjacent to a leaf node (which corresponds to the mean time from the last secondary infection to removal for each individual); the number of secondary infections caused by each infected individual (that is, for each infected individual v we count the number of internal nodes that have the form (ti, ui, v), for some i); and, the distribution of infective descendants for each individual, v, which is defined recursively as the sum of secondary infections caused by v and the secondary infections caused by the secondary infections of v and so on.", [["internal nodes", "ANATOMY", 495, 509], ["branches", "ANATOMY", 625, 633], ["leaf node", "ANATOMY", 648, 657], ["infections", "DISEASE", 560, 570], ["infection", "DISEASE", 718, 727], ["infections", "DISEASE", 785, 795], ["infections", "DISEASE", 1079, 1089], ["infections", "DISEASE", 1120, 1130], ["infections", "DISEASE", 1155, 1165], ["internal nodes", "MULTI-TISSUE_STRUCTURE", 495, 509], ["leaf node", "MULTI-TISSUE_STRUCTURE", 648, 657], ["internal nodes", "MULTI-TISSUE_STRUCTURE", 895, 909], ["infected", "PROBLEM", 45, 53], ["tk", "TEST", 112, 114], ["k", "TEST", 124, 125], ["\u2026", "TEST", 131, 132], ["ti", "TEST", 171, 173], ["tj", "TEST", 176, 178], ["\u2026", "TEST", 198, 199], ["um\u2212", "TEST", 201, 204], ["ti", "TEST", 329, 331], ["ti+", "TEST", 333, 336], ["i", "TEST", 344, 345], ["internal nodes", "PROBLEM", 495, 509], ["secondary infections", "PROBLEM", 550, 570], ["a leaf node", "PROBLEM", 646, 657], ["the last secondary infection", "PROBLEM", 699, 727], ["removal", "TREATMENT", 731, 738], ["secondary infections", "PROBLEM", 775, 795], ["internal nodes", "PROBLEM", 895, 909], ["infective descendants", "PROBLEM", 980, 1001], ["secondary infections", "PROBLEM", 1069, 1089], ["the secondary infections", "PROBLEM", 1106, 1130], ["the secondary infections of v", "PROBLEM", 1141, 1170], ["infected", "OBSERVATION", 45, 53], ["branches", "ANATOMY_MODIFIER", 264, 272], ["length", "OBSERVATION_MODIFIER", 480, 486], ["internal", "ANATOMY_MODIFIER", 495, 503], ["nodes", "OBSERVATION", 504, 509], ["infections", "OBSERVATION", 560, 570], ["mean", "OBSERVATION_MODIFIER", 597, 601], ["branch", "OBSERVATION_MODIFIER", 602, 608], ["length", "OBSERVATION_MODIFIER", 609, 615], ["branches", "ANATOMY_MODIFIER", 625, 633], ["leaf node", "OBSERVATION", 648, 657], ["infection", "OBSERVATION", 718, 727], ["secondary", "OBSERVATION_MODIFIER", 775, 784], ["infections", "OBSERVATION", 785, 795], ["internal nodes", "ANATOMY", 895, 909], ["infective", "OBSERVATION", 980, 989], ["secondary", "OBSERVATION_MODIFIER", 1069, 1078], ["infections", "OBSERVATION", 1079, 1089], ["secondary", "OBSERVATION_MODIFIER", 1110, 1119], ["infections", "OBSERVATION", 1120, 1130], ["secondary", "OBSERVATION_MODIFIER", 1145, 1154], ["infections", "OBSERVATION", 1155, 1165]]], ["An equivalent definition is to say that number of infective descendants of v is the number of leaves that have a node of the form (t, ui, v) as an ancestor.", [["leaves", "ANATOMY", 94, 100], ["node", "ANATOMY", 113, 117], ["infective", "OBSERVATION", 50, 59], ["node", "OBSERVATION", 113, 117]]], ["Finally, we consider the number of cherries in the tree [33] which is the number of pairs of leaves that are adjacent to a common internal node.", [["leaves", "ANATOMY", 93, 99], ["node", "ANATOMY", 139, 143], ["cherries", "ORGANISM_SUBDIVISION", 35, 43], ["internal node", "MULTI-TISSUE_STRUCTURE", 130, 143], ["a common internal node", "PROBLEM", 121, 143], ["leaves", "ANATOMY_MODIFIER", 93, 99], ["common", "ANATOMY_MODIFIER", 123, 129], ["internal", "ANATOMY_MODIFIER", 130, 138], ["node", "OBSERVATION", 139, 143]]], ["This simple statistic is chosen as it is easy to compute and contains information about the topology or shape of the tree.", [["tree", "ANATOMY_MODIFIER", 117, 121]]], ["To compare the number of cherries in outbreaks of different size, we look at the ratio of extant cherries to the maximum possible number of cherries for the given outbreak.Summarising Epidemic Data ::: MethodsThe experimental pipeline can thus be summarised as:Repeat for i = 1, \u2026, 500:Sample a graph Yi according to given degree distribution.Simulate two further graphsYihi andYilo with high clustering and low clustering, respectively, using a Monte Carlo sampler that rewires Yi to alter the clustering level while preserving the degree of each node.Simulate SEIR epidemics overYihi andYilo, conditioning on a major outbreak occurring in each.Extract resulting transmission trees fromYihi andYilo and calculate the respective summaries,Sihi and mmSilo.Compare sets of summaries, Shi and Slo.ResultsWe report results here for SEIR epidemics run over Bernoulli and power-law networks.", [["node", "ANATOMY", 548, 552], ["cherries", "ORGANISM_SUBDIVISION", 25, 33], ["cherries", "ORGANISM_SUBDIVISION", 97, 105], ["cherries", "ORGANISM_SUBDIVISION", 140, 148], ["node", "MULTI-TISSUE_STRUCTURE", 548, 552], ["mmSilo", "PROTEIN", 748, 754], ["outbreak", "PROBLEM", 163, 171], ["Methods", "TREATMENT", 202, 209], ["high clustering and low clustering", "PROBLEM", 388, 422], ["a Monte Carlo sampler", "TREATMENT", 444, 465], ["each node", "PROBLEM", 543, 552], ["SEIR epidemics", "PROBLEM", 828, 842], ["different", "OBSERVATION_MODIFIER", 50, 59], ["size", "OBSERVATION_MODIFIER", 60, 64], ["high", "OBSERVATION_MODIFIER", 388, 392], ["low clustering", "OBSERVATION_MODIFIER", 408, 422], ["each", "OBSERVATION_MODIFIER", 543, 547], ["node", "OBSERVATION", 548, 552]]], ["A number of smaller trials that we do not report were run: with different values chosen for the network and epidemic parameters; on networks with the same degree distributions as a random intersection graph; and, using an SIR epidemic rather than an SEIR.", [["epidemic parameters", "TEST", 108, 127], ["smaller", "OBSERVATION_MODIFIER", 12, 19]]], ["The results for those smaller trials were qualitatively similar to the results reported here.ResultsThe distributions of the measured clustering coefficients is shown in Figure 3 and show that the simulated networks with high and low clustering for a given degree distribution are easily distinguished from one another.", [["high", "OBSERVATION_MODIFIER", 221, 225]]], ["The Bernoulli networks with low clustering contain no triangles, so the clustering coefficient for each of these networks is zero, while for highly-clustered Bernoulli networks, clustering coefficients are in the range (0.28,0.33).", [["Bernoulli networks", "MULTI-TISSUE_STRUCTURE", 4, 22], ["Bernoulli networks", "MULTI-TISSUE_STRUCTURE", 158, 176], ["no triangles", "OBSERVATION", 51, 63]]], ["For the power-law networks, the low clustered networks have clustering in the range (0.00,0.09) while the highly clustered networks have clustering in the range (0.24,0.38).ResultsFigures 4 and 5 show comparisons of summary statistics for networks with differing levels of clustering and Bernoulli degree distributions.", [["clustering and Bernoulli degree distributions", "PROBLEM", 273, 318], ["Bernoulli degree", "OBSERVATION", 288, 304]]], ["The summaries show some differences between the outbreaks on the differently clustered networks.", [["some", "OBSERVATION_MODIFIER", 19, 23], ["differences", "OBSERVATION_MODIFIER", 24, 35]]], ["In particular, the outbreaks in the highly-clustered networks spread more slowly, on average, leading to marginally longer epidemics with fewer individuals infected at the peak of the outbreak, that occurs slightly later, than we see in outbreaks on the networks with low clustering.", [["marginally longer epidemics", "PROBLEM", 105, 132], ["low clustering", "PROBLEM", 268, 282], ["slowly", "OBSERVATION_MODIFIER", 74, 80], ["peak", "OBSERVATION_MODIFIER", 172, 176], ["outbreak", "OBSERVATION", 184, 192], ["slightly", "OBSERVATION_MODIFIER", 206, 214]]], ["The variances of the measured statistics, however, are sufficiently large due to stochastic effects in the model that the ranges of the distributions overlap almost completely in most cases.", [["stochastic effects", "PROBLEM", 81, 99], ["variances", "OBSERVATION_MODIFIER", 4, 13], ["large", "OBSERVATION_MODIFIER", 68, 73], ["stochastic effects", "OBSERVATION", 81, 99], ["ranges", "OBSERVATION_MODIFIER", 122, 128], ["distributions", "OBSERVATION_MODIFIER", 136, 149]]], ["Statistics derived from the transmission tree appear to add little information, with only the number of cherries differing in the mean.ResultsFigures 6 and 7 show the corresponding distributions for networks with power-law degree distributions.", [["ResultsFigures", "TEST", 135, 149], ["law degree", "OBSERVATION_MODIFIER", 219, 229]]], ["Again, differences in the means between the two sets of statistics are apparent with the mean length of epidemic, total number infected and number infected at peak all lower in the epidemics on networks with high-clustering.", [["epidemic", "PROBLEM", 104, 112], ["total number infected", "PROBLEM", 114, 135], ["total", "OBSERVATION_MODIFIER", 114, 119], ["number", "OBSERVATION_MODIFIER", 120, 126], ["infected", "OBSERVATION", 127, 135], ["number", "OBSERVATION_MODIFIER", 140, 146], ["infected", "OBSERVATION", 147, 155], ["high", "OBSERVATION_MODIFIER", 208, 212]]], ["The largest difference is found in the total number infected, where in the low-clustered networks, the range of the statistic is (231, 445) while it is just (211, 361) in the high-clustered networks.", [["largest", "OBSERVATION_MODIFIER", 4, 11], ["difference", "OBSERVATION_MODIFIER", 12, 22], ["total", "OBSERVATION_MODIFIER", 39, 44], ["number", "OBSERVATION_MODIFIER", 45, 51], ["infected", "OBSERVATION", 52, 60], ["low", "OBSERVATION_MODIFIER", 75, 78], ["range", "OBSERVATION_MODIFIER", 103, 108]]], ["The primary cause here is due to the change in size of the largest connected component of the network.", [["the change in size", "PROBLEM", 33, 51], ["change", "OBSERVATION_MODIFIER", 37, 43], ["size", "OBSERVATION_MODIFIER", 47, 51], ["largest", "OBSERVATION_MODIFIER", 59, 66], ["component", "OBSERVATION_MODIFIER", 77, 86]]], ["If we adjust for this by looking instead at the proportion of the giant component infected, the distributions again overlap almost completely with the range for the proportion infected in the low-clustered networks being (0.39, 0.74) and (0.42, 0.74) for the high-clustered networks.Discussion and conclusionsThe results presented above suggest that the behaviour of an epidemic on a random network with a given degree sequence is relatively unaffected by the level of clustering in the network.", [["network", "MULTI-TISSUE_STRUCTURE", 391, 398], ["an epidemic", "PROBLEM", 367, 378], ["giant", "OBSERVATION_MODIFIER", 66, 71], ["component", "OBSERVATION_MODIFIER", 72, 81], ["infected", "OBSERVATION", 82, 90], ["proportion", "OBSERVATION_MODIFIER", 165, 175], ["infected", "OBSERVATION", 176, 184], ["low", "OBSERVATION_MODIFIER", 192, 195]]], ["Some effect is seen, but it is small relative to the random variation we see between epidemics on similarly clustered networks.", [["epidemics", "PROBLEM", 85, 94], ["effect", "OBSERVATION_MODIFIER", 5, 11], ["small", "OBSERVATION_MODIFIER", 31, 36]]], ["These results do not imply that clustering has little effect, rather they suggest as noted in [16], the apparently strong effect of clustering observed by some is more likely to due to a change in the degree distribution\u2014an effect we have nullified by holding the degree sequence constant.", [["a change in the degree distribution\u2014an effect", "PROBLEM", 185, 230], ["strong", "OBSERVATION_MODIFIER", 115, 121], ["more likely", "UNCERTAINTY", 163, 174]]], ["These broader effects are probably best analysed on a grosser level such as the household or subgroup level rather than at the individual level at which clustering is measured.Discussion and conclusionsOur simulation method, in which the degree sequence for each network is held constant while clustering levels are adjusted, places significant restrictions on the space of possible graphs and therefore clustering coefficients.", [["Our simulation method", "TEST", 202, 223]]], ["The levels of clustering achieved in the simulations reported here (for example, having a clustering coefficient in the low-clustered Bernoulli case of 0 versus a mean of 0.30 for the high-clustered case) are not so high as those considered in the some of the simulations and theoretical work described in Section 1, and this may partly account for the limited effect on epidemic outcomes that we find here.", [["a clustering coefficient", "PROBLEM", 88, 112], ["may partly account for", "UNCERTAINTY", 326, 348]]], ["There is little known about the levels of clustering found in real contact networks [31] (though one recent detailed study [34] find values for clustering in a social contact network in the region 0.15\u20130.5) and no evidence to suggest that very extreme values of clustering are achieved for a given degree sequence.", [["detailed study", "TEST", 108, 122], ["little", "OBSERVATION_MODIFIER", 9, 15], ["no evidence to suggest", "UNCERTAINTY", 211, 233]]], ["It is plausible, however, that the degree sequence of a social network of interest could be found\u2014for example, via ego-centric or full-network sampling [34\u201336]\u2014and therefore reasonable to explore the achievable levels of clustering conditional on the degree sequence.", [["clustering conditional on the degree sequence", "PROBLEM", 221, 266]]], ["In doing so, we separate the effects on epidemic dynamics of change in the degree sequence of the contact network from those of clustering.Discussion and conclusionsFrom a statistical point of view, these results indicate that even with full data from a particular epidemic outbreak, such as complete knowledge of the transmission tree, it is unlikely that the level of clustering in the underlying contact network could be accurately inferred independently of the degree distribution.", [["contact network", "MULTI-TISSUE_STRUCTURE", 399, 414]]], ["This is primarily due to the large stochastic variation found from one epidemic to the next that masks the relatively modest effects of clustering on an outbreak.", [["the large stochastic variation", "PROBLEM", 25, 55], ["primarily due to", "UNCERTAINTY", 8, 24], ["large", "OBSERVATION_MODIFIER", 29, 34], ["stochastic variation", "OBSERVATION", 35, 55], ["one", "OBSERVATION_MODIFIER", 67, 70], ["epidemic", "OBSERVATION_MODIFIER", 71, 79], ["relatively", "OBSERVATION_MODIFIER", 107, 117], ["modest", "OBSERVATION_MODIFIER", 118, 124]]], ["With this much stochastic noise, we suggest that it would require data from many outbreaks over the same network (that is, pathogens with a similar mode of transmission spreading in the same population) to infer the clustering level of that network with any accuracy.", [["pathogens", "PROBLEM", 123, 132]]], ["The results also suggest that attempting to estimate a clustering parameter without either estimating or fixing the degree sequence, as in Goudie [37], may see the estimated clustering parameter acting chiefly a proxy for the degree sequence.Discussion and conclusionsIt cannot be ruled out that a statistical method, which takes into account the complete data rather than the summaries we use here, or which takes data from parts of the parameter space that we have not touched on here, could find some signal of clustering from such data.", [["a clustering parameter", "PROBLEM", 53, 75]]], ["A more realistic data set might include times of onset and recovery from disease symptoms for some individuals in the population and sequences taken from viral genetic material.", [["disease symptoms", "PROBLEM", 73, 89], ["some individuals", "PROBLEM", 94, 110], ["viral genetic material", "PROBLEM", 154, 176]]]], "4d376686c92a900a5f6a3ed88b78100d34105e59": [["Table of Contents.", [["Contents", "OBSERVATION", 9, 17]]], ["Atom numberings of teicoplanin pseudoaglycon for NMR assignment (used for all derivatives) Figure S2 .", [["teicoplanin", "CHEMICAL", 19, 30], ["teicoplanin", "CHEMICAL", 19, 30], ["teicoplanin", "SIMPLE_CHEMICAL", 19, 30], ["pseudoaglycon", "SIMPLE_CHEMICAL", 31, 44], ["teicoplanin pseudoaglycon", "TREATMENT", 19, 44], ["all derivatives", "TREATMENT", 74, 89]]], ["Atom numberings of Series 1 side chains for NMR assignmentTable of Contents*only signals that are crucial for identification are listed ** \uf064 to \uf077\uf02d\uf033\uf020methylene groups of alkyl substituents S6 Figure S3 .", [["\uf077\uf02d\uf033\uf020methylene", "CHEMICAL", 144, 157], ["alkyl substituents", "CHEMICAL", 168, 186], ["\uf077\uf02d\uf033\uf020methylene", "CHEMICAL", 144, 157], ["NMR assignment", "TEST", 44, 58]]], ["Atom numberings of Series 2 side chains for NMR assignment (This structure is only an illustration) *only signals that are crucial for identification are listed S11 Figure S4 .", [["Series 2 side chains", "TREATMENT", 19, 39], ["NMR assignment", "TEST", 44, 58]]], ["Atom numberings of Series 3 side chains for NMR assignment (First structure is an illustration) Figure S5 .", [["Series 3 side chains", "TREATMENT", 19, 39], ["NMR assignment", "TEST", 44, 58]]], ["Atom numberings of Series 5 side chains for NMR assignment Figure S6 .", [["S6", "PROTEIN", 66, 68], ["Series 5 side chains", "TREATMENT", 19, 39], ["NMR", "TEST", 44, 47]]], ["Atom numberings of Series 6 side chains for NMR assignment (for compounds 72 and 73, respectively)S14Data represent the averages of two independent tests.", [["NMR assignment", "TEST", 44, 58], ["compounds", "TEST", 64, 73], ["two independent tests", "TEST", 132, 153]]], ["ND, not determined.", [["ND", "PROBLEM", 0, 2], ["not determined", "UNCERTAINTY", 4, 18]]], ["02.", [["02", "TREATMENT", 0, 2]]], ["0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 f1 ( -4.51 (m, 2H) , 3.88 (t, J = 5.1 Hz, 2H), 3.76 -3.70 (m, 2H), 3.67 (dd, J = 6.0, 2.7 Hz, 2H), 3.61 (q, J = 4.5 Hz, 8H), 3.53 (t, J = 6.6 Hz, 2H), 2.94 (s, 1H), 1.58 (dt, J = 14.5, 6.7 Hz, 2H), 1.37 (dq, J = 14.5, 7.3 Hz, 2H), 0.91 (t, J = 7.3 Hz, 3H).", [["2H", "CHEMICAL", 215, 217], ["1H", "CHEMICAL", 229, 231], ["J", "TEST", 99, 100], ["Hz", "TEST", 107, 109], ["dd", "TEST", 142, 144], ["J", "TEST", 146, 147], ["Hz", "TEST", 159, 161], ["J", "TEST", 177, 178], ["Hz", "TEST", 185, 187], ["t", "TEST", 200, 201], ["J", "TEST", 203, 204], ["Hz", "TEST", 211, 213], ["dt", "TEST", 240, 242], ["J", "TEST", 244, 245], ["Hz", "TEST", 258, 260], ["dq", "TEST", 273, 275], ["J", "TEST", 277, 278], ["Hz", "TEST", 291, 293], ["t", "TEST", 306, 307], ["J", "TEST", 309, 310], ["Hz", "TEST", 317, 319]]]], "PMC7454919": [["IntroductionThe novel coronavirus SARS-CoV-2, associate disease, COVID-19, has evolved as a major pandemic in less than three months because of the highly infectious nature of the virus and the current intensive social interaction which favors transmission of the virus.", [["COVID-19", "CHEMICAL", 65, 73], ["coronavirus SARS-CoV-2", "ORGANISM", 22, 44], ["coronavirus", "SPECIES", 22, 33], ["The novel coronavirus SARS", "TEST", 12, 38], ["CoV", "TEST", 39, 42], ["associate disease", "PROBLEM", 46, 63], ["COVID", "TEST", 65, 70], ["the virus", "PROBLEM", 176, 185], ["the virus", "PROBLEM", 260, 269], ["disease", "OBSERVATION", 56, 63], ["highly", "OBSERVATION_MODIFIER", 148, 154], ["infectious", "OBSERVATION", 155, 165], ["virus", "OBSERVATION", 180, 185]]], ["Such an explosive pandemic has created unprecedented stress on the healthcare system globally.", [["explosive", "OBSERVATION_MODIFIER", 8, 17], ["pandemic", "OBSERVATION", 18, 26]]], ["Protecting healthcare workers is critical for functioning of the system and to prevent the workers serving as a vector for disease transmission.IntroductionAlthough China is a major supplier of personal protective equipment (PPE), the impact of COVID-19 initially created a critical shortage of PPE.1 The National Health Commission of China has previously issued technical guidance for prevention of airborne transmission diseases in healthcare facilities with three hierarchical levels of personal protection in 2017, which were further updated for prevention of the spread of COVID-19 in February 2020.2,3 A Chinese expert panel also reported a consensus on personal protection in medical institutions during the COVID-19 epidemic.4IntroductionThe efficacy of such measures, however, was never tested in a real pandemic situation until COVID-19.", [["COVID-19", "CHEMICAL", 245, 253], ["airborne transmission diseases", "DISEASE", 400, 430], ["COVID-19", "CHEMICAL", 245, 253], ["disease transmission", "PROBLEM", 123, 143], ["COVID", "TREATMENT", 245, 250], ["a critical shortage of PPE", "TREATMENT", 272, 298], ["airborne transmission diseases", "PROBLEM", 400, 430], ["the COVID", "TEST", 711, 720], ["such measures", "TREATMENT", 762, 775], ["COVID", "TEST", 838, 843]]], ["China was building new temporary hospitals within 10 days and a large number of healthcare workers were called to Wuhan.", [["large", "OBSERVATION_MODIFIER", 64, 69]]], ["Here, we describe the logistics behind some of the personnel efforts and whether or not the personnel protection strategy was effective.Study design and participants ::: MethodsWe enrolled a total of 8529 healthcare workers, including medical teams aiding Hubei, local healthcare workers in Wuhan and Jingzhou of Hubei Province.", [["participants", "SPECIES", 153, 165], ["the personnel protection strategy", "TREATMENT", 88, 121], ["Methods", "TREATMENT", 170, 177]]], ["Employees in the participating hospitals, including those without direct patient care responsibilities, were invited to take a serological test for antibodies against SARS-CoV-2 and to submit a self-report of gender, age, division, occupation, history of confirmed COVID-19, and history of working in the isolation area for COVID-19 management .", [["SARS", "DISEASE", 167, 171], ["patient", "ORGANISM", 73, 80], ["SARS-CoV-2", "ORGANISM", 167, 177], ["antibodies", "PROTEIN", 148, 158], ["patient", "SPECIES", 73, 80], ["SARS-CoV", "SPECIES", 167, 175], ["a serological test", "TEST", 125, 143], ["antibodies", "PROBLEM", 148, 158], ["SARS", "PROBLEM", 167, 171], ["COVID", "TEST", 265, 270], ["COVID-19 management", "TREATMENT", 324, 343]]], ["The serologic survey was performed between 20 March and 15 April 2020.", [["The serologic survey", "TEST", 0, 20]]], ["The Medical Ethics Committee of Nanfang Hospital approved the study and all participants signed the consent form.Classification of working area ::: MethodsHealthcare workers were classified into three groups according to their working areas during the epidemic.", [["participants", "SPECIES", 76, 88], ["the study", "TEST", 58, 67]]], ["Members of medical teams aiding Hubei as well as local healthcare workers who had a self-reported history of working in the isolation medical area for COVID-19 management were classified as working in the isolation medical area.", [["COVID-19 management", "TREATMENT", 151, 170]]], ["Healthcare workers who did not work in the isolation medical area but were directly involved in patient care (physicians, nurses, and technical staff) or those potentially exposed to infectious materials (sanitary workers, staff in the laundry/disinfection facilities) were classified as working in the non-isolation medical area.", [["patient", "ORGANISM", 96, 103], ["patient", "SPECIES", 96, 103]]], ["Healthcare workers without direct patient care responsibility nor exposure to infectious material under the hospital settings (clerical staff or executives) were classified as working in the non-medical area.Determination of PPE level ::: MethodsUse of PPE for the healthcare workers was determined by their working area according to the protection guidelines issued by the National Health Commission of China (Table 1).", [["patient", "ORGANISM", 34, 41], ["PPE", "GENE_OR_GENE_PRODUCT", 225, 228], ["PPE", "PROTEIN", 225, 228], ["patient", "SPECIES", 34, 41], ["infectious", "OBSERVATION", 78, 88]]], ["In brief, Level 1 protection is required for healthcare workers working in routine or emergency patient care.", [["patient", "ORGANISM", 96, 103], ["patient", "SPECIES", 96, 103], ["emergency patient care", "TREATMENT", 86, 108]]], ["PPE for Level 1 protection includes disposable caps, surgical masks, white coats, and hand hygiene.", [["hand", "ANATOMY", 86, 90], ["hand", "ORGANISM_SUBDIVISION", 86, 90], ["PPE", "TREATMENT", 0, 3], ["Level 1 protection", "TREATMENT", 8, 26], ["disposable caps", "TREATMENT", 36, 51], ["surgical masks", "TREATMENT", 53, 67], ["white coats", "TREATMENT", 69, 80], ["surgical masks", "OBSERVATION", 53, 67]]], ["N95/FFP (filtering facepiece, FFP), isolation gowns, and disposable gloves are used when necessary.", [["N95", "PROTEIN", 0, 3], ["FFP", "PROTEIN", 4, 7], ["FFP", "PROTEIN", 30, 33], ["FFP", "TREATMENT", 4, 7], ["filtering facepiece", "TREATMENT", 9, 28], ["FFP", "TREATMENT", 30, 33], ["isolation gowns", "TREATMENT", 36, 51], ["disposable gloves", "TREATMENT", 57, 74]]], ["Level 2 protection is required for healthcare workers who need to enter the isolation medical areas where patients with suspected or confirmed infection are managed.", [["infection", "DISEASE", 143, 152], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["infection", "PROBLEM", 143, 152], ["infection", "OBSERVATION", 143, 152]]], ["In addition to PPE for Level 1 protection, goggles and full-face shields, long sleeved, fluid repellent gowns, and shoe covers are used.", [["PPE", "TREATMENT", 15, 18], ["Level 1 protection", "TREATMENT", 23, 41], ["goggles", "TREATMENT", 43, 50], ["full-face shields", "TREATMENT", 55, 72], ["fluid repellent gowns", "TREATMENT", 88, 109]]], ["For healthcare workers engaged in aerosol-generating procedures or management of bio-samples from patients with infection, Level 3 protection, including full face shields, eye protection, FFP masks, gloves, and fluid repellent sleeved gowns, is required.", [["eye", "ANATOMY", 172, 175], ["infection", "DISEASE", 112, 121], ["patients", "ORGANISM", 98, 106], ["eye", "ORGAN", 172, 175], ["patients", "SPECIES", 98, 106], ["aerosol-generating procedures", "TREATMENT", 34, 63], ["management", "TREATMENT", 67, 77], ["bio-samples", "TEST", 81, 92], ["infection", "PROBLEM", 112, 121], ["Level 3 protection", "TREATMENT", 123, 141], ["full face shields", "TREATMENT", 153, 170], ["eye protection", "TREATMENT", 172, 186], ["FFP masks", "TREATMENT", 188, 197], ["gloves", "TREATMENT", 199, 205], ["fluid repellent sleeved gowns", "TREATMENT", 211, 240], ["infection", "OBSERVATION", 112, 121], ["eye", "ANATOMY", 172, 175]]], ["Positive pressure helmets can be used when necessary.Laboratory measurements ::: MethodsSerum samples were collected at local hospitals.", [["samples", "ANATOMY", 94, 101], ["MethodsSerum samples", "CANCER", 81, 101], ["Positive pressure helmets", "TREATMENT", 0, 25], ["MethodsSerum samples", "TEST", 81, 101], ["pressure helmets", "OBSERVATION", 9, 25]]], ["All samples were inactivated at 56 \u00b0C for 30 min and stored at \u221220 \u00b0C before testing.", [["samples", "ANATOMY", 4, 11], ["All samples", "TEST", 0, 11], ["testing", "TEST", 77, 84]]], ["The antibodies against SARS-CoV-2 were measured at local hospitals using one of the commercialized assay kits approved by the National Medical Products Administration of China.", [["SARS-CoV-2", "ORGANISM", 23, 33], ["antibodies", "PROTEIN", 4, 14], ["SARS-CoV", "SPECIES", 23, 31], ["The antibodies", "TEST", 0, 14], ["SARS", "PROBLEM", 23, 27], ["CoV", "TEST", 28, 31], ["the commercialized assay kits", "TREATMENT", 80, 109]]], ["According to the manufacturers, the sensitivity of the assay kits ranged from 87.3% to 94.3%, and the specificity from 99.5% to 100%.Statistical analysis ::: MethodsThe seropositive rate of the healthcare workers was expressed as a percentage and the corresponding confidence interval was calculated from binomial probabilities using Wilson's method.", [["the sensitivity", "TEST", 32, 47], ["the assay kits", "TEST", 51, 65], ["the specificity", "TEST", 98, 113], ["Methods", "TREATMENT", 158, 165], ["Wilson's method", "TREATMENT", 334, 349]]], ["For healthcare workers working in the non-isolation medical area, seropositive rates stratified by region and division were also estimated, and the top five divisions ranked by the lower boundary of the estimate were listed.Study population ::: ResultsWe conducted a serological survey on the cumulative attack rate of SARS-CoV-2 in 8529 healthcare workers in Hubei Province, of which 943 were sent from Guangzhou to Wuhan to care for patients with suspected/confirmed COVID-19; 4495 were local healthcare workers from Wuhan, the epicenter in China, and 3091 were from Jingzhou of Hubei Province, a city 200 km west of Wuhan.", [["SARS", "DISEASE", 319, 323], ["patients", "ORGANISM", 435, 443], ["patients", "SPECIES", 435, 443], ["SARS-CoV", "SPECIES", 319, 327], ["seropositive rates", "PROBLEM", 66, 84], ["lower", "ANATOMY_MODIFIER", 181, 186]]], ["Among the healthcare workers, 71% were female and the median age was 33 years (Table 2).Seropositive rate in healthcare workers ::: ResultsAll 943 healthcare workers from Guangzhou who were sent to assist Wuhan to combat COVID-19, tested negative for all four reverse transcription polymerase chain reaction (RT-PCR) performed on days 1, 2, 7, and 14.", [["COVID", "TEST", 221, 226], ["RT-PCR", "TEST", 309, 315]]], ["All also tested seronegative for both IgG and IgM for SARS-CoV-2 (10\u201311 days after they had contact with COVID-19 patients/contacts) (Table 2).Seropositive rate in healthcare workers ::: ResultsIn contrast, among the local healthcare workers in Wuhan and Jingzhou of Hubei Province, 2.5% (113 out of 4495) and 0.32% (10 out of 3091) had RT-PCR confirmed COVID-19, respectively.", [["IgG", "GENE_OR_GENE_PRODUCT", 38, 41], ["IgM", "GENE_OR_GENE_PRODUCT", 46, 49], ["SARS-CoV-2", "ORGANISM", 54, 64], ["patients", "ORGANISM", 114, 122], ["IgG", "PROTEIN", 38, 41], ["IgM", "PROTEIN", 46, 49], ["patients", "SPECIES", 114, 122], ["SARS-CoV", "SPECIES", 54, 62], ["both IgG", "TEST", 33, 41], ["IgM", "TEST", 46, 49], ["SARS", "PROBLEM", 54, 58], ["CoV", "TEST", 59, 62], ["RT-PCR", "TEST", 337, 343], ["COVID", "TEST", 354, 359]]], ["The seropositivity for SARS-CoV-2 antibodies (IgG, IgM, or both IgG/IgM positive) was 3.4% (53/1571) in local healthcare workers from Wuhan with Level 2/3 PPE working in isolation areas and 5.4% (126/2336) in healthcare staff with Level 1 PPE working in non-isolation medical areas, respectively (Table 3).", [["SARS-CoV-2 antibodies", "GENE_OR_GENE_PRODUCT", 23, 44], ["IgG", "GENE_OR_GENE_PRODUCT", 46, 49], ["IgM", "GENE_OR_GENE_PRODUCT", 51, 54], ["IgG", "GENE_OR_GENE_PRODUCT", 64, 67], ["IgM", "GENE_OR_GENE_PRODUCT", 68, 71], ["SARS-CoV-2 antibodies", "PROTEIN", 23, 44], ["IgG", "PROTEIN", 46, 49], ["IgM", "PROTEIN", 51, 54], ["IgG", "PROTEIN", 64, 67], ["IgM", "PROTEIN", 68, 71], ["CoV-2", "SPECIES", 28, 33], ["SARS-CoV", "SPECIES", 23, 31], ["The seropositivity", "TEST", 0, 18], ["SARS", "TEST", 23, 27], ["CoV", "TEST", 28, 31], ["antibodies", "TEST", 34, 44], ["IgG", "TEST", 46, 49], ["IgM", "TEST", 51, 54], ["both IgG/IgM", "TEST", 59, 71], ["Level", "TEST", 145, 150]]], ["Similar analysis for the Jingzhou healthcare workers identified seropositivity of 0.3% for those working in the isolation area with Level 2/3 PPE and 1.6% for those working in the non-isolation areas with Level 1 PPE.", [["seropositivity", "TEST", 64, 78]]], ["Note that for those staff who did not provide direct medical services (including sanitary workers, laundry/disinfection staff, elevator operators), 4.4% of the Wuhan healthcare workers and 1.0% of the Jingzhou area were antibody-seropositive, respectively (Table 3).", [["the Jingzhou area", "TEST", 197, 214], ["antibody", "TEST", 220, 228]]], ["For Wuhan, the top five divisions with the highest estimated cumulative attack rate based on antibody-seropositivity were the hemodialysis unit (12/96, 12.5%), emergency department (6/40, 15%), endoscopy area (9/80, 11.3%), surgery department (40/586, 6.8%), and sanitary department (12/154, 7.8%) (Table 4).DiscussionTo the best of our knowledge, this is the largest serological survey on the accumulative rate of SARS-CoV-2 infection and the effectiveness of PPE use in healthcare workers.", [["SARS", "DISEASE", 415, 419], ["infection", "DISEASE", 426, 435], ["PPE", "CHEMICAL", 461, 464], ["SARS-CoV-2", "ORGANISM", 415, 425], ["PPE", "ORGANISM", 461, 464], ["CoV-", "SPECIES", 420, 424], ["SARS-CoV-2", "SPECIES", 415, 425], ["the highest estimated cumulative attack rate", "PROBLEM", 39, 83], ["antibody", "TEST", 93, 101], ["endoscopy area", "TEST", 194, 208], ["SARS", "PROBLEM", 415, 419], ["CoV-2 infection", "PROBLEM", 420, 435], ["infection", "OBSERVATION", 426, 435]]], ["The healthcare staff sent from Guangzhou to Wuhan received infection precaution training before their mission and were equipped with Level 2/3 PPE.", [["infection", "DISEASE", 59, 68], ["infection precaution training", "TREATMENT", 59, 88]]], ["Serial tests for SARS-CoV-2 RNA and tests for SARS-CoV-2 immunoglobulin M and G after the 6\u20138 week mission revealed a zero cumulative attack rate, confirming that adequate training/PPE can protect medical personnel against SARS-CoV-2.DiscussionTable 3 summarizes the guideline issued by the National Health Commission of China for personal protection in medical institutions during COVID-19.2,3 Note that this guideline was mainly designed for airborne transmitted pathogens and attention was focused on aerosol and contact transmission.", [["SARS", "DISEASE", 223, 227], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 17, 27], ["immunoglobulin M", "GENE_OR_GENE_PRODUCT", 57, 73], ["SARS-CoV-2 RNA", "RNA", 17, 31], ["SARS-CoV", "SPECIES", 17, 25], ["SARS-CoV", "SPECIES", 46, 54], ["SARS-CoV", "SPECIES", 223, 231], ["Serial tests", "TEST", 0, 12], ["SARS", "TEST", 17, 21], ["CoV", "TEST", 22, 25], ["tests", "TEST", 36, 41], ["SARS", "TEST", 46, 50], ["CoV", "TEST", 51, 54], ["SARS", "PROBLEM", 223, 227], ["COVID", "TEST", 382, 387], ["airborne transmitted pathogens", "PROBLEM", 444, 474], ["aerosol", "TREATMENT", 504, 511]]], ["Also note that Level 3 differs from Level 2 with the addition of an isolation gown on top of the disposable coverall and potential use of a positive pressure helmet.", [["an isolation gown", "TREATMENT", 65, 82], ["a positive pressure helmet", "TREATMENT", 138, 164], ["pressure helmet", "OBSERVATION", 149, 164]]], ["In the Wuhan situation, positive pressure helmets were generally not used.DiscussionHealthcare workers in Wuhan city and the nearby Jingzhou city (around 200 km away from Wuhan, both are in Hubei Province) were updated regularly on the latest recommendations for their protection.", [["positive pressure helmets", "TREATMENT", 24, 49], ["pressure helmets", "OBSERVATION", 33, 49]]], ["The challenge in analysis of data from this group was that these healthcare workers could acquire the virus via patients/staff in the hospital but also through community transmission when not at work.DiscussionFor healthcare workers coming from outside Hubei Province whose primary role was to engage in direct patient care and clinical management patients with suspected or confirmed COVID-19, an additional strategy was adopted for protection.", [["patients", "ORGANISM", 112, 120], ["patient", "ORGANISM", 311, 318], ["patients", "ORGANISM", 348, 356], ["patients", "SPECIES", 112, 120], ["patient", "SPECIES", 311, 318], ["patients", "SPECIES", 348, 356], ["clinical management", "TREATMENT", 328, 347], ["COVID", "TEST", 385, 390], ["an additional strategy", "TREATMENT", 395, 417]]], ["For this study, our aim was to evaluate the clinical outcomes of this group.", [["this study", "TEST", 4, 14]]], ["Second, they were given personal protection training and as all would be summoned to care for patients with suspected/confirmed COVID-19, they were all provided with Level 2 or 3 protection (but no positive pressure helmets).", [["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102], ["personal protection training", "TREATMENT", 24, 52], ["COVID", "TEST", 128, 133], ["positive pressure helmets", "TREATMENT", 198, 223]]], ["Third, it was arranged for all the workers to stay in designated hotels in which only medical staff were accommodated, and all were informed to practice social distancing, limit their exposure to the local community, and wear face masks whenever possible.", [["face masks", "TREATMENT", 226, 236]]], ["Finally, there was also a medical team to monitor the mental status of these healthcare workers.DiscussionWith the epidemic under control around 6\u20138 weeks after their deployment, the healthcare workers from outside Hubei underwent the following procedures before heading home: around 4\u20135 days prior to leaving Wuhan, they stopped working in the hospitals, ceased patient contact, and participated in a debriefing period, both to receive information on the next phase but also to give their input on how to improve the system.", [["patient", "ORGANISM", 363, 370], ["patient", "SPECIES", 363, 370]]], ["They were requested to wear face masks whenever possible.", [["face masks", "TREATMENT", 28, 38]]], ["When they came back to Guangzhou (on 20 March 2020), they were required to undergo 14 days of quarantine.", [["quarantine", "TREATMENT", 94, 104]]], ["They all had SARS-CoV-2 nucleic acid RT-PCR tests performed four times (upon arrival, and on day 2, day 7, and day 14) and serology for SARS-CoV-2 immunoglobulin (IgG and IgM) performed on day 6 (or 10 days after they stopped seeing patients or working in hospital in Wuhan).", [["nucleic acid", "CHEMICAL", 24, 36], ["SARS-CoV-2 immunoglobulin", "GENE_OR_GENE_PRODUCT", 136, 161], ["IgG", "GENE_OR_GENE_PRODUCT", 163, 166], ["IgM", "GENE_OR_GENE_PRODUCT", 171, 174], ["patients", "ORGANISM", 233, 241], ["immunoglobulin", "PROTEIN", 147, 161], ["IgG", "PROTEIN", 163, 166], ["IgM", "PROTEIN", 171, 174], ["CoV-2", "SPECIES", 141, 146], ["patients", "SPECIES", 233, 241], ["SARS-CoV", "SPECIES", 136, 144], ["SARS", "TEST", 13, 17], ["CoV", "TEST", 18, 21], ["nucleic acid RT", "TEST", 24, 39], ["PCR tests", "TEST", 40, 49], ["serology", "TEST", 123, 131], ["SARS", "TEST", 136, 140], ["CoV", "TEST", 141, 144], ["immunoglobulin", "TEST", 147, 161], ["IgG", "TEST", 163, 166], ["IgM", "TEST", 171, 174]]], ["All RT-PCR and serology tests were performed in government-approved laboratories using protocols approved by the Chinese FDA as previously described.5DiscussionThis study identifies two important points.", [["All RT-PCR", "TEST", 0, 10], ["serology tests", "TEST", 15, 29], ["protocols", "TREATMENT", 87, 96], ["This study", "TEST", 160, 170]]], ["First, prior training on use of Level 2/3 PPE, in conjunction with standard infection control practice, was very effective in protecting healthcare personnel from SARS-CoV-2 infection even though they were in direct contact with patients and were actively involved in management of patients with confirmed/suspected COVID-19.", [["infection", "DISEASE", 76, 85], ["SARS-CoV-2 infection", "DISEASE", 163, 183], ["CoV-2", "ORGANISM", 168, 173], ["patients", "ORGANISM", 229, 237], ["patients", "ORGANISM", 282, 290], ["patients", "SPECIES", 229, 237], ["patients", "SPECIES", 282, 290], ["SARS-CoV-2", "SPECIES", 163, 173], ["Level 2/3 PPE", "TREATMENT", 32, 45], ["standard infection control practice", "TREATMENT", 67, 102], ["SARS", "PROBLEM", 163, 167], ["CoV-2 infection", "PROBLEM", 168, 183], ["COVID", "TEST", 316, 321], ["infection", "OBSERVATION", 174, 183]]], ["This is in striking contrast to previous observations that PPE did not effectively protect healthcare workers from infection during the 2003 SARS outbreak.6,7 One possible explanation is that the previous SARS incidence had created a high alert and that current adherence to the personal protection protocol makes the difference.DiscussionThe second point was the relatively high seropositive rate for SARS-CoV-2 antibodies among the local healthcare workers with Level 1 protection and those working in the non-medical area with no PPE.", [["PPE", "CHEMICAL", 59, 62], ["infection", "DISEASE", 115, 124], ["SARS", "DISEASE", 141, 145], ["SARS", "DISEASE", 205, 209], ["SARS-CoV-2 antibodies", "PROTEIN", 402, 423], ["SARS-CoV", "SPECIES", 402, 410], ["PPE", "PROBLEM", 59, 62], ["infection", "PROBLEM", 115, 124], ["the previous SARS incidence", "PROBLEM", 192, 219], ["a high alert", "PROBLEM", 232, 244], ["the personal protection protocol", "TREATMENT", 275, 307], ["SARS", "PROBLEM", 402, 406], ["CoV", "TEST", 407, 410], ["Level 1 protection", "TREATMENT", 464, 482], ["PPE", "PROBLEM", 533, 536], ["infection", "OBSERVATION", 115, 124], ["possible explanation is", "UNCERTAINTY", 163, 186], ["no", "UNCERTAINTY", 530, 532], ["PPE", "OBSERVATION", 533, 536]]], ["It is worth re-examining the need for additional training and PPE support for healthcare staff working in non-isolation medical areas, and even non-medical areas with an epidemic of an airborne highly infectious pathogen, especially if PPE supply is not limited.DiscussionOne potential limitation of this study was that enrollment of subjects for this study was based on voluntary participation (apart from the 943 medical staff from Guangzhou which was mandatory), thus there might be potential bias in the volunteering participants being more eager to observe the rules.", [["participants", "SPECIES", 521, 533], ["additional training", "TREATMENT", 38, 57], ["PPE support", "TREATMENT", 62, 73], ["healthcare staff", "TREATMENT", 78, 94], ["non-isolation medical areas", "TREATMENT", 106, 133], ["an airborne highly infectious pathogen", "PROBLEM", 182, 220], ["this study", "TEST", 300, 310], ["this study", "TEST", 347, 357], ["infectious", "OBSERVATION", 201, 211]]], ["Even with this limitation, the personnel protection strategy, coupled together with appropriate coaching and practice, was shown to protect the healthcare personnel sent from Guangzhou to Wuhan with zero cumulative attack rate in this SARS-CoV-2 epidemic.", [["SARS", "DISEASE", 235, 239], ["the personnel protection strategy", "TREATMENT", 27, 60], ["this SARS", "PROBLEM", 230, 239], ["CoV", "TEST", 240, 243]]], ["However, there is room for improvement in terms of staff with Level 1 protection working in non-isolated areas and staff in non-medical areas.", [["Level 1 protection", "TREATMENT", 62, 80]]], ["These data provide a framework to assist other countries that are still in the midst of combating this pandemic, and could be used to prepare for future epidemics/pandemics.ConclusionsOur study confirmed that adequate training and PPE can protect medical personnel against SARS-CoV-2 infection.", [["SARS-CoV-2 infection", "DISEASE", 273, 293], ["SARS-CoV-2", "ORGANISM", 273, 283], ["SARS-CoV-2", "SPECIES", 273, 283], ["pandemics", "PROBLEM", 163, 172], ["Our study", "TEST", 184, 193], ["adequate training", "TREATMENT", 209, 226], ["PPE", "TREATMENT", 231, 234], ["SARS", "PROBLEM", 273, 277], ["CoV", "PROBLEM", 278, 281], ["2 infection", "PROBLEM", 282, 293], ["infection", "OBSERVATION", 284, 293]]]], "9ea1002a17ada9616294ad293210211a35787fce": [["IntroductionIt is widely recognized that hepatitis B virus (HBV) replicates non-cytopathically in the hepatocyte.", [["hepatocyte", "ANATOMY", 102, 112], ["hepatitis B", "DISEASE", 41, 52], ["hepatitis B virus", "ORGANISM", 41, 58], ["HBV", "ORGANISM", 60, 63], ["hepatocyte", "CELL", 102, 112], ["hepatitis B virus", "SPECIES", 41, 58], ["hepatitis B virus", "SPECIES", 41, 58], ["HBV", "SPECIES", 60, 63], ["IntroductionIt", "TREATMENT", 0, 14], ["hepatitis B virus (HBV", "PROBLEM", 41, 63], ["hepatitis", "OBSERVATION", 41, 50], ["hepatocyte", "ANATOMY", 102, 112]]], ["Most of the clinical complications related to this infection is reflected in the adaptive immune response, particularly the virus-specific effector CD8 + T cell response.", [["CD8 + T cell", "ANATOMY", 148, 160], ["infection", "DISEASE", 51, 60], ["CD8", "GENE_OR_GENE_PRODUCT", 148, 151], ["CD8", "PROTEIN", 148, 151], ["the clinical complications", "PROBLEM", 8, 34], ["this infection", "PROBLEM", 46, 60], ["the virus", "TEST", 120, 129], ["infection", "OBSERVATION", 51, 60], ["cell response", "OBSERVATION", 156, 169]]], ["[1] [2] [3] [4] [5] Indeed, by killing infected cells and secreting antiviral cytokines, effector CD8 + T cells (CD8 T E ) reaching the infection sites are major contributors to viral clearance as well as tissue immunopathology.", [["cells", "ANATOMY", 48, 53], ["CD8 + T cells", "ANATOMY", 98, 111], ["CD8 T E", "ANATOMY", 113, 120], ["tissue", "ANATOMY", 205, 211], ["infection", "DISEASE", 136, 145], ["[1] [2] [3] [4] [5]", "SIMPLE_CHEMICAL", 0, 19], ["cells", "CELL", 48, 53], ["CD8", "GENE_OR_GENE_PRODUCT", 98, 101], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 113, 120], ["tissue", "TISSUE", 205, 211], ["infected cells", "CELL_TYPE", 39, 53], ["antiviral cytokines", "PROTEIN", 68, 87], ["effector CD8 + T cells", "CELL_TYPE", 89, 111], ["CD8 T E", "PROTEIN", 113, 120], ["killing infected cells", "PROBLEM", 31, 53], ["secreting antiviral cytokines", "TEST", 58, 87], ["effector CD8", "TEST", 89, 101], ["T cells", "TEST", 104, 111], ["the infection sites", "PROBLEM", 132, 151], ["viral clearance", "PROBLEM", 178, 193], ["tissue immunopathology", "PROBLEM", 205, 227], ["infection", "OBSERVATION", 136, 145], ["immunopathology", "OBSERVATION", 212, 227]]], ["[1] [2] [3] [4] [5] Paradoxically, during some acute viral infections (e.g. those caused by influenza virus, respiratory syncytial virus, coronavirus and vaccinia virus), CD8 T E have been shown to produce the regulatory cytokine interleukin (IL)-10, [6] [7] [8] [9] [10] [11] in addition to pro-inflammatory cytokines, chemokines and effector molecules.", [["viral infections", "DISEASE", 53, 69], ["influenza virus", "DISEASE", 92, 107], ["respiratory syncytial virus", "DISEASE", 109, 136], ["[6] [7] [8] [9] [10] [11]", "CHEMICAL", 251, 276], ["[1] [2] [3] [4] [5]", "SIMPLE_CHEMICAL", 0, 19], ["influenza virus", "ORGANISM", 92, 107], ["respiratory syncytial virus", "ORGANISM", 109, 136], ["coronavirus", "ORGANISM", 138, 149], ["vaccinia virus", "ORGANISM", 154, 168], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 171, 178], ["interleukin (IL)-10", "SIMPLE_CHEMICAL", 230, 249], ["[6] [7] [8] [9] [10] [11]", "SIMPLE_CHEMICAL", 251, 276], ["CD8 T E", "PROTEIN", 171, 178], ["pro-inflammatory cytokines", "PROTEIN", 292, 318], ["chemokines", "PROTEIN", 320, 330], ["effector molecules", "PROTEIN", 335, 353], ["influenza virus", "SPECIES", 92, 107], ["respiratory syncytial virus", "SPECIES", 109, 136], ["coronavirus", "SPECIES", 138, 149], ["vaccinia virus", "SPECIES", 154, 168], ["respiratory syncytial virus", "SPECIES", 109, 136], ["vaccinia virus", "SPECIES", 154, 168], ["some acute viral infections", "PROBLEM", 42, 69], ["influenza virus", "PROBLEM", 92, 107], ["respiratory syncytial virus", "PROBLEM", 109, 136], ["coronavirus", "PROBLEM", 138, 149], ["vaccinia virus", "PROBLEM", 154, 168], ["CD8 T E", "TEST", 171, 178], ["the regulatory cytokine interleukin (IL)", "TEST", 206, 246], ["pro-inflammatory cytokines", "TEST", 292, 318], ["chemokines", "TEST", 320, 330], ["acute", "OBSERVATION_MODIFIER", 47, 52], ["viral", "OBSERVATION_MODIFIER", 53, 58], ["infections", "OBSERVATION", 59, 69]]], ["CD8 T E -derived IL-10 is generally thought to limit tissue damage, 6, 7, 11 however the net effect induced by this cytokine might depend on the pathophysiological context.", [["tissue", "ANATOMY", 53, 59], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 0, 7], ["IL-10", "GENE_OR_GENE_PRODUCT", 17, 22], ["tissue", "TISSUE", 53, 59], ["CD8", "PROTEIN", 0, 3], ["IL-10", "PROTEIN", 17, 22], ["cytokine", "PROTEIN", 116, 124], ["limit tissue", "OBSERVATION_MODIFIER", 47, 59], ["damage", "OBSERVATION", 60, 66]]], ["12 Whether HBV-specific CD8 T E produce IL-10 upon hepatocellular antigen (Ag) recognition and the role that this cytokine plays in liver immunopathology are currently unknown.IntroductionWe show here that serum IL-10 is readily detectable in an acutely HBV-infected adult chimpanzee in a manner that coincides with intrahepatic CD8 + T cell infiltration.", [["hepatocellular", "ANATOMY", 51, 65], ["liver", "ANATOMY", 132, 137], ["serum", "ANATOMY", 206, 211], ["intrahepatic CD8 + T cell", "ANATOMY", 316, 341], ["liver immunopathology", "DISEASE", 132, 153], ["HBV-infected", "DISEASE", 254, 266], ["HBV", "ORGANISM", 11, 14], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 24, 31], ["IL-10", "GENE_OR_GENE_PRODUCT", 40, 45], ["hepatocellular antigen", "GENE_OR_GENE_PRODUCT", 51, 73], ["Ag", "GENE_OR_GENE_PRODUCT", 75, 77], ["liver", "ORGAN", 132, 137], ["serum", "ORGANISM_SUBSTANCE", 206, 211], ["IL-10", "GENE_OR_GENE_PRODUCT", 212, 217], ["HBV", "ORGANISM", 254, 257], ["chimpanzee", "ORGANISM", 273, 283], ["CD8", "GENE_OR_GENE_PRODUCT", 329, 332], ["CD8 T E", "PROTEIN", 24, 31], ["IL-10", "PROTEIN", 40, 45], ["hepatocellular antigen", "PROTEIN", 51, 73], ["Ag", "PROTEIN", 75, 77], ["cytokine", "PROTEIN", 114, 122], ["serum IL-10", "PROTEIN", 206, 217], ["CD8", "PROTEIN", 329, 332], ["HBV", "SPECIES", 11, 14], ["HBV", "SPECIES", 254, 257], ["HBV", "TEST", 11, 14], ["IL", "TEST", 40, 42], ["hepatocellular antigen", "TEST", 51, 73], ["this cytokine plays in liver immunopathology", "PROBLEM", 109, 153], ["serum IL", "TEST", 206, 214], ["an acutely HBV", "PROBLEM", 243, 257], ["T cell infiltration", "PROBLEM", 335, 354], ["hepatocellular", "ANATOMY", 51, 65], ["liver", "ANATOMY", 132, 137], ["immunopathology", "OBSERVATION", 138, 153], ["HBV", "OBSERVATION", 254, 257], ["infected", "OBSERVATION", 258, 266], ["intrahepatic", "ANATOMY", 316, 328], ["CD8", "OBSERVATION", 329, 332], ["T cell infiltration", "OBSERVATION", 335, 354]]], ["Using mouse models of acute HBV pathogenesis, we confirmed that IL-10 is indeed produced by HBV-specific CD8 T E upon hepatocellular Ag recognition in vivo.", [["hepatocellular Ag", "ANATOMY", 118, 135], ["Ag", "CHEMICAL", 133, 135], ["mouse", "ORGANISM", 6, 11], ["HBV", "ORGANISM", 28, 31], ["IL-10", "GENE_OR_GENE_PRODUCT", 64, 69], ["HBV", "ORGANISM", 92, 95], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 105, 112], ["hepatocellular Ag", "GENE_OR_GENE_PRODUCT", 118, 135], ["IL-10", "PROTEIN", 64, 69], ["CD8 T E", "PROTEIN", 105, 112], ["mouse", "SPECIES", 6, 11], ["mouse", "SPECIES", 6, 11], ["HBV", "SPECIES", 28, 31], ["HBV", "SPECIES", 92, 95], ["acute HBV pathogenesis", "PROBLEM", 22, 44], ["HBV", "TEST", 92, 95], ["hepatocellular Ag recognition", "TREATMENT", 118, 147], ["acute", "OBSERVATION_MODIFIER", 22, 27], ["HBV", "OBSERVATION", 28, 31], ["hepatocellular", "ANATOMY", 118, 132]]], ["To our surprise, IL-10 blockade ameliorated rather than worsened liver disease.", [["liver", "ANATOMY", 65, 70], ["liver disease", "DISEASE", 65, 78], ["IL-10", "GENE_OR_GENE_PRODUCT", 17, 22], ["liver", "ORGAN", 65, 70], ["IL", "PROTEIN", 17, 19], ["worsened liver disease", "PROBLEM", 56, 78], ["liver", "ANATOMY", 65, 70], ["disease", "OBSERVATION", 71, 78]]], ["Ex vivo analyses of HBV-specific CD8 T E isolated from the livers of HBV replication-competent transgenic mice or from the blood of acutely infected patients revealed that IL-10 acts in an autocrine/paracrine fashion to increase IL-2 responsiveness and rescue CD8 T E from Ag-induced apoptosis.Materials and methodsChimpanzees Chimpanzee A0A006 has already been described.", [["CD8 T E", "ANATOMY", 33, 40], ["livers", "ANATOMY", 59, 65], ["blood", "ANATOMY", 123, 128], ["acutely infected", "DISEASE", 132, 148], ["Ag", "CHEMICAL", 273, 275], ["A0A006", "CHEMICAL", 338, 344], ["Ag", "CHEMICAL", 273, 275], ["HBV", "ORGANISM", 20, 23], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 33, 40], ["livers", "ORGAN", 59, 65], ["HBV", "ORGANISM", 69, 72], ["mice", "ORGANISM", 106, 110], ["blood", "ORGANISM_SUBSTANCE", 123, 128], ["patients", "ORGANISM", 149, 157], ["IL-10", "GENE_OR_GENE_PRODUCT", 172, 177], ["IL-2", "GENE_OR_GENE_PRODUCT", 229, 233], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 260, 267], ["Ag", "GENE_OR_GENE_PRODUCT", 273, 275], ["CD8 T E", "CELL_TYPE", 33, 40], ["IL-10", "PROTEIN", 172, 177], ["IL", "PROTEIN", 229, 231], ["CD8", "PROTEIN", 260, 263], ["Ag", "PROTEIN", 273, 275], ["mice", "SPECIES", 106, 110], ["patients", "SPECIES", 149, 157], ["HBV", "SPECIES", 20, 23], ["HBV", "SPECIES", 69, 72], ["mice", "SPECIES", 106, 110], ["Ex vivo analyses", "TEST", 0, 16], ["HBV", "TEST", 20, 23], ["HBV replication", "TREATMENT", 69, 84], ["IL", "TREATMENT", 172, 174], ["an autocrine/paracrine fashion", "TREATMENT", 186, 216], ["IL", "TEST", 229, 231], ["Ag", "TEST", 273, 275], ["apoptosis", "PROBLEM", 284, 293], ["Materials", "TREATMENT", 294, 303], ["methodsChimpanzees Chimpanzee A0A006", "TREATMENT", 308, 344], ["livers", "ANATOMY", 59, 65], ["HBV", "OBSERVATION", 69, 72], ["apoptosis", "OBSERVATION", 284, 293]]], ["The chimpanzee was individually housed at Bioqual Laboratories (Rockville, MD), an American Association for Accreditation of Laboratory Animal Care International-accredited institution under contract to the National Institute of Allergy and Infectious Diseases.", [["Infectious Diseases", "DISEASE", 241, 260], ["chimpanzee", "ORGANISM", 4, 14], ["chimpanzee", "SPECIES", 4, 14], ["Allergy", "PROBLEM", 229, 236], ["Infectious", "OBSERVATION", 241, 251]]], ["Chimpanzee A0A006 was inoculated with 10 10 genome equivalents of HBV obtained from an HBV-positive serum of chimpanzee 5835 that was previously inoculated with a monoclonal HBV isolate (genotype D, ayw subtype; GenBank accession no. V01460) 25 contained in HBV transgenic mouse serum, 14 as described.", [["serum", "ANATOMY", 100, 105], ["serum", "ANATOMY", 279, 284], ["A0A006", "CHEMICAL", 11, 17], ["Chimpanzee A0A006", "CELL", 0, 17], ["HBV", "ORGANISM", 66, 69], ["HBV", "ORGANISM", 87, 90], ["serum", "ORGANISM_SUBSTANCE", 100, 105], ["chimpanzee", "ORGANISM", 109, 119], ["5835", "ORGANISM", 120, 124], ["HBV", "ORGANISM", 174, 177], ["HBV", "ORGANISM", 258, 261], ["mouse", "ORGANISM", 273, 278], ["serum", "ORGANISM_SUBSTANCE", 279, 284], ["chimpanzee", "SPECIES", 109, 119], ["mouse", "SPECIES", 273, 278], ["HBV", "SPECIES", 66, 69], ["HBV", "SPECIES", 87, 90], ["HBV", "SPECIES", 174, 177], ["HBV", "SPECIES", 258, 261], ["mouse", "SPECIES", 273, 278], ["Chimpanzee A0A006", "TREATMENT", 0, 17], ["HBV", "PROBLEM", 66, 69], ["an HBV", "TEST", 84, 90], ["positive serum of chimpanzee", "PROBLEM", 91, 119], ["a monoclonal HBV isolate (genotype D", "PROBLEM", 161, 197]]], ["Blood was obtained by venipuncture and analyzed for serum IL-10 (see below).Materials and methodsMice C57BL/6, CD45.1 (inbred C57BL/6), and Balb/c mice were purchased from Charles River.", [["Blood", "ANATOMY", 0, 5], ["serum", "ANATOMY", 52, 57], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["serum", "ORGANISM_SUBSTANCE", 52, 57], ["IL-10", "GENE_OR_GENE_PRODUCT", 58, 63], ["Mice", "ORGANISM", 97, 101], ["C57BL/6", "ORGANISM", 102, 109], ["CD45.1 (inbred C57BL/6)", "ORGANISM", 111, 134], ["Balb/c mice", "ORGANISM", 140, 151], ["Charles River", "ORGANISM", 172, 185], ["IL", "PROTEIN", 58, 60], ["Mice", "SPECIES", 97, 101], ["mice", "SPECIES", 147, 151], ["mice", "SPECIES", 147, 151], ["Blood", "TEST", 0, 5], ["venipuncture", "TEST", 22, 34], ["serum IL", "TEST", 52, 60], ["CD45.1", "TEST", 111, 117], ["Balb/c mice", "TREATMENT", 140, 151]]], ["IL-10 \u00c0/\u00c0 mice (B6.129P2-Il10 tm1Cgn /J) were purchased from The Jackson Laboratory.", [["IL-10", "GENE_OR_GENE_PRODUCT", 0, 5], ["mice", "ORGANISM", 10, 14], ["IL", "PROTEIN", 0, 2], ["mice", "SPECIES", 10, 14], ["mice", "SPECIES", 10, 14], ["IL", "TEST", 0, 2]]], ["HBV replication-competent transgenic mice (lineage 1.3.32, inbred C57BL/6, H-2 b ), that express all of the HBV antigens and replicate HBV in the liver at high levels without any evidence of cytopathology, were previously described.", [["C57BL/6", "ANATOMY", 66, 73], ["H-2 b", "ANATOMY", 75, 80], ["liver", "ANATOMY", 146, 151], ["HBV", "ORGANISM", 0, 3], ["mice", "ORGANISM", 37, 41], ["lineage 1.3.32", "CELL", 43, 57], ["inbred C57BL/6", "ORGANISM", 59, 73], ["H-2 b", "CELL", 75, 80], ["HBV", "ORGANISM", 108, 111], ["HBV", "ORGANISM", 135, 138], ["liver", "ORGAN", 146, 151], ["HBV antigens", "PROTEIN", 108, 120], ["mice", "SPECIES", 37, 41], ["HBV", "SPECIES", 0, 3], ["mice", "SPECIES", 37, 41], ["HBV", "SPECIES", 108, 111], ["HBV", "SPECIES", 135, 138], ["HBV replication", "TREATMENT", 0, 15], ["the HBV antigens", "PROBLEM", 104, 120], ["HBV in the liver", "PROBLEM", 135, 151], ["cytopathology", "PROBLEM", 191, 204], ["HBV", "OBSERVATION", 108, 111], ["HBV", "OBSERVATION", 135, 138], ["liver", "ANATOMY", 146, 151], ["without any evidence of", "UNCERTAINTY", 167, 190], ["cytopathology", "OBSERVATION", 191, 204]]], ["13, 14 In indicated experiments, these mice were used as C57BL/6 x Balb/c H-2 bxd F1 hybrids.", [["mice", "ORGANISM", 39, 43], ["C57BL/6 x Balb/c H-2 bxd F1 hybrids", "CELL", 57, 92], ["C57BL/6 x Balb/c H-2 bxd F1 hybrids", "CELL_LINE", 57, 92], ["mice", "SPECIES", 39, 43], ["mice", "SPECIES", 39, 43], ["Balb/c H", "TEST", 67, 75]]], ["HBV nucleocapsid (Cor)-specific (referred to as Cor93 cells) T cell receptor (TCR) transgenic mice (lineage BC10.3, inbred CD45.1), in which >98% of the splenic CD8 + T cells recognize a K b -restricted epitope located between residues 93-100 in the HBV Core protein (MGLKFRQL), were previously described.", [["Cor93 cells", "ANATOMY", 48, 59], ["T cell", "ANATOMY", 61, 67], ["CD45.1", "ANATOMY", 123, 129], ["splenic CD8 + T cells", "ANATOMY", 153, 174], ["HBV nucleocapsid", "ORGANISM", 0, 16], ["Cor", "GENE_OR_GENE_PRODUCT", 18, 21], ["Cor93 cells", "CELL", 48, 59], ["T cell receptor", "GENE_OR_GENE_PRODUCT", 61, 76], ["TCR", "GENE_OR_GENE_PRODUCT", 78, 81], ["CD45.1", "CELL", 123, 129], ["CD8", "GENE_OR_GENE_PRODUCT", 161, 164], ["K b", "GENE_OR_GENE_PRODUCT", 187, 190], ["HBV", "ORGANISM", 250, 253], ["MGLKFRQL", "GENE_OR_GENE_PRODUCT", 268, 276], ["HBV nucleocapsid", "PROTEIN", 0, 16], ["Cor93 cells", "CELL_LINE", 48, 59], ["T cell receptor", "PROTEIN", 61, 76], ["TCR", "PROTEIN", 78, 81], ["inbred CD45.1", "CELL_LINE", 116, 129], ["splenic CD8 + T cells", "CELL_TYPE", 153, 174], ["K b -restricted epitope", "PROTEIN", 187, 210], ["HBV Core protein", "PROTEIN", 250, 266], ["MGLKFRQL", "PROTEIN", 268, 276], ["mice", "SPECIES", 94, 98], ["HBV", "SPECIES", 0, 3], ["mice", "SPECIES", 94, 98], ["HBV", "SPECIES", 250, 253], ["HBV nucleocapsid", "PROBLEM", 0, 16], ["T cell receptor", "TEST", 61, 76], ["TCR", "TEST", 78, 81], ["lineage BC", "TEST", 100, 110], ["the splenic CD8", "TEST", 149, 164], ["T cells", "PROBLEM", 167, 174], ["a K b", "TEST", 185, 190], ["splenic", "ANATOMY", 153, 160], ["CD8", "ANATOMY_MODIFIER", 161, 164]]], ["17 Env28 (envelope) TCR transgenic mice (lineage 6C2.36, inbred Balb/ c), in which $83% of the splenic CD8 + T cells recognize a L d -restricted epitope located between residues 28-39 of HBsAg (IPQSLDSWWTSL), were previously described.", [["splenic CD8 + T cells", "ANATOMY", 95, 116], ["residues 28-39 of HBsAg", "CHEMICAL", 169, 192], ["Env28", "GENE_OR_GENE_PRODUCT", 3, 8], ["TCR", "GENE_OR_GENE_PRODUCT", 20, 23], ["CD8", "GENE_OR_GENE_PRODUCT", 103, 106], ["HBsAg", "GENE_OR_GENE_PRODUCT", 187, 192], ["TCR", "PROTEIN", 20, 23], ["splenic CD8 + T cells", "CELL_TYPE", 95, 116], ["L d -restricted epitope", "PROTEIN", 129, 152], ["HBsAg", "PROTEIN", 187, 192], ["IPQSLDSWWTSL", "PROTEIN", 194, 206], ["mice", "SPECIES", 35, 39], ["mice", "SPECIES", 35, 39], ["the splenic CD8", "TEST", 91, 106], ["T cells", "PROBLEM", 109, 116], ["a L d -restricted epitope", "TREATMENT", 127, 152], ["HBsAg", "TEST", 187, 192], ["splenic", "ANATOMY", 95, 102], ["CD8", "OBSERVATION", 103, 106]]], ["17 In indicated experiments, lineage BC10.3 or lineage 1.3.32 were crossed with IL-10 \u00c0/\u00c0 mice.", [["lineage BC10.3", "CELL", 29, 43], ["lineage 1.3.32", "CELL", 47, 61], ["IL-10", "GENE_OR_GENE_PRODUCT", 80, 85], ["mice", "ORGANISM", 90, 94], ["lineage 1.3.32", "CELL_LINE", 47, 61], ["IL", "PROTEIN", 80, 82], ["mice", "SPECIES", 90, 94], ["mice", "SPECIES", 90, 94], ["lineage BC", "TEST", 29, 39], ["IL", "TEST", 80, 82]]], ["Mice were housed under specific pathogen-free conditions and used at 8-10 weeks of age.", [["Mice", "ORGANISM", 0, 4], ["Mice", "SPECIES", 0, 4]]], ["In all experiments, mice were matched for age, sex and (for the 1.3.32 animals) serum HBeAg levels before experimental manipulations.", [["serum", "ANATOMY", 80, 85], ["HBeAg", "CHEMICAL", 86, 91], ["mice", "ORGANISM", 20, 24], ["serum", "ORGANISM_SUBSTANCE", 80, 85], ["HBeAg", "GENE_OR_GENE_PRODUCT", 86, 91], ["mice", "SPECIES", 20, 24], ["mice", "SPECIES", 20, 24], ["serum HBeAg levels", "TEST", 80, 98], ["experimental manipulations", "TREATMENT", 106, 132]]], ["All experimental animal procedures were approved by the Institutional Animal Committee of San Raffaele Scientific Institute.PatientsFive patients with acute self-limited HBV infection were enrolled at the Unit of Infectious Diseases and Hepatology in Parma, Italy.", [["HBV infection", "DISEASE", 170, 183], ["Infectious Diseases", "DISEASE", 213, 232], ["Patients", "ORGANISM", 124, 132], ["patients", "ORGANISM", 137, 145], ["HBV", "ORGANISM", 170, 173], ["Patients", "SPECIES", 124, 132], ["patients", "SPECIES", 137, 145], ["HBV", "SPECIES", 170, 173], ["acute self-limited HBV infection", "PROBLEM", 151, 183], ["acute", "OBSERVATION_MODIFIER", 151, 156], ["infection", "OBSERVATION", 174, 183], ["Infectious", "OBSERVATION", 213, 223]]], ["Patients had clinical, biochemical, and virological evidence of acute HBV infection (aminotransferase levels at least 10 times the upper normal limit and detection of HBsAg and IgM anti-HBcAg Ab in the serum).", [["serum", "ANATOMY", 202, 207], ["HBV infection", "DISEASE", 70, 83], ["HBsAg", "CHEMICAL", 167, 172], ["Patients", "ORGANISM", 0, 8], ["HBV", "ORGANISM", 70, 73], ["aminotransferase", "SIMPLE_CHEMICAL", 85, 101], ["HBsAg", "GENE_OR_GENE_PRODUCT", 167, 172], ["IgM anti-HBcAg Ab", "GENE_OR_GENE_PRODUCT", 177, 194], ["serum", "ORGANISM_SUBSTANCE", 202, 207], ["HBsAg", "PROTEIN", 167, 172], ["IgM", "PROTEIN", 177, 180], ["anti-HBcAg Ab", "PROTEIN", 181, 194], ["Patients", "SPECIES", 0, 8], ["HBV", "SPECIES", 70, 73], ["acute HBV infection", "PROBLEM", 64, 83], ["aminotransferase levels", "TEST", 85, 108], ["HBsAg", "TEST", 167, 172], ["IgM anti-HBcAg Ab", "TEST", 177, 194], ["evidence of", "UNCERTAINTY", 52, 63], ["acute", "OBSERVATION_MODIFIER", 64, 69], ["HBV", "OBSERVATION", 70, 73]]], ["Patients were negative for anti-HCV, anti-delta virus, anti-HIV-1 and anti-HIV-2 Ab and for other markers of viral or autoimmune hepatitis.", [["viral or autoimmune hepatitis", "DISEASE", 109, 138], ["Patients", "ORGANISM", 0, 8], ["anti-delta virus", "ORGANISM", 37, 53], ["anti-HIV-1", "ORGANISM", 55, 65], ["anti-HIV-2", "ORGANISM", 70, 80], ["Ab", "GENE_OR_GENE_PRODUCT", 81, 83], ["Ab", "PROTEIN", 81, 83], ["Patients", "SPECIES", 0, 8], ["HIV-1", "SPECIES", 60, 65], ["anti-delta virus", "SPECIES", 37, 53], ["HIV-1", "SPECIES", 60, 65], ["anti-HCV", "TEST", 27, 35], ["anti-delta virus", "TREATMENT", 37, 53], ["anti-HIV", "TREATMENT", 55, 63], ["anti-HIV", "TREATMENT", 70, 78], ["viral", "PROBLEM", 109, 114], ["autoimmune hepatitis", "PROBLEM", 118, 138], ["viral", "OBSERVATION", 109, 114], ["autoimmune hepatitis", "OBSERVATION", 118, 138]]], ["T cell response was tested one month from the time of acute illness.PatientsThe study was approved by the Ethical Committee of the Azienda Ospedaliero-Universitaria of Parma, and all subjects gave written informed consent.Generation of CD8 T E and adoptive transferIn vitro generation of CD8 T E was performed as described.", [["T cell", "ANATOMY", 0, 6], ["T cell", "CELL", 0, 6], ["Patients", "ORGANISM", 68, 76], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 236, 243], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 288, 295], ["CD8", "PROTEIN", 236, 239], ["CD8", "PROTEIN", 288, 291], ["Patients", "SPECIES", 68, 76], ["acute illness", "PROBLEM", 54, 67], ["The study", "TEST", 76, 85], ["acute", "OBSERVATION_MODIFIER", 54, 59], ["illness", "OBSERVATION", 60, 67]]], ["16, 26 Briefly, splenocytes from Cor93 or Env28 TCR transgenic mice were incubated with 10 lg/ml of Cor93-100 (K b ; MGLKFRQL) or Env28-39 (L d ; IPQSLDSWWTSL) peptides (Primm), respectively, at 37\u00b0C for 1 h, washed, and cultured in complete RPMI 1640 (10% FBS, 2 mM L-glutamine, 50 lM 2-mercaptoethanol, HEPES 10 mM, non essential amino acid 100 lM and penicillin plus streptomycin).", [["splenocytes", "ANATOMY", 16, 27], ["FBS", "ANATOMY", 257, 260], ["L-glutamine", "CHEMICAL", 267, 278], ["lM 2-mercaptoethanol", "CHEMICAL", 283, 303], ["amino acid", "CHEMICAL", 332, 342], ["lM", "CHEMICAL", 347, 349], ["penicillin", "CHEMICAL", 354, 364], ["streptomycin", "CHEMICAL", 370, 382], ["Env28-39", "CHEMICAL", 130, 138], ["L-glutamine", "CHEMICAL", 267, 278], ["2-mercaptoethanol", "CHEMICAL", 286, 303], ["HEPES", "CHEMICAL", 305, 310], ["amino acid", "CHEMICAL", 332, 342], ["penicillin", "CHEMICAL", 354, 364], ["streptomycin", "CHEMICAL", 370, 382], ["splenocytes", "CELL", 16, 27], ["Cor93", "GENE_OR_GENE_PRODUCT", 33, 38], ["Env28", "GENE_OR_GENE_PRODUCT", 42, 47], ["TCR", "GENE_OR_GENE_PRODUCT", 48, 51], ["mice", "ORGANISM", 63, 67], ["Cor93-100", "SIMPLE_CHEMICAL", 100, 109], ["K b", "SIMPLE_CHEMICAL", 111, 114], ["Env28-39", "SIMPLE_CHEMICAL", 130, 138], ["FBS", "ORGANISM_SUBSTANCE", 257, 260], ["L-glutamine", "SIMPLE_CHEMICAL", 267, 278], ["2-mercaptoethanol", "SIMPLE_CHEMICAL", 286, 303], ["non essential amino acid", "SIMPLE_CHEMICAL", 318, 342], ["penicillin", "SIMPLE_CHEMICAL", 354, 364], ["streptomycin", "SIMPLE_CHEMICAL", 370, 382], ["splenocytes", "CELL_TYPE", 16, 27], ["TCR", "PROTEIN", 48, 51], ["mice", "SPECIES", 63, 67], ["mice", "SPECIES", 63, 67], ["splenocytes", "TEST", 16, 27], ["Cor93", "TEST", 33, 38], ["Cor93", "TEST", 100, 105], ["K b", "TEST", 111, 114], ["MGLKFRQL", "TEST", 117, 125], ["Env28", "TEST", 130, 135], ["peptides", "TEST", 160, 168], ["FBS", "TEST", 257, 260], ["L-glutamine", "TEST", 267, 278], ["mercaptoethanol", "TREATMENT", 288, 303], ["HEPES", "TEST", 305, 310], ["non essential amino acid", "TREATMENT", 318, 342], ["penicillin", "TREATMENT", 354, 364], ["streptomycin", "TREATMENT", 370, 382]]], ["Two days later, cells were cultured in fresh medium supplemented with 2.5% EL-4 supernatant.", [["cells", "ANATOMY", 16, 21], ["EL-4", "CHEMICAL", 75, 79], ["cells", "CELL", 16, 21], ["cells", "TEST", 16, 21]]], ["Media sup-plemented with cytokines were replaced every 2 days.", [["cytokines", "PROTEIN", 25, 34], ["cytokines", "TREATMENT", 25, 34]]], ["After 8 or 9 days of culture, cells were tested for the expression of CD8, CD69, CD25, CD44, CD62L, CCR7, IFNc and granzyme B by FACS prior to subsequent use, as described.", [["cells", "ANATOMY", 30, 35], ["cells", "CELL", 30, 35], ["CD8", "GENE_OR_GENE_PRODUCT", 70, 73], ["CD69", "GENE_OR_GENE_PRODUCT", 75, 79], ["CD25", "GENE_OR_GENE_PRODUCT", 81, 85], ["CD44", "GENE_OR_GENE_PRODUCT", 87, 91], ["CD62L", "GENE_OR_GENE_PRODUCT", 93, 98], ["CCR7", "GENE_OR_GENE_PRODUCT", 100, 104], ["IFNc", "GENE_OR_GENE_PRODUCT", 106, 110], ["granzyme B", "GENE_OR_GENE_PRODUCT", 115, 125], ["CD8", "PROTEIN", 70, 73], ["CD69", "PROTEIN", 75, 79], ["CD25", "PROTEIN", 81, 85], ["CD44", "PROTEIN", 87, 91], ["CD62L", "PROTEIN", 93, 98], ["CCR7", "PROTEIN", 100, 104], ["IFNc", "PROTEIN", 106, 110], ["granzyme B", "PROTEIN", 115, 125], ["culture", "TEST", 21, 28], ["cells", "TEST", 30, 35], ["CD8", "TEST", 70, 73], ["CD69", "TEST", 75, 79], ["CD25", "TEST", 81, 85], ["CD44", "TEST", 87, 91], ["CD62L", "TEST", 93, 98], ["CCR7", "TEST", 100, 104], ["IFNc", "TEST", 106, 110]]], ["16 10 7 cells of each cell type were injected intravenously into recipient animals.RNA analysesTotal RNA was isolated from cultured cells or frozen livers (left lobe) with Relia-Prep RNA Miniprep system (Promega) following the manufacturer's instructions.RNA analysesFor quantitative RT-PCR, 1 lg of total RNA was reverse transcribed prior to qPCR analysis for mouse il10 and ifng (TaqMan Mm01288386 and Mm01168134 probes, Applied Biosystems) in an ABI 7900HT fast real-time PCR system (Applied Biosystems).", [["cells", "ANATOMY", 8, 13], ["cell", "ANATOMY", 22, 26], ["intravenously", "ANATOMY", 46, 59], ["cells", "ANATOMY", 132, 137], ["livers", "ANATOMY", 148, 154], ["left lobe", "ANATOMY", 156, 165], ["cells", "CELL", 8, 13], ["cell type", "CELL", 22, 31], ["cells", "CELL", 132, 137], ["livers", "ORGAN", 148, 154], ["left lobe", "MULTI-TISSUE_STRUCTURE", 156, 165], ["Miniprep", "ORGANISM", 187, 195], ["mouse", "ORGANISM", 361, 366], ["il10", "GENE_OR_GENE_PRODUCT", 367, 371], ["ifng", "GENE_OR_GENE_PRODUCT", 376, 380], ["cultured cells", "CELL_LINE", 123, 137], ["mouse il10", "DNA", 361, 371], ["TaqMan Mm01288386 and Mm01168134 probes", "DNA", 382, 421], ["mouse", "SPECIES", 361, 366], ["mouse", "SPECIES", 361, 366], ["each cell type", "TREATMENT", 17, 31], ["RNA analysesTotal RNA", "TEST", 83, 104], ["cultured cells", "TEST", 123, 137], ["frozen livers", "TEST", 141, 154], ["Relia", "TREATMENT", 172, 177], ["RNA analyses", "TEST", 255, 267], ["quantitative RT-PCR", "TEST", 271, 290], ["total RNA", "TEST", 300, 309], ["qPCR analysis", "TEST", 343, 356], ["mouse il10", "TEST", 361, 371], ["TaqMan", "TEST", 382, 388], ["an ABI", "TEST", 446, 452], ["livers", "ANATOMY", 148, 154], ["left lobe", "ANATOMY", 156, 165]]], ["All experiments were performed in triplicate and normalized to the reference gene GAPDH.RNA analysesEnzyme-linked immunosorbent assays IL-10 and IFN-c in mouse sera or cell supernatants were measured by ELISA (Biolegend and R&D, respectively), according to the manufacturer's instructions.", [["sera", "ANATOMY", 160, 164], ["cell supernatants", "ANATOMY", 168, 185], ["GAPDH", "GENE_OR_GENE_PRODUCT", 82, 87], ["IL-10", "GENE_OR_GENE_PRODUCT", 135, 140], ["IFN-c", "GENE_OR_GENE_PRODUCT", 145, 150], ["mouse", "ORGANISM", 154, 159], ["sera", "ORGANISM_SUBSTANCE", 160, 164], ["cell", "CELL", 168, 172], ["reference gene GAPDH", "DNA", 67, 87], ["IFN-c", "PROTEIN", 145, 150], ["Biolegend", "PROTEIN", 210, 219], ["mouse", "SPECIES", 154, 159], ["mouse", "SPECIES", 154, 159], ["All experiments", "TEST", 0, 15], ["RNA analyses", "TEST", 88, 100], ["Enzyme", "TEST", 100, 106], ["immunosorbent assays", "TEST", 114, 134], ["IL", "TEST", 135, 137], ["IFN", "TEST", 145, 148], ["cell supernatants", "TEST", 168, 185], ["ELISA", "TEST", 203, 208]]], ["HBeAg in mouse sera was measured by ELISA (Diapro) following the manufacturer's instructions.", [["sera", "ANATOMY", 15, 19], ["HBeAg", "CHEMICAL", 0, 5], ["HBeAg", "GENE_OR_GENE_PRODUCT", 0, 5], ["mouse", "ORGANISM", 9, 14], ["sera", "ORGANISM_SUBSTANCE", 15, 19], ["mouse", "SPECIES", 9, 14], ["mouse", "SPECIES", 9, 14], ["HBeAg in mouse sera", "PROBLEM", 0, 19]]], ["IL-10 in chimpanzee sera was measured using a human IL-10 ELISA (R&D Systems) according to the manufacturer's instructions.Biochemical analysesThe extent of hepatocellular injury was monitored by measuring serum alanine aminotransferase (ALT) activity at multiple time points after treatment, as previously described.", [["sera", "ANATOMY", 20, 24], ["hepatocellular", "ANATOMY", 157, 171], ["serum", "ANATOMY", 206, 211], ["hepatocellular injury", "DISEASE", 157, 178], ["alanine", "CHEMICAL", 212, 219], ["alanine", "CHEMICAL", 212, 219], ["IL-10", "GENE_OR_GENE_PRODUCT", 0, 5], ["chimpanzee", "ORGANISM", 9, 19], ["sera", "ORGANISM_SUBSTANCE", 20, 24], ["human", "ORGANISM", 46, 51], ["IL-10", "GENE_OR_GENE_PRODUCT", 52, 57], ["hepatocellular", "ORGAN", 157, 171], ["serum", "ORGANISM_SUBSTANCE", 206, 211], ["alanine aminotransferase", "GENE_OR_GENE_PRODUCT", 212, 236], ["ALT", "GENE_OR_GENE_PRODUCT", 238, 241], ["IL-10", "PROTEIN", 0, 5], ["serum alanine aminotransferase", "PROTEIN", 206, 236], ["ALT", "PROTEIN", 238, 241], ["human", "SPECIES", 46, 51], ["chimpanzee", "SPECIES", 9, 19], ["human", "SPECIES", 46, 51], ["IL", "TREATMENT", 0, 2], ["chimpanzee sera", "TREATMENT", 9, 24], ["a human IL", "TREATMENT", 44, 54], ["Biochemical analyses", "TEST", 123, 143], ["hepatocellular injury", "PROBLEM", 157, 178], ["serum alanine aminotransferase", "TEST", 206, 236], ["ALT", "TEST", 238, 241], ["treatment", "TREATMENT", 282, 291], ["extent", "OBSERVATION_MODIFIER", 147, 153], ["hepatocellular", "ANATOMY", 157, 171], ["injury", "OBSERVATION", 172, 178]]], ["16 In vivo IL-10R-specific antibody treatmentIsolation of primary hepatocytesPrimary hepatocytes were isolated from wild-type or IL-10 \u00c0/\u00c0 HBV replicationcompetent transgenic mice (inbred C57BL/6) exactly as described.", [["hepatocytes", "ANATOMY", 66, 77], ["hepatocytes", "ANATOMY", 85, 96], ["IL-10R", "GENE_OR_GENE_PRODUCT", 11, 17], ["hepatocytes", "CELL", 66, 77], ["hepatocytes", "CELL", 85, 96], ["IL-10", "GENE_OR_GENE_PRODUCT", 129, 134], ["\u00c0", "GENE_OR_GENE_PRODUCT", 135, 136], ["\u00c0", "GENE_OR_GENE_PRODUCT", 137, 138], ["HBV", "ORGANISM", 139, 142], ["mice", "ORGANISM", 175, 179], ["inbred C57BL/6", "ORGANISM", 181, 195], ["IL", "PROTEIN", 11, 13], ["10R", "PROTEIN", 14, 17], ["primary hepatocytes", "CELL_TYPE", 58, 77], ["hepatocytes", "CELL_TYPE", 85, 96], ["mice", "SPECIES", 175, 179], ["mice", "SPECIES", 175, 179], ["vivo IL", "TREATMENT", 6, 13], ["specific antibody treatment", "TREATMENT", 18, 45], ["primary hepatocytesPrimary hepatocytes", "PROBLEM", 58, 96], ["IL", "TEST", 129, 131], ["HBV replicationcompetent transgenic mice (inbred C57BL/6)", "TREATMENT", 139, 196]]], ["16 Hepatocyte purity (assessed by flow cytometry-based parameters of size) and viability (assessed by light microscopy-based morphology and Trypan blue dye exclusion) were routinely greater than 70% and 80%, respectively.", [["Hepatocyte", "ANATOMY", 3, 13], ["Trypan blue", "CHEMICAL", 140, 151], ["Trypan blue", "CHEMICAL", 140, 151], ["Trypan blue dye", "SIMPLE_CHEMICAL", 140, 155], ["Hepatocyte purity", "TEST", 3, 20], ["flow cytometry", "TEST", 34, 48], ["viability", "TEST", 79, 88], ["light microscopy", "TEST", 102, 118], ["Trypan blue dye exclusion", "TEST", 140, 165], ["Hepatocyte purity", "OBSERVATION", 3, 20], ["size", "OBSERVATION_MODIFIER", 69, 73]]], ["Hepatocytes (10 6 cells/ml) were incubated at a 1:2 ratio with Cor93 CD8 T E for 4 h in the presence of 10 lg/ml brefeldin A (BFA, Sigma) prior to intracellular IFN-c staining.Cell isolation and flow cytometrySingle-cell suspensions of livers were generated as described.", [["Hepatocytes", "ANATOMY", 0, 11], ["cells", "ANATOMY", 18, 23], ["intracellular", "ANATOMY", 147, 160], ["Cell", "ANATOMY", 176, 180], ["cell", "ANATOMY", 216, 220], ["livers", "ANATOMY", 236, 242], ["brefeldin A", "CHEMICAL", 113, 124], ["BFA", "CHEMICAL", 126, 129], ["brefeldin A", "CHEMICAL", 113, 124], ["BFA", "CHEMICAL", 126, 129], ["Hepatocytes", "CELL", 0, 11], ["cells", "CELL", 18, 23], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 69, 76], ["brefeldin A", "SIMPLE_CHEMICAL", 113, 124], ["BFA", "SIMPLE_CHEMICAL", 126, 129], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 147, 160], ["IFN-c", "GENE_OR_GENE_PRODUCT", 161, 166], ["Cell", "CELL", 176, 180], ["Single-cell", "CELL", 209, 220], ["livers", "ORGAN", 236, 242], ["CD8", "PROTEIN", 69, 72], ["IFN", "PROTEIN", 161, 164], ["Hepatocytes", "TEST", 0, 11], ["intracellular IFN", "TEST", 147, 164], ["staining", "PROBLEM", 167, 175], ["Cell isolation", "TEST", 176, 190], ["flow cytometry", "TEST", 195, 209], ["Single-cell suspensions of livers", "TREATMENT", 209, 242], ["10 6 cells", "OBSERVATION_MODIFIER", 13, 23], ["flow cytometry", "OBSERVATION", 195, 209], ["cell suspensions", "OBSERVATION", 216, 232], ["livers", "ANATOMY", 236, 242]]], ["18 For analysis of ex vivo intracellular cytokine production, cell suspensions of livers were obtained as described above except that 1 lg/ml of BFA (Sigma) was included in the digestion buffer.", [["intracellular", "ANATOMY", 27, 40], ["cell", "ANATOMY", 62, 66], ["livers", "ANATOMY", 82, 88], ["BFA", "CHEMICAL", 145, 148], ["BFA", "CHEMICAL", 145, 148], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 27, 40], ["cell", "CELL", 62, 66], ["livers", "ORGAN", 82, 88], ["BFA", "SIMPLE_CHEMICAL", 145, 148], ["cytokine", "PROTEIN", 41, 49], ["analysis of ex vivo intracellular cytokine production", "TEST", 7, 60], ["cell suspensions of livers", "TEST", 62, 88], ["BFA", "PROBLEM", 145, 148], ["the digestion buffer", "TREATMENT", 173, 193], ["cytokine production", "OBSERVATION", 41, 60], ["livers", "ANATOMY", 82, 88]]], ["All flow cytometry stainings of surface-expressed and intracellular molecules were performed as described.", [["surface", "ANATOMY", 32, 39], ["intracellular", "ANATOMY", 54, 67], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 54, 67], ["intracellular molecules", "PROTEIN", 54, 77], ["All flow cytometry stainings", "TEST", 0, 28], ["surface", "TEST", 32, 39], ["intracellular molecules", "TEST", 54, 77], ["flow cytometry", "OBSERVATION", 4, 18], ["surface", "OBSERVATION_MODIFIER", 32, 39], ["intracellular molecules", "OBSERVATION", 54, 77]]], ["27 Antibodies (Abs) used included PB-and PE-conjugated anti-CD8a (53-6.7), Alexa Fluor 488-, PerCP-, and APC-Cy7-conjugated anti-CD45.1 (A20), Alexa Fluor 488-, and Alexa Fluor 647-conjugated anti-IFN-c (XMG1.2), PE-and PB-conjugated anti-CD25 (PC61), APC-conjugated Annexin V (EOS9.1), 7AAD (BD Pharmingen).", [["PB", "CHEMICAL", 34, 36], ["PE", "CHEMICAL", 41, 43], ["Alexa Fluor 488", "CHEMICAL", 75, 90], ["Alexa Fluor 488", "CHEMICAL", 143, 158], ["Alexa Fluor 647", "CHEMICAL", 165, 180], ["PB", "SIMPLE_CHEMICAL", 34, 36], ["PE", "SIMPLE_CHEMICAL", 41, 43], ["anti-CD8a", "SIMPLE_CHEMICAL", 55, 64], ["Alexa Fluor 488", "SIMPLE_CHEMICAL", 75, 90], ["PerCP", "SIMPLE_CHEMICAL", 93, 98], ["APC-Cy7", "SIMPLE_CHEMICAL", 105, 112], ["A20", "GENE_OR_GENE_PRODUCT", 137, 140], ["Alexa Fluor 488", "SIMPLE_CHEMICAL", 143, 158], ["Alexa Fluor 647", "SIMPLE_CHEMICAL", 165, 180], ["IFN-c", "SIMPLE_CHEMICAL", 197, 202], ["XMG1.2", "SIMPLE_CHEMICAL", 204, 210], ["PE", "SIMPLE_CHEMICAL", 213, 215], ["PB-conjugated anti-CD25", "SIMPLE_CHEMICAL", 220, 243], ["PC61", "SIMPLE_CHEMICAL", 245, 249], ["APC", "GENE_OR_GENE_PRODUCT", 252, 255], ["Annexin V", "GENE_OR_GENE_PRODUCT", 267, 276], ["7AAD", "SIMPLE_CHEMICAL", 287, 291], ["27 Antibodies", "PROTEIN", 0, 13], ["Abs", "PROTEIN", 15, 18], ["PerCP", "PROTEIN", 93, 98], ["APC", "PROTEIN", 105, 108], ["Cy7", "PROTEIN", 109, 112], ["CD45.1", "PROTEIN", 129, 135], ["A20", "PROTEIN", 137, 140], ["Alexa Fluor 488", "PROTEIN", 143, 158], ["Alexa Fluor 647", "PROTEIN", 165, 180], ["IFN", "PROTEIN", 197, 200], ["XMG1", "PROTEIN", 204, 208], ["PE", "PROTEIN", 213, 215], ["PB", "PROTEIN", 220, 222], ["anti-CD25", "PROTEIN", 234, 243], ["PC61", "PROTEIN", 245, 249], ["APC", "PROTEIN", 252, 255], ["Annexin V", "PROTEIN", 267, 276], ["EOS9", "PROTEIN", 278, 282], ["7AAD", "PROTEIN", 287, 291], ["BD Pharmingen", "PROTEIN", 293, 306], ["Alexa Fluor 647", "SPECIES", 165, 180], ["Antibodies (Abs", "TEST", 3, 18], ["PB", "TEST", 34, 36], ["PE", "TEST", 41, 43], ["conjugated anti-CD8a", "TEST", 44, 64], ["Alexa Fluor", "TEST", 75, 86], ["PerCP", "TEST", 93, 98], ["APC", "TEST", 105, 108], ["Cy7", "TEST", 109, 112], ["Alexa Fluor", "TEST", 143, 154], ["Alexa Fluor", "TEST", 165, 176], ["XMG1", "TEST", 204, 208], ["PE", "TEST", 213, 215], ["PB-conjugated anti-CD25", "TREATMENT", 220, 243], ["PC61", "TEST", 245, 249], ["APC", "TEST", 252, 255], ["conjugated Annexin V", "TREATMENT", 256, 276], ["7AAD (BD Pharmingen", "TREATMENT", 287, 306], ["PE", "OBSERVATION", 41, 43], ["PE", "OBSERVATION", 213, 215]]], ["All Abs were purchased from BioLegend, unless otherwise indicated.", [["BioLegend", "GENE_OR_GENE_PRODUCT", 28, 37], ["Abs", "PROTEIN", 4, 7], ["BioLegend", "PROTEIN", 28, 37]]], ["For phosphorylated STAT5 analysis, cells were fixed with 4% paraformaldehyde, permeabilized with absolute methanol and stained with Pe-Cy7-conjugated anti-phosphoSTAT5 (47/Stat5pY694, eBioscience).", [["cells", "ANATOMY", 35, 40], ["Pe-Cy7", "CHEMICAL", 132, 138], ["paraformaldehyde", "CHEMICAL", 60, 76], ["methanol", "CHEMICAL", 106, 114], ["anti-phosphoSTAT5", "CHEMICAL", 150, 167], ["STAT5", "GENE_OR_GENE_PRODUCT", 19, 24], ["cells", "CELL", 35, 40], ["paraformaldehyde", "SIMPLE_CHEMICAL", 60, 76], ["methanol", "SIMPLE_CHEMICAL", 106, 114], ["Pe-Cy7-conjugated anti-phosphoSTAT5", "SIMPLE_CHEMICAL", 132, 167], ["STAT5", "PROTEIN", 19, 24], ["Cy7", "PROTEIN", 135, 138], ["anti-phosphoSTAT5", "PROTEIN", 150, 167], ["Stat5pY694", "PROTEIN", 172, 182], ["eBioscience", "PROTEIN", 184, 195], ["phosphorylated STAT5 analysis", "TEST", 4, 33], ["cells", "TEST", 35, 40], ["4% paraformaldehyde", "TREATMENT", 57, 76], ["absolute methanol", "TREATMENT", 97, 114], ["Pe-Cy7", "TEST", 132, 138]]], ["All flow cytometry analyses were performed in FACS buffer containing PBS with 2 mM EDTA and 2% FBS on a FACS CANTO (BD Pharmingen) and analyzed with FlowJo software (Treestar).HistochemistryFor Haemotoxylin and Eosin staining, livers were perfused with PBS, harvested in Zn-formalin and transferred into 70% ethanol 24 h later.", [["FBS", "ANATOMY", 95, 98], ["livers", "ANATOMY", 227, 233], ["Zn-formalin", "CHEMICAL", 271, 282], ["ethanol", "CHEMICAL", 308, 315], ["EDTA", "CHEMICAL", 83, 87], ["Haemotoxylin", "CHEMICAL", 194, 206], ["Eosin", "CHEMICAL", 211, 216], ["formalin", "CHEMICAL", 274, 282], ["ethanol", "CHEMICAL", 308, 315], ["EDTA", "SIMPLE_CHEMICAL", 83, 87], ["FBS", "ORGANISM_SUBSTANCE", 95, 98], ["Haemotoxylin", "SIMPLE_CHEMICAL", 194, 206], ["Eosin", "SIMPLE_CHEMICAL", 211, 216], ["livers", "ORGAN", 227, 233], ["Zn-", "SIMPLE_CHEMICAL", 271, 274], ["formalin", "SIMPLE_CHEMICAL", 274, 282], ["ethanol", "SIMPLE_CHEMICAL", 308, 315], ["BD Pharmingen", "PROTEIN", 116, 129], ["All flow cytometry analyses", "TEST", 0, 27], ["2 mM EDTA", "TREATMENT", 78, 87], ["a FACS CANTO (BD Pharmingen)", "TREATMENT", 102, 130], ["Histochemistry", "TEST", 176, 190], ["Haemotoxylin", "TREATMENT", 194, 206], ["Eosin staining", "TEST", 211, 225], ["PBS", "TREATMENT", 253, 256], ["harvested in Zn-formalin", "TREATMENT", 258, 282], ["flow cytometry", "OBSERVATION", 4, 18], ["livers", "ANATOMY", 227, 233]]], ["Tissue was then processed, embedded in paraffin and stained as previously described.", [["Tissue", "ANATOMY", 0, 6], ["paraffin", "CHEMICAL", 39, 47], ["Tissue", "TISSUE", 0, 6]]], ["16 Bright-field images were acquired through an Aperio Scanscope System CS2 microscope and an ImageScope program (Leica Biosystem) following the manufacturer's instructions.", [["Bright-field images", "TEST", 3, 22], ["an ImageScope program", "TREATMENT", 91, 112]]], ["The extent of hepatocellular injury was monitored by histopathological and quantitative morphometric analyses as described.", [["hepatocellular", "ANATOMY", 14, 28], ["hepatocellular injury", "DISEASE", 14, 35], ["hepatocellular", "ORGAN", 14, 28], ["hepatocellular injury", "PROBLEM", 14, 35], ["quantitative morphometric analyses", "TEST", 75, 109], ["extent", "OBSERVATION_MODIFIER", 4, 10], ["hepatocellular", "ANATOMY", 14, 28], ["injury", "OBSERVATION", 29, 35]]], ["18 The number of injured hepatocytes (identified as either apoptotic or necrotic based on standard cytopathological criteria) and intrahepatic inflammatory cells (mononuclear and polymorphonuclear) were counted in at least 50 high power fields of liver tissue (corresponding to about 2 mm 2 ).", [["hepatocytes", "ANATOMY", 25, 36], ["intrahepatic inflammatory cells", "ANATOMY", 130, 161], ["mononuclear", "ANATOMY", 163, 174], ["polymorphonuclear", "ANATOMY", 179, 196], ["liver tissue", "ANATOMY", 247, 259], ["necrotic", "DISEASE", 72, 80], ["hepatocytes", "CELL", 25, 36], ["intrahepatic inflammatory cells", "CELL", 130, 161], ["mononuclear", "CELL", 163, 174], ["polymorphonuclear", "CELL", 179, 196], ["liver tissue", "TISSUE", 247, 259], ["injured hepatocytes", "CELL_TYPE", 17, 36], ["intrahepatic inflammatory cells", "CELL_TYPE", 130, 161], ["mononuclear and polymorphonuclear", "CELL_TYPE", 163, 196], ["injured hepatocytes", "PROBLEM", 17, 36], ["apoptotic", "PROBLEM", 59, 68], ["necrotic", "PROBLEM", 72, 80], ["standard cytopathological criteria", "TEST", 90, 124], ["intrahepatic inflammatory cells", "PROBLEM", 130, 161], ["number", "OBSERVATION_MODIFIER", 7, 13], ["injured", "OBSERVATION", 17, 24], ["hepatocytes", "ANATOMY", 25, 36], ["apoptotic", "OBSERVATION_MODIFIER", 59, 68], ["necrotic", "OBSERVATION_MODIFIER", 72, 80], ["intrahepatic", "ANATOMY", 130, 142], ["inflammatory cells", "OBSERVATION", 143, 161], ["mononuclear", "OBSERVATION_MODIFIER", 163, 174], ["polymorphonuclear", "OBSERVATION_MODIFIER", 179, 196], ["high", "OBSERVATION_MODIFIER", 226, 230], ["power", "OBSERVATION_MODIFIER", 231, 236], ["fields", "OBSERVATION_MODIFIER", 237, 243], ["liver", "ANATOMY", 247, 252], ["tissue", "ANATOMY_MODIFIER", 253, 259]]], ["Results are expressed as number of cells per mm 2 .HistochemistryIn vitro cell culture assays with murine CD8 T E To test the expression and production of IL-10 and IFN-c by Cor93 T E , cells were incubated in complete RPMI 1640 media with 2 lg/ml of rhIL-2 (Roche) at 5\u00c210 6 cells/ml for 4 h at 37\u00b0C in the presence or absence of the Cor93 peptide.", [["cells", "ANATOMY", 35, 40], ["cell", "ANATOMY", 74, 78], ["cells", "ANATOMY", 186, 191], ["cells", "ANATOMY", 276, 281], ["cells", "CELL", 35, 40], ["cell", "CELL", 74, 78], ["murine", "ORGANISM", 99, 105], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 106, 113], ["IL-10", "GENE_OR_GENE_PRODUCT", 155, 160], ["IFN-c", "GENE_OR_GENE_PRODUCT", 165, 170], ["Cor93 T E", "CELL", 174, 183], ["cells", "CELL", 186, 191], ["rhIL-2", "GENE_OR_GENE_PRODUCT", 251, 257], ["Roche", "ORGANISM", 259, 264], ["cells", "CELL", 276, 281], ["Cor93", "GENE_OR_GENE_PRODUCT", 335, 340], ["murine CD8 T E", "CELL_LINE", 99, 113], ["IL-10", "PROTEIN", 155, 160], ["IFN", "PROTEIN", 165, 168], ["murine", "SPECIES", 99, 105], ["Histochemistry", "TEST", 51, 65], ["vitro cell culture assays", "TEST", 68, 93], ["IL", "TEST", 155, 157], ["IFN", "TEST", 165, 168], ["rhIL", "TEST", 251, 255]]], ["To assess the effect of IL-10 on Ag-induced apoptosis, Cor93 CD8 T E (10 7 cells/ ml) were incubated for 1 h at 37\u00b0C with 18 lg/ml of anti-IL-10R Ab (BioXCell), 400 ng/ml of recombinant mIL-10 (Biolegend) or left untreated prior to the addition of Cor93 peptide (1 mg/ml) and human IL-2 (1 mg/ml).", [["Cor93 CD8 T E", "ANATOMY", 55, 68], ["cells", "ANATOMY", 75, 80], ["Ag", "CHEMICAL", 33, 35], ["Ag", "CHEMICAL", 33, 35], ["IL-10", "GENE_OR_GENE_PRODUCT", 24, 29], ["Ag", "GENE_OR_GENE_PRODUCT", 33, 35], ["Cor93", "CELL", 55, 60], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 61, 68], ["anti-IL-10R Ab", "SIMPLE_CHEMICAL", 134, 148], ["BioXCell", "SIMPLE_CHEMICAL", 150, 158], ["mIL-10", "GENE_OR_GENE_PRODUCT", 186, 192], ["Biolegend", "GENE_OR_GENE_PRODUCT", 194, 203], ["Cor93 peptide", "SIMPLE_CHEMICAL", 248, 261], ["human", "ORGANISM", 276, 281], ["IL-2", "GENE_OR_GENE_PRODUCT", 282, 286], ["IL", "PROTEIN", 24, 26], ["Ag", "PROTEIN", 33, 35], ["Cor93 CD8 T E", "CELL_LINE", 55, 68], ["anti-IL-10R Ab", "PROTEIN", 134, 148], ["BioXCell", "PROTEIN", 150, 158], ["recombinant mIL-10", "PROTEIN", 174, 192], ["Biolegend", "PROTEIN", 194, 203], ["human", "SPECIES", 276, 281], ["human", "SPECIES", 276, 281], ["IL", "TEST", 24, 26], ["Ag", "TEST", 33, 35], ["anti-IL", "TREATMENT", 134, 141], ["recombinant mIL", "TREATMENT", 174, 189], ["Cor93 peptide", "TREATMENT", 248, 261], ["human IL", "TREATMENT", 276, 284], ["left", "ANATOMY_MODIFIER", 208, 212]]], ["For the assessment of cell viability, cells were harvested 8 h later and stained with Annexin V and 7AAD, as described above.", [["cell", "ANATOMY", 22, 26], ["cells", "ANATOMY", 38, 43], ["cell", "CELL", 22, 26], ["cells", "CELL", 38, 43], ["Annexin V", "GENE_OR_GENE_PRODUCT", 86, 95], ["the assessment", "TEST", 4, 18], ["cell viability", "PROBLEM", 22, 36], ["Annexin V", "TEST", 86, 95], ["cell viability", "OBSERVATION", 22, 36], ["Annexin V", "OBSERVATION_MODIFIER", 86, 95]]], ["For the assessment of CD25 expression, cells were harvested 24 h after peptide stimulation.", [["cells", "ANATOMY", 39, 44], ["CD25", "GENE_OR_GENE_PRODUCT", 22, 26], ["cells", "CELL", 39, 44], ["CD25", "PROTEIN", 22, 26], ["the assessment", "TEST", 4, 18], ["peptide stimulation", "TREATMENT", 71, 90]]], ["For STAT5 phosphorylation, Cor93 CD8 T E were cultured overnight in serum-free RPMI complete medium (Gibco, Life Technologies), prior to treating them as described above.", [["serum", "ANATOMY", 68, 73], ["STAT5", "GENE_OR_GENE_PRODUCT", 4, 9], ["Cor93 CD8 T E", "GENE_OR_GENE_PRODUCT", 27, 40], ["serum", "ORGANISM_SUBSTANCE", 68, 73], ["STAT5", "PROTEIN", 4, 9], ["Cor93 CD8 T E", "CELL_LINE", 27, 40], ["STAT5 phosphorylation", "TEST", 4, 25], ["serum", "TEST", 68, 73]]], ["Cells were harvested 15 min after peptide stimulation.In vitro cell culture assays with human CD8 T ETo measure the effect of IL-10 on Ag-induced apoptosis, peripheral blood mononuclear cells (PBMC) from five HLA-A201 + patients with acute self-limited hepatitis B (concentration of 2\u00c210 6 /ml) were incubated for 1 h at 37\u00b0C with 20 lg/ml of anti-IL-10R Ab (BD Pharmingen), 200 ng/ml of recombinant human IL-10 (BioLegend) or left untreated prior to the addition of Core 18-27 peptide (1 lg/ml) and human IL-2 (100 IU/ml).", [["Cells", "ANATOMY", 0, 5], ["cell", "ANATOMY", 63, 67], ["peripheral blood mononuclear cells", "ANATOMY", 157, 191], ["PBMC", "ANATOMY", 193, 197], ["Ag", "CHEMICAL", 135, 137], ["hepatitis B", "DISEASE", 253, 264], ["Ag", "CHEMICAL", 135, 137], ["Cells", "CELL", 0, 5], ["cell", "CELL", 63, 67], ["human", "ORGANISM", 88, 93], ["CD8 T ETo", "GENE_OR_GENE_PRODUCT", 94, 103], ["IL-10", "GENE_OR_GENE_PRODUCT", 126, 131], ["Ag", "GENE_OR_GENE_PRODUCT", 135, 137], ["peripheral blood mononuclear cells", "CELL", 157, 191], ["PBMC", "CELL", 193, 197], ["HLA-A201", "ORGANISM", 209, 217], ["patients", "ORGANISM", 220, 228], ["anti-IL-10R Ab", "GENE_OR_GENE_PRODUCT", 343, 357], ["BD Pharmingen", "GENE_OR_GENE_PRODUCT", 359, 372], ["human", "ORGANISM", 400, 405], ["IL-10", "GENE_OR_GENE_PRODUCT", 406, 411], ["BioLegend", "GENE_OR_GENE_PRODUCT", 413, 422], ["human", "ORGANISM", 500, 505], ["IL-2", "GENE_OR_GENE_PRODUCT", 506, 510], ["human CD8 T ETo", "PROTEIN", 88, 103], ["IL", "PROTEIN", 126, 128], ["Ag", "PROTEIN", 135, 137], ["peripheral blood mononuclear cells", "CELL_TYPE", 157, 191], ["PBMC", "CELL_TYPE", 193, 197], ["anti-IL-10R Ab", "PROTEIN", 343, 357], ["BD Pharmingen", "PROTEIN", 359, 372], ["recombinant human IL-10", "PROTEIN", 388, 411], ["BioLegend", "PROTEIN", 413, 422], ["human", "SPECIES", 88, 93], ["patients", "SPECIES", 220, 228], ["human", "SPECIES", 400, 405], ["human", "SPECIES", 500, 505], ["human", "SPECIES", 88, 93], ["human", "SPECIES", 400, 405], ["human", "SPECIES", 500, 505], ["peptide stimulation", "TREATMENT", 34, 53], ["vitro cell culture assays", "TEST", 57, 82], ["IL", "TEST", 126, 128], ["Ag", "TEST", 135, 137], ["apoptosis", "PROBLEM", 146, 155], ["peripheral blood mononuclear cells", "TEST", 157, 191], ["PBMC", "TEST", 193, 197], ["five HLA", "TEST", 204, 212], ["acute self-limited hepatitis B", "PROBLEM", 234, 264], ["anti-IL", "TREATMENT", 343, 350], ["Ab (BD Pharmingen", "TREATMENT", 355, 372], ["recombinant human IL", "TREATMENT", 388, 408], ["Core", "TEST", 467, 471], ["human IL", "TREATMENT", 500, 508], ["peripheral", "ANATOMY_MODIFIER", 157, 167], ["blood", "ANATOMY", 168, 173], ["mononuclear cells", "OBSERVATION", 174, 191], ["acute", "OBSERVATION_MODIFIER", 234, 239], ["left", "ANATOMY_MODIFIER", 427, 431]]], ["After a 5 h incubation, cells were extensively washed, stained with Core 18-27 dextramer, anti-CD8 and anti-CD3 mouse Abs for 15 min in the dark, then stained with Annexin V and 7AAD (BD Pharmingen), according to the Annexin V staining protocol (BD Pharmingen).", [["cells", "ANATOMY", 24, 29], ["cells", "CELL", 24, 29], ["anti-CD8", "SIMPLE_CHEMICAL", 90, 98], ["mouse", "ORGANISM", 112, 117], ["Annexin V", "GENE_OR_GENE_PRODUCT", 164, 173], ["Annexin V", "GENE_OR_GENE_PRODUCT", 217, 226], ["Core 18-27 dextramer", "PROTEIN", 68, 88], ["anti-CD8", "PROTEIN", 90, 98], ["anti-CD3 mouse Abs", "PROTEIN", 103, 121], ["Annexin V", "PROTEIN", 164, 173], ["7AAD", "PROTEIN", 178, 182], ["BD Pharmingen", "PROTEIN", 184, 197], ["Annexin V", "PROTEIN", 217, 226], ["BD Pharmingen", "PROTEIN", 246, 259], ["mouse", "SPECIES", 112, 117], ["mouse", "SPECIES", 112, 117], ["a 5 h incubation", "TREATMENT", 6, 22], ["Core", "TEST", 68, 72], ["anti-CD8", "TREATMENT", 90, 98], ["anti-CD3 mouse Abs", "TREATMENT", 103, 121], ["Annexin V", "TREATMENT", 164, 173], ["7AAD (BD Pharmingen", "TREATMENT", 178, 197], ["the Annexin V staining protocol", "TREATMENT", 213, 244]]], ["The cells were acquired immediately on a FACSCANTO II multicolor flow cytometer and were analyzed with the DIVA software (BD Biosciences, Immunocytometry Systems, CA, USA).Tissue DNA analysesTotal DNA was isolated from frozen livers (left lobe) for Southern blot analysis, as previously described.", [["cells", "ANATOMY", 4, 9], ["Tissue", "ANATOMY", 172, 178], ["livers", "ANATOMY", 226, 232], ["left lobe", "ANATOMY", 234, 243], ["cells", "CELL", 4, 9], ["Tissue", "ORGANISM_SUBSTANCE", 172, 178], ["DNA", "CELLULAR_COMPONENT", 179, 182], ["DNA", "CELLULAR_COMPONENT", 197, 200], ["livers", "ORGAN", 226, 232], ["left lobe", "MULTI-TISSUE_STRUCTURE", 234, 243], ["FACSCANTO II", "PROTEIN", 41, 53], ["Tissue DNA analysesTotal DNA", "DNA", 172, 200], ["a FACSCANTO II multicolor flow cytometer", "TREATMENT", 39, 79], ["Tissue DNA analysesTotal DNA", "TEST", 172, 200], ["Southern blot analysis", "TEST", 249, 271], ["livers", "ANATOMY", 226, 232], ["left lobe", "ANATOMY", 234, 243]]], ["All statistical analyses were performed in Prism 5 (GraphPad Software).", [["All statistical analyses", "TEST", 0, 24]]], ["Means between two groups were compared with two-tailed t test.", [["tailed t test", "TEST", 48, 61]]], ["Means among three or more groups were compared with oneway or two-way analysis of variance (ANOVA) with Bonferroni's post-hoc test.", [["Bonferroni's post-hoc test", "TEST", 104, 130]]], ["Some data were analyzed using Fisher's Least Significant Difference (LSD) testCD8 T E produce IL-10 upon hepatocellular Ag recognitionWe first assessed whether IL-10 is produced upon acute HBV infection.", [["hepatocellular", "ANATOMY", 105, 119], ["HBV infection", "DISEASE", 189, 202], ["Ag", "CHEMICAL", 120, 122], ["IL-10", "GENE_OR_GENE_PRODUCT", 94, 99], ["hepatocellular Ag", "CELL", 105, 122], ["IL-10", "GENE_OR_GENE_PRODUCT", 160, 165], ["HBV", "ORGANISM", 189, 192], ["IL-10", "PROTEIN", 94, 99], ["IL-10", "PROTEIN", 160, 165], ["HBV", "SPECIES", 189, 192], ["testCD8", "TEST", 74, 81], ["IL", "TEST", 94, 96], ["hepatocellular Ag recognitionWe", "TREATMENT", 105, 136], ["IL", "TEST", 160, 162], ["acute HBV infection", "PROBLEM", 183, 202], ["hepatocellular", "ANATOMY", 105, 119], ["acute", "OBSERVATION_MODIFIER", 183, 188], ["HBV", "OBSERVATION", 189, 192], ["infection", "OBSERVATION", 193, 202]]], ["We longitudinally analyzed the sera of a chimpanzee (A0A006) that had been inoculated with a monoclonal HBV inoculum of 10 10 GE of HBV DNA, as described.", [["sera", "ANATOMY", 31, 35], ["sera", "ORGANISM_SUBSTANCE", 31, 35], ["chimpanzee", "ORGANISM", 41, 51], ["HBV", "ORGANISM", 132, 135], ["DNA", "CELLULAR_COMPONENT", 136, 139], ["HBV DNA", "DNA", 132, 139], ["chimpanzee", "SPECIES", 41, 51], ["HBV", "SPECIES", 104, 107], ["HBV", "SPECIES", 132, 135], ["a monoclonal HBV inoculum", "PROBLEM", 91, 116], ["HBV DNA", "PROBLEM", 132, 139], ["monoclonal", "OBSERVATION_MODIFIER", 93, 103], ["HBV inoculum", "OBSERVATION", 104, 116], ["HBV DNA", "OBSERVATION", 132, 139]]], ["13 Serum IL-10 was not detectable until CD8 + T cells accumulated in the liver and its appearance coincided with the onset of a necroinflammatory liver disease (Fig. 1A) , suggesting that this cytokine might have been produced by virus-specific CD8 T E upon hepatocellular Ag recognition.", [["CD8 + T cells", "ANATOMY", 40, 53], ["liver", "ANATOMY", 73, 78], ["liver", "ANATOMY", 146, 151], ["hepatocellular Ag", "ANATOMY", 258, 275], ["necroinflammatory liver disease", "DISEASE", 128, 159], ["Ag", "CHEMICAL", 273, 275], ["Serum", "ORGANISM_SUBSTANCE", 3, 8], ["IL-10", "GENE_OR_GENE_PRODUCT", 9, 14], ["CD8", "GENE_OR_GENE_PRODUCT", 40, 43], ["liver", "ORGAN", 73, 78], ["liver", "ORGAN", 146, 151], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 245, 252], ["hepatocellular Ag", "GENE_OR_GENE_PRODUCT", 258, 275], ["IL", "PROTEIN", 9, 11], ["CD8", "PROTEIN", 40, 43], ["T cells", "CELL_TYPE", 46, 53], ["cytokine", "PROTEIN", 193, 201], ["CD8 T E", "PROTEIN", 245, 252], ["Serum IL", "TEST", 3, 11], ["CD8", "TEST", 40, 43], ["T cells", "PROBLEM", 46, 53], ["a necroinflammatory liver disease", "PROBLEM", 126, 159], ["this cytokine", "PROBLEM", 188, 201], ["hepatocellular Ag recognition", "PROBLEM", 258, 287], ["liver", "ANATOMY", 73, 78], ["necroinflammatory", "OBSERVATION_MODIFIER", 128, 145], ["liver", "ANATOMY", 146, 151], ["disease", "OBSERVATION", 152, 159], ["hepatocellular", "ANATOMY", 258, 272]]], ["To test this hypothesis and to assess the role of IL-10 in liver immunopathology, we employed a well-established model of acute HBV pathogenesis, i.e. the adoptive transfer of HBV-specific CD8 + T E into HBV replication-competent transgenic mice.", [["liver", "ANATOMY", 59, 64], ["liver immunopathology", "DISEASE", 59, 80], ["IL-10", "GENE_OR_GENE_PRODUCT", 50, 55], ["liver", "ORGAN", 59, 64], ["HBV", "ORGANISM", 128, 131], ["HBV", "ORGANISM", 176, 179], ["CD8 + T E", "GENE_OR_GENE_PRODUCT", 189, 198], ["HBV", "ORGANISM", 204, 207], ["mice", "ORGANISM", 241, 245], ["IL-10", "PROTEIN", 50, 55], ["CD8", "PROTEIN", 189, 192], ["mice", "SPECIES", 241, 245], ["HBV", "SPECIES", 128, 131], ["HBV", "SPECIES", 176, 179], ["HBV", "SPECIES", 204, 207], ["mice", "SPECIES", 241, 245], ["IL", "TEST", 50, 52], ["acute HBV pathogenesis", "PROBLEM", 122, 144], ["HBV", "TEST", 176, 179], ["HBV replication", "TREATMENT", 204, 219], ["liver", "ANATOMY", 59, 64], ["immunopathology", "OBSERVATION", 65, 80], ["acute", "OBSERVATION_MODIFIER", 122, 127], ["HBV", "OBSERVATION", 128, 131]]], ["14-16 Na\u00efve CD8 + T cells from HBV nucleocapsid (Cor)specific TCR transgenic mice 17 (referred to as Cor93 cells) were differentiated in vitro into bona fide CD8 T E .", [["CD8 + T cells", "ANATOMY", 12, 25], ["Cor93 cells", "ANATOMY", 101, 112], ["CD8", "GENE_OR_GENE_PRODUCT", 12, 15], ["HBV nucleocapsid", "ORGANISM", 31, 47], ["Cor", "GENE_OR_GENE_PRODUCT", 49, 52], ["TCR", "GENE_OR_GENE_PRODUCT", 62, 65], ["Cor93 cells", "CELL", 101, 112], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 158, 165], ["CD8", "PROTEIN", 12, 15], ["T cells", "CELL_TYPE", 18, 25], ["TCR", "PROTEIN", 62, 65], ["Cor93 cells", "CELL_LINE", 101, 112], ["bona fide CD8 T E", "CELL_LINE", 148, 165], ["mice", "SPECIES", 77, 81], ["HBV", "SPECIES", 31, 34], ["mice", "SPECIES", 77, 81], ["Na\u00efve CD8", "TEST", 6, 15], ["T cells", "PROBLEM", 18, 25], ["HBV nucleocapsid", "PROBLEM", 31, 47], ["fide CD8", "OBSERVATION", 153, 161]]], ["Upon intravenous injection of 10 7 Cor93 CD8 T E into HBV replication-competent transgenic mice, the hepatic mRNA expression of the il10 gene increased sharply, reaching peak levels at 4-8 h after T cell transfer and mirroring the kinetics of the prototypical CD8 T E -derived pro-inflammatory and antiviral cytokine gene ifng (Fig. 1B) .", [["intravenous", "ANATOMY", 5, 16], ["hepatic", "ANATOMY", 101, 108], ["T cell", "ANATOMY", 197, 203], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 5, 16], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 41, 48], ["HBV", "ORGANISM", 54, 57], ["mice", "ORGANISM", 91, 95], ["hepatic", "ORGAN", 101, 108], ["il10", "GENE_OR_GENE_PRODUCT", 132, 136], ["T cell", "CELL", 197, 203], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 260, 267], ["hepatic mRNA", "RNA", 101, 113], ["il10 gene", "DNA", 132, 141], ["CD8 T E", "PROTEIN", 260, 267], ["antiviral cytokine gene", "DNA", 298, 321], ["ifng", "DNA", 322, 326], ["mice", "SPECIES", 91, 95], ["HBV", "SPECIES", 54, 57], ["mice", "SPECIES", 91, 95], ["intravenous injection", "TREATMENT", 5, 26], ["HBV replication", "TREATMENT", 54, 69], ["peak levels", "TEST", 170, 181], ["T cell transfer", "TREATMENT", 197, 212], ["the prototypical CD8 T E -derived pro-inflammatory", "TREATMENT", 243, 293], ["antiviral cytokine gene ifng (Fig", "TREATMENT", 298, 331], ["hepatic", "ANATOMY", 101, 108], ["increased", "OBSERVATION_MODIFIER", 142, 151], ["sharply", "OBSERVATION_MODIFIER", 152, 159]]], ["Accordingly, IL-10 was also detected in the serum of these mice between 4 and 8 h after T cell transfer, again echoing the IFN-c kinetics (Fig. 1C) .", [["serum", "ANATOMY", 44, 49], ["T cell", "ANATOMY", 88, 94], ["IL-10", "GENE_OR_GENE_PRODUCT", 13, 18], ["serum", "ORGANISM_SUBSTANCE", 44, 49], ["mice", "ORGANISM", 59, 63], ["T cell", "CELL", 88, 94], ["IFN-c", "GENE_OR_GENE_PRODUCT", 123, 128], ["IL-10", "PROTEIN", 13, 18], ["IFN", "PROTEIN", 123, 126], ["mice", "SPECIES", 59, 63], ["mice", "SPECIES", 59, 63], ["IL", "TREATMENT", 13, 15]]], ["Consistent with the hypothesis that IL-10 is produced by CD8 T E upon hepatocellular antigen recognition, we found that Cor93 T E cells stimulated for 4 h in vitro with the cognate Cor93 peptide produced both cytokines (Fig. 1D-G; Fig. S1 ).", [["hepatocellular", "ANATOMY", 70, 84], ["Cor93 T E cells", "ANATOMY", 120, 135], ["IL-10", "GENE_OR_GENE_PRODUCT", 36, 41], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 57, 64], ["hepatocellular antigen", "GENE_OR_GENE_PRODUCT", 70, 92], ["Cor93 T E cells", "CELL", 120, 135], ["Cor93", "GENE_OR_GENE_PRODUCT", 181, 186], ["IL-10", "PROTEIN", 36, 41], ["CD8 T E", "PROTEIN", 57, 64], ["Cor93 T E cells", "CELL_LINE", 120, 135], ["cytokines", "PROTEIN", 209, 218], ["hepatocellular antigen recognition", "TEST", 70, 104], ["Cor93 T E cells", "TREATMENT", 120, 135], ["hepatocellular", "ANATOMY", 70, 84]]], ["Finally, to unambiguously identify the cellular source of the IL-10 detected in the liver of HBV replication-competent transgenic mice upon adoptive transfer of Cor93 CD8 T E , we genetically deleted the il10 gene in HBV replication-competent recipient mice, in Cor93 CD8 T E or in both.", [["cellular", "ANATOMY", 39, 47], ["liver", "ANATOMY", 84, 89], ["Cor93 CD8 T E", "ANATOMY", 262, 275], ["cellular", "CELL", 39, 47], ["IL-10", "GENE_OR_GENE_PRODUCT", 62, 67], ["liver", "ORGAN", 84, 89], ["HBV", "ORGANISM", 93, 96], ["mice", "ORGANISM", 130, 134], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 167, 174], ["il10", "GENE_OR_GENE_PRODUCT", 204, 208], ["HBV", "ORGANISM", 217, 220], ["mice", "ORGANISM", 253, 257], ["Cor93", "CELL", 262, 267], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 268, 275], ["IL-10", "PROTEIN", 62, 67], ["Cor93 CD8 T E", "CELL_LINE", 161, 174], ["il10 gene", "DNA", 204, 213], ["Cor93 CD8 T E", "CELL_LINE", 262, 275], ["mice", "SPECIES", 130, 134], ["mice", "SPECIES", 253, 257], ["HBV", "SPECIES", 93, 96], ["mice", "SPECIES", 130, 134], ["HBV", "SPECIES", 217, 220], ["mice", "SPECIES", 253, 257], ["the IL", "TEST", 58, 64], ["HBV replication", "TREATMENT", 93, 108], ["HBV replication", "TREATMENT", 217, 232], ["liver", "ANATOMY", 84, 89], ["HBV", "OBSERVATION", 93, 96]]], ["By using this approach, we could demonstrate that the transferred CD8 T E cells are the unique source of IL-10 in this experimental setting, as il10 expression was only detected when the transferred T cells were IL10-competent, regardless of the recipient genotype (Fig. 1H) .IL-10 promotes liver immunopathology by preventing CD8 T E apoptosisTo gain insight into the role of CD8 T E -derived IL-10 expression in liver immunopathology, we selectively blocked IL-10 receptor signaling by injecting HBV replication-competent transgenic mice with an anti-IL-10Ra Ab 2 h prior to Cor93 T E transfer.", [["CD8 T E cells", "ANATOMY", 66, 79], ["T cells", "ANATOMY", 199, 206], ["liver", "ANATOMY", 291, 296], ["liver", "ANATOMY", 414, 419], ["liver immunopathology", "DISEASE", 291, 312], ["liver immunopathology", "DISEASE", 414, 435], ["CD8", "GENE_OR_GENE_PRODUCT", 66, 69], ["IL-10", "GENE_OR_GENE_PRODUCT", 105, 110], ["il10", "GENE_OR_GENE_PRODUCT", 144, 148], ["T cells", "CELL", 199, 206], ["IL10", "GENE_OR_GENE_PRODUCT", 212, 216], ["IL-10", "GENE_OR_GENE_PRODUCT", 276, 281], ["liver", "ORGAN", 291, 296], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 327, 334], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 377, 384], ["IL-10", "GENE_OR_GENE_PRODUCT", 394, 399], ["liver", "ORGAN", 414, 419], ["IL-10 receptor", "GENE_OR_GENE_PRODUCT", 460, 474], ["HBV", "ORGANISM", 498, 501], ["mice", "ORGANISM", 535, 539], ["anti-IL-10Ra", "GENE_OR_GENE_PRODUCT", 548, 560], ["Cor93 T E", "GENE_OR_GENE_PRODUCT", 577, 586], ["CD8 T E cells", "CELL_TYPE", 66, 79], ["IL", "PROTEIN", 105, 107], ["il10", "PROTEIN", 144, 148], ["T cells", "CELL_TYPE", 199, 206], ["IL10", "PROTEIN", 212, 216], ["IL-10", "PROTEIN", 276, 281], ["CD8 T E", "PROTEIN", 377, 384], ["IL-10", "PROTEIN", 394, 399], ["IL-10 receptor", "PROTEIN", 460, 474], ["anti-IL", "PROTEIN", 548, 555], ["mice", "SPECIES", 535, 539], ["HBV", "SPECIES", 498, 501], ["mice", "SPECIES", 535, 539], ["IL", "TEST", 105, 107], ["IL", "TREATMENT", 276, 278], ["CD8 T E -derived IL", "TREATMENT", 377, 396], ["selectively blocked IL", "TREATMENT", 440, 462], ["HBV replication", "TREATMENT", 498, 513], ["an anti-IL", "TREATMENT", 545, 555], ["liver", "ANATOMY", 291, 296], ["liver", "ANATOMY", 414, 419]]], ["To our surprise, we found that IL-10 blockade decreased, rather than increased, liver damage by about 3-fold at the peak of the disease ( Fig. 2A) .", [["liver", "ANATOMY", 80, 85], ["liver damage", "DISEASE", 80, 92], ["IL-10", "GENE_OR_GENE_PRODUCT", 31, 36], ["liver", "ORGAN", 80, 85], ["IL", "PROTEIN", 31, 33], ["IL", "TREATMENT", 31, 33], ["liver damage", "PROBLEM", 80, 92], ["increased", "OBSERVATION_MODIFIER", 69, 78], ["liver", "ANATOMY", 80, 85], ["damage", "OBSERVATION", 86, 92], ["disease", "OBSERVATION", 128, 135]]], ["Of note, anti-IL-10Ra Ab injection did not affect the total number of circulating Cor93 T E cells (data not shown), indicating that this treatment did not deplete the transferred T cells.", [["Cor93 T E cells", "ANATOMY", 82, 97], ["T cells", "ANATOMY", 179, 186], ["anti-IL-10Ra", "CHEMICAL", 9, 21], ["anti-IL-10Ra", "GENE_OR_GENE_PRODUCT", 9, 21], ["Ab", "GENE_OR_GENE_PRODUCT", 22, 24], ["Cor93 T E cells", "CELL", 82, 97], ["T cells", "CELL", 179, 186], ["anti-IL", "PROTEIN", 9, 16], ["Cor93 T E cells", "CELL_LINE", 82, 97], ["T cells", "CELL_TYPE", 179, 186], ["anti-IL", "TREATMENT", 9, 16], ["Ab injection", "TREATMENT", 22, 34]]], ["Also, anti-IL-10Ra Ab treatment significantly reduced liver disease when HBV envelope-specific TCR transgenic 16, 17 or polyclonal CD8 T E 18 were injected into HBV replication-competent transgenic mice instead of Cor93 T E (data not shown).", [["liver", "ANATOMY", 54, 59], ["anti-IL-10Ra", "CHEMICAL", 6, 18], ["liver disease", "DISEASE", 54, 67], ["anti-IL-10Ra", "GENE_OR_GENE_PRODUCT", 6, 18], ["Ab", "GENE_OR_GENE_PRODUCT", 19, 21], ["liver", "ORGAN", 54, 59], ["HBV", "ORGANISM", 73, 76], ["TCR", "GENE_OR_GENE_PRODUCT", 95, 98], ["HBV", "ORGANISM", 161, 164], ["mice", "ORGANISM", 198, 202], ["Cor93 T E", "GENE_OR_GENE_PRODUCT", 214, 223], ["anti-IL", "PROTEIN", 6, 13], ["TCR", "PROTEIN", 95, 98], ["CD8 T E 18", "CELL_LINE", 131, 141], ["mice", "SPECIES", 198, 202], ["HBV", "SPECIES", 73, 76], ["HBV", "SPECIES", 161, 164], ["mice", "SPECIES", 198, 202], ["Ab treatment", "TREATMENT", 19, 31], ["reduced liver disease", "PROBLEM", 46, 67], ["HBV envelope", "PROBLEM", 73, 85], ["specific TCR transgenic", "TEST", 86, 109], ["polyclonal CD8 T E", "TREATMENT", 120, 138], ["HBV replication", "TREATMENT", 161, 176], ["liver", "ANATOMY", 54, 59], ["disease", "OBSERVATION", 60, 67]]], ["Moreover, consistent with IL-10 being produced exclusively by the transferred CD8 T E in this model, deletion of the il10 gene in HBV replication-competent recipient mice -which did not alter the Ag presentation capacity of hepatocytes (Fig. S2 ) -did not affect the severity of liver disease induced by Cor93 T E transfer (Fig. 2B) .IL-10 promotes liver immunopathology by preventing CD8 T E apoptosisTo explore the mechanisms underlying this IL-10-mediated increase in liver immunopathology, we quantified the number, function and viability of intrahepatic Cor93 CD8 T E 2, 8, and 24 h after adoptive transfer into HBV replication-competent transgenic mice that were or were not subjected to anti-IL-10Ra Ab treatment.", [["hepatocytes", "ANATOMY", 224, 235], ["liver", "ANATOMY", 279, 284], ["liver", "ANATOMY", 349, 354], ["liver", "ANATOMY", 471, 476], ["intrahepatic Cor93", "ANATOMY", 546, 564], ["Ag", "CHEMICAL", 196, 198], ["liver disease", "DISEASE", 279, 292], ["liver immunopathology", "DISEASE", 349, 370], ["liver immunopathology", "DISEASE", 471, 492], ["anti-IL-10Ra", "CHEMICAL", 694, 706], ["Ag", "CHEMICAL", 196, 198], ["Cor93 T E", "CHEMICAL", 304, 313], ["IL-10", "GENE_OR_GENE_PRODUCT", 26, 31], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 78, 85], ["il10", "GENE_OR_GENE_PRODUCT", 117, 121], ["HBV replication-competent recipient mice", "ORGANISM", 130, 170], ["Ag", "GENE_OR_GENE_PRODUCT", 196, 198], ["hepatocytes", "CELL", 224, 235], ["liver", "ORGAN", 279, 284], ["Cor93 T E", "GENE_OR_GENE_PRODUCT", 304, 313], ["IL-10", "GENE_OR_GENE_PRODUCT", 334, 339], ["liver", "ORGAN", 349, 354], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 385, 392], ["IL-10", "GENE_OR_GENE_PRODUCT", 444, 449], ["liver", "ORGAN", 471, 476], ["HBV", "ORGANISM", 617, 620], ["mice", "ORGANISM", 654, 658], ["anti-IL-10Ra", "GENE_OR_GENE_PRODUCT", 694, 706], ["Ab", "GENE_OR_GENE_PRODUCT", 707, 709], ["IL", "PROTEIN", 26, 28], ["CD8 T E", "CELL_LINE", 78, 85], ["il10 gene", "DNA", 117, 126], ["Ag", "PROTEIN", 196, 198], ["hepatocytes", "CELL_TYPE", 224, 235], ["IL-10", "PROTEIN", 334, 339], ["IL-10", "PROTEIN", 444, 449], ["intrahepatic Cor93 CD8 T E", "CELL_LINE", 546, 572], ["anti-IL", "PROTEIN", 694, 701], ["mice", "SPECIES", 166, 170], ["mice", "SPECIES", 654, 658], ["HBV", "SPECIES", 130, 133], ["mice", "SPECIES", 166, 170], ["HBV", "SPECIES", 617, 620], ["mice", "SPECIES", 654, 658], ["the il10 gene", "TREATMENT", 113, 126], ["HBV replication", "TREATMENT", 130, 145], ["liver disease", "PROBLEM", 279, 292], ["IL", "TREATMENT", 334, 336], ["CD8 T E apoptosis", "PROBLEM", 385, 402], ["this IL", "TEST", 439, 446], ["liver immunopathology", "PROBLEM", 471, 492], ["HBV replication", "TREATMENT", 617, 632], ["Ab treatment", "TREATMENT", 707, 719], ["hepatocytes", "ANATOMY", 224, 235], ["liver", "ANATOMY", 279, 284], ["disease", "OBSERVATION", 285, 292], ["liver", "ANATOMY", 349, 354], ["increase", "OBSERVATION_MODIFIER", 459, 467], ["liver", "ANATOMY", 471, 476], ["immunopathology", "OBSERVATION", 477, 492], ["intrahepatic", "ANATOMY", 546, 558]]], ["IL-10R blockade significantly decreased the number of total and IFN-c + intrahepatic Cor93 CD8 T E cells recovered 24 h after injection ( Fig. 2C and D) .", [["intrahepatic Cor93 CD8 T E cells", "ANATOMY", 72, 104], ["IL-10R", "GENE_OR_GENE_PRODUCT", 0, 6], ["IFN", "PROTEIN", 64, 67], ["intrahepatic Cor93 CD8 T E cells", "CELL_LINE", 72, 104], ["IL-10R blockade", "TREATMENT", 0, 15], ["IFN-c", "TEST", 64, 69], ["intrahepatic", "ANATOMY", 72, 84]]], ["We next addressed if this reflected an increase in cell death.", [["cell", "ANATOMY", 51, 55], ["death", "DISEASE", 56, 61], ["cell", "CELL", 51, 55], ["an increase in cell death", "PROBLEM", 36, 61], ["increase", "OBSERVATION_MODIFIER", 39, 47], ["cell death", "OBSERVATION", 51, 61]]], ["Indeed, the percentage of intrahepatic Cor93 CD8 T E that underwent apoptosis at 8 and 24 h after transfer was significantly increased by IL-10R blockade ( Fig. 2E; Fig. S3 ), and this was reflected by a lower disease severity ( Fig. 2F and G) .", [["intrahepatic Cor93 CD8 T E", "ANATOMY", 26, 52], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 45, 52], ["IL-10R", "GENE_OR_GENE_PRODUCT", 138, 144], ["intrahepatic Cor93 CD8 T E", "CELL_LINE", 26, 52], ["IL", "PROTEIN", 138, 140], ["10R", "PROTEIN", 141, 144], ["apoptosis", "PROBLEM", 68, 77], ["IL", "TEST", 138, 140], ["a lower disease severity", "PROBLEM", 202, 226], ["percentage", "OBSERVATION_MODIFIER", 12, 22], ["intrahepatic", "ANATOMY_MODIFIER", 26, 38], ["lower", "OBSERVATION_MODIFIER", 204, 209], ["disease", "OBSERVATION", 210, 217]]], ["Although the number of intrahepatic Cor93 T E was reduced upon IL-10R blockade, these cells probably produced enough IFN-c to abolish viral replication (Fig. S4 ).IL-10 rescues CD8 T E from Ag-induced apoptosis by increasing IL-2 responsivenessTo explore if CD8 T E -derived IL-10 directly decreased Ag-induced apoptosis, we exposed purified Cor93 CD8 T E to Ag in the presence or absence of IL-10R blockade or exogenous IL-10.", [["cells", "ANATOMY", 86, 91], ["Ag", "CHEMICAL", 190, 192], ["Ag", "CHEMICAL", 300, 302], ["Ag", "CHEMICAL", 359, 361], ["Ag", "CHEMICAL", 190, 192], ["Ag", "CHEMICAL", 300, 302], ["Ag", "CHEMICAL", 359, 361], ["Cor93 T E", "GENE_OR_GENE_PRODUCT", 36, 45], ["IL-10R", "GENE_OR_GENE_PRODUCT", 63, 69], ["cells", "CELL", 86, 91], ["IFN-c", "GENE_OR_GENE_PRODUCT", 117, 122], ["IL-10", "GENE_OR_GENE_PRODUCT", 163, 168], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 177, 184], ["Ag", "GENE_OR_GENE_PRODUCT", 190, 192], ["IL-2", "GENE_OR_GENE_PRODUCT", 225, 229], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 258, 265], ["IL-10", "GENE_OR_GENE_PRODUCT", 275, 280], ["Ag", "GENE_OR_GENE_PRODUCT", 300, 302], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 348, 355], ["Ag", "GENE_OR_GENE_PRODUCT", 359, 361], ["IL-10R", "GENE_OR_GENE_PRODUCT", 392, 398], ["IL-10", "GENE_OR_GENE_PRODUCT", 421, 426], ["intrahepatic Cor93 T E", "PROTEIN", 23, 45], ["IL", "PROTEIN", 63, 65], ["10R", "PROTEIN", 66, 69], ["IFN", "PROTEIN", 117, 120], ["IL-10", "PROTEIN", 163, 168], ["CD8", "PROTEIN", 177, 180], ["Ag", "PROTEIN", 190, 192], ["IL", "PROTEIN", 225, 227], ["CD8", "PROTEIN", 258, 261], ["IL-10", "PROTEIN", 275, 280], ["Ag", "PROTEIN", 300, 302], ["Cor93 CD8 T E", "CELL_LINE", 342, 355], ["Ag", "PROTEIN", 359, 361], ["IL", "PROTEIN", 392, 394], ["IL", "PROTEIN", 421, 423], ["IL-10R blockade", "TREATMENT", 63, 78], ["these cells", "PROBLEM", 80, 91], ["viral replication", "TREATMENT", 134, 151], ["IL", "TEST", 163, 165], ["Ag", "TEST", 190, 192], ["apoptosis", "PROBLEM", 201, 210], ["increasing IL", "PROBLEM", 214, 227], ["CD8", "TEST", 258, 261], ["IL", "TEST", 275, 277], ["apoptosis", "PROBLEM", 311, 320], ["IL-10R blockade", "TREATMENT", 392, 407], ["exogenous IL", "TREATMENT", 411, 423], ["intrahepatic", "ANATOMY", 23, 35]]], ["As shown in Fig. 3A , Ag exposure for 8 h triggered Cor93 CD8 T E apoptosis.IL-10 rescues CD8 T E from Ag-induced apoptosis by increasing IL-2 responsivenessNotably, IL-10R blockade increased the percentage of Cor93 CD8 T E that became apoptotic, whereas the addition of exogenous recombinant IL-10 decreased Cor93 CD8 T E apoptosis ( Fig. 3A and Fig. S5A) .", [["Cor93 CD8 T E", "ANATOMY", 210, 223], ["Ag", "CHEMICAL", 22, 24], ["Ag", "CHEMICAL", 103, 105], ["Ag", "CHEMICAL", 22, 24], ["Ag", "CHEMICAL", 103, 105], ["3A", "GENE_OR_GENE_PRODUCT", 17, 19], ["Ag", "GENE_OR_GENE_PRODUCT", 22, 24], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 58, 65], ["IL-10", "GENE_OR_GENE_PRODUCT", 76, 81], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 90, 97], ["Ag", "GENE_OR_GENE_PRODUCT", 103, 105], ["IL-2", "GENE_OR_GENE_PRODUCT", 138, 142], ["IL-10R", "GENE_OR_GENE_PRODUCT", 166, 172], ["Cor93", "CELL", 210, 215], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 216, 223], ["IL-10", "GENE_OR_GENE_PRODUCT", 293, 298], ["Cor93 CD8 T E", "GENE_OR_GENE_PRODUCT", 309, 322], ["Ag", "PROTEIN", 22, 24], ["CD8", "PROTEIN", 58, 61], ["IL-10", "PROTEIN", 76, 81], ["CD8", "PROTEIN", 90, 93], ["Ag", "PROTEIN", 103, 105], ["IL", "PROTEIN", 138, 140], ["IL", "PROTEIN", 166, 168], ["10R", "PROTEIN", 169, 172], ["Cor93 CD8 T E", "CELL_LINE", 210, 223], ["IL", "PROTEIN", 293, 295], ["CD8", "PROTEIN", 315, 318], ["S5A", "PROTEIN", 352, 355], ["IL", "TEST", 76, 78], ["Ag", "TEST", 103, 105], ["apoptosis", "PROBLEM", 114, 123], ["increasing IL", "PROBLEM", 127, 140], ["IL-10R blockade", "TREATMENT", 166, 181], ["apoptotic", "PROBLEM", 236, 245], ["exogenous recombinant IL", "TEST", 271, 295], ["Fig", "OBSERVATION", 12, 15]]], ["We next set out to determine the mechanism whereby IL-10 prevents CD8 T E from dying.", [["IL-10", "GENE_OR_GENE_PRODUCT", 51, 56], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 66, 73], ["IL", "PROTEIN", 51, 53], ["CD8", "PROTEIN", 66, 69]]], ["Since IL-10 has been proposed to enhance the growth of activated CD8 + T cells in the presence of IL-2, [19] [20] [21] we reasoned that CD8 T E -derived IL-10 might increase IL-2 responsiveness by, for instance, modulating IL-2 receptor expression.", [["CD8 + T cells", "ANATOMY", 65, 78], ["IL-10", "GENE_OR_GENE_PRODUCT", 6, 11], ["CD8", "GENE_OR_GENE_PRODUCT", 65, 68], ["IL-2", "GENE_OR_GENE_PRODUCT", 98, 102], ["[19] [20] [21]", "SIMPLE_CHEMICAL", 104, 118], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 136, 143], ["IL-10", "GENE_OR_GENE_PRODUCT", 153, 158], ["IL-2", "GENE_OR_GENE_PRODUCT", 174, 178], ["IL-2 receptor", "GENE_OR_GENE_PRODUCT", 223, 236], ["IL-10", "PROTEIN", 6, 11], ["activated CD8 + T cells", "CELL_TYPE", 55, 78], ["IL", "PROTEIN", 98, 100], ["IL-2 receptor", "PROTEIN", 223, 236], ["IL", "TEST", 98, 100], ["IL", "TEST", 153, 155]]], ["Indeed, Ag-induced IL-2Ra (CD25) upregulation on CD8 T E was lower upon IL-10R blockade, whereas the addition of exogenous recombinant IL-10 increased CD25 upregulation (Fig. 3B and Fig. S5B ).", [["Ag", "CHEMICAL", 8, 10], ["Ag", "CHEMICAL", 8, 10], ["Ag", "GENE_OR_GENE_PRODUCT", 8, 10], ["IL-2Ra", "GENE_OR_GENE_PRODUCT", 19, 25], ["CD25", "GENE_OR_GENE_PRODUCT", 27, 31], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 49, 56], ["IL-10R", "GENE_OR_GENE_PRODUCT", 72, 78], ["IL-10", "GENE_OR_GENE_PRODUCT", 135, 140], ["CD25", "GENE_OR_GENE_PRODUCT", 151, 155], ["Fig. S5B", "GENE_OR_GENE_PRODUCT", 182, 190], ["Ag", "PROTEIN", 8, 10], ["CD25", "PROTEIN", 27, 31], ["CD8 T E", "CELL_LINE", 49, 56], ["IL", "PROTEIN", 135, 137], ["CD25", "PROTEIN", 151, 155], ["Ag", "TEST", 8, 10], ["IL-10R blockade", "TREATMENT", 72, 87], ["exogenous recombinant IL", "TREATMENT", 113, 137], ["increased CD25 upregulation", "TREATMENT", 141, 168]]], ["Accordingly, blocking IL-10R signaling decreased the capacity of CD8 T E to respond to IL-2 (as assessed by STAT5 phosphorylation), and IL-10 treatment increased IL-2 sensitivity ( Fig. 3C; Fig. S5C ).", [["IL-10R", "GENE_OR_GENE_PRODUCT", 22, 28], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 65, 72], ["IL-2", "GENE_OR_GENE_PRODUCT", 87, 91], ["STAT5", "GENE_OR_GENE_PRODUCT", 108, 113], ["IL-10", "GENE_OR_GENE_PRODUCT", 136, 141], ["IL-2", "GENE_OR_GENE_PRODUCT", 162, 166], ["IL-10R", "PROTEIN", 22, 28], ["CD8 T E", "PROTEIN", 65, 72], ["IL-2", "PROTEIN", 87, 91], ["STAT5", "PROTEIN", 108, 113], ["IL", "PROTEIN", 162, 164], ["blocking IL", "TREATMENT", 13, 24], ["IL", "TEST", 87, 89], ["IL", "TREATMENT", 136, 138], ["IL", "TEST", 162, 164]]], ["Finally, we explored whether the capacity of CD8 T E -derived IL-10 to act in an autocrine/paracrine fashion to rescue CD8 T E from Ag-triggered apoptosis was restricted to murine CD8 T E or it extended to HBV-specific CD8 T E isolated from acutely infected patients.", [["CD8 T E", "ANATOMY", 180, 187], ["CD8 T E", "ANATOMY", 219, 226], ["Ag", "CHEMICAL", 132, 134], ["acutely infected", "DISEASE", 241, 257], ["Ag", "CHEMICAL", 132, 134], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 45, 52], ["IL-10", "GENE_OR_GENE_PRODUCT", 62, 67], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 119, 126], ["Ag", "GENE_OR_GENE_PRODUCT", 132, 134], ["murine", "ORGANISM", 173, 179], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 180, 187], ["HBV", "ORGANISM", 206, 209], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 219, 226], ["patients", "ORGANISM", 258, 266], ["CD8 T E", "PROTEIN", 45, 52], ["IL-10", "PROTEIN", 62, 67], ["CD8", "PROTEIN", 119, 122], ["Ag", "PROTEIN", 132, 134], ["murine CD8 T E", "CELL_LINE", 173, 187], ["CD8 T E", "CELL_TYPE", 219, 226], ["murine", "SPECIES", 173, 179], ["patients", "SPECIES", 258, 266], ["HBV", "SPECIES", 206, 209], ["an autocrine/paracrine fashion", "TREATMENT", 78, 108], ["Ag", "TEST", 132, 134], ["apoptosis", "PROBLEM", 145, 154], ["HBV", "TEST", 206, 209], ["acutely", "OBSERVATION_MODIFIER", 241, 248], ["infected", "OBSERVATION", 249, 257]]], ["To this end, PBMCs from 5 HLA-A201 + patients with acute hepatitis B, in whom HBV-specific CD8 + T cells can be specifically visualized by HBV-specific dextramers 22 (Fig. S6 ), were stimulated with the cognate Cor18 peptide in the presence or absence of anti-IL-10Ra Abs or exogenous IL-10.", [["PBMCs", "ANATOMY", 13, 18], ["CD8 + T cells", "ANATOMY", 91, 104], ["acute hepatitis B", "DISEASE", 51, 68], ["anti-IL-10Ra", "CHEMICAL", 255, 267], ["PBMCs", "CELL", 13, 18], ["HLA-A201", "ORGANISM", 26, 34], ["patients", "ORGANISM", 37, 45], ["HBV", "ORGANISM", 78, 81], ["CD8", "GENE_OR_GENE_PRODUCT", 91, 94], ["HBV", "ORGANISM", 139, 142], ["S6", "GENE_OR_GENE_PRODUCT", 172, 174], ["Cor18", "GENE_OR_GENE_PRODUCT", 211, 216], ["anti-IL-10Ra", "GENE_OR_GENE_PRODUCT", 255, 267], ["IL-10", "GENE_OR_GENE_PRODUCT", 285, 290], ["PBMCs", "CELL_TYPE", 13, 18], ["CD8 + T cells", "CELL_TYPE", 91, 104], ["dextramers 22", "PROTEIN", 152, 165], ["S6", "PROTEIN", 172, 174], ["anti-IL", "PROTEIN", 255, 262], ["Abs", "PROTEIN", 268, 271], ["exogenous IL-10", "PROTEIN", 275, 290], ["patients", "SPECIES", 37, 45], ["HBV", "SPECIES", 78, 81], ["HBV", "SPECIES", 139, 142], ["PBMCs", "TEST", 13, 18], ["HLA", "TEST", 26, 29], ["acute hepatitis B", "PROBLEM", 51, 68], ["HBV", "TEST", 78, 81], ["T cells", "PROBLEM", 97, 104], ["HBV", "TEST", 139, 142], ["specific dextramers", "TEST", 143, 162], ["anti-IL", "TREATMENT", 255, 262], ["exogenous IL", "TEST", 275, 287], ["acute", "OBSERVATION_MODIFIER", 51, 56], ["hepatitis", "OBSERVATION", 57, 66], ["exogenous IL", "OBSERVATION", 275, 287]]], ["The results mirrored those obtained with murine CD8 T E , in that IL-10R blockade increased Ag-induced apoptosis, whereas the addition of recombinant IL-10 partially rescued CD8 T E from cell death (Fig. 3D ).ConclusionIn conclusion, our results indicate that CD8 T E -derived IL-10 acts in an autocrine/paracrine fashion to increase IL-2 responsiveness, rescuing CD8 T E from Ag-induced apoptosis.", [["CD8 T E", "ANATOMY", 48, 55], ["CD8 T E", "ANATOMY", 174, 181], ["cell", "ANATOMY", 187, 191], ["Ag", "CHEMICAL", 92, 94], ["Ag", "CHEMICAL", 377, 379], ["Ag", "CHEMICAL", 92, 94], ["Ag", "CHEMICAL", 377, 379], ["murine", "ORGANISM", 41, 47], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 48, 55], ["IL-10R", "GENE_OR_GENE_PRODUCT", 66, 72], ["Ag", "GENE_OR_GENE_PRODUCT", 92, 94], ["IL-10", "GENE_OR_GENE_PRODUCT", 150, 155], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 174, 181], ["cell", "CELL", 187, 191], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 260, 267], ["IL-10", "GENE_OR_GENE_PRODUCT", 277, 282], ["IL-2", "GENE_OR_GENE_PRODUCT", 334, 338], ["CD8 T E", "GENE_OR_GENE_PRODUCT", 364, 371], ["Ag", "GENE_OR_GENE_PRODUCT", 377, 379], ["murine CD8 T E", "CELL_LINE", 41, 55], ["Ag", "PROTEIN", 92, 94], ["recombinant IL-10", "PROTEIN", 138, 155], ["CD8 T E", "PROTEIN", 174, 181], ["CD8", "PROTEIN", 260, 263], ["IL-10", "PROTEIN", 277, 282], ["CD8 T E", "PROTEIN", 364, 371], ["Ag", "PROTEIN", 377, 379], ["murine", "SPECIES", 41, 47], ["IL", "TEST", 66, 68], ["apoptosis", "PROBLEM", 103, 112], ["recombinant IL", "TREATMENT", 138, 152], ["cell death", "PROBLEM", 187, 197], ["CD8 T E -derived IL", "TREATMENT", 260, 279], ["an autocrine/paracrine fashion", "TREATMENT", 291, 321], ["IL", "TEST", 334, 336], ["Ag", "TEST", 377, 379], ["apoptosis", "PROBLEM", 388, 397], ["apoptosis", "OBSERVATION", 388, 397]]], ["Although the net contribution that IL-10 plays during a natural HBV infection -where this cytokine may be produced by additional cell types 23,24 -remains to be determined, the results described herein suggest that IL-10 may promote rather than suppress liver immunopathology. with medium (white), anti-IL-10Ra (20 lg/ml, light blue), or rIL-10 (200 ng/ml, dark blue).", [["cell", "ANATOMY", 129, 133], ["liver", "ANATOMY", 254, 259], ["HBV infection", "DISEASE", 64, 77], ["liver immunopathology", "DISEASE", 254, 275], ["rIL-10", "CHEMICAL", 338, 344], ["IL-10", "GENE_OR_GENE_PRODUCT", 35, 40], ["HBV", "ORGANISM", 64, 67], ["cell", "CELL", 129, 133], ["IL-10", "GENE_OR_GENE_PRODUCT", 215, 220], ["liver", "ORGAN", 254, 259], ["anti-IL-10Ra", "SIMPLE_CHEMICAL", 298, 310], ["rIL-10", "GENE_OR_GENE_PRODUCT", 338, 344], ["IL-10", "PROTEIN", 35, 40], ["cytokine", "PROTEIN", 90, 98], ["IL-10", "PROTEIN", 215, 220], ["HBV", "SPECIES", 64, 67], ["a natural HBV infection", "PROBLEM", 54, 77], ["liver immunopathology", "PROBLEM", 254, 275], ["anti-IL", "TEST", 298, 305], ["light blue", "TEST", 322, 332], ["rIL", "TEST", 338, 341], ["infection", "OBSERVATION", 68, 77], ["liver", "ANATOMY", 254, 259], ["immunopathology", "OBSERVATION", 260, 275], ["medium", "OBSERVATION_MODIFIER", 282, 288]]], ["After 1 h Cor18-27 peptide (1 lg/ml) was added (+Cor18) or not (Ctrl).Financial supportThe percentage of Annexin V+ (apoptotic) cells was determined on Core 18-27 dextramer + cells 5 h later.", [["Annexin V+ (apoptotic) cells", "ANATOMY", 105, 133], ["Core 18-27 dextramer + cells", "ANATOMY", 152, 180], ["Cor18-27 peptide", "CHEMICAL", 10, 26], ["Annexin V", "GENE_OR_GENE_PRODUCT", 105, 114], ["cells", "CELL", 175, 180], ["Annexin V+ (apoptotic) cells", "CELL_LINE", 105, 133], ["Core 18-27 dextramer + cells", "CELL_LINE", 152, 180], ["Financial support", "TREATMENT", 70, 87], ["Annexin V", "TEST", 105, 114], ["Core", "TEST", 152, 156]]], ["Means between two groups were compared with two-tailed t test.", [["tailed t test", "TEST", 48, 61]]], ["Means among three or more groups were compared with one-way or two-way analysis of variance with Bonferroni's post-hoc test.", [["Bonferroni's post-hoc test", "TEST", 97, 123]]]]}